U.S. patent application number 13/336269 was filed with the patent office on 2012-06-21 for pyrimidine sulphonamide derivatives as chemokine receptor modulators.
Invention is credited to David Ranulf Cheshire, Rhona Jane Cox, Premji Meghani, Cherylin Francis Preston, Neal Michael Smith, Jeffrey Paul Stonehouse.
Application Number | 20120157431 13/336269 |
Document ID | / |
Family ID | 35549576 |
Filed Date | 2012-06-21 |
United States Patent
Application |
20120157431 |
Kind Code |
A1 |
Cheshire; David Ranulf ; et
al. |
June 21, 2012 |
Pyrimidine Sulphonamide Derivatives as Chemokine Receptor
Modulators
Abstract
A compound of formula (I), or a pharmaceutically acceptable
salt, solvate or in vivo hydrolysable ester thereof and
pharmaceutical compositions comprising these, all for use in the
treatment of chemokine mediated diseases and disorders.
##STR00001##
Inventors: |
Cheshire; David Ranulf;
(Leicestershire, GB) ; Cox; Rhona Jane;
(Leicestershire, GB) ; Meghani; Premji;
(Leicestershire, GB) ; Smith; Neal Michael;
(Leicestershire, GB) ; Stonehouse; Jeffrey Paul;
(Leicestershire, GB) ; Preston; Cherylin Francis;
(Torquay, GB) |
Family ID: |
35549576 |
Appl. No.: |
13/336269 |
Filed: |
December 23, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12947916 |
Nov 17, 2010 |
|
|
|
13336269 |
|
|
|
|
11574340 |
Feb 27, 2007 |
7838675 |
|
|
PCT/GB05/03257 |
Aug 23, 2005 |
|
|
|
12947916 |
|
|
|
|
Current U.S.
Class: |
514/210.18 ;
514/210.2; 514/218; 514/227.8; 514/235.8; 514/252.14; 514/274;
540/477; 540/575; 544/122; 544/123; 544/295; 544/296; 544/310;
544/312; 544/314; 544/317; 544/318; 544/58.2 |
Current CPC
Class: |
A61P 1/06 20180101; A61P
25/08 20180101; A61P 11/02 20180101; A61P 31/04 20180101; A61P 9/10
20180101; A61P 11/00 20180101; A61P 7/00 20180101; A61P 31/18
20180101; A61P 1/00 20180101; A61P 31/08 20180101; A61P 25/00
20180101; A61P 17/08 20180101; A61P 29/00 20180101; A61P 15/08
20180101; A61P 5/14 20180101; A61P 25/14 20180101; A61P 37/08
20180101; A61P 17/06 20180101; A61P 25/06 20180101; A61P 15/00
20180101; A61P 19/02 20180101; A61P 37/06 20180101; A61P 43/00
20180101; A61P 1/04 20180101; A61P 19/00 20180101; A61P 25/28
20180101; C07D 405/12 20130101; A61P 19/10 20180101; A61P 21/04
20180101; A61P 35/00 20180101; A61P 37/02 20180101; A61P 9/00
20180101; A61P 11/06 20180101; C07D 405/14 20130101; A61P 3/10
20180101; A61P 13/12 20180101; A61P 17/00 20180101; A61P 7/04
20180101; A61P 17/04 20180101; A61P 27/14 20180101; A61P 11/08
20180101; A61P 15/06 20180101; A61P 41/00 20180101; A61P 17/02
20180101; A61P 17/14 20180101; A61P 35/04 20180101 |
Class at
Publication: |
514/210.18 ;
544/312; 544/317; 544/310; 544/295; 544/123; 544/296; 544/122;
544/58.2; 540/575; 540/477; 514/210.2; 514/274; 514/252.14;
514/235.8; 514/227.8; 514/218; 544/314; 544/318 |
International
Class: |
A61K 31/506 20060101
A61K031/506; C07D 401/12 20060101 C07D401/12; C07D 239/56 20060101
C07D239/56; C07D 413/12 20060101 C07D413/12; C07D 413/14 20060101
C07D413/14; C07D 405/14 20060101 C07D405/14; C07D 405/12 20060101
C07D405/12; C07D 403/14 20060101 C07D403/14; C07D 487/08 20060101
C07D487/08; A61K 31/505 20060101 A61K031/505; A61K 31/5377 20060101
A61K031/5377; A61K 31/541 20060101 A61K031/541; A61K 31/551
20060101 A61K031/551; A61P 11/06 20060101 A61P011/06; A61P 11/00
20060101 A61P011/00; A61P 1/00 20060101 A61P001/00; A61P 19/02
20060101 A61P019/02; A61P 17/06 20060101 A61P017/06; A61P 35/00
20060101 A61P035/00; A61P 19/10 20060101 A61P019/10; C07D 239/38
20060101 C07D239/38; C07D 403/12 20060101 C07D403/12 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 28, 2004 |
GB |
0419235.7 |
Feb 8, 2005 |
GB |
0502544.0 |
Claims
1. A compound of formula (1) ##STR00173## wherein R.sup.1 is a
group selected from C.sub.3-7carbocyclyl, C.sub.1-8alkyl,
C.sub.2-6alkenyl and C.sub.2-6alkynyl; wherein the group is
optionally substituted by 1, 2 or 3 substituents independently
selected from fluoro, nitrile, --OR.sup.4, --NR.sup.5R.sup.6,
--CONR.sup.5R.sup.6, --COOR.sup.7, --NR.sup.8COR.sup.9,
--SR.sup.10, --SO.sub.2R.sup.10, --SO.sub.2NR.sup.5R.sup.6,
--NR.sup.8SO.sub.2R.sup.9, phenyl or heteroaryl; wherein phenyl and
heteroaryl are optionally substituted by 1, 2 or 3 substituents
independently selected from halo, cyano, nitro, --OR.sup.4,
--NR.sup.5R.sup.6, --CONR.sup.5R.sup.6, --COOR.sup.7,
--NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.5R.sup.6, --NR.sup.8SO.sub.2R.sup.9,
C.sub.1-6alkyl and trifluoromethyl; X is --CH.sub.2--, a bond,
oxygen, sulphur, sulphoxide, or sulphone; R.sup.2 is
C.sub.3-7carbocyclyl, optionally substituted by 1, 2 or 3
substituents independently selected from: fluoro, --OR.sup.4,
--NR.sup.5R.sup.6--CONR.sup.5R.sup.6, --COOR.sup.7,
--NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.5R.sup.6, --NR.sup.8SO.sub.2R.sup.9; or R.sup.2 is
a 3-8 membered ring optionally containing 1, 2 or 3 atoms selected
from O, S, --NR.sup.8 and whereby the ring is optionally
substituted by 1, 2 or 3 substituents independently selected from
C.sub.1-3alkyl, fluoro, --OR.sup.4,
--NR.sup.5R.sup.6--CONR.sup.5R.sup.6, --COOR.sup.7,
--NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.5R.sup.6, --NR.sup.8SO.sub.2R.sup.9; or R.sup.2 is
phenyl or heteroaryl, each of which is optionally substituted by 1,
2 or 3 substituents independently selected from halo, cyano, nitro,
--OR.sup.4, --NR.sup.5R.sup.6, --CONR.sup.5R.sup.6,
--NR.sup.8COR.sup.9, --SO.sub.2NR.sup.5R.sup.6,
--NR.sup.8SO.sub.2R.sup.9, C.sub.1-6alkyl and trifluoromethyl; or
R.sup.2 is a group selected from C.sub.1-8alkyl, C.sub.2-6alkenyl
or C.sub.2-6alkynyl wherein the group is substituted by 1, 2 or 3
substituents independently selected from hydroxy, amino,
C.sub.1-6alkoxy, C.sub.1-6alkylamino, di(C.sub.1-6alkyl)amino,
N--(C.sub.1-6alkyl)-N-(phenyl)amino, N--C.sub.1-6alkylcarbamoyl,
N,N-di(C.sub.1-6alkyl)carbamoyl,
N--(C.sub.1-6alkyl)-N-(phenyl)carbamoyl, carboxy, phenoxycarbonyl,
--NR.sup.8COR.sup.9, --SO.sub.2R.sup.10, --SO.sub.2NR.sup.5R.sup.6,
--NR.sup.8SO.sub.2R.sup.9 and --CONR.sup.5R.sup.6; R.sup.3 is
trifluoromethyl or a group-NR.sup.5R.sup.6, or R.sup.3 is phenyl,
napthyl, monocyclic or bicyclic heteroaryl wherein a heteroring may
be partially or fully saturated and one or more ring carbon atoms
may form a carbonyl group, and wherein each phenyl or heteroaryl
group is optionally substituted by 1, 2 or 3 substituents
independently selected from halo, cyano, nitro, phenyl, heteroaryl,
--OR.sup.4, --NR.sup.5R.sup.6, --CONR.sup.5R.sup.6, --COR.sup.7-,
--COR.sup.20, --COOR.sup.7, --NR.sup.8COR.sup.9, --SR.sup.10,
--SO.sub.2R.sup.10, --SO.sub.2NR.sup.5R.sup.6,
--NR.sup.8SO.sub.2R.sup.9, trifluoromethyl or C.sub.1-6alkyl
[optionally further substituted by 1, 2 or 3 substituents
independently selected from halo, cyano, nitro, --OR.sup.20,
--COOR.sup.20, --COR.sup.20, --NR.sup.18R.sup.19,
--CONR.sup.18R.sup.19, --NR.sup.18COR.sup.19, --SO.sub.2R.sup.20,
--SO.sub.2NR.sup.18R.sup.19, NR.sup.18SO.sub.2R.sup.19, phenyl or
monocyclic or bicyclic heteroaryl, wherein a heteroring may be
partially or fully saturated; and wherein each phenyl or heteroaryl
group is optionally substituted by 1, 2 or 3 substituents
independently selected from halo, cyano, nitro, --OR.sup.20,
--NR.sup.5R.sup.6, --CONR.sup.5R.sup.6, --COR.sup.7, --COOR.sup.7,
--NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.5R.sup.6, --NR.sup.8SO.sub.2R.sup.9, heteroaryl,
C.sub.1-6alkyl (optionally further substituted by 1, 2 or 3
substituents independently selected from halo, cyano, nitro,
--OR.sup.20, --COOR.sup.20, --COR.sup.20, --NR.sup.18R.sup.19,
--CONR.sup.18R.sup.19, --NR.sup.18COR.sup.19, --SO.sub.2R.sup.20,
--SO.sub.2NR.sup.18R.sup.19, NR.sup.18R.sup.19, or R.sup.3 is a
group selected from C.sub.3-7carbocyclyl, C.sub.1-8alkyl,
C.sub.2-6alkenyl and C.sub.2-6alkynyl whereby the group is
optionally substituted by 1, 2 or 3 substituents independently
selected from halo, --OR.sup.4, --NR.sup.5R.sup.6,
--CONR.sup.5R.sup.6, --COR.sup.7, --COOR.sup.7,
--NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.5R.sup.6, --NR.sup.8SO.sub.2R.sup.9, phenyl or
monocyclic or bicyclic heteroaryl, wherein a heteroring may be
partially or fully saturated; and wherein each phenyl or monocyclic
or bicyclic heteroaryl group is optionally substituted by 1, 2 or 3
substituents independently selected from halo, cyano, nitro,
--OR.sup.4, --NR.sup.5R.sup.6, --CONR.sup.5R.sup.6, --COR.sup.7,
--COOR.sup.7, --NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.5R.sup.6, --NR.sup.8SO.sub.2R.sup.9,
C.sub.1-6alkyl, or trifluoromethyl; R.sup.4 is hydrogen or a group
selected from C.sub.1-6alkyl and phenyl, wherein the group is
optionally substituted by 1 or 2 substituents independently
selected from halo, phenyl, --OR.sup.11 and --NR.sup.12R.sup.13;
R.sup.5 and R.sup.6 are independently hydrogen or a group selected
from C.sub.1-6alkyl and phenyl and monocyclic or bicyclic
heteroaryl, wherein a heteroring may be partially or fully
saturated; wherein the group is optionally substituted by 1, 2 or 3
substituents independently selected from halo, phenyl, --OR.sup.14,
--NR.sup.15R.sup.16, --COOR.sup.14, --CONR.sup.15R.sup.16,
--NR.sup.15COR.sup.16, --SO.sub.2R.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.15R.sup.16 and NR.sup.15SO.sub.2R.sup.16; or
R.sup.5 and R.sup.6 together with the nitrogen atom to which they
are attached form a 4- to 7-membered saturated heterocyclic ring
system optionally containing a further heteroatom selected from
oxygen, --SO.sub.(n)-- (where n=0, 1 or 2) and nitrogen atoms, in
which the ring is optionally substituted by 1, 2 or 3 substituents
independently selected from phenyl, heteroaryl, --OR.sup.14,
--COR.sup.20, --COOR.sup.14, --NR.sup.15R.sup.16,
--CONR.sup.15R.sup.16, --NR.sup.15COR.sup.16, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.15R.sup.16, NR.sup.15SO.sub.2R.sup.16 or
C.sub.1-6alkyl (optionally further substituted by 1 or 2 or 3
substituents independently selected from halo, --NR.sup.15R.sup.16
and --OR.sup.17 or cyano, nitro, --OR.sup.20, --COOR.sup.20,
--COR.sup.20, --NR.sup.18R.sup.19, --CONR.sup.18R.sup.19,
--NR.sup.18COR.sup.19, --SO.sub.2R.sup.20,
--SO.sub.2NR.sup.18R.sup.19, NR.sup.18SO.sub.2R.sup.19 groups);
R.sup.10 is hydrogen or a group selected from C.sub.1-6alkyl or
phenyl, wherein the group is optionally substituted by 1, 2 or 3
substituents independently selected from halo, phenyl, --OR.sup.17
and --NR.sup.15R.sup.16; and each of R.sup.7, R.sup.8, R.sup.9,
R.sup.11, R.sup.12, R.sup.13, R.sup.14 R.sup.15, R.sup.16, R.sup.17
is independently hydrogen, C.sub.1-6alkyl or phenyl. R.sup.18,
R.sup.19, and R.sup.20 are hydrogen or a group selected from
C.sub.1-6alkyl or heteroaryl (wherein a heteroring may be partially
or fully saturated) or phenyl, wherein the group is optionally
substituted by 1, 2 or 3 substituents independently selected from
halo, nitro, --CN, --OR.sup.4, --NR.sup.8R.sup.9,
--CONR.sup.8R.sup.9, --COR.sup.7, --COOR.sup.7,
--NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.8R.sup.9, --NR.sup.8SO.sub.2R.sup.9,
C.sub.1-6alkyl or heteroaryl or a pharmaceutically acceptable salt,
solvate or in vivo hydrolysable ester thereof:
2. A compound, pharmaceutically acceptable salt, solvate or in vivo
hydrolysable ester thereof according to claim 1 wherein R.sup.1 is
C.sub.1-8alkyl substituted by phenyl which is optionally
substituted by 1, 2 or 3 substituents independently selected from
fluoro, chloro, bromo, methoxy, methyl and trifluoromethyl.
3. A compound, pharmaceutically acceptable salt, solvate or in vivo
hydrolysable ester thereof according to claim 1 wherein X is
selected from --CH.sub.2--, a bond, oxygen and sulphur.
4. A compound, or a pharmaceutically acceptable salt, solvate or in
vivo hydrolysable ester thereof according to claim 1 wherein
R.sup.2 is C.sub.1-8alkyl optionally substituted by 1, 2 or 3
substituents independently selected from C.sub.1-6alkoxy, hydroxy
and fluoro; or R.sup.2 is a 5-6 membered ring optionally containing
1, 2 or 3 heteroatoms selected from O, S, --NR.sup.8 and whereby
the ring is optionally substituted by --OR.sup.4.
5. A compound, pharmaceutically acceptable salt, solvate or in vivo
hydrolysable ester thereof according to claim 1 wherein R.sup.3 is
C.sub.3-7carbocyclyl, C.sub.1-8alkyl, --NR.sup.5R.sup.6, phenyl,
monocyclic or bicyclic heteroaryl wherein a heteroring may be
partially or fully saturated and one or more ring carbon atoms may
form a carbonyl group, and wherein each phenyl or heteroaryl group
is optionally substituted by 1, 2 or 3 substituents independently
selected from cyano, heteroaryl, --OR.sup.10, --NR.sup.5R.sup.6,
--CONR.sup.5R.sup.6, --COR.sup.7-, --COR.sup.20,
--NR.sup.8COR.sup.9, --SO.sub.2R.sup.10, --SO.sub.2NR.sup.5R.sup.6,
C.sub.1-6alkyl [optionally further substituted by 1, 2 or 3
substituents independently selected from --OR.sup.20, --COR.sup.20,
--NR.sup.18R.sup.19, --CONR.sup.18R.sup.19, phenyl or monocyclic or
bicyclic heteroaryl, wherein a heteroring may be partially or fully
saturated; and wherein each phenyl or heteroaryl group is
optionally substituted by 1, 2 or 3 substituents independently
selected from nitro, --OR.sup.20, --NR.sup.5R.sup.6,
--NR.sup.8COR.sup.9, heteroaryl, C.sub.1-6alkyl (optionally further
substituted by 1, 2 or 3 substituents independently selected from
cyano, --OR.sup.20.
6. A compound according to claim 1 selected from the group
consisting of: N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[2-hydr
oxy-1-(hydroxymethyl)ethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide
R,S)N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[3,4-dihydroxybutyl]pyrimid-
in-4-yl]azetidine-1-sulphonamide; and
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[3-hydroxy-2-(hydroxymethyl)pro-
pyl]pyrimidin-4-yl]azetidine-1-sulphonamide
N-(2-[(2,3-difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-
pyrimidin-4-yl)azetidine-1-sulfonamide; and
N-(2-[(2,3-difluorobenzyl)thio]-6-{[(1S,2S)-2-hydroxy-1-methylpropyl]oxy}-
pyrimidin-4-yl)azetidine-1-sulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(2S)-2,3-dihydroxypropyl]oxy]-
-4-pyrimidinyl]-1-azetidinesulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[2-hydr
oxy-1-(hydroxymethyl)-1-methylethoxy]-4-pyrimidinyl]-1-azetidinesulfonami-
de
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethox-
y]-4-pyrimidinyl]-2-thiazolesulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-4-pyridinesulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-1-piperazinesulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-1,6-dihydro-1-methyl-6-oxo-3-pyridinesulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-1-azetidinesulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-methanesulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-4-morpholinesulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-1-pyrrolidinesulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-cyclopropanesulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-1-methyl-1H-imidazole-4-sulfonamide
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]azetidine-
-1-sulfonamide
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]piperazin-
e-1-sulfonamide
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]-1-methyl-
-1H-imidazole-4-sulfonamide
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-{[(1R,2R)-2,3-dihydroxy-1-methy-
lpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-{[(1R,2R)-2,3-dihydroxy-1-methy-
lpropyl]oxy}-4-pyrimidinyl]-methanesulfonamide
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methy-
lpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methy-
lpropyl]oxy}-4-pyrimidinyl]-1-piperazinesulfonamide
5-(azetidin-1-ylcarbonyl)-N-{2-[(2,3-difluorobenzyl)thio]-6-[(1R)-2-hydro-
xy-1-methylethoxy]pyrimidin-4-yl}furan-2-sulfonamide or a
pharmaceutically acceptable salt, solvate or in vivo hydrolysable
ester thereof.
7. (canceled)
8. A method for the treatment of asthma, allergic rhinitis, COPD,
inflammatory bowel disease, osteoarthritis, osteoporosis,
rheumatoid arthritis, or psoriasis, which comprises administering
to a patient a therapeutically effective amount of a compound, or a
pharmaceutically acceptable salt, solvate or in vivo hydrolysable
ester thereof according to claim 1.
9. A method for the treatment of cancer, which comprises
administering to a patient a therapeutically effective amount of a
compound, or a pharmaceutically acceptable salt, solvate or in vivo
hydrolysable ester thereof according to claim 1.
10. A method for the treatment of human diseases or conditions in
which modulation of chemokine receptor activity is beneficial,
which comprises administering to a patient a therapeutically
effective amount of a compound, or a pharmaceutically acceptable
salt, solvate or in vivo hydrolysable ester thereof according to
claim 1.
11. (canceled)
12. (canceled)
13. A pharmaceutical composition comprising a compound, or a
pharmaceutically acceptable salt, solvate or in vivo hydrolysable
ester thereof according to claim 1 and a
pharmaceutically-acceptable diluent or carrier.
14. A process for the preparation of a compound according to claim
1 or a pharmaceutically acceptable salt, solvate or in vivo
hydrolysable ester thereof, which comprises the steps of: (a)
treating a compound of formula (2a): ##STR00174## wherein R.sup.1,
R.sup.2, R.sup.3 and X are as defined in formula (1) and L is a
leaving group with a sulfonamide of formula R.sup.3SO.sub.2NH.sub.2
where R.sup.3 is as defined in formula (1); and optionally
thereafter, one or more of steps (i), (ii), (iii), (iv), or (v) in
any order: i) removing any protecting groups; ii) converting the
compound of formula (1) into a further compound of formula (1) iii)
forming a salt iv) forming a prodrug v) forming an in vivo
hydrolysable ester; or (b) treating a compound of formula (2b):
##STR00175## wherein R.sup.1 and R.sup.3 are as defined in formula
(1), L is a leaving group, PG is a protecting group or hydrogen and
where X is oxygen or sulphur, with alcohols HOR.sup.2 or thiols
HSR.sup.2 respectively wherein R.sup.2 is as defined in formula (1)
in the presence of a suitable base and solvent, and optionally
thereafter, one or more of steps (i), (ii), (iii), (iv), or (v) in
any order: i) removing any protecting groups; ii) converting the
compound of formula (1) into a further compound of formula (1) iii)
forming a salt iv) forming a prodrug v) forming an in vivo
hydrolysable ester.
15. A compound of the formula (2a) ##STR00176## wherein R.sup.1,
R.sup.2 and X are as defined in formula (1) and L is a leaving
group, provided that when R.sup.1 is benzyl, X is oxygen, R.sup.2
is methyl then L is not chlorine or when R.sup.1 is benzyl, X is a
bond, R2 is propyl then L is not chlorine.
16. A combination therapy which comprises administering a compound
of claim 1, formula (1) or a pharmaceutically acceptable salt,
solvate or in vivo hydrolysable ester thereof, concurrently or
sequentially with other therapy and/or another pharmaceutical
agent.
17. A combination therapy as claimed in claim 16 for the treatment
of asthma, allergic rhinitis, COPD, inflammatory bowel disease,
irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid
arthritis, or psoriasis.
18. A combination therapy as claimed in claim 16 for the treatment
of cancer.
19. A pharmaceutical composition which comprises a compound of
formula (1) or a pharmaceutically acceptable salt, solvate or in
vivo hydrolysable ester thereof as claimed in claim 1, in
conjunction with another pharmaceutical agent.
20. (canceled)
21. (canceled)
22. A combination therapy which comprises administering a
pharmaceutical composition or formulation comprising a compound of
formula (1), or a pharmaceutically acceptable salt, solvate or in
vivo hydrolysable ester thereof as claimed in claim 1, concurrently
or sequentially with other therapy and/or another pharmaceutical
agent.
Description
[0001] The present invention relates to certain heterocyclic
compounds, processes and intermediates used in their preparation,
pharmaceutical compositions containing them and their use in
therapy.
[0002] Chemokines play an important role in immune and inflammatory
responses in various diseases and disorders, including asthma and
allergic diseases, as well as autoimmune pathologies such as
rheumatoid arthritis and atherosclerosis. These small secreted
molecules are a growing superfamily of 8-14 kDa proteins
characterised by a conserved cysteine motif. At the present time,
the chemokine superfamily comprises three groups exhibiting
characteristic structural motifs, the C--X--C, C--C and
C--X.sub.3--C families. The C--X--C and C--C families have sequence
similarity and are distinguished from one another on the basis of a
single amino acid insertion between the NH-proximal pair of
cysteine residues. The C--X.sub.3--C family is distinguished from
the other two families on the basis of having a triple amino acid
insertion between the NH-proximal pair of cysteine residues.
[0003] The C--X--C chemokines include several potent
chemoattractants and activators of neutrophils such as
interleukin-8 (IL-8) and neutrophil-activating peptide 2
(NAP-2).
[0004] The C--C chemokines include potent chemoattractants of
monocytes and lymphocytes but not neutrophils. Examples include
human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3),
RANTES (Regulated on Activation, Normal T Expressed and Secreted),
eotaxin and the macrophage inflammatory proteins 1.alpha. and
1.beta. (MIP-1.alpha. and MIP-1.beta.).
[0005] The C--X.sub.3--C chemokine (also known as fractalkine) is a
potent chemoattractant and activator of microglia in the central
nervous system (CNS) as well as of monocytes, T cells, NK cells and
mast cells.
[0006] Studies have demonstrated that the actions of the chemokines
are mediated by subfamilies of G protein-coupled receptors, among
which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3,
CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and CCR11 (for the C--C
family); CXCR1, CXCR2, CXCR3, CXCR5 and CXCR5 (for the C--X--C
family) and CX.sub.3CR1 for the C--X.sub.3--C family. These
receptors represent good targets for drug development since agents
which modulate these receptors would be useful in the treatment of
disorders and diseases such as those mentioned above.
[0007] In our PCT patent application WO 2004/011443 we disclosed
amino-substituted pyrimidine sulfonamides for use as modulators of
chemokine receptors.
[0008] The present invention now provides a compound of formula
(1), or a pharmaceutically acceptable salt, solvate or in vivo
hydrolysable ester thereof:
##STR00002##
wherein R.sup.1 is a group selected from C.sub.3-7carbocyclyl,
C.sub.1-8alkyl, C.sub.2-6alkenyl and C.sub.2-6alkynyl; wherein the
group is optionally substituted by 1, 2 or 3 substituents
independently selected from fluoro, nitrile, --OR.sup.4,
--NR.sup.5R.sup.6, --CONR.sup.5R.sup.6, --COOR.sup.7,
--NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.5R.sup.6, --NR.sup.8SO.sub.2R.sup.9, phenyl or
heteroaryl; wherein phenyl and heteroaryl are optionally
substituted by 1, 2 or 3 substituents independently selected from
halo, cyano, nitro, --OR.sup.4, --NR.sup.5R.sup.6,
--CONR.sup.5R.sup.6, --COOR.sup.7, --NR.sup.8COR.sup.9,
--SR.sup.10, --SO.sub.2R.sup.10, --SO.sub.2NR.sup.5R.sup.6,
--NR.sup.8SO.sub.2R.sup.9, C.sub.1-6alkyl and trifluoromethyl; X is
--CH.sub.2--, a bond, oxygen, sulphur, sulphoxide, or sulphone;
R.sup.2 is C.sub.3-7carbocyclyl, optionally substituted by 1, 2 or
3 substituents independently selected from: fluoro, --OR.sup.4,
--NR.sup.5R.sup.6--CONR.sup.5R.sup.6, --COOR.sup.7,
--NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.5R.sup.6, --NR.sup.8SO.sub.2R.sup.9; or R.sup.2 is
a 3-8 membered ring optionally containing 1, 2 or 3 atoms selected
from O, S, --NR.sup.8 and whereby the ring is optionally
substituted by 1, 2 or 3 substituents independently selected from
C.sub.1-3alkyl, fluoro, --OR.sup.4,
--NR.sup.5R.sup.6--CONR.sup.5R.sup.6, --COOR.sup.7,
--NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.5R.sup.6, --NR.sup.8SO.sub.2R.sup.9; or R.sup.2 is
phenyl or heteroaryl, each of which is optionally substituted by 1,
2 or 3 substituents independently selected from halo, cyano, nitro,
--OR.sup.4, --NR.sup.5R.sup.6, --CONR.sup.5R.sup.6,
--NR.sup.8COR.sup.9, --SO.sub.2NR.sup.5R.sup.6,
--NR.sup.8SO.sub.2R.sup.9, C.sub.1-6alkyl and trifluoromethyl; or
R.sup.2 is a group selected from C.sub.1-8alkyl, C.sub.2-6alkenyl
or C.sub.2-6alkynyl wherein the group is substituted by 1, 2 or 3
substituents independently selected from hydroxy, amino,
C.sub.1-6alkoxy, C.sub.1-6alkylamino, di(C.sub.1-6alkyl)amino,
N--(C.sub.1-6alkyl)-N-(phenyl)amino, N--C.sub.1-6alkylcarbamoyl,
N,N-di(C.sub.1-6alkyl)carbamoyl,
N--(C.sub.1-6alkyl)-N-(phenyl)carbamoyl, carboxy, phenoxycarbonyl,
--NR.sup.8COR.sup.9, --SO.sub.2R.sup.10, --SO.sub.2NR.sup.5R.sup.6,
--NR.sup.8SO.sub.2R.sup.9 and --CONR.sup.5R.sup.6; R.sup.3 is
trifluoromethyl or a group-NR.sup.5R.sup.6, or R.sup.3 is phenyl,
napthyl, monocyclic or bicyclic heteroaryl wherein a heteroring may
be partially or fully saturated and one or more ring carbon atoms
may form a carbonyl group, and wherein each phenyl or heteroaryl
group is optionally substituted by 1, 2 or 3 substituents
independently selected from halo, cyano, nitro, phenyl, heteroaryl,
--OR.sup.4, --NR.sup.5R.sup.6, --CONR.sup.5R.sup.6, --COR.sup.7-,
--COR.sup.20, --COOR.sup.7, --NR.sup.8COR.sup.9, --SR.sup.10,
--SO.sub.2R.sup.10, --SO.sub.2NR.sup.5R.sup.6,
--NR.sup.8SO.sub.2R.sup.9, trifluoromethyl or C.sub.1-6alkyl
[optionally further substituted by 1, 2 or 3 substituents
independently selected from halo, cyano, nitro, --OR.sup.20,
--COOR.sup.20, --COR.sup.20, --NR.sup.18R.sup.19,
--CONR.sup.18R.sup.19, --NR.sup.18COR.sup.19, --SO.sub.2R.sup.20,
--SO.sub.2NR.sup.18R.sup.19, NR.sup.18SO.sub.2R.sup.19, phenyl or
monocyclic or bicyclic heteroaryl, wherein a heteroring may be
partially or fully saturated; and wherein each phenyl or heteroaryl
group is optionally substituted by 1, 2 or 3 substituents
independently selected from halo, cyano, nitro, --OR.sup.20,
--NR.sup.5R.sup.6, --CONR.sup.5R.sup.6, --COR.sup.7, --COOR.sup.7,
--NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.5R.sup.6, --NR.sup.8SO.sub.2R.sup.9, heteroaryl,
C.sub.1-6allyl (optionally further substituted by 1, 2 or 3
substituents independently selected from halo, cyano, nitro,
--OR.sup.20, --COOR.sup.20, --COR.sup.20, --NR.sup.18R.sup.19,
--CONR.sup.18R.sup.19, --NR.sup.18COR.sup.19, --SO.sub.2R.sup.20,
--SO.sub.2NR.sup.18R.sup.19, NR.sup.18SO.sub.2R.sup.19. or R.sup.3
is a group selected from C.sub.3-7carbocyclyl, C.sub.1-8alkyl,
C.sub.2-6alkenyl and C.sub.2-6alkynyl whereby the group is
optionally substituted by 1, 2 or 3 substituents independently
selected from halo, --OR.sup.4, --NR.sup.5R.sup.6,
--CONR.sup.5R.sup.6, --COR.sup.7, --COOR.sup.7,
--NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.5R.sup.6, --NR.sup.8SO.sub.2R.sup.9, phenyl or
monocyclic or bicyclic heteroaryl, wherein a heteroring may be
partially or fully saturated; and wherein each phenyl or monocyclic
or bicyclic heteroaryl group is optionally substituted by 1, 2 or 3
substituents independently selected from halo, cyano, nitro,
--OR.sup.4, --NR.sup.5R.sup.6, --CONR.sup.5R.sup.6, --COR.sup.7,
--COOR.sup.7, --NR.sup.8COR.sup.9, --SR.sup.10, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.5R.sup.6, --NR.sup.8SO.sub.2R.sup.9,
C.sub.1-6alkyl, or trifluoromethyl; R.sup.4 is hydrogen or a group
selected from C.sub.1-6alkyl and phenyl, wherein the group is
optionally substituted by 1 or 2 substituents independently
selected from halo, phenyl, --OR.sup.11 and --NR.sup.12R.sup.13;
R.sup.5 and R.sup.6 are independently hydrogen or a group selected
from C.sub.1-6alkyl and phenyl and monocyclic or bicyclic
heteroaryl, wherein a heteroring may be partially or fully
saturated; wherein the group is optionally substituted by 1, 2 or 3
substituents independently selected from halo, phenyl, --OR.sup.14,
--NR.sup.15R.sup.16, --COOR.sup.14, --CONR.sup.15R.sup.16,
--NR.sup.15COR.sup.16, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.15R.sup.16 and NR.sup.15SO.sub.2R.sup.16; or
R.sup.5 and R.sup.6 together with the nitrogen atom to which they
are attached form a 4- to 7-membered saturated heterocyclic ring
system optionally containing a further heteroatom selected from
oxygen, --SO.sub.(n)-- (where n=0, 1 or 2) and nitrogen atoms, in
which the ring is optionally substituted by 1, 2 or 3 substituents
independently selected from phenyl, heteroaryl, --OR.sup.14,
--COR.sup.20, --COOR.sup.14, --NR.sup.15R.sup.16,
--CONR.sup.15R.sup.16, --NR.sup.15COR.sup.16, --SO.sub.2R.sup.10,
--SO.sub.2NR.sup.15R.sup.16, NR.sup.15SO.sub.2R.sup.16 or
C.sub.1-6alkyl (optionally further substituted by 1 or 2 or 3
substituents independently selected from halo, --NR.sup.15R.sup.16
and --OR.sup.17 or cyano, nitro, --OR.sup.20, --COOR.sup.20,
--COR.sup.20, --NR.sup.18R.sup.19, --CONR.sup.18R.sup.19,
--SO.sub.2R.sup.20, --SO.sub.2NR.sup.18R.sup.19, and
NR.sup.18SO.sub.2R.sup.19 groups). R.sup.10 is hydrogen or a group
selected from C.sub.1-6alkyl or phenyl, wherein the group is
optionally substituted by 1, 2 or 3 substituents independently
selected from halo, phenyl, --OR.sup.17 and --NR.sup.15R.sup.16;
and each of R.sup.7, R.sup.8, R.sup.9, R.sup.11, R.sup.12,
R.sup.13, R.sup.14, R.sup.15, R.sup.16, R.sup.17 is independently
hydrogen, C.sub.1-6alkyl or phenyl. R.sup.18, R.sup.19, and
R.sup.20 are hydrogen or a group selected from C.sub.1-6alkyl or
heteroaryl (wherein a heteroring may be partially or fully
saturated) or phenyl, wherein the group is optionally substituted
by 1, 2 or 3 substituents independently selected from halo, nitro,
--CN, --OR.sup.4, --NR.sup.8R.sup.9, --CONR.sup.8R.sup.9,
--COR.sup.7---COOR.sup.7, --NR.sup.8COR.sup.9, --SR.sup.10,
--SO.sub.2R.sup.10, --SO.sub.2NR.sup.8R.sup.9,
--NR.sup.8SO.sub.2R.sup.9, C.sub.1-6alkyl or heteroaryl.
[0009] Certain compounds of formula (1) are capable of existing in
stereoisomeric forms. It will be understood that the invention
encompasses all geometric and optical isomers of the compounds of
formula (1) and mixtures thereof including racemates.
[0010] The synthesis of optically active forms may be carried out
by standard techniques of organic chemistry well known in the art,
for example by synthesis from optically active starting materials
or by resolution of a racemic form. Similarly, the above-mentioned
activity may be evaluated using the standard laboratory techniques
referred to hereinafter.
[0011] Within the present invention it is to be understood that a
compound of formula (1) or a salt, solvate or in vivo hydrolysable
ester thereof may exhibit the phenomenon of tautomerism and that
the formulae drawings within this specification can represent only
one of the possible tautomeric forms. It is to be understood that
the invention encompasses any tautomeric form and mixtures thereof
and is not to be limited merely to any one tautomeric form utilised
within the formulae drawings. The formulae drawings within this
specification can represent only one of the possible tautomeric
forms and it is to be understood that the specification encompasses
all possible tautomeric forms of the compounds drawn not just those
forms which it has been possible to show graphically herein.
[0012] It is also to be understood that certain compounds of
formula (1) and salts thereof can exist in solvated as well as
unsolvated forms such as, for example, hydrated forms. It is to be
understood that the invention encompasses all such solvated
forms.
[0013] The present invention relates to the compounds of formula
(1) as hereinbefore defined as well as to the salts thereof. Salts
for use in pharmaceutical compositions will be pharmaceutically
acceptable salts, but other salts may be useful in the production
of the compounds of formula (1) and their pharmaceutically
acceptable salts. Pharmaceutically acceptable salts of the
invention may, for example, include acid addition salts of the
compounds of formula (1) as hereinbefore defined which are
sufficiently basic to form such salts. Such acid addition salts
include for example salts with inorganic or organic acids affording
pharmaceutically acceptable anions such as with hydrogen halides
(especially hydrochloric or hydrobromic acid of which hydrochloric
acid is particularly preferred) or with sulphuric or phosphoric
acid, or with trifluoroacetic, citric or maleic acid. Suitable
salts include hydrochlorides, hydrobromides, phosphates, sulphates,
hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates,
benzoates, citrates, maleates, fumarates, succinates, lactates,
tartrates, oxalates, methanesulphonates or p-toluenesulphonates.
Pharmaceutically acceptable salts of the invention may also include
basic addition salts of the compounds of formula (1) as
hereinbefore defined which are sufficiently acidic to form such
salts. Such salts may be formed with an inorganic or organic base
which affords a pharmaceutically acceptable cation. Such salts with
inorganic or organic bases include for example an alkali metal
salt, such as a lithium, sodium or potassium salt, an alkaline
earth metal salt such as a calcium or magnesium salt, an ammonium
salt or an organic amine salt, for example a salt with methylamine,
dimethylamine, trimethylamine, triethylamine, piperidine,
morpholine or tris-(2-hydroxyethyl)amine. Other basic addition
salts include aluminium, zinc, benzathine, chloroprocaine, choline,
diethanolamine, ethanolamine, ethyldiamine, meglumine, tromethamine
or procaine.
[0014] The present invention further relates to an in vivo
hydrolysable ester of a compound of formula (1). An in vivo
hydrolysable ester of a compound of formula (1) which contains
carboxy or hydroxy group is, for example a pharmaceutically
acceptable ester which is cleaved in the human or animal body to
produce the parent acid or alcohol. Such esters can be identified
by administering, for example, intravenously to a test animal, the
compound under test and subsequently examining the test animal's
body fluid.
[0015] Suitable pharmaceutically acceptable esters for carboxy
include C.sub.1-6alkoxymethyl esters for example methoxymethyl,
C.sub.1-6alkanoyloxymethyl esters for example pivaloyloxymethyl,
phthalidyl esters, C.sub.3-8cycloalkoxycarbonyloxyC.sub.1-6alkyl
esters for example 1-cyclohexycarbonyloxyethyl;
1,3-dioxolen-2-onylmethyl esters for example
5-methyl-1,3-dioxolen-2-onylmethyl; and
C.sub.1-6alkoxycarbonyloxyethyl esters, for example
1-methoxycarbonyloxyethyl and may be formed at any carboxy group in
the compounds of this invention.
[0016] Suitable pharmaceutically-acceptable esters for hydroxy
include inorganic esters such as phosphate esters (including
phosphoramidic cyclic esters) and .alpha.-acyloxyalkyl ethers and
related compounds which as a result of the in vivo hydrolysis of
the ester breakdown to give the parent hydroxy group/s. Examples of
.alpha.-acyloxyalkyl ethers include acetoxymethoxy and
2,2-dimethylpropionyloxymethoxy. A selection of in-vivo
hydrolysable ester forming groups for hydroxy include
C.sub.1-10alkanoyl, for example acetyl; benzoyl; phenylacetyl;
substituted benzoyl and phenylacetyl, C.sub.1-10alkoxycarbonyl (to
give alkyl carbonate esters), for example ethoxycarbonyl;
di-(C.sub.1-4)alkylcarbamoyl and
N-(di-(C.sub.1-4)alkylaminoethyl)-N--(C.sub.1-4)alkylcarbamoyl (to
give carbamates); di-(C.sub.1-4)alkylaminoacetyl and carboxyacetyl.
Examples of ring substituents on phenylacetyl and benzoyl include
aminomethyl, (C.sub.1-4)alkylaminomethyl and
di-((C.sub.1-4)alkyl)aminomethyl, and morpholino or piperazino
linked from a ring nitrogen atom via a methylene linking group to
the 3- or 4-position of the benzoyl ring. Other interesting in-vivo
hydrolysable esters include, for example,
R.sup.AC(O)O(C.sub.1-6)alkyl-CO--, wherein R.sup.A is for example,
benzyloxy-(C.sub.1-4)alkyl, or phenyl). Suitable substituents on a
phenyl group in such esters include, for example,
4-(C.sub.1-4)piperazino-(C.sub.1-4)alkyl,
piperazino-(C.sub.1-4)alkyl and morpholino-(C.sub.1-4)alkyl.
[0017] In this specification the term "alkyl" includes both
straight-chain and branched-chain alkyl groups. However references
to individual alkyl groups such as "propyl" are specific for the
straight chain version only and references to individual
branched-chain alkyl groups such as t-butyl are specific for the
branched chain version only. For example, "C.sub.1-3alkyl" includes
methyl, ethyl, propyl and isopropyl and examples of
"C.sub.1-6alkyl" include the examples of "C.sub.1-3alkyl" and
additionally t-butyl, pentyl, 2,3-dimethylpropyl, 3-methylbutyl and
hexyl. Examples of "C.sub.1-8alkyl" include the examples of
"C.sub.1-6alkyl" and additionally heptyl, 2,3-dimethylpentyl,
1-propylbutyl and octyl. An analogous convention applies to other
terms, for example "C.sub.2-6alkenyl" includes vinyl, allyl,
1-propenyl, 2-butenyl, 3-butenyl, 3-methylbut-1-enyl, 1-pentenyl
and 4-hexenyl and examples of "C.sub.2-6alkynyl" includes ethynyl,
1-propynyl, 3-butynyl, 2-pentynyl and 1-methylpent-2-ynyl.
[0018] "C.sub.3-7carbocyclyl" is a saturated, partially saturated
or unsaturated, monocyclic ring containing 3 to 7 carbon ring atoms
wherein a --CH.sub.2-- group can optionally be replaced by a
--C(O)--. Suitable examples of "carbocyclyl" are cyclopropyl,
cyclopentyl, cyclobutyl, cyclohexyl, cyclohexenyl,
4-oxocyclohex-1-yl and 3-oxocyclohept-5-en-1-yl.
[0019] The term "halo" refers to fluoro, chloro, bromo and
iodo.
[0020] Examples of "C.sub.1-6alkoxy" include methoxy, ethoxy,
propoxy, isopropoxy, butyloxy, pentyloxy, 1-ethylpropoxy and
hexyloxy. Examples of "C.sub.1-6alkylamino" include methylamino,
ethylamino, propylamino, butylamino and 2-methylpropylmino.
Examples of "di(C.sub.1-6alkyl)amino" include dimethylamino,
N-methyl-N-ethylamino, diethylamino, N-propyl-N-3-methylbutylamino.
Examples of "N--(C.sub.1-6alkyl)-N-(phenyl)amino" include
N-methyl-N-phenylamino, N-propyl-N-phenylamino and
N-(2-methylbutyl)-N-phenylamino. Examples of
"N--(C.sub.1-6alkyl)carbamoyl" are N-methylcarbamoyl,
N-ethylcarbamoyl and N-(2-ethylbutylcarbamoyl. Examples of
"N--(C.sub.1-6alkyl)-N-(phenyl)carbamoyl" include
N-methyl-N-phenylcarbamoyl, N-butyl-N-phenylcarbamoyl and
N-(3-methylpentyl)-N-(phenyl)carbamoyl. Examples of "N
N-di(C.sub.1-6alkyl)carbamoyl" include N,N-dimethylcarbamoyl,
N-methyl-N-ethylcarbamoyl and N-propyl-N-(2-methylbutyl)carbamoyl.
Examples of "C.sub.1-6alkylthio" include methylthio, ethylthio,
propylthio, butylthio and 2-methylbutylthio.
[0021] "Heteroaryl" is a monocyclic or bicyclic aryl ring,
containing 5 to 10 ring atoms of which 1, 2, 3 or 4 ring atoms are
chosen from nitrogen, sulphur or oxygen. Examples of heteroaryl
include pyrrolyl, furanyl, thienyl, thiazolyl, isothiazolyl,
oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl,
isoxadiazolyl, oxadiazolyl, isothiadiazolyl, thiadiazolyl, pyridyl,
pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, pyridinonyl,
pyrimidindionyl, benzfuranyl, benzthieno, indolyl, benzimidazolyl,
benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl,
benzisothiazolyl, benztriazolyl, quinolinyl, isoquinolinyl,
4H-chromen-4-onyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl,
and naphthiridinyl. Conveniently heteroaryl is selected from
imidazolyl, pyrazolyl, thiazolyl, isoxazolyl, furanyl, thienyl,
isoxazolyl, or indazolyl. Fully saturated heterocyclic rings
include examples such as oxetanyl, azetidinyl, pyrrolidinyl,
tetrahydrofuranyl, isoxazolidinyl, tetrahydropyranyl, piperidinyl,
piperazinyl, piperazinonyl, morpholinyl, thiomorpholinyl,
thiomorpholinyl-1-oxide, thiomorpholinyl-1,1-dioxide, oxazinanonyl,
quinuclidinyl, homopiperidinyl and homopiperazinyl,
9-methyl-3,9-diazabicyclo[4.2.1]nonanyl and
tetrahydropyridinyl.
[0022] Examples of "a 3-8 membered ring optionally containing 1, 2
or 3 atoms selected from O, S and NR.sup.8" include oxetanyl,
azetidinyl, benzodiazolyl, pyrrolidinyl, tetrahydrofuranyl,
isoxazolidinyl, tetrahydrothiophenyl, tetrahydropyranyl,
piperidinyl, piperazinyl, piperazinonyl, morpholinyl,
thiomorpholinyl, thiomorpholinyl-1-oxide,
thiomorpholinyl-1,1-dioxide, oxazinanonyl, quinuclidinyl,
homopiperidinyl and homopiperazinyl tetrahydrodioxanyl. Examples of
"a 4- to 7-membered saturated heterocyclic ring system" include
azetidinyl, pyrrolidinyl, isoxazolidinyl, piperidinyl, piperazinyl,
piperazinonyl, homopiperazinyl, thiomorpholinyl,
thiomorpholinyl-1-oxide, thiomorpholinyl-1,1-dioxide, oxazinanonyl,
quinuclidinyl and morpholinyl,
[0023] Where optional substituents are chosen from "1, 2 or 3"
groups it is to be understood that this definition includes all
substituents being chosen from one of the specified groups or the
substituents being chosen from two or more of the specified groups.
An analogous convention applies to substituents chosen from "1 or
2" groups.
[0024] Convenient values of R.sup.1, R.sup.2, R.sup.3, and X are as
follows:
R.sup.1 is C.sub.1-8allyl, wherein the group is substituted by
phenyl optionally substituted by 1, 2 or 3 substituents
independently selected from fluoro, chloro, bromo, methoxy, methyl
and trifluoromethyl. X is --CH.sub.2--, a bond, oxygen, sulphur,
sulphoxide, or sulphone; R.sup.2 is C.sub.1-8alkyl wherein the
group is optionally substituted by 1, 2 or 3 substituents
independently selected from C.sub.1-6alkoxy, hydroxy and fluoro; or
R.sup.2 is a 5-6 membered ring optionally containing 1, 2 or 3
heteroatoms selected from O, S, --NR.sup.8 and whereby the ring is
optionally substituted by --OR.sup.4. R.sup.3 is
C.sub.3-7carbocyclyl, C.sub.1-8allyl, --NR.sup.5R.sup.6, phenyl,
monocyclic or bicyclic heteroaryl wherein a heteroring may be
partially or fully saturated and one or more ring carbon atoms may
form a carbonyl group, and wherein each phenyl or heteroaryl group
is optionally substituted by 1, 2 or 3 substituents independently
selected from cyano, heteroaryl, --OR.sup.4, --NR.sup.5R.sup.6,
--CONR.sup.5R.sup.6, --COR.sup.7-, --COR.sup.20,
--NR.sup.8COR.sup.9, --SO.sub.2R.sup.10, --SO.sub.2NR.sup.5R.sup.6,
C.sub.1-6alkyl [optionally further substituted by 1, 2 or 3
substituents independently selected from --OR.sup.20, --COR.sup.20,
--NR.sup.18R.sup.19, --CONR.sup.18R.sup.19, phenyl or monocyclic or
bicyclic heteroaryl, wherein a heteroring may be partially or fully
saturated; and wherein each phenyl or heteroaryl group is
optionally substituted by 1, 2 or 3 substituents independently
selected from nitro, --OR.sup.20, --NR.sup.5R.sup.6,
--NR.sup.8COR.sup.9, heteroaryl, C.sub.1-6alkyl (optionally further
substituted by 1, 2 or 3 substituents independently selected from
cyano, --OR.sup.20).
[0025] Convenient values of R.sup.4-R.sup.17 are as follows:
R.sup.4 is hydrogen or C.sub.1-6alkyl; R.sup.5 and R.sup.6 are a
group selected from C.sub.1-6alkyl or R.sup.5 and R.sup.6 together
with the nitrogen atom to which they are attached form a 4- to
7-membered saturated heterocyclic ring optionally containing a
further heteroatom selected from oxygen and nitrogen atoms.
R.sup.7, R.sup.8, R.sup.9, R.sup.11, R.sup.12, R.sup.13, R.sup.14
R.sup.15, R.sup.16, R.sup.17 are independently hydrogen,
C.sub.1-6alkyl or phenyl.
[0026] Convenient values of R.sup.18-R.sup.20 are as follows:
R.sup.18, R.sup.19 and R.sup.20 are hydrogen, phenyl, heteroaryl,
or C.sub.1-6alkyl (optionally further substituted by
NR.sup.8R.sup.9).
[0027] Preferred values of R.sup.1, R.sup.2, R.sup.3, and X are as
follows:
R.sup.1 is C.sub.1-3alkyl (such as --CH.sub.2--,
--(CH.sub.2).sub.2--, --(CH.sub.2).sub.3--, --CH.sub.2(CH.sub.3)--
or --CH.sub.2(CH.sub.3)CH.sub.2--) wherein the group is substituted
by phenyl optionally substituted by 1, 2 or 3 substituents
independently selected from fluoro and chloro. Benzyl is
particularly preferred. X is --CH.sub.2--, a bond, oxygen, or
sulphur. Oxygen is particularly preferred. R.sup.2 is C.sub.1-8
alkyl, such as C.sub.1-4 alkyl, wherein the group is optionally
substituted by 1 or 2 substituents independently selected from
C.sub.1-3alkoxy (such as methoxy, ethoxy, cyclopropyloxy or
isopropyloxy), hydroxy and fluoro, hydroxy is particularly
preferred; or R.sup.2 is a 5-membered ring optionally containing a
heteroatom selected from 0 or --NR.sup.8 and whereby the ring is
optionally substituted by --OR.sup.4. R.sup.3 is C.sub.1-3allyl
(such as methyl, ethyl, isopropyl or cyclopropyl) or
--NR.sup.5R.sup.6 (such as azetidinyl, pyrrolidinyl, morpholinyl,
piperidinyl, piperazinyl) or phenyl or a monocyclic or bicyclic
heteroaryl group (such as 1-methylimidazolyl or
1,2-dimethylimidazolyl).
[0028] Preferred values of R.sup.4-R.sup.17 are as follows:
R.sup.4 is hydrogen, or C.sub.1-3alkyl (such as methyl, ethyl,
cyclopropyl or isopropyl) R.sup.5 and R.sup.6 are a group selected
from C.sub.1-2alkyl (such as methyl and ethyl) or R.sup.5 and
R.sup.6 together with the nitrogen atom to which they are attached
form a 4- to 6-membered saturated heterocyclic ring (such as
azetidinyl, pyrrolidinyl, piperidinyl) or optionally containing a
further heteroatom selected from oxygen (such as morpholinyl) or
nitrogen (such as piperazinyl). R.sup.7, R.sup.8, R.sup.9,
R.sup.11, R.sup.12, R.sup.13, R.sup.14 R.sup.15, R.sup.16, R.sup.17
are independently hydrogen, or C.sub.1-2alkyl (such as methyl or
ethyl).
[0029] Preferred values of R.sup.18-R.sup.20 are as follows:
R.sup.18, R.sup.19 and R.sup.20 are hydrogen or C.sub.1-6alkyl
(optionally further substituted by NR.sup.8R.sup.9).
[0030] Such values may be used where appropriate with any of the
definitions, claims or embodiments defined hereinbefore or
hereinafter.
[0031] Particular compounds of the invention include: [0032]
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[2-hydroxy-1-(hydroxymethyl)eth-
oxy]-4-pyrimidinyl]-1-azetidinesulfonamide [0033]
R,S)N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[3,4-dihydroxybutyl]pyrimid-
in-4-yl]azetidine-1-sulphonamide; and [0034]
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[3-hydroxy-2-(hydroxymethyl)pro-
pyl]pyrimidin-4-yl]azetidine-1-sulphonamide [0035]
N-(2-[(2,3-difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-
pyrimidin-4-yl)azetidine-1-sulfonamide; and [0036]
N-(2-[(2,3-difluorobenzyl)thio]-6-{[(1S,2S)-2-hydroxy-1-methylpropyl]oxy}-
pyrimidin-4-yl)azetidine-1-sulfonamide [0037]
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(2S)-2,3-dihydroxypropyl]oxy]-
-4-pyrimidinyl]-1-azetidinesulfonamide [0038]
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[2-hydroxy-1-(hydroxymethyl)-1--
methylethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide [0039]
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-2-thiazolesulfonamide [0040]
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-4-pyridine sulfonamide [0041]
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-1-piperazinesulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-1,6-dihydro-1-methyl-6-oxo-3-pyridinesulfonamide
[0042]
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-1-azetidine sulfonamide
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-methanesulfonamide [0043]
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-4-morpholine sulfonamide [0044]
N-[2-[[(2,3-difluoro
phenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-4-pyrimidinyl]-1-py-
rrolidinesulfonamide [0045]
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-cyclopropanesulfonamide [0046]
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]-
-4-pyrimidinyl]-1-methyl-1H-imidazole-4-sulfonamide [0047]
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]azetidine-
-1-sulfonamide [0048]
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]piperazin-
e-1-sulfonamide [0049]
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]-1-methyl-
-1H-imidazole-4-sulfonamide [0050]
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-{[(1R,2R)-2,3-dihydroxy-1-methy-
lpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide [0051]
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[[(1R,2R)-2,3-dihydroxy-1-methy-
lpropyl]oxy]-4-pyrimidinyl]-methanesulfonamide [0052]
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methy-
lpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide [0053]
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methy-
lpropyl]oxy}-4-pyrimidinyl]-1-piperazinesulfonamide [0054]
5-(azetidin-1-ylcarbonyl)-N-{2-[(2,3-difluorobenzyl)thio]-6-[(1R)-2-hydro-
xy-1-methylethoxy]pyrimidin-4-yl}furan-2-sulfonamide
[0055] Each of the above mentioned compounds and the
pharmaceutically acceptable salts, solvates or in vivo hydrolysable
esters thereof, taken individually is a particular aspect of the
invention.
[0056] The present invention further provides a process for the
preparation of compounds of formula (1) as defined above which
comprises:
(a) treating a compound of formula (2a):
##STR00003##
wherein R.sup.1, R.sup.2 and X are as defined in formula (1) and L
is a leaving group such as halogen with sulfonamides
(R.sup.3SO.sub.2NH.sub.2) where R.sup.3 is as defined in formula
(1). and optionally thereafter (i), (iv), or (v) in any order: i)
removing any protecting groups; ii) converting the compound of
formula (1) into a further compound of formula (1) iii) forming a
salt iv) forming a prodrug v) forming an in vivo hydrolysable
ester.
[0057] Reaction of compounds of formula (2a) wherein R.sup.1,
R.sup.2 and X are as defined in formula (1) with sulfonamides
(R.sup.3SO.sub.2NH.sub.2), where R.sup.3 is as defined in formula
(1), can be carried out in the presence of a suitable base, solvent
and catalyst heated thermally or by microwaves. Examples of
suitable bases include metal carbonates such as those from cesium,
potassium, lithium or sodium. Most preferably Cesium carbonate is
used. Suitable solvents include toluene and ethers such as anisole,
tetrahydrofuran, 1,4-dioxane, glyme and diglyme. Preferably
1,4-dioxane is used. The temperature of the reaction can be
performed between 10.degree. C. and 120.degree. C., preferably at
100.degree. C. Examples of suitable catalysts include a suitable
palladium(0) source such as palladium
tris(dibenzylideneacetone)dipalladium(0) (Pd.sub.2(dba).sub.3), or
tetrakistriphenylphosphinepalladium (Pd(Ph.sub.3).sub.4) (either in
0.01-0.5 mol equivalents) in the presence of a suitable ligand such
as (9,9-dimethyl-9H-xanthene-4,5-diyl)bis[diphenyl-phosphine
(Xantphos), or
2-dicyclohexyl-phosphino-2'-(N,N-dimethylamino)biphenyl or
2-dicyclohexyl-phosphino-2',4',6'-tri-isopropyl,1,1'-biphenyl
(XPHOS) (either in 0.01-0.5 mol equivalents). Preferably the
catalyst combination is tris(dibenzylideneacetone)dipalladium(0)
(Pd.sub.2(dba).sub.3) with
2-dicyclohexyl-phosphino-2',4',6'-tri-isopropyl,1,1'-biphenyl
(Xphos) in 0.01-0.5 mol equivalents in 1,4-dioxane at 100.degree.
C. with cesium carbonate as the base; [0058] or (b) treating a
compound of formula (2b):
[0058] ##STR00004## [0059] wherein R.sup.1 and R.sup.3 are as
defined in formula (1), L is a leaving group such as halogen, PG is
a convenient protecting group or hydrogen and where X is oxygen or
sulphur, with alcohols HOR.sup.2 or thiols HSR.sup.2 respectively
wherein R.sup.2 is as defined in formula (1) in the presence of a
suitable base and solvent,
[0060] and optionally thereafter (i), (ii), (iv), or (v) in any
order:
i) removing any protecting groups; ii) converting the compound of
formula (1) into a further compound of formula (1) iii) forming a
salt iv) forming a prodrug v) forming an in vivo hydrolysable
ester.
[0061] Examples of suitable bases include the alkali metal hydrides
such as Na or K, or metal alkoxides such as Li, Na or
K-tert-butoxide, alkali metal hexamethyldisilazides such as Li, Na
or K-hexamethyldisilazide, or metal carbonates such as Na, K, Cs.
Suitable solvents include N,N-dimethylamides,
1-methyl-2-pyrrolidinone, toluene and ethers such as anisole,
tetrahydrofuran, 1,4-dioxane, glyme and diglyme.
[0062] Also, compounds of formula (1) wherein Wand R.sup.3 are as
defined in formula (1), L is a leaving group such as halogen, PG is
a convenient protecting group or hydrogen and X is --CH.sub.2-- or
a bond, can be prepared from compounds of formula (2b) wherein
R.sup.2 is as defined in formula (1) by treatment with a suitably
protected alkene under "Heck coupling" type reaction conditions
(Synlett, 2003, no 8 pp 1133-1136) or with a suitably protected
boronic acid or ester under "Suzuki coupling" type reaction
conditions (JACS, 1999, no 121, pp 9550-9561, JACS 2001, no 123, pp
10099-10100) in the presence of a suitable palladium catalyst,
ligand, salt, base and solvent with thermal or microwave
heating.
[0063] For "Heck" type couplings, examples of suitable palladium
catalysts, salts, bases and solvents include
tris(dibenzylideneacetone)dipalladium(0) (Pd.sub.2(dba).sub.3), or
palladium di-acatate (Pd(OAc).sub.2); added salts include potassium
chloride, tetra-n-butylanamonium chloride; and bases include
tri-n-butylamine or di-isopropylethylamine; and solvents include
N,N-dimethylformamide or N-methyl-pyrrolidin-2-one.
[0064] For "Suzuki" type couplings, examples of suitable palladium
catalysts, ligands, salts, bases and solvents include palladium
di-acetate; with ligands tri-cyclohexylphosphine, or
2,2'bis-dicyclohexyl-phosphino-1,1'-biphenyl or
di-t-butyl-phosphino-1,1'-biphenyl or tri-t-butylphosphine; with
salts potassium phosphate (K.sub.3PO.sub.4) or potassium fluoride
in solvents tetrahydrofuran or 1,4-dioxane.
[0065] Compounds of formula (2a) wherein R.sup.1, and R.sup.2 are
as defined in formula (1), and X is oxygen or sulphur can be
prepared from compounds of formula (3) wherein R.sup.1 is as
defined in formula (1) and L is a leaving group such as halogen by
treatment with alcohols HOR.sup.2 or thiols HSR.sup.2 wherein
R.sup.2 is as defined in formula (1) in the presence of a suitable
base and solvent.
##STR00005##
[0066] Examples of suitable bases include the alkali metal hydrides
such as Na or K, or metal alkoxides such as Li, Na or
K-tert-butoxide, alkali metal hexamethyldisilazides such as Li, Na
or K-hexamethyldisilazide, or metal carbonates such as Na, K, Cs.
Suitable solvents include N,N-dimethylamides,
1-methyl-2-pyrrolidinone, ethers such as tetrahydrofuran,
1,4-dioxane, glyme and diglyme. Preferably sodium hydride in
tetrahydrofuran at ambient to reflux temperature is employed.
[0067] Also, compounds of formula (2a) wherein R.sup.1 and R.sup.2
are as defined in formula (1), and X is --CH.sub.2-- or a bond can
be prepared from compounds of formula (3) wherein R.sup.1 is as
defined in formula (1) and L is a leaving group such as halogen, by
treatment with a suitably protected alkene under "Heck coupling"
type reaction conditions (Synlett, 2003, no 8 pp 1133-1136) or with
a suitably protected boronic acid or ester under "Suzuki coupling"
type reaction conditions (JACS, 1999, no 121, pp 9550-9561, JACS
2001, no 123, pp 10099-10100) in the presence of a suitable
palladium catalyst, ligand, salt, base and solvent with thermal or
microwave heating.
[0068] For "Heck" type couplings, examples of suitable palladium
catalysts, salts, bases and solvents include
tris(dibenzylideneacetone)dipalladium(0) (Pd.sub.2(dba).sub.3), or
palladium di-acatate (Pd(OAc).sub.2); added salts include potassium
chloride, tetra-n-butylammonium chloride; and bases include
tri-n-butylamine or di-isopropylethylamine; and solvents include
N,N-dimethylformamide or N-methyl-pyrrolidin-2-one. Preferably
palladium di-acetate, with salt tetra-n-butylammonium chloride,
with base tri-n-butylamine in solvent NN-dimethylformamide at
95.degree. C. is employed.
[0069] For "Suzuki" type couplings, Examples of suitable palladium
catalysts, ligands, salts, bases and solvents include palladium
di-acetate; with ligands tri-cyclohexylphosphine, or
2,2'bis-dicyclohexyl-phosphino-1,1'-biphenyl or
di-t-butyl-phosphino-1,1'-biphenyl or tri-t-butylphosphine; with
salts potassium phosphate (K.sub.3PO.sub.4) or potassium fluoride
in solvents tetrahydrofuran or 1,4-dioxane. Preferably palladium
di-acetate with ligand 2,2'bis-dicyclohexyl-phosphino-1,1'-biphenyl
with salt potassium phosphate (K.sub.3PO.sub.4) in solvent
tetrahydrofuran at reflux temperature is employed.
[0070] Compounds of formula (2b) wherein R.sup.1 and R.sup.3 are as
defined in formula (1), L is a leaving group such as halogen and PG
is a suitable protecting group or halogen may be prepared by
reaction of compounds of formula (3), wherein R.sup.1 is as defined
in formula (1) and L is a leaving group such as halogen with
sulfonamides (R.sup.3SO.sub.2NHPG) where R.sup.3 is as defined in
formula (1) and PG is a suitable protecting group or hydrogen, in
the presence of a suitable base, solvent and catalyst heated
thermally or by microwaves.
and optionally thereafter (i) or (ii) in any order: i) adding any
protecting groups; ii) converting the compound of formula (2b) into
a further compound of formula (2b)
[0071] Examples of suitable bases include the alkali metal hydrides
such as Na or K, or metal alkoxides such as Li, Na or
K-tert-butoxide, alkali metal hexamethyldisilazides such as Li, Na
or K-hexamethyldisilazide, or metal carbonates such as Na, K, Cs.
Suitable solvents include acetonitrile, tetrahydrofuran,
1,4-dioxane, glyme and diglyme. The temperature of the reaction can
be performed between 10.degree. C. and 120.degree. C. Examples of
suitable catalysts include a suitable palladium(0) source such as
tetrakistriphenylphosphinepalladium (Pd(Ph.sub.3).sub.4) or
tris(dibenzylideneacetone)dipalladium(0) (Pd.sub.2(dba).sub.3) in
the presence of a suitable ligand such as
(9,9-dimethyl-9H-xanthene-4,5-diyl)bis[diphenyl-phosphine
(Xantphos), or
2-dicyclohexyl-phosphino-2'-(N,N-dimethylamino)biphenyl or
2-dicyclohexyl-phosphino-2',4',6'-tri-isopropyl, 1,1'-biphenyl
(XPHOS).
[0072] Compounds of formula (3) wherein R.sup.1 is as defined in
formula (1) and L is halogen may be prepared from compounds of
formula (3) wherein R.sup.1 is as defined in formula (1) and L is
OH by reaction with a halogenating agent such as phosphorous
oxychloride. The reaction may be carried out in the presence of
N,N-dimethylaniline at reflux.
[0073] Compounds of formula (3) wherein R.sup.1 is as defined in
formula (1) and L is OH;
##STR00006##
may be prepared from compounds of formula (4) wherein L is OH by
reaction with alkylhalides (R.sup.1A) where R.sup.1 is as defined
in formula (1) and A is halogen in the presence of a suitable base
and solvent.
[0074] Examples of suitable bases include the alkali metal
hydroxides such as Li, Na, or K, or metal carbonates such as Li,
Na, K or Cs, or metal acetates such as Li, Na, K or Cs, or metal
alkoxides such as Li, Na, K tert-butoxide. Suitable solvents
include water, N,N-dimethylamides, 1-methyl-2-pyrrolidinone, ethers
such as tetrahydrofuran, 1,4-dioxane, glyme and diglyme and
alcohols such as methanol, ethanol and tert-butanol or
acetonitrile. Preferably sodium acetate in acetonitrile and water
at 40.degree. C. temperature is used.
[0075] Compounds of formulae (4) are either commercially available,
are well known in the literature or may be easily prepared using
known techniques.
[0076] In each of the process variants outlined above for
preparation of compounds of the formula 1 or a pharmaceutically
acceptable salt, solvate, or in vivo hydrolysable ester thereof,
each of the stated convenient or suitable materials or reaction
conditions represents an individual and distinct aspect of the
present invention.
[0077] It will be appreciated by those skilled in the art that in
the processes of the present invention certain functional groups
such as hydroxyl or amino groups in the starting reagents or
intermediate compounds may need to be protected by protecting
groups. Thus, the preparation of the compounds of formula (1) may
involve, at an appropriate stage, the removal of one or more
protecting groups. The protection and deprotection of functional
groups is fully described in `Protective Groups in Organic
Chemistry`, edited by J. W. F. McOmie, Plenum Press (1973), and
`Protective Groups in Organic Synthesis`, 2nd edition, T. W. Greene
& P. G. M. Wuts, Wiley-Interscience (1991).
[0078] Examples of convenient leaving groups are provided in
standard chemistry textbooks such as "Organic Chemistry" by
Jonathan Clayden et al, published by Oxford University Press
(3.sup.rd Edn 2005) They include halogen, mesylate and tosylate
groups. Halogen, such as chlorine is a preferred leaving group.
[0079] A compound of formula (1) may be prepared from another
compound of formula (1) and a compound of formula (2b) may be
prepared from a compound of formula (2b) by chemical modification.
Examples of chemical modifications include standard alkylation,
arylation, heteroarylation, acylation, sulphonylation,
phosphorylation, aromatic halogenation and coupling reactions.
These reactions may be used to add new substituents or to modify
existing substituents. Alternatively, existing substituents in
compounds of formula (1) and formula (2b) may be modified by, for
example, oxidation, reduction, elimination, hydrolysis or other
cleavage reactions to yield other compounds of formula (1) and
formula (2b) respectively.
[0080] Compounds of the formula (2a)
##STR00007##
wherein R.sup.1, R.sup.2 and X are as defined in formula (1) and L
is a leaving group such as halogen, provided that when R.sup.1 is
benzyl, X is oxygen, R2 is methyl then L is not chlorine or when
R.sup.1 is benzyl, X is a bond, R2 is propyl then L is not
chlorine, represent a further aspect of the invention.
[0081] The compounds of formula (1) above may be converted to a
pharmaceutically acceptable salt, solvate or in vivo hydrolysable
ester thereof, as discussed above. The salt is preferably a basic
addition salt.
[0082] The compounds of formula (1) have activity as
pharmaceuticals, in particular as modulators of chemokine receptor
(especially CXCR2) activity, and may be used in the treatment
(therapeutic or prophylactic) of conditions/diseases in human and
non-human animals which are exacerbated or caused by excessive or
unregulated production of chemokines. Examples of such
conditions/diseases include (each taken independently):
[0083] (1) the respiratory tract--obstructive airways diseases
including chronic obstructive pulmonary disease (COPD); asthma,
such as bronchial, allergic, intrinsic, extrinsic and dust asthma,
particularly chronic or inveterate asthma (e.g. late asthma and
airways hyper-responsiveness); bronchitis; acute, allergic,
atrophic rhinitis and chronic rhinitis including rhinitis caseosa,
hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca and
rhinitis medicamentosa; membranous rhinitis including croupous,
fibrinous and pseudomembranous rhinitis and scrofoulous rhinitis;
seasonal rhinitis including rhinitis nervosa (hay fever) and
vasomotor rhinitis; sarcoidosis, farmer's lung and related
diseases, fibroid lung and idiopathic interstitial pneumonia;
[0084] (2) bone and joints--rheumatoid arthritis, seronegative
spondyloarthropathies (including ankylosing spondylitis, psoriatic
arthritis and Reiter's disease), Behchet's disease, Sjogren's
syndrome and systemic sclerosis;
[0085] (3) skin--psoriasis, atopical dermatitis, contact dermatitis
and other eczmatous dermitides, seborrhoetic dermatitis, Lichen
planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa,
urticaria, angiodermas, vasculitides, erythemas, cutaneous
eosinophilias, uveitis, Alopecia areata and vernal
conjunctivitis;
[0086] (4) gastrointestinal tract--Coeliac disease, proctitis,
eosinopilic gastro-enteritis, mastocytosis, Crohn's disease,
ulcerative colitis, indeterminate colitis, microscopic colitis,
inflammatory bowel disease, irritable bowel syndrome,
non-inflammatory diarrhea, food-related allergies which have
effects remote from the gut, e.g., migraine, rhinitis and
eczema;
[0087] (5) central and peripheral nervous system--Neurodegenerative
diseases and dementia disorders, e.g. Alzheimer's disease,
amyotrophic lateral sclerosis and other motor neuron diseases,
Creutzfeldt-Jacob's disease and other prion diseases, HIV
encephalopathy (AIDS dementia complex), Huntington's disease,
frontotemporal dementia, Lewy body dementia and vascular dementia;
polyneuropathies, e.g. Guillain-Barre syndrome, chronic
inflammatory demyelinating polyradiculoneuropathy, multifocal motor
neuropathy, plexopathies; CNS demyelination, e.g. multiple
sclerosis, acute disseminated/haemorrhagic encephalomyelitis, and
subacute sclerosing panencephalitis; neuromuscular disorders, e.g.
myasthenia gravis and Lambert-Eaton syndrome; spinal disorders,
e.g. tropical spastic paraparesis, and stiff-man syndrome:
paraneoplastic syndromes, e.g. cerebellar degeneration and
encephalomyelitis; CNS trauma; migraine; and stroke.
[0088] (6) other tissues and systemic disease--atherosclerosis,
Acquired Immunodeficiency Syndrome (AIDS), lupus erythematosus,
systemic lupus, erythematosus, Hashimoto's thyroiditis, type I
diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE
syndrome, lepromatous leprosy, and idiopathic thrombocytopenia
pupura; post-operative adhesions, and sepsis.
[0089] (7) allograft rejection--acute and chronic following, for
example, transplantation of kidney, heart, liver, lung, bone
marrow, skin and cornea; and chronic graft versus host disease;
[0090] (8) cancers--especially non-small cell lung cancer (NSCLC),
malignant melanoma, prostate cancer and squamous sarcoma, and
tumour metastasis, non melanoma skin cancer and chemoprevention
metastases;
[0091] (9) diseases--in which angiogenesis is associated with
raised CXCR2 chemokine levels (e.g. NSCLC, diabetic
retinopathy);
[0092] (10) cystic fibrosis;
[0093] (11) burn wounds & chronic skin ulcers;
[0094] (12) reproductive diseases--for example disorders of
ovulation, menstruation and implantation, pre-term labour,
endometriosis;
[0095] (13) re-perfusion injury--in the heart, brain, peripheral
limbs and other organs, inhibition of atherosclerosis.
[0096] Thus, the present invention provides a compound of formula
(1), or a pharmaceutically-acceptable salt, solvate or an in vivo
hydrolysable ester thereof, as hereinbefore defined for use in
therapy.
[0097] Preferably the compounds of the invention are used to treat
diseases in which the chemokine receptor belongs to the CXC
chemokine receptor subfamily, more preferably the target chemokine
receptor is the CXCR2 receptor.
[0098] Particular conditions which can be treated with the
compounds of the invention are cancer, diseases in which
angiogenesis is associated with raised CXCR2 chemokine levels, and
inflammatory diseases such as asthma, allergic rhinitis, COPD,
rheumatoid arthritis, psoriasis, inflammatory bowel diseases,
osteoarthritis or osteoporosis.
[0099] As a further aspect of the present invention, the compounds
of formula (1) may have utility as antagonists of the CX3CR1
receptor. Such compounds are expected to be particularly useful in
the treatment of disorders within the central and peripheral
nervous system and other conditions characterized by an activation
of microglia and/or infiltration of leukocytes (e.g.
stroke/ischemia and head trauma). In particular, the compounds are
indicated for use in the treatment of neurodegenerative disorders
or demyelinating disease in mammals including man. More
particularly, the compounds are indicated for use in the treatment
of multiple sclerosis. The compounds are also indicated to be
useful in the treatment of pain, rheumatoid arthritis,
osteoarthritis, stroke, atherosclerosis and pulmonary arterial
hypertension.
[0100] The compounds of the invention may also be used to treat
diseases in which the chemokine receptor belongs to the CCR
chemokine receptor subfamily, more preferably the target chemokine
receptor is the CCR2b receptor.
[0101] In a further aspect, the present invention provides a
compound of formula (1), or a pharmaceutically acceptable salt,
solvate or in vivo hydrolysable ester thereof, as hereinbefore
defined for use as a medicament.
[0102] In a still further aspect, the present invention provides
the use of a compound of formula (1), or a pharmaceutically
acceptable salt, solvate or in vivo hydrolysable ester thereof, as
hereinbefore defined for use as a medicament for the treatment of
human diseases or conditions in which modulation of chemokine
receptor activity is beneficial.
[0103] In a still further aspect, the present invention provides
the use of a compound of formula (1), or a pharmaceutically
acceptable salt, solvate or in vivo hydrolysable ester thereof, as
hereinbefore defined for use as a medicament for the treatment of
asthma, allergic rhinitis, cancer, COPD, rheumatoid arthritis,
psoriasis, inflammatory bowel diseases, osteoarthritis or
osteoporosis.
[0104] In a further aspect, the present invention provides the use
of a compound of formula (1), or a pharmaceutically acceptable
salt, solvate or in vivo hydrolysable ester thereof, as
hereinbefore defined in the manufacture of a medicament for use in
therapy.
[0105] In a still further aspect, the present invention provides
the use of a compound of formula (1), or a pharmaceutically
acceptable salt, solvate or in vivo hydrolysable ester thereof, as
hereinbefore defined in the manufacture of a medicament for the
treatment of human diseases or conditions in which modulation of
chemokine receptor activity is beneficial.
[0106] In a still further aspect, the present invention provides
the use of a compound of formula (1), or a pharmaceutically
acceptable salt, solvate or in vivo hydrolysable ester thereof, as
hereinbefore defined in the manufacture of a medicament for the
treatment of asthma, allergic rhinitis, cancer, COPD, rheumatoid
arthritis, psoriasis, inflammatory bowel diseases, osteoarthritis
or osteoporosis.
[0107] In the context of the present specification, the term
"therapy" also includes "prophylaxis" unless there are specific
indications to the contrary. The terms "therapeutic" and
"therapeutically" should be construed accordingly.
[0108] The invention still further provides a method of treating a
chemokine mediated disease wherein the chemokine binds to a
chemokine (especially CXCR2) receptor, which comprises
administering to a patient a therapeutically effective amount of a
compound of formula, or a pharmaceutically acceptable salt, solvate
or in vivo hydrolysable ester, as hereinbefore defined.
[0109] The invention also provides a method of treating an
inflammatory disease, especially asthma, allergic rhinitis, COPD,
rheumatoid arthritis, psoriasis, inflammatory bowel diseases,
osteoarthritis or osteoporosis, in a patient suffering from, or at
risk of, said disease, which comprises administering to the patient
a therapeutically effective amount of a compound of formula (1), or
a pharmaceutically acceptable salt, solvate or in vivo hydrolysable
ester thereof, as hereinbefore defined.
[0110] For the above-mentioned therapeutic uses the dosage
administered will, of course, vary with the compound employed, the
mode of administration, the treatment desired and the disorder
indicated.
[0111] The compounds of formula (1) and pharmaceutically acceptable
salts, solvates or in vivo hydrolysable esters thereof may be used
on their own but will generally be administered in the form of a
pharmaceutical composition in which formula (1)
compound/salt/solvate/ester (active ingredient) is in association
with a pharmaceutically acceptable adjuvant, diluent or carrier.
Depending on the mode of administration, the pharmaceutical
composition will preferably comprise from 0.05 to 99% w (percent by
weight), more preferably from 0.05 to 80% w, still more preferably
from 0.10 to 70% w, and even more preferably from 0.10 to 50% w, of
active ingredient, all percentages by weight being based on total
composition.
[0112] The present invention also provides a pharmaceutical
composition comprising a compound of formula (1), or a
pharmaceutically acceptable salt, solvate or in vivo hydrolysable
ester thereof, as hereinbefore defined, in association with a
pharmaceutically acceptable adjuvant, diluent or carrier.
[0113] The invention further provides a process for the preparation
of a pharmaceutical composition of the invention which comprises
mixing a compound of formula (1), or a pharmaceutically acceptable
salt, solvate or in vivo hydrolysable ester thereof, as
hereinbefore defined, with a pharmaceutically acceptable adjuvant,
diluent or carrier. The pharmaceutical compositions may be
administered topically (e.g. to the lung and/or airways or to the
skin) in the form of solutions, suspensions, heptafluoroalkane
aerosols and dry powder formulations; or systemically, e.g. by oral
administration in the form of tablets, capsules, syrups, powders or
granules, or by parenteral administration in the form of solutions
or suspensions, or by subcutaneous administration or by rectal
administration in the form of suppositories or transdermally.
Preferably the compounds of the invention are administered
orally.
[0114] In addition to their use as therapeutic medicines, the
compounds of formula (1) and their pharmaceutically acceptable
salts, solvate or in vivo hydrolysable esters are also useful as
pharmacological tools in the development and standardisation of in
vitro and in vivo test systems for the evaluation of the effect of
chemokine modulation activity in laboratory animals such as cats,
dogs, rabbits, monkeys, rats and mice, as part of the search for
new therapeutic agents.
[0115] The invention further relates to combination therapies
wherein a compound of formula (1) or a pharmaceutically acceptable
salts, solvate or in vivo hydrolysable ester thereof, or a
pharmaceutical composition or formulation comprising a compound of
formula (1) is administered concurrently or sequentially with
therapy and/or an agent for the treatment of any one of asthma,
allergic rhinitis, cancer, COPD, rheumatoid arthritis, psoriasis,
inflammatory bowel disease, irritable bowel syndrome,
osteoarthritis or osteoporosis.
[0116] In particular, for the treatment of the inflammatory
diseases rheumatoid arthritis, psoriasis, inflammatory bowel
disease, irritable bowel syndrome, COPD, asthma and allergic
rhinitis the compounds of the invention may be combined with agents
such as TNF-.alpha. inhibitors such as anti-TNF monoclonal
antibodies (such as Remicade, CDP-870 and D.sub2.E.sub7.) and TNF
receptor immunoglobulin molecules (such as Enbrel.reg.),
non-selective COX-1/COX-2 inhibitors (such as piroxicam,
diclofenac, propionic acids such as naproxen, flubiprofen,
fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic
acid, indomethacin, sulindac, apazone, pyrazolones such as
phenylbutazone, salicylates such as aspirin), COX-2 inhibitors
(such as meloxicam, celecoxib, rofecoxib, valdecoxib and
etoricoxib) low dose methotrexate, lefunomide; ciclesonide;
hydroxychloroquine, d-penicillamine, auranofin or parenteral or
oral gold. For inflammatory bowel disease and irritable bowel
disorder further convenient agents include sulphasalazine and
5-ASAs, topical and systemic steroids, immunomodulators and
immunosuppressants, antibiotics, probiotics and anti-integrins.
[0117] The present invention still further relates to the
combination of a compound of the invention together with a
leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor
or 5-lipoxygenase activating protein (FLAP) antagonist such as
zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175;
Abbott-85761; N-(5-substituted)-thiophene-2-alkylsulfonamides;
2,6-di-tert-butylphenol hydrazones; methoxytetrahydropyrans such as
Zeneca ZD-2138; the compound SB-210661; pyridinyl-substituted
2-cyanonaphthalene compounds such as L-739,010; 2-cyanoquinoline
compounds such as L-746,530; indole and quinoline compounds such as
MK-591, MK-886, and BAY.times.1005.
[0118] The present invention still further relates to the
combination of a compound of the invention together with a receptor
antagonist for leukotrienes LTB.sub4., LTC.sub4., LTD.sub4., and
LTE.sub4. selected from the group consisting of the
phenothiazin-3-ones such as L-651,392; amidino compounds such as
CGS-25019c; benzoxalamines such as ontazolast;
benzenecarboximidamides such as MIL 284/260; and compounds such as
zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679),
RG-12525, Ro-245913, iralukast (CGP 45715A), and
BAY.times.7195.
[0119] The present invention still further relates to the
combination of a compound of the invention together with a PDE4
inhibitor including inhibitors of the isoform PDE4D.
[0120] The present invention still further relates to the
combination of a compound of the invention together with a
antihistaminic H.sub1. receptor antagonists such as cetirizine,
loratadine, desloratadine, fexofenadine, astemizole, azelastine,
and chlorpheniramine.
[0121] The present invention still further relates to the
combination of a compound of the invention together with a
gastroprotective H.sub2. receptor antagonist.
[0122] The present invention still further relates to the
combination of a compound of the invention together with an
a.sub1.- and cc.sub2.-adrenoceptor agonist vasoconstrictor
sympathomimetic agent, such as propylhexedrine, phenylephrine,
phenylpropanolamine, pseudoephedrine, naphazoline hydrochloride,
oxymetazoline hydrochloride, tetrahydrozoline hydrochloride,
xylometazoline hydrochloride, and ethylnorepinephrine
hydrochloride.
[0123] The present invention still further relates to the
combination of a compound of the invention together with
anticholinergic agents such as ipratropium bromide; tiotropium
bromide; oxitropium bromide; pirenzepine; and telenzepine.
[0124] The present invention still further relates to the
combination of a compound of the invention together with a
.beta..sub1.- to .beta..sub4.-adrenoceptor agonists such as
metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol,
formoterol, salmeterol, terbutaline, orciprenaline, bitolterol
mesylate, and pirbuterol; or methylxanthanines including
theophylline and aminophylline; sodium cromoglycate; or muscarinic
receptor (M1, M2, and M3) antagonist.
[0125] The present invention still further relates to the
combination of a compound of the invention together with an
insulin-like growth factor type I (IGF-1) mimetic.
[0126] The present invention still further relates to the
combination of a compound of the invention together with an inhaled
glucocorticoid with reduced systemic side effects, such as
prednisone, prednisolone, flunisolide, triamcinolone acetonide,
beclomethasone dipropionate, budesonide, fluticasone propionate,
and mometasone furoate.
[0127] The present invention still further relates to the
combination of a compound of the invention together with an
inhibitor of matrix metalloproteases (MMPs), i.e., the
stromelysins, the collagenases, and the gelatinases, as well as
aggrecanase; especially collagenase-1 (MMP-1), collagenase-2
(MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3),
stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11) and MMP-12.
[0128] The present invention still further relates to the
combination of a compound of the invention together with other
modulators of chemokine receptor function such as CCR1, CCR2,
CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 and
CCR11 (for the C--C family); CXCR1, CXCR3, CXCR4 and CXCR5 (for the
C--X--C family) and CX.sub.3CR1 for the C--X.sub.3--C family.
[0129] The present invention still further relates to the
combination of a compound of the invention together with antiviral
agents such as Viracept, AZT, aciclovir and famciclovir, and
antisepsis compounds such as Valant.
[0130] The present invention still further relates to the
combination of a compound of the invention together with
cardiovascular agents such as calcium channel blockers, lipid
lowering agents such as statins, fibrates, beta-blockers, Ace
inhibitors, Angiotensin-2 receptor antagonists and platelet
aggregation inhibitors.
[0131] The present invention still further relates to the
combination of a compound of the invention together with CNS agents
such as antidepressants (such as sertraline), anti-Parkinsonian
drugs (such as deprenyl, L-dopa, Requip, Mirapex, MAOB inhibitors
such as selegine and rasagiline, comP inhibitors such as Tasmar,
A-2 inhibitors, dopamine reuptake inhibitors, NMDA antagonists,
Nicotine agonists, Dopamine agonists and inhibitors of neuronal
nitric oxide synthase), and anti-Alzheimer's drugs such as
donepezil, tacrine, COX-2 inhibitors, propentofylline or
metrifonate.
[0132] The present invention still further relates to the
combination of a compound of the invention together with (i)
tryptase inhibitors; (ii) platelet activating factor (PAF)
antagonists; (iii) interleukin converting enzyme (ICE) inhibitors;
(iv) IMPDH inhibitors; (v) adhesion molecule inhibitors including
VLA-4 antagonists; (vi) cathepsins; (vii) MAP kinase inhibitors;
(viii) glucose-6 phosphate dehydrogenase inhibitors; (ix)
kinin-B.sub1.- and B.sub2.-receptor antagonists; (x) anti-gout
agents, e.g., colchicine; (xi) xanthine oxidase inhibitors, e.g.,
allopurinol; (xii) uricosuric agents, e.g., probenecid,
sulfinpyrazone, and benzbromarone; (xiii) growth hormone
secretagogues; (xiv) transforming growth factor (TGF.beta.); (xv)
platelet-derived growth factor (PDGF); (xvi) fibroblast growth
factor, e.g., basic fibroblast growth factor (bFGF); (xvii)
granulocyte macrophage colony stimulating factor (GM-CSF); (xviii)
capsaicin cream; (xix) Tachykinin NK.sub1. and NK.sub3. receptor
antagonists selected from the group consisting of NKP-608C;
SB-233412 (talnetant); and D-4418; (xx) elastase inhibitors
selected from the group consisting of UT-77 and ZD-0892; (xxi)
TNF.quadrature. converting enzyme inhibitors (TACE); (xxii) induced
nitric oxide synthase inhibitors (iNOS) or (xxiii) chemoattractant
receptor-homologous molecule expressed on TH2 cells, (CRTH2
antagonists).
[0133] The compounds of the present invention may also be used in
combination with osteoporosis agents such as roloxifene,
droloxifene, lasofoxifene or fosomax and immunosuppressant agents
such as FK-506, rapamycin, cyclosporine, azathioprine, and
methotrexate.
[0134] The compounds of the invention may also be used in
combination with existing therapeutic agents for the treatment of
osteoarthritis. Suitable agents to be used in combination include
standard non-steroidal anti-inflammatory agents (hereinafter
NSAID's) such as piroxicam, diclofenac, propionic acids such as
naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen,
fenamates such as mefenamic acid, indomethacin, sulindac, apazone,
pyrazolones such as phenylbutazone, salicylates such as aspirin,
COX-2 inhibitors such as celecoxib, valdecoxib, rofecoxib and
etoricoxib, analgesics and intraarticular therapies such as cortico
steroids and hyaluronic acids such as hyalgan and synvisc and P2X7
receptor antagonists.
[0135] The compounds of the invention can also be used in
combination with existing therapeutic agents for the treatment of
cancer. Suitable agents to be used in combination include:
(i) antiproliferative/antineoplastic drugs and combinations
thereof, as used in medical oncology, such as alkylating agents
(for example cis-platin, carboplatin, cyclophosphamide, nitrogen
mustard, melphalan, chlorambucil, busulphan and nitrosoureas);
antimetabolites (for example antifolates such as fluoropyrimidines
like 5-fluorouracil and tegafur, raltitrexed, methotrexate,
cytosine arabinoside, hydroxyurea, gemcitabine and paclitaxel
(Taxol.RTM.); antitumour antibiotics (for example anthracyclines
like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin,
idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic
agents (for example vinca alkaloids like vincristine, vinblastine,
vindesine and vinorelbine and taxoids like taxol and taxotere); and
topoisomerase inhibitors (for example epipodophyllotoxins like
etoposide and teniposide, amsacrine, topotecan and camptothecin);
(ii) cytostatic agents such as antioestrogens (for example
tamoxifen, toremifene, raloxifene, droloxifene and iodoxyfene),
oestrogen receptor down regulators (for example fulvestrant),
antiandrogens (for example bicalutamide, flutamide, nilutamide and
cyproterone acetate), LHRH antagonists or LHRH agonists (for
example goserelin, leuprorelin and buserelin), progestogens (for
example megestrol acetate), aromatase inhibitors (for example as
anastrozole, letrozole, vorazole and exemestane) and inhibitors of
5.alpha.-reductase such as finasteride; (iii) Agents which inhibit
cancer cell invasion (for example metalloproteinase inhibitors like
marimastat and inhibitors of urokinase plasminogen activator
receptor function); (iv) inhibitors of growth factor function, for
example such inhibitors include growth factor antibodies, growth
factor receptor antibodies (for example the anti-erbb2 antibody
trastuzumab [Herceptin.TM.] and the anti-erbb1 antibody cetuximab
[C225]), farnesyl transferase inhibitors, tyrosine kinase
inhibitors and serine/threonine kinase inhibitors, for example
inhibitors of the epidermal growth factor family (for example EGFR
family tyrosine kinase inhibitors such as
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-
-amine (gefitinib, AZD1839),
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
(erlotinib, OSI-774) and
6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazoli-
n-4-amine (CI 1033)), for example inhibitors of the
platelet-derived growth factor family and for example inhibitors of
the hepatocyte growth factor family; (v) antiangiogenic agents such
as those which inhibit the effects of vascular endothelial growth
factor, (for example the anti-vascular endothelial cell growth
factor antibody bevacizumab [Avastin.TM.], compounds such as those
disclosed in International Patent Applications WO 97/22596, WO
97/30035, WO 97/32856 and WO 98/13354) and compounds that work by
other mechanisms (for example linomide, inhibitors of integrin
.alpha.v.beta.3 function and angiostatin); (vi) vascular damaging
agents such as Combretastatin A4 and compounds disclosed in
International Patent Applications WO 99/02166, WO00/40529, WO
00/41669, WO01/92224, WO02/04434 and WO02/08213; (vii) antisense
therapies, for example those which are directed to the targets
listed above, such as ISIS 2503, an anti-ras antisense; (viii) gene
therapy approaches, including for example approaches to replace
aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2,
GDEPT (gene-directed enzyme pro-drug therapy) approaches such as
those using cytosine deaminase, thymidine kinase or a bacterial
nitroreductase enzyme and approaches to increase patient tolerance
to chemotherapy or radiotherapy such as multi-drug resistance gene
therapy; and (ix) immunotherapy approaches, including for example
ex-vivo and in-vivo approaches to increase the immunogenicity of
patient tumour cells, such as transfection with cytokines such as
interleukin 2, interleukin 4 or granulocyte-macrophage colony
stimulating factor, approaches to decrease T-cell anergy,
approaches using transfected immune cells such as
cytokine-transfected dendritic cells, approaches using
cytokine-transfected tumour cell lines and approaches using
anti-idiotypic antibodies.
Pharmacological Data
Ligand Binding Assay
[0136] [.sup.125I]IL-8 (human, recombinant) was purchased from
Amersham, U.K. with a specific activity of 2,000Ci/mmol. All other
chemicals were of analytical grade. High levels of hrCXCR2 were
expressed in HEK 293 cells (human embryo kidney 293 cells ECACC No.
85120602) (Lee et al. (1992) J. Biol. Chem. 267, pp 16283-16291).
hrCXCR2 cDNA was amplified and cloned from human neutrophil mRNA.
The DNA was cloned into PCRScript (Stratagene) and clones were
identified using DNA. The coding sequence was sub-cloned into the
eukaryotic expression vector RcCMV (Invitrogen). Plasmid DNA was
prepared using Quiagen Megaprep 2500 and transfected into HEK 293
cells using Lipofectamine reagent (Gibco BRL). Cells of the highest
expressing clone were harvested in phosphate-buffered saline
containing 0.2% (w/v) ethylenediaminetetraacetic acid (EDTA) and
centrifuged (200 g, 5 min.). The cell pellet was resuspended in ice
cold homogenisation buffer [10 mM HEPES (pH 7.4), 1 mM
dithiothreitol, 1 mM EDTA and a panel of protease inhibitors (1 mM
phenyl methyl sulphonyl fluoride, 2 .mu.g/ml soybean trypsin
inhibitor, 3 mM benzamidine, 0.5 .mu.g/ml leupeptin and 100
.mu.g/ml bacitracin)] and the cells left to swell for 10 minutes.
The cell preparation was disrupted using a hand held glass
mortar/PTFE pestle homogeniser and cell membranes harvested by
centrifugation (45 minutes, 100,000 g, 4.degree. C.). The membrane
preparation was stored at -70.degree. C. in homogenisation buffer
supplemented with Tyrode's salt solution (137 mM NaCl, 2.7 mM KCl,
0.4 mM NaH.sub.2PO.sub.4), 0.1% (w/v) gelatin and 10% (v/v)
glycerol.
[0137] All assays were performed in a 96-well MultiScreen 0.45
.mu.m filtration plates (Millipore, U.K.). Each assay contained -50
pM [.sup.125]IL-8 and membranes (equivalent to -200,000 cells) in
assay buffer [Tyrode's salt solution supplemented with 10 mM HEPES
(pH 7.4), 1.8 mM CaCl.sub.2, 1 mM MgCl.sub.2, 0.125 mg/ml
bacitracin and 0.1% (w/v) gelatin]. In addition, a compound of
formula (1) according to the Examples was pre-dissolved in DMSO and
added to reach a final concentration of 1% (v/v) DMSO. The assay
was initiated with the addition of membranes and after 1.5 hours at
room temperature the membranes were harvested by filtration using a
Millipore MultiScreen vacuum manifold and washed twice with assay
buffer (without bacitracin). The backing plate was removed from the
MultiScreen plate assembly, the filters dried at room temperature,
punched out and then counted on a Cobra .gamma.-counter.
[0138] The compounds of formula (1) according to the Examples 1-156
were found to have piC.sub.50 values of greater than (>)
5.0.
Intracellular Calcium Mobilisation Assay
[0139] Human neutrophils were prepared from EDTA-treated peripheral
blood, as previously described (Baly et al. (1997) Methods in
Enzymology 287 pp 70-72), in storage buffer [Tyrode's salt solution
(137 mM NaCl, 2.7 mM KCl, 0.4 mM NaH.sub.2PO.sub.4) supplemented
with 5.7 mM glucose and 10 mM HEPES (pH 7.4)].
[0140] The chemokine GRO.alpha. (human, recombinant) was purchased
from R&D Systems (Abingdon, U.K.). All other chemicals were of
analytical grade. Changes in intracellular free calcium were
measured fluorometrically by loading neutrophils with the calcium
sensitive fluorescent dye, fluo-3, as described previously (Merritt
et al. (1990) Biochem. J. 269, pp 513-519). Cells were loaded for 1
hour at 37.degree. C. in loading buffer (storage buffer with 0.1%
(w/v) gelatin) containing 5 .mu.M fluo-3 AM ester, washed with
loading buffer and then resuspended in Tyrode's salt solution
supplemented with 5.7 mM glucose, 0.1% (w/v) bovine serum albumin
(BSA), 1.8 mM CaCl.sub.2 and 1 mM MgCl.sub.2. The cells were
pipetted into black walled, clear bottom, 96 well micro plates
(Costar, Boston, U.S.A.) and centrifuged (200 g, 5 minutes, room
temperature).
[0141] A compound of formula (1) according to the Examples was
pre-dissolved in DMSO and added to a final concentration of 0.1%
(v/v) DMSO. Assays were initiated by the addition of an A.sub.50
concentration of GRO.quadrature. and the transient increase in
fluo-3 fluorescence (.lamda..sub.Ex=490 nm and .lamda..sub.Em=520
nm) monitored using a FLIPR (Fluorometric Imaging Plate Reader,
Molecular Devices, Sunnyvale, U.S.A.).
[0142] The compounds of formula (1) according to the Examples were
tested and found to be antagonists of the CXCR2 receptor in human
neutrophils.
[0143] The invention will now be illustrated by the following
non-limiting Examples in which, unless stated otherwise: [0144] (i)
when given Nuclear Magnetic Resonance (NMR) spectra were measured
on a Varian Unity Inova 300 or 400 MHz spectrometer. .sup.1H NMR
data is quoted in the form of delta values for major diagnostic
protons, given in parts per million (ppm) relative to
tetramethylsilane (TMS) as an internal standard. [0145] (ii) Mass
Spectrometry (MS) spectra were measured on a Finnigan Mat SSQ7000
or Micromass Platform spectrometer. [0146] (iii) the title and
sub-titled compounds of the Examples and methods were named using
the ACD/Name program (version 4.55) from Advanced Chemical
Development Inc, Canada. [0147] (iv) Normal phase column
chromatography and normal phase HPLC was conducted using a silica
column. Reverse phase High Pressure Liquid Chromatography (HPLC)
purification was performed using either a Waters Micromass LCZ with
a Waters 600 pump controller, Waters 2487 detector and Gilson FC024
fraction collector or a Waters Delta Prep 4000 or a Gilson Auto
Purification System, using a Symmetry, NovaPak or Ex-Terra reverse
phase silica column. [0148] (v) The following abbreviations are
used: [0149] AcOH acetic acid [0150] CHCl.sub.3 chloroform [0151]
DCM dichloromethane [0152] DMF N,N-dimethylformamide [0153] DMSO
dimethylsulfoxide [0154] Et.sub.2O diethyl ether [0155] EtOAc ethyl
acetate [0156] MgSO.sub.4 magnesium sulfate [0157] NMP
1-methylpyrrolidin-2-one [0158] THF tetrahydrofuran [0159] H.sub.2O
water [0160] NH.sub.3 ammonia
EXAMPLE 1
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[2-hydroxy-1-(hydroxymethyl)etho-
xy]-4-pyrimidinyl]-1-azetidinesulfonamide
##STR00008##
[0162] To a suspension of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2-phenyl-1,3-dioxan-5-yl)oxy]-
-4-pyrimidinyl]-1-azetidinesulfonamide (the product of step iv)
(220 mg) in methanol (5 ml)/water (0.1 ml) was added pyridinium
p-toluenesulfonate (20 mg) and the mixture was stirred at ambient
temperature for 1.5 hour, then at reflux for 20 hour. The reaction
mixture was evaporated, suspended in water and extracted with ethyl
acetate (.times.2). The combined organic layers were dried with
magnesium sulfate, filtered and evaporated. The residue was
purified by column chromatography on silica gel using a 98:2
mixture of methylene chloride and methanol as eluent to give the
title compound as a white solid. Yield: 120 mg
[0163] MS: APCI (+ve) 463, [M+H.sup.+]
[0164] .sup.1H NMR: (DMSO) .delta. 2.13 (quintet, 2H), 3.57 (m,
4H), 3.89 (t, 4), 4.44 (s, 2H), 4.78 (t, 2H), 5.13 (quintet, 1H),
6.15 (s, 1H), 7.17 (dq, 1H), 7.36 (dq, 1H), 7.45 (dt, 1H), 11.11
(bs, 1H);
[0165] The intermediates for this compound were prepared as
follows:
i) 2-[(2,3-Difluorobenzyl)thio]pyrimidine-4,6-diol
[0166] To a slurry of 2-mercaptopyrimidine-4,6-diol (55.6 g) in
water (735 ml) was added sodium acetate (47.4 g) with stirring
forming a complete solution over 20 minutes. A solution of
2,3-difluorobenzyl bromide (80 g) in acetonitrile (73.5 ml) was
then added dropwise over 15 minutes and the resulting mixture
heated at 40.degree. C. with stirring for 18 h. After cooling to
ambient temperature the resulting precipitate was then filtered and
washed with H.sub.2O (1 L) before drying in vacuo at 100.degree. C.
to afford the subtitle compound as a cream solid.
[0167] Yield: 101.5 g.
[0168] .sup.1H NMR: .delta. (DMSO) 7.74 (1H, s), 7.39-7.32 (2H, m),
7.21-7.15 (1H, m), 4.48 (2H, s).
ii) 4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine
[0169] To a mixture of the subtitle product of step i) (101.5 g)
with benzyltriethylammonium chloride (8.6 g) in 1,2-dimethoxyethane
(550 ml) was added phosphorus oxychloride (70 ml) and the mixture
heated at 85.degree. C. for 5 h. The reaction was allowed to cool
and solvents and excess phosphorus oxychloride were removed in
vacuo before partitioning between ethyl acetate and ice water. The
layers were separated and the dried (MgSO.sub.4) organics
concentrated in vacuo to afford the crude product as a pale brown
oil which solidified on standing. The crude product was purified by
column chromatography (4% EtOAc/iso-hexane) to yield the subtitle
compound as a white solid. Yield: 90 g.
[0170] .sup.1H NMR: .delta. (DMSO) 7.74 (1H, s), 7.39-7.32 (2H, m),
7.21-7.15 (1H, m) 4.48 (2H, s)
iii)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2-phenyl-1,3-dioxan-
-5-yl)oxy]-pyrimidine
[0171] To a solution of 2-phenyl-1,3-dioxan-5-ol (484 mg) in
anhydrous tetrahydrofuran (10 ml) at 0.degree. C. was added 60%
sodium hydride (110 mg) and the mixture was heated to reflux for 25
minutes. On allowing to cool to ambient temperature
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
step (ii) (75 mg) was added and the reaction was heated to reflux
for a further 90 minutes. The reaction mixture was allowed to cool,
diluted with water and extracted with ethyl acetate (.times.3). The
combined organic layers were dried with magnesium sulfate, filtered
and evaporated. The residue was purified by column chromatography
on silica using a 95:5 to 90:10 mixture of iso-hexane and ethyl
acetate as eluent to give the sub-title compound as a white solid.
Yield: 350 mg
[0172] MS: APCI (+ve) 451 [M+H.sup.+]
iv)
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2-phenyl-1,3-dioxan-5-yl)o-
xy]-4-pyrimidinyl]-1-azetidinesulfonamide
[0173] A mixture of azetidine-1-sulphonamide (420 mg),
tris(dibenzylideneacetone)dipalladium (0) (71 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (37 mg), cesium carbonate (380 mg) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2-phenyl-1,3-dioxan-5-y-
l)oxy]-pyrimidine (350 mg) in anhydrous dioxane (8 ml) was heated
to reflux in a microwave at 100.degree. C., 300 W, open vessel with
cooling for 10 minutes. The reaction mixture was diluted with
methylene chloride, filtered through arbocel and the filtrate
evaporated. The residue was purified by column chromatography on
silica using a 80:20 to 70:30 mixture of iso-hexane and ethyl
acetate as eluent to give the sub-title compound as a white
solid.
[0174] Yield: 220 mg.
[0175] MS: APCI (+ve) 551 [M+H.sup.+]
EXAMPLE 2
(R,S)N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[3,4-dihydroxybutyl]pyrimid-
in-4-yl]azetidine-1-sulphonamide
##STR00009##
[0177] A solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[2-(2,2-dimethyl[1,3]dioxolan-4-
yl)-ethyl]-pyrimidin-4-yl]azetidine-1-sulphonamide (the product of
step (43 mg) and pyridinium para-toluenesulphonate (43 mg) in
methanol (1 ml) and one drop of water was heated at 60.degree. C.
for 1.5 h. The solution was cooled and the solvent evaporated under
reduced pressure. The residue was dissolved in dichloromethane and
washed with water, dried (MgSO.sub.4) and the solvent evaporated
under reduced pressure. The residual yellow solid was purified by
preparative plate chromatography eluting with ethyl acetate. The
isolated product was dissolved in dichloromethane and the solvent
evaporated at room temperature under reduced pressure to give the
title product as a white solid. Yield 20 mg.
[0178] MS: APCI (-ve) 459 [M-1]
[0179] .sup.1H NMR: .delta. (DMSO) 11.18 (s, 1H), 7.44 (t, 1H),
7.33 (q, 1H), 7.14 (m, 1H), 6.66 (s, 1H), 4.57 (d, 1H), 4.51 (t,
1H), 4.45 (s, 2H), 3.93 (t, 4H), 3.41 (m, 1H), 3.26 (m, 1H), 2.71
(m, 1H), 2.65 (m, 1H), 2.12 (p, 2H), 1.82 (m, 1H), 1.53 (m,
1H).
[0180] The intermediates for this compound were prepared as
follows:
i) (cis/trans)
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[2-(2,2-dimethyl[1,3]diox-
olan-4-yl)-vinyl]-pyrimidine
[0181] A mixture of
4,6-dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (product of
example 1 step ii) (0.5 g),
tris(dibenzylideneacetone)dipalladium(0) (45 mg),
2,2-dimethyl-4-vinyl-1,3-dioxolane (630 mg), tri-n-butylamine (610
mg) and tetra-n-butylammonium chloride (460 mg) in anhydrous
N,N-dimethylformamide (6.5 ml) were heated at 90.degree. C. for 3
h. then stirred at room temperature overnight. The reaction mixture
was partitioned between ethyl acetate and water. The organic phase
was washed with water and brine, dried (MgSO.sub.4) and the solvent
evaporated under reduced pressure. The residue was purified by
flash silica-gel chromatography eluting with 10% diethyl ether in
iso-hexane to give the sub-title compound as a yellow viscous oil.
Yield: 98 mg.
[0182] MS: APCI (+ve) 399 [M+1]
ii) (R,S)
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[2-(2,2-dimethyl-
[1,3]dioxolan-4-yl)ethyl]-pyrimidine
[0183] A solution of the product of step i) (96.8 mg) in ethanol
(10 ml) was hydrogenated over platinum oxide (5 mg) at 3
atmospheres over 2 days. Further platinum oxide (20 mg) was added
and the mixture was hydrogenated for further 3 days at 5
atmospheres. The catalyst was filtered (Celite) and the filtrate
evaporated under reduced pressure. The residue was purified by
flash silica-gel chromatography eluting with 10% diethyl ether in
iso-hexane to give the sub-title compound as a viscous oil. Yield:
33 mg.
[0184] MS: APCI (+ve) 401 [M+1]
iii)
(R,S)N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[2-(2,2-dimethyl[1,3]d-
ioxolan-4yl)-ethyl]-pyrimidin-4-yl]azetidine-1-sulphonamide
[0185] A solution of the product of step ii) (47 mg),
tris(dibenzylideneacetone)dipalladium(0) (6 mg),
azetidine-1-sulphonamide (62 mg),
2-dicyclohexyl-phosphino-2',4',6'-tri-isopropyl,1,1'-biphenyl
(XPHOS) (6 mg) and cesium carbonate (52 mg) in anhydrous dioxane (1
ml) was heated at 100.degree. C. for 45 min. The reaction mixture
was partitioned between ethyl acetate and water. Acetic acid (0.2
ml) was added and the separated organic phase was washed with water
and brine, dried (MgSO.sub.4) and the solvent evaporated under
reduced pressure. The residue was purified by flash silica-gel
chromatography eluting with 40% ethyl acetate in iso-hexane to give
the sub-title compound as a yellow viscous oil. Yield: 46 mg.
[0186] MS: APCI (+ve) 501 [M+1]
EXAMPLE 3
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[3-hydroxy-2-(hydroxymethyl)prop-
yl]pyrimidin-4-yl]azetidine-1-sulphonamide
##STR00010##
[0188] A solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2,2-dimethyl-1,3-dioxan-5-yl)-
methyl]-4-pyrimidinyl]azetidine-1-sulphonamide (the product of step
ii) (78 mg) and pyridinium para-toluenesulphonate (79 mg) in
methanol (1.8 ml) and one drop of water was heated at 60.degree. C.
for 15 min. The solution was cooled and the solvent evaporated
under reduced pressure. The residue was dissolved in
dichloromethane and washed with 2N hydrochloric acid and water,
dried (MgSO.sub.4) and the solvent evaporated under reduced
pressure to give a viscous yellow oil (17 mg). The aqueous washings
were combined, the pH adjusted to 5 with aqueous sodium bicarbonate
and then extracted with ethyl acetate. The organic solution was
dried (MgSO.sub.4) and the solvent evaporated under reduced
pressure. The residual viscous oil was dissolved in dichloromethane
and the solvent evaporated at room temperature under reduced
pressure to give the title product as a white solid. Yield 62
mg.
[0189] MS: APCI (-ve) 459 [M-1]
[0190] .sup.1H NMR: .delta. (DMSO) 11.17 (s, 1H), 7.44 (t, 1H),
7.33 (m, 1H), 7.14 (m, 1H), 6.65 (s, 1H), 4.45 (s, 4H), 3.92 (t,
4H), 3.38 (m, 4H), 2.57 (d, 2H), 2.12 (p, 2H), 1.98 (m, 1H)
[0191] The intermediates for this compound were prepared as
follows:
i)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2,2-dimethyl-1,3-diox-
an-5-yl)methyl]pyrimidine
[0192] A solution of 0.5M 9-borabicyclo[3.3.1]nonane (9-BBN) in
tetrahydrofuran (17.12 ml) and
2,2-dimethyl-5-methylene-1,3-dioxane. (Tet. Lett. (1988) 29 (45)
5703-5706) (1.3 g) was heated at 45.degree. C. for 18 h. The
solution was cooled and added to mixture of palladium(II) acetate,
potassium phosphate (1.16 g), (biphenyl-2-yl)dicyclohexyl-phosphine
(0.14 g) and 4,6-dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine
(1.5 g) stirred under nitrogen. The mixture was heated in a
microwave at 70.degree. C., 250 W for a total of 1.5 h, then
70.degree. C. on a hot-plate for 2 days. The reaction mixture was
adsorbed onto silica-gel, the solvent evaporated under reduced
pressure and the residue purified by flash silica-gel
chromatography eluting with 20% ethyl acetate in iso-hexane to give
a yellow oil. The oil was further purified by flash silica-gel
chromatography eluting with dichloromethane to give the sub-title
product as a viscous oil.
[0193] Yield: 110 mg.
[0194] MS: APCI (-ve) 399 [M-1]
ii)
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2,2-dimethyl-1,3-dioxan-5--
yl)methyl]-4-pyrimidinyl]azetidine-1-sulphonamide
[0195] A solution of the product of step i) (109 mg),
tris(dibenzylideneacetone)dipalladium(0) (14 mg),
azetidine-1-sulphonamide (145 mg),
2-dicyclohexyl-phosphino-2',4',6'-tri-isopropyl,1,1'-biphenyl(XPHOS)
(14 mg) and cesium carbonate (120 mg) in anhydrous dioxane (2.3 ml)
was heated at 100.degree. C. for 45 min. The reaction mixture was
partitioned between ethyl acetate and water. Acetic acid (0.2 ml)
was added and the separated organic phase was washed with water and
brine, dried (MgSO.sub.4) and the solvent evaporated under reduced
pressure. The residue was purified by flash silica-gel
chromatography eluting with 40% ethyl acetate in iso-hexane to give
the sub-title compound as a yellow viscous oil.
[0196] Yield: 78 mg.
[0197] MS: APCI (-ve) 499 [M-1]
EXAMPLE 4
N-(2-[(2,3-difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}p-
yrimidin-4-yl)azetidine-1-sulfonamide
##STR00011##
[0199] The title compound was prepared according to the procedure
outlined in example 1 step (iv) using a mixture of
azetidine-1-sulfonamide (150 mg),
tris(dibenzylideneacetone)dipalladium (0) (25 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (25 mg), cesium carbonate (244 mg) and
(2R,3R)-3-({6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)butan-
-2-ol (200 mg) in anhydrous dioxane (10 ml). Purification was by
reverse phase HPLC eluting with acetonitrile/aq. 0.1% ammonium
acetate mixtures to give title compound as a white solid. Yield: 79
mg
[0200] MS: APCI (+ve) 461 [M+1]
[0201] .sup.1H NMR: .delta. (CDCl.sub.3) 7.26-7.22 (1H, m),
7.10-6.99 (2H, m), 6.33 (1H, s), 5.07-5.00 (1H, m), 4.37 (2H, s),
4.02 (4H, t), 3.89-3.82 (1H, m), 2.25 (2H, quintet), 1.26-1.21 (6H,
m)
[0202] The intermediates for this compound were prepared as
follows:
i)
(2R,3R)-3-({6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)but-
an-2-ol
[0203] To a solution of (2R,3R)-butane-2,3-diol (250 mg) and
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step (ii)) (427 mg) in anhydrous tetrahydrofuran (20 ml)
at ambient temperature was added 60% sodium hydride (33.4 mg).
After stirring for 15 minutes the reaction mixture was partitioned
between aq. ammonium chloride solution and ethyl acetate. The
organics collected, dried (MgSO.sub.4) and solvents removed under
vacuo to give the subtitle compound as colourless gum. Yield: 525
mg.
[0204] MS: APCI (+ve) 361 [M+H.sup.+]
EXAMPLE 5
N-(2-[(2,3-difluorobenzyl)thio]-6-{[(1S,2S)-2-hydroxy-1-methylpropyl]oxy}p-
yrimidin-4-yl)azetidine-1-sulfonamide
##STR00012##
[0206] The title compound was prepared according to the procedure
outlined in example 4 using a mixture of azetidine-1-sulfonamide
(150 mg), tris(dibenzylideneacetone)dipalladium (0) (25 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (25 mg), cesium carbonate (244 mg) and
(2S,3S)-3-({6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)butan-
-2-ol (200 mg) in anhydrous dioxane (10 ml). Purification was by
reverse phase HPLC eluting with acetonitrile/aq. 0.1% ammonium
acetate mixtures to give title compound as a white solid. Yield: 60
mg
[0207] MS: APCI (+ve) 461 [M+1]
[0208] .sup.1H NMR: .delta. (CDCl.sub.3) 7.25-7.21 (1H, m),
7.10-6.99 (2H, m), 6.32 (1H, s), 5.07-5.00 (1H, m), 4.37 (2H, s),
4.02 (4H, t), 3.88-3.81 (1H, m), 2.26 (2H, quintet), 1.26-1.21 (6H,
m)
[0209] The intermediates for this compound were prepared as
follows:
i)
(2S,3S)-3-({6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)but-
an-2-ol
[0210] The subtitle compound was prepared according to the
procedure outlined in example 4 step (i) using
(2S,3S)-butane-2,3-diol (250 mg) and
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step (ii)) (427 mg) in anhydrous tetrahydrofuran (20 ml)
and 60% sodium hydride (33.4 mg) to give the subtitle compound as a
colourless gum. Yield: 440 mg.
[0211] MS: APCI (+ve) 361 [M+H.sup.+]
EXAMPLE 6
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(2R)-2,3-dihydroxypropyl]oxy]--
4-pyrimidinyl]-1-azetidinesulfonamide
##STR00013##
[0213] To a solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2S)-1,4-dioxaspiro[4.5]dec-2--
ylmethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide (the product of
step ii) (0.34 g) in methanol (5 mL)/H.sub.2O (0.1 mL) was added
pyridinium p-toluenesulfonate (78 mg) and the mixture was stirred
at reflux for 2 h and then ambient temperature for 20 h. The
reaction mixture was evaporated, suspended in H.sub.2O and
extracted with EtOAc (.times.2). The combined organic layers were
dried (MgSO.sub.4), filtered and evaporated. The residue was
purified by column chromatography on silica gel using DCM/MeOH
(98:2) as eluent to give the title compound as a white solid.
Yield: 0.15 g
[0214] MS: APCI (+ve) 463 [M+H.sup.+]
[0215] .sup.1H NMR: .delta. (DMSO) 2.13 (quintet, 2H), 3.42 (m,
2H), 3.77 (m, 1H), 3.82 (t, 4H), 4.16 (dd, 1H), 4.35 (dd, 1H), 4.46
(s, 2H), 4.67 (t, 1H), 4.97 (d, 1H), 6.16 (s, 1H), 7.17 (m, 1H),
7.35 (m, 1H), 7.44 (m, 1H), 11.13 (br s, 1H);
[0216] The intermediates for this compound were prepared as
follows:
i)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2.5)-1,4-dioxaspiro[4-
.5]dec-2-ylmethoxy]-pyrimidine
[0217] The subtitle compound was prepared according to the
procedure outlined in example 1 step iii) using
(2S)-1,4-dioxaspiro[4.5]decane-2-methanol (0.46 g) and
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step (ii) (0.75 g) in THF (8 mL) and 60% sodium hydride
(39 mg) to give the subtitle compound as a pale yellow solid.
Yield: 0.70 g.
[0218] MS: APCI (+ve) 403/405 [M+H.sup.+]
ii)
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2S)-1,4-dioxaspiro[4.5]dec-
-2-ylmethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide
[0219] The subtitle compound was prepared according to the
procedure outlined in example 1 step iv) using a mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.25 g), tris(dibenzylideneacetone)dipalladium (0) (83
mg), 2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (43 mg), cesium carbonate (0.44 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2S)-1,4-dioxaspiro[4.5]-
dec-2-ylmethoxy]-pyrimidine (0.40 g) in dioxane (8 mL).
Purification was by column chromatography on silica gel using
EtOAC/isohexane (1:9 to 1:2 gradient) as eluent to give the
subtitle compound as a pale yellow oil. Yield: 0.34 g
[0220] MS: APCI (+ve) 543 [M+H.sup.+]
EXAMPLE 7
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(2S)-2,3-dihydroxypropyl]oxy]--
4-pyrimidinyl]-1-azetidinesulfonamide
##STR00014##
[0222] To a solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(4R)-2,2-dimethyl-1,3-dioxola-
n-4-yl]methoxy]-4-pyrimidinyl]-1-azetidinesulfonamide (the product
of step (0.48 g) in methanol (5 mL)/H.sub.2O (0.1 mL) was added
pyridinium p-toluenesulfonate (0.12 g) and the mixture was stirred
at reflux for 2 h. The reaction mixture was evaporated, suspended
in H.sub.2O and extracted with EtOAc (.times.2). The combined
organic layers were dried (MgSO.sub.4), filtered and evaporated.
The residue was triturated with DCM to give the title compound as a
white solid. Yield: 0.30 g
[0223] MS: APCI (+ve) 463 [M+H.sup.+]
[0224] .sup.1H NMR: .delta. (DMSO) 2.15 (quintet, 2H), 3.42 (m,
2H), 3.77 (m, 1H), 3.90 (t, 4H), 4.17 (dd, 1H), 4.35 (dd, 1H), 4.46
(s, 2H), 4.67 (t, 1H), 4.98 (d, 1H), 6.16 (s, 1H), 7.16 (m, 1H),
7.34 (m, 1H), 7.44 (m, 1H), 11.13 (br s, 1H);
[0225] The intermediates for this compound were prepared as
follows:
1)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(4R)-2,2-dimethyl-1,3-
-dioxolan-4-yl]methoxy]-pyrimidine
[0226] The subtitle compound was prepared according to the
procedure outlined in example 1 step iii) using
2,2-dimethyl-(4R)-1,3-dioxolane-4-methanol (0.26 g) and
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step ii) (0.50 g) in THF (5 mL) and 60% sodium hydride
(79 mg) to give the subtitle compound as a clear, colourless oil.
Yield: 0.47 g.
[0227] MS: APCI (+ve) 403/405 [M+H.sup.+]
ii)
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(4R)-2,2-dimethyl-1,3-diox-
olan-4-yl]methoxy]-4-pyrimidinyl]-1-azetidinesulfonamide
[0228] The subtitle compound was prepared according to the
procedure outlined in example 1 step iv) using a mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.24 g), tris(dibenzylideneacetone)dipalladium (0)
(0.11 g),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (55 mg), cesium carbonate (0.57 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(4R)-2,2-dimethyl-1,3-d-
ioxolan-4-yl]methoxy]-pyrimidine (0.47 g) in dioxane (8 mL).
Purification was by column chromatography on silica using
EtOAc/isohexane (3:7) as eluent to give the subtitle compound as a
pale yellow solid. Yield: 0.49 g
[0229] MS: APCI (+ve) 503 [M+H.sup.+]
EXAMPLE 8
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(2R)-2,3-dihydroxy-1,1-dimethy-
lpropyl]oxy]-4-pyrimidinyl]-1-azetidinesulfonamide
##STR00015##
[0231] To a suspension of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[1-[(4R)-2,2-dimethyl-1,3-dioxo-
lan-4-yl]-1-methylethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide
(the product from step iii) 0.34 g) in DCM (9 mL) was added iron
(III) chloride hexahydrate (0.61 g) and the mixture was stirred at
ambient temperature for 35 min. The reaction mixture was diluted
with sat. sodium hydrogencarbonate solution and extracted with DCM
(.times.3). The combined organic layers were dried (MgSO.sub.4),
filtered and evaporated. The residue was purified by column
chromatography on silica gel using MeOH/DCM (99:1 to 98:2 gradient)
as eluent to give the title compound as a white foam. Yield: 0.20
g
[0232] MS: APCI (+ve) 489 [M+H.sup.+]
[0233] .sup.1H NMR: .delta. (DMSO) 1.41 (s, 3H), 1.44 (s, 3H), 2.16
(quintet, 2H), 3.32 (m, 1H), 3.56 (m, 1H), 3.87 (m, 1H), 3.91 (t,
4H), 4.46 (m, 3H), 4.98 (d, 1H), 6.06 (s, 1H), 7.18 (m, 1H), 7.37
(m, 1H), 7.42 (m, 1H), 11.06 (br s, 1H)
[0234] The intermediates for this compound were prepared as
follows:
i)
.alpha.,.alpha.-2,2-tetramethyl-(4R)-1,3-dioxolane-4-methanol
[0235] To anhydrous cerium (III) chloride (8.1 g of heptahydrate
dried under high vacuum at 150.degree. C. for 20 h) was added THF
(10 mL) then methyllithium (1.6M, 11.7 mL) and the reaction mixture
was stirred at ambient temperature for 10 min. A solution of
2,2-dimethyl-(4R)-1,3-dioxolane-4-carboxylic acid methyl ester (1
g) in THF (5 mL) was added and the mixture was stirred at ambient
temperature for 1.5 h. The reaction mixture was quenched by a slow
addition of H.sub.2O (10 mL) and then extracted with Et.sub.2O
(.times.2). The combined organic layers were dried (MgSO.sub.4),
filtered and evaporated to afford the subtitle compound as a yellow
oil. Yield: 0.40 g.
[0236] .sup.1H NMR: .delta. (CDCl.sub.3) 1.16 (s, 3H), 1.24 (s,
3H), 1.37 (s, 3H), 1.46 (s, 3H), 3.83 (m, 1H), 3.96 (m, 2H)
ii)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[1-[(4R)-2,2-dimethyl--
1,3-dioxolan-4-yl]-1-methylethoxy]-pyrimidine
[0237] The subtitle compound was prepared according to the
procedure outlined in example 1 step iii) using
.alpha.,.alpha.-2,2-tetramethyl-(4R)-1,3-dioxolane-4-methanol (0.32
g) and 4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the
product of example 1 step ii) (0.56 g) in THF (5 mL) and 60% sodium
hydride (80 mg) to give the subtitle compound as a pale yellow oil.
Yield: 0.43 g.
[0238] .sup.1H NMR: .delta. (CDCl.sub.3) 1.16 (s, 3H), 1.24 (s,
3H), 1.55 (s, 3H), 1.57 (s, 3H), 3.87 (dd, 1H), 4.02 (dd, 1H), 4.35
(t, 1H), 4.41 (s, 2H), 6.38 (s, 1H), 7.04 (m, 2H), 7.26 (m, 1H)
iii)
N12-[[(2,3-difluorophenyl)methyl]thio]-6-[1-[(4R)-2,2-dimethyl-1,3-di-
oxolan-4-yl]-1-methylethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide
[0239] The subtitle compound was prepared according to the
procedure outlined in example 1 step iv) using a mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.20 g), tris(dibenzylideneacetone)dipalladium (0) (91
mg), 2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (42 mg), cesium carbonate (0.49 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[1-[(4R)-2,2-dimethyl-1,3-
-dioxolan-4-yl]-1-methylethoxy]-pyrimidine (0.43 g) in dioxane (8
mL). Purification was by column chromatography on silica gel using
EtOAc/isohexane (2:8) as eluent to give the subtitle compound as a
pale yellow foam. Yield: 0.43 g
[0240] MS: APCI (-ve) 529 [M+H.sup.+]
EXAMPLE 9
N-(2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(2,5)-2,3-dihydroxy-1,1-dimeth-
ylpropyl]oxy]-4-pyrimidinyl]-1-azetidinesulfonamide
##STR00016##
[0242] To a suspension of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[1-[(4S)-2,2-dimethyl-1,3-dioxo-
lan-4-yl]-1-methylethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide
(the product from step (0.37 g) in DCM (10 mL) was added iron (III)
chloride hexahydrate (0.66 g) and the mixture was stirred at
ambient temperature for 1 h. The reaction mixture was diluted with
sat. sodium hydrogencarbonate solution and extracted with DCM
(.times.3). The combined organic layers were dried (MgSO.sub.4),
filtered and evaporated. The residue was purified by column
chromatography on silica gel using a MeOH/DCM (99:1 to 98:2
gradient) as eluent to give the title compound as a white solid.
Yield: 0.16 g
[0243] MS: APCI (+ve) 489 [M+H.sup.+]
[0244] .sup.1H NMR: .delta. (DMSO) 1:42 (s, 3H), 1.44 (s, 3H), 2.15
(quintet, 2H), 3.33 (m, 1H), 3.56 (m, 1H), 3.87 (m, 1H), 3.90 (t,
4H), 4.44 (m, 3H), 4.98 (d, 1H), 6.06 (s, 1H), 7.17 (m, 1H), 7.36
(m, 1H), 7.41 (m, 1H), 11.06 (br s, 1H)
[0245] The intermediates for this compound were prepared as
follows:
i)
.alpha.,.alpha.-2,2-tetramethyl-(4S)-1,3-dioxolane-4-methanol
[0246] To anhydrous cerium (III) chloride (8.1 g of heptahydrate
dried under high vacuum at 150.degree. C. for 20 h) was added THF
(10 mL) then methyllithium (1.6M, 11.7 mL) and the reaction mixture
was stirred at ambient temperature for 10 min. A solution of
2,2-dimethyl-1-(4S)-1,3-dioxolane-4-carboxylic acid methyl ester (1
g) in THF (5 mL) was added and the mixture was stirred at ambient
temperature for 1.5 h. The reaction mixture was quenched by a slow
addition of H.sub.2O (10 mL) and then extracted with Et.sub.2O
(.times.2). The combined organic layers were dried (MgSO.sub.4),
filtered and evaporated to afford the subtitle compound as a yellow
oil.
[0247] Yield: 0.75 g.
[0248] .sup.1H NMR: .delta. (CDCl.sub.3) 1.15 (s, 3H), 1.24 (s,
3H), 1.38 (s, 3H), 1.43 (s, 3H), 3.84 (m, 1H), 3.97 (m, 2H)
ii)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[1-[(4S)-2,2-dimethyl--
1,3-dioxolan-4-yl]-1-methylethoxy]-pyrimidine
[0249] The subtitle compound was prepared according to the
procedure outlined in example 1 step iii) using
.alpha.,.alpha.-2,2-tetramethyl-(4S)-1,3-dioxolane-4-methanol (0.32
g) and 4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the
product of example 1 step (0.56 g) in THF (5 mL) and 60% sodium
hydride (80 mg) to give the subtitle compound as a colourless oil.
Yield: 0.37 g.
[0250] .sup.1H NMR: .delta. (CDCl.sub.3) 1.15 (s, 3H), 1.24 (s,
3H), 1.55 (s, 3H), 1.57 (s, 3H), 3.88 (dd, 1H), 4.02 (dd, 1H), 4.35
(t, 1H), 4.41 (s, 2H), 6.38 (s, 1H), 7.03 (m, 2H), 7.26 (m, 1H)
iii)
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[1-[(4S)-2,2-dimethyl-1,3-d-
ioxolan-4-yl]-1-methylethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide
[0251] The subtitle compound was prepared according to the
procedure outlined in example 1 step iv) using a mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.17 g), tris(dibenzylideneacetone)dipalladium (0) (78
mg), 2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (40 mg), cesium carbonate (0.42 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[1-[(4S)-2,2-dimethyl-1,3-
-dioxolan-4-yl]-1-methylethoxy]-pyrimidine (0.37 g) in dioxane (8
mL). Purification was by column chromatography on silica gel using
EtOAc/isohexane (2:8 to 3:7 gradient) as eluent to give the
subtitle compound as a pale yellow oil. Yield: 0.37 g
[0252] MS: APCI (-ve) 529 [M+H.sup.-]
EXAMPLE 10
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[2-hydroxy-1-(hydroxymethyl)-1-m-
ethylethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide
##STR00017##
[0254] To a suspension of
N-[2-[[(2,3-difluorophenyl)methyl]thio)-6-[(2,2,5-trimethyl-1,3-dioxan-5--
yl)oxy]-4-pyrimidinyl]-1-azetidinesulfonamide (the product from
step (0.46 g) in DCM (15 mL) was added iron (III) chloride
hexahydrate (0.85 g) and the mixture was stirred and ambient
temperature for 30 min. A saturated solution of sodium
hydrogencarbonate was added and then extracted with DCM (.times.4).
The combined organic layers were dried (MgSO.sub.4), filtered and
evaporated. The residue was purified by column chromatography on
silica gel using a MeOH/DCM (99:1 to 98:2 gradient) as eluent to
give the title compound as a white foam. Yield: 100 mg
[0255] MS: APCI (-ve) 475 [M+H.sup.+]
[0256] .sup.1H NMR: .delta. (DMSO) 1.43 (s, 3H), 2.15 (quintet,
2H), 3.63 (dd, 2H), 3.73 (dd, 2H), 3.92 (t, 4H), 4.44 (s, 2H), 4.78
(t, 2H), 6.09 (s, 1H), 7.17 (m, 1H), 7.36 (m, 1H), 7.43 (m, 1H),
11.06 (s, 1H)
[0257] The intermediates for this compound were prepared as
follows:
i)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2,2,5-trimethyl-1,3-d-
ioxan-5-yl)oxy]-pyrimidine
[0258] The subtitle compound was prepared according to the
procedure outlined in example 1 step iii) using
2,2,5-trimethyl-1,3-dioxan-5-ol (as prepared in Synthesis, 1998, p
879) (0.29 g) and
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step (0.51 g) in THF (5 mL) and 60% sodium hydride (80
mg) to give the subtitle compound as a yellow oil.
[0259] Yield: 0.44 g.
[0260] .sup.1H NMR: .delta. (CDCl.sub.3) 1.16 (s, 3H), 1.24 (s,
3H), 1.53 (s, 3H), 3.85 (d, 2H), 4.14 (d, 2H), 4.38 (s, 2H), 6.48
(s, 1H), 7.04 (m, 2H), 7.26 (m, 1H)
ii)
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2,2,5-trimethyl-1,3-dioxan-
-5-yl)oxy]-4-pyrimidinyl]-1-azetidinesulfonamide
[0261] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using a mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.22 g), tris(dibenzylideneacetone)dipalladium (0) (97
mg), 2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.52 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2,2,5-trimethyl-1,3-dio-
xan-5-yl)oxy]-pyrimidine (0.44 g) in dioxane (10 mL). Purification
was by column chromatography on silica gel using EtOAc/isohexane
(2:8 to 3:7 gradient) as eluent to give the subtitle compound as a
pale yellow oil. Yield: 0.46 g
[0262] MS: APCI (+ve) 517 [M+H.sup.+]
EXAMPLE 11
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-2-thiazolesulfonamide
##STR00018##
[0264] To a solution of
2-[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2-thiazolylsulfonyl)amino]-4-
-pyrimidinyl]oxy]-(2R)-propanoic acid ethyl ester (the product from
step ii) (0.11 g) in THF (3 mL) was added lithium borohydride (2M
solution in THF, 0.23 mL) and the mixture was mixture was stirred
at ambient temperature for 20 h. The reaction mixture was cooled to
0.degree. C., quenched with 0.5M HCl solution and the aqueous was
extracted with EtOAc (.times.2). The combined organic layers were
dried (MgSO.sub.4), filtered and evaporated. The residue was
purified by column chromatography on silica gel using MeOH/DCM
(99:1 to 98:2 gradient) as eluent to give the title compound as a
white solid. Yield: 15 mg
[0265] MS: APCI (+ve) 475 [M+H.sup.+]
[0266] .sup.1H NMR: .delta. (CDCl.sub.3) 1.44 (d, 3H), 3.72 (m,
2H), 4.34 (q, 2H), 5.25 (m, 1H), 5.29 (s, 1H), 6.43 (s, 1H), 7.03
(m, 2H), 7.17 (t, 1H), 7.66 (s, 1H), 7.98 (s, 1H)
[0267] The intermediates for this compound were prepared as
follows:
i)
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2-
R)-propanoic acid ethyl ester
[0268] The subtitle compound was prepared according to the
procedure outlined in example 1 step iii) using
2-hydroxy-(2R)-propanoic acid ethyl ester (1.45 mL) and
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step (3 g) in THF (40 mL) and 60% sodium hydride (0.55 g)
to give the subtitle compound as a clear, colourless oil. Yield:
2.85 g.
[0269] MS: APCI (+ve) 389/391 [M+H.sup.+]
ii)
2-[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2-thiazolylsulfonyl)amino-
]-4-pyrimidinyl]oxy]-(2R)-propanoic acid ethyl ester
[0270] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using a mixture of
2-thiazolesulfonamide (0.17 g),
tris(dibenzylideneacetone)dipalladium (0) (64 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (33 mg), cesium carbonate (0.34 g) and
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (0.27 g) in dioxane (5 mL).
Purification was by column chromatography on silica using
EtOAc/isohexane (1:9 to 1:1 gradient) as eluent to give the
subtitle compound as a pale yellow oil. Yield: 0.11 g
[0271] MS: APCI (+ve) 517 [M+H.sup.+]
EXAMPLE 12
N-[6-(difluoromethoxy)-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]-
-1-azetidinesulfonamide
##STR00019##
[0273] The title compound was prepared according to the procedure
outlined in example 1 step (iv) using a mixture of
azetidine-1-sulphonamide (prepared according to patent WO
2004/011443, 0.11 g), tris(dibenzylideneacetone)dipalladium (0)
(0.10 g),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (60 mg), cesium carbonate (0.26 g),
4-chloro-6-(difluoromethoxy)-2-[[(2,3-difluorophenyl)methyl]thio]-pyrimid-
ine (product of step (0.18 g) and anhydrous dioxane (5 mL).
Purification was by column chromatography on silica gel using
EtOAc/isohexane (3:7) as eluent and the relevant fractions were
evaporated. The resulting oil was triturated with diethyl
ether/iso-hexane to give the title compound as a white solid.
Yield: 70 mg
[0274] MS: APCI (+ve) 439 [M+H.sup.+]
[0275] .sup.1H NMR: .delta. (DMSO) 2.13 (quintet, 2H), 3.93 (t,
4H), 4.50 (s, 2H), 6.30 (s, 1H), 7.19-7.12 (m, 1H), 7.45-7.30 (m,
2H), 7.79 (t, 1H), 11.53 (s, 1H)
[0276] The intermediates for this compound were prepared as
follows:
i)
6-(difluoromethoxy)-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinol
[0277] To a solution of
2-[[(2,3-difluorophenyl)methyl]thio]-4,6-pyrimidinediol (3 g) in
DMF (30 mL), cesium carbonate (4.3 g) and chlorodifluoro-acetic
acid sodium salt (1.9 g) was added. The resulting mixture was
heated at 100.degree. C. for 2 h. The reaction mixture was cooled
then diluted with H.sub.2O and extracted with EtOAc. The organic
layer was washed with H.sub.2O and dried (MgSO.sub.4), filtered and
evaporated. Purification was by column chromatography on silica gel
using EtOAc/isohexane (2:8) as eluent to give the subtitle compound
as a white solid. Yield: 0.4 g
[0278] MS: APCI (+ve) 421 [M+H.sup.+]
[0279] .sup.1H NMR: .delta. (DMSO) 4.53 (s, 2H), 7.13-7.22 (m, 1H),
7.30-7.42 (m, 2H), 7.75 (t, 1H)
ii)
4-chloro-6-(difluoromethoxy)-2-[[(2,3-difluorophenyl)methyl]thio]-pyri-
midine
[0280] To a solution of
6-(difluoromethoxy)-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinol
(product of step i) (0.4 g) in 1,2-dimethoxyethane was added
benzyltriethylammonium chloride (3 mg) and phosphorous oxychloride
(0.23 mL). The resulting mixture was heated to reflux for 16 hours.
The reaction mixture was cooled then diluted with H.sub.2O and
extracted with EtOAc. The organic layer was washed with H.sub.2O
and dried (MgSO.sub.4), filtered and evaporated. Purification was
by column chromatography on silica gel using EtOAc/isohexane (2:8)
as eluent to give the subtitle compound as a clear, colourless oil.
Yield: 0.35 g
[0281] .sup.1H NMR: .delta. (DMSO) 4.54 (s, 2H), 7.12-7.22 (m, 2H),
7.25 (s, 1H), 7.30-7.42 (m, 2H), 7.81 (t, 1H)
EXAMPLE 13
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-4-pyridinesulfonamide
##STR00020##
[0283] To a solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-methyl-2-(triphenylmeth-
oxy)ethoxy]-4-pyrimidinyl]-4-pyridinesulfonamide (the product from
step iv). (100 mg) in MeOH (10 mL) was added p-toluenesulfonic acid
(31 mg) and anisole (0.15 g). The reaction was then stirred at room
temperature for 18 h. The reaction was partitioned between EtOAc
(100 mL) and H.sub.2O (100 mL). The aqueous layer was then further
extracted with EtOAc (2.times.100 mL). The combined organic layers
were dried (MgSO.sub.4), filtered and evaporated. The residue was
purified by reverse phase HPLC using a TFA (0.2%)/MeCN to give the
title compound as a white solid. Yield: 50 mg.
[0284] MS: APCI (+ve) 496 [M+H.sup.+]
[0285] .sup.1H NMR: .delta. (DMSO) 1.13 (d, 3H), 4.30 (s, 2H),
5.06-5.12 (m, 1H), 6.0 (s, 1H), 7.07-7.38 (m, 3H), 7.84 (d, 2H),
8.86 (d, 2H)
[0286] The intermediates for this compound were prepared as
follows:
i) 4-pyridinesulfonamide
[0287] A solution of 4-pyridinethione (3.33 g) in c.HCl (22.5 mL)
and H.sub.2O (6 mL) was bubbled with chlorine gas at room
temperature for 3 h. The reaction mixture was then poured onto ice
(15 g), and the slurry was then transferred to ice-cold 0.88
ammonia (120 mL). This mixture was then stirred at room temperature
overnight before being concentrated in vacuo until solid began to
precipitate. At this point the reaction mixture was cooled
overnight in the refrigerator and the solid collected by filtration
as a yellow solid. Yield: 1.51 g.
[0288] .sup.1H NMR: .delta. (DMSO) 7.73 (s, 2H), 7.75 (d, 2H), 8.84
(d, 2H)
ii) (2R)-1-(triphenylmethoxy)-2-propanol
[0289] To a suspension of (2R)-1,2-propanediol (1.9 mL) in toluene
(20 mL) was added triethylamine (8.3 mL) and
4-dimethylaminopyridine (32 mg). The mixture was ice-cooled and
1,1',1''-(chloromethylidyne)tris-benzene (6.6 g) was added and the
mixture stirred at ambient temperature for 20 h. The reaction
mixture was diluted with toluene then extracted with ammonium
chloride solution (.times.2), then brine (.times.1) and the organic
layer was dried (MgSO.sub.4), filtered and evaporated. The
resulting oil was triturated with iso-hexane to give subtitle
compound as a white solid. Yield: 4 g
[0290] .sup.1H NMR: .delta. (CDCl.sub.3) 1.09 (d, 3H), 2.34 (d,
1H), 2.97 (dt, 1H), 3.15 (dd, 1H), 3.97 (m, 1H), 7.23 (m, 3H), 7.28
(m, 6H), 7.45 (m, 6H)
iii)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-methyl-2-(tri-
phenylmethoxy)ethoxy]-pyrimidine
[0291] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iii) using
(2R)-1-(triphenylmethoxy)-2-propanol (1.35 g) and
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step (ii) (1 g) in THF (15 mL) and 60% sodium hydride
(0.18 g) to give the subtitle compound as a pale yellow oil. Yield:
1.8 g.
[0292] MS: APCI (+ve) 589 [M+H.sup.+]
iv)
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-methyl-2-(triphenylm-
ethoxy)ethoxy]-4-pyrimidinyl]-4-pyridinesulfonamide
[0293] A mixture of 4-pyridinesulfonamide (the product from step i)
(0.21 g), tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,r-biphenyl (XPHOS)
(50 mg), cesium carbonate (0.66 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-methyl-2-(triphen-
ylmethoxy)ethoxy]-pyrimidine (the product from step iii) (0.40 g)
in dioxane (20 mL) was heated at reflux in a microwave at
100.degree. C., 300 W, open vessel with cooling for 3 h. The
reaction mixture was diluted with DCM, filtered through arbocel and
the filtrate evaporated. The residue was purified by reverse phase
HPLC using a TFA (0.2%)/MeCN system to give the title compound as a
yellow solid. Yield: 0.21 g.
[0294] MS: APCI (+ve) 711 [M+H.sup.+]
[0295] .sup.1H NMR: .delta. (DMSO) 8.85-8.76 (m, 2H), 7.83-7.73 (m,
2H), 7.26-7.17 (m, 18H), 6.03 (s, 1H), 5.44-5.35 (m, 1H), 4.29 (s,
2H), 3.08-3.01 (m, 2H), 1.22-1.14 (m, 3H)
EXAMPLE 14
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-ethoxy-4-pyrimidinyl]-1-azetidin-
esulfonamide
##STR00021##
[0297] The title compound was prepared according to the procedure
outlined in example 1 step iv) using a mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.17 g), tris(dibenzylideneacetone)dipalladium (0) (75
mg), 2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (40 mg), cesium carbonate (0.40 g)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-ethoxy-pyrimidine
(the product from step i) (0.26 g)) in dioxane (5 mL). Purification
was by column chromatography on silica gel using EtOAc/isohexane
(1:9) as eluent to give the title compound as a white solid. Yield:
0.17 g
[0298] MS: APCI (-1-ve) 417 [M+H.sup.+]
[0299] .sup.1H NMR: .delta. (DMSO) 1.27 (t, 3H), 2.13 (quintet,
2H), 3.90 (t, 4H), 4.34 (q, 2H), 4.47 (s, 2H), 6.12 (s, 1H), 7.15
(m, 1H), 7.33 (m, 1H), 7.42 (m, 1H), 11.11 (br s, 1H)
[0300] The intermediate for this compound was prepared as
follows:
i)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-ethoxy-pyrimidine
[0301] To a solution of
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (0.50 g) in
ethanol (5 mL) was added 60% sodium hydride (72 mg) and the
reaction mixture was stirred at ambient temperature for 6 h. The
mixture was diluted with H.sub.2O and extracted with EtOAc
(.times.2). The combined organic layers were dried (MgSO.sub.4),
filtered and evaporated to give the subtitle compound as a clear,
colourless oil. Yield: 0.53 g
[0302] MS: APCI (.+-.ve) 317/319 [M+H.sup.+]
EXAMPLE 15
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-ethoxy-4-pyrimidinyl]-1-piperazi-
nesulfonamide
##STR00022##
[0304] To a solution of
4-[[[2-[[(2,3-difluorophenyl)methyl]thio]-6-ethoxy-4-pyrimidinyl]amino]su-
lfonyl]-1-piperazinecarboxylic acid-1,1-dimethylethyl ester (the
product from step ii) (0.24 g) in DCM (2 mL) was added
trifluoroacetic acid (2 mL) and the reaction mixture was stirred at
ambient temperature for 2.5 h. The reaction mixture was evaporated,
the residue was azeotroped with DCM (.times.2) and then purified by
reverse phase HPLC eluting with acetonitrile/aq. 0.2%
trifluoroacetic acid mixtures to give title compound as a white
solid. Yield: 0.18 g
[0305] MS: APCI (-ve) 446 [M+H.sup.+]
[0306] .sup.1H NMR: .delta. (DMSO) 1.28 (t, 3H), 3.18 (m, 4H), 3.44
(m, 4H), 4.36 (q, 2H), 4.47 (s, 2H), 6.05 (s, 1H), 7.18 (m, 1H),
7.37 (m, 2H), 8.73 (br s, 1H), 11.33 (br s, 1H)
[0307] The intermediate for this compound was prepared as
follows:
i) 4-(aminosulfonyl)-1,1-dimethylethyl ester-1-piperazinecarboxylic
acid
[0308] To a solution of 1,1-dimethylethyl
ester-1-piperazinecarboxylic acid (2.94 g) in dioxane (40 mL) was
added sulfamide (4.0 g). The reaction mixture was then heated at
reflux for 24 h. The reaction mixture was allowed to cool before
being reduced in vacuo. The residue was separated between EtOAc
(300 mL) and H.sub.2O (300 mL) and the aqueous was further
extracted (2.times.300 mL) with EtOAc. Combined organic layers were
dried (MgSO.sub.4), filtered and evaporated. The residue was
purified by column chromatography on silica gel using
EtOAc/isohexane (1:1) as eluent to give the subtitle compound as a
white solid. Yield: 2.03 g.
[0309] .sup.1H NMR: .delta. (DMSO) 1.41 (s, 9H), 2.89 (t, 4H), 3.40
(t, 4H), 6.81 (s, 2H)
ii)
4-[[[2-[[(2,3-difluorophenyl)methyl]thio]-6-ethoxy-4-pyrimidinyl]amino-
]sulfonyl]-1-piperazinecarboxylic acid-1,1-dimethylethyl ester
[0310] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using a mixture of
4-(aminosulfonyl)-1-piperazinecarboxylic acid-1,1-dimethylethyl
ester (the product from step i) (0.29 g),
tris(dibenzylideneacetone)dipalladium (0) (67 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (35 mg), cesium carbonate (0.36 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-ethoxy-pyrimidine
(the product from example 14, step i) (0.23 g) in dioxane (5 mL).
Purification was by column chromatography on silica using
EtOAc/isohexane (1:9 to 1:3 gradient) as eluent to give the
subtitle compound as a yellow oil. Yield: 0.25 g
[0311] MS: APCI (-ve) 544 [M+H.sup.+]
EXAMPLE 16
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-(2,2,2-trifluoroethoxy)-4-pyrimi-
dinyl]-1-azetidinesulfonamide
##STR00023##
[0313] The title compound was prepared according to the procedure
outlined in example 1 step iv) using a mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.14 g), tris(dibenzylideneacetone)dipalladium (0) (60
mg), 2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (30 mg), cesium carbonate (0.32 g)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-(2,2,2-trifluoroethoxy)-p-
yrimidine (the product from step i) (0.24 g) in dioxane (5 mL).
Purification was by column chromatography on silica gel using
EtOAc/isohexane (1:9 to 2:8 gradient) as eluent to give the title
compound as a white solid. Yield: 0.11 g
[0314] MS: APCI (+ve) 471 [M+H.sup.+]
[0315] .sup.1H NMR: .delta. (DMSO) 2.1 (quintet, 2H), 3.83 (t, 4H),
4.51 (s, 2H), 5.03 (q, 2H), 6.22 (s, 1H), 7.16 (m, 1H), 7.36 (m,
1H), 7.42 (m, 1H), 11.33 (s, 1H)
[0316] The intermediate for this compound was prepared as
follows:
i)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-(2,2,2-trifluoroethoxy)-
-pyrimidine
[0317] The subtitle compound was prepared according to the
procedure outlined in example 1 step iii) using
2,2,2-trifluoroethanol (0.16 mL) and
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step ii) (0.60 g) in THF (6 mL) and 60% sodium hydride
(94 mg) to give the subtitle compound as a clear, colourless oil.
Yield: 0.6 g.
[0318] .sup.1H NMR: .delta. (DMSO) 4.54 (s, 2H, 5.14 (m, 2H), 7.13
(s, 1H), 7.19 (m, 1H), 7.37 (m, 2H)
EXAMPLE 17
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-(2,2,2-trifluoroethoxy)-4-pyrimi-
dinyl]-1-piperazinesulfonamide
##STR00024##
[0320] To a solution of
4-M2-[[(2,3-difluorophenyl)methyl]thio)-6-(2,2,2-trifluoroethoxy)-4-pyrim-
idinyl]amino]sulfonyl]-1-piperazinecarboxylic
acid-1,1-dimethylethyl ester (the product from step i) (0.21 g) in
DCM (2 mL) was added trifluoroacetic acid (2 mL) and the reaction
mixture was stirred at ambient temperature for 4 h. The reaction
mixture was evaporated, the residue was azeotroped with Et.sub.2O
(.times.2) and then purified by reverse phase HPLC eluting with
acetonitrile/aq. 0.2% trifluoroacetic acid mixtures to give title
compound as a white solid. Yield: 0.14 g
[0321] MS: APCI (+ve) 500 [M+H.sup.+]
[0322] .sup.1H NMR: .delta. (DMSO) 3.17 (m, 4H), 3.50 (m, 4H), 4.51
(s, 2H), 5.06 (q, 2H), 6.17 (s, 1H), 6.96-7.42 (m, 3H), 8.82 (br s,
2H)
[0323] The intermediate for this compound was prepared as
follows:
i)
4-[[[2-[[(2,3-difluorophenyl)methyl]thio]-6-(2,2,2-trifluoroethoxy)-4-p-
yrimidinyl]amino]sulfonyl]-1-piperazinecarboxylic
acid-1,1-dimethylethyl ester
[0324] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using a mixture of
4-(aminosulfonyl)-1-piperazinecarboxylic acid-1,1-dimethylethyl
ester (the product from example 15, step i), 0.40 g),
tris(dibenzylideneacetone)dipalladium (0) (91 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (48 mg), cesium carbonate (0.49 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-(2,2,2-trifluoroethoxy)-p-
yrimidine (the product from example 16, step i) (0.37 g) in dioxane
(6 mL). Purification was by column chromatography on silica gel
using EtOAc/isohexane (1:9 to 2:8 gradient) as eluent to give the
subtitle compound as a yellow solid. Yield: 0.22 g
[0325] MS: APCI (-ve) 598 [M+H.sup.-]
EXAMPLE 18
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-(1,1-dimethylethoxy)-4-pyrimidin-
yl]-1-azetidinesulfonamide
##STR00025##
[0327] The title compound was prepared according to the procedure
outlined in example 1 step iv) using a mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.16 g), tris(dibenzylideneacetone)dipalladium (0) (70
mg), 2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (36 mg), cesium carbonate (0.37 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-(1,1-dimethylethoxy)-pyri-
midine (the product from step i) (0.26 g) in dioxane (6 mL).
Purification was by column chromatography on silica gel using
EtOAc/isohexane (1:9 to 2:8 gradient) as eluent to give the title
compound as a white solid. Yield: 0.28 g
[0328] MS: APCI (-ve) 443 [M+H.sup.-]
[0329] .sup.1H NMR: .delta. (DMSO) 1.48 (s, 9H), 2.16 (quintet,
2H), 3.92 (t, 4H), 4.46 (s, 2H), 6.03 (s, 1H), 7.17 (m, 1H), 7.35
(m, 1H), 7.42 (m, 1H), 11.05 (br s, 1H)
[0330] The intermediate for this compound was prepared as
follows:
i)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-(1,1-dimethylethoxy)-py-
rimidine
[0331] To a solution of
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step (2 g) in THF (20 mL) was added potassium
tert-butoxide (0.8 g) and the reaction mixture was stirred at
ambient temperature for 20 h. Further potassium tert-butoxide (0.8
g) was added and the reaction mixture was stirred at ambient
temperature for 411. The mixture was diluted with H.sub.2O and
extracted with EtOAc (.times.3). The combined organic layers were
washed with H.sub.2O and dried (MgSO.sub.4), filtered and
evaporated. The resulting oil was purified by column chromatography
on silica gel using MeOH/DCM (99:1 to 98:2 gradient) as eluent to
give the subtitle compound as a clear, colourless oil. Yield: 0.68
g
[0332] .sup.1H NMR: .delta. (DMSO) 1.50 (s, 9H), 4.47 (s, 2H), 6.70
(s, 1H), 7.19 (m, 1H), 7.37 (m, 2H)
EXAMPLE 19
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[[2-hydroxy-1-(hydroxymethyl)eth-
yl]thio]-pyrimidin-4-yl]azetidine-1-sulfonamide
##STR00026##
[0334] A solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2-phenyl-1,3-dioxan-5-yl)thio-
]pyrimidin-4-yl]azetidine-1-sulfonamide (the product of step (0.11
g) and pyridinium para-toluenesulfonate (99 mg) in methanol (5 mL)
and H.sub.2O (2 drops) was heated at 60.degree. C. for 1 h. The
solution was cooled and the solvent evaporated under reduced
pressure. The residue was dissolved in EtOAc, washed with H.sub.2O,
dried (MgSO.sub.4) and filtered. The solvent was evaporated under
reduced pressure and the residue was purified by flash
chromatography on silica gel, eluting with EtOAc/iso-hexane (8:2)
to give the subtitle product as a yellow gum. The gum was dissolved
in DCM and methanol, filtered through charcoal and the filtrate
evaporated under reduced pressure. The residual solid was dried
under high vacuum at 40.degree. C. to give the title product as a
white solid. Yield: 50 mg
[0335] MS: APCI (-ve) 477 [M-H]
[0336] .sup.1H NMR: .delta. (DMSO) 2.13 (m, 2H), 3.66 (octet, 4H),
3.92 (t, 5H), 4.49 (s, 2H), 4.99 (t, 2H), 6.65 (s, 1H), 7.17 (m,
1H), 7.36 (m, 2H), 11.18 (s, 1H).
[0337] The intermediates for this compound were prepared as
follows:
i)
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2-phenyl-1,3-dioxan-5-
-yl)thio]pyrimidine
[0338] Sodium methoxide (0.1 mL of 25-30% methanol solution) was
added to a solution of ethyl
S-(2-phenyl-1,3-dioxan-5-yl)ethanethioate (0.12 g; prepare
according to the procedure in Chem. Pharm. Bull., 2000, 48, (5), p
694-707) in THF (2 mL). After stirring for 15 min, the product of
Example 1, step (0.12 g) was added. The reaction mixture was
stirred at room temperature for 18 h. The solvent was evaporated
under reduced pressure and the residue purified by flash
chromatography on silica gel, eluting with Et.sub.2O/iso-hexane
(1:9) to give the subtitle product as a beige solid. Yield: 0.18
g.
[0339] MS: APCI (+ve) 467/469 [M+H]
ii)
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(2-phenyl-1,3-dioxan-5-yl)t-
hio]pyrimidin-4-yl]azetidine-1-sulfonamide
[0340] The subtitle compound was prepared from
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.11 g) and
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(2-phenyl-1,3-dioxan-5-y-
l)thio]pyrimidine (the product of step i) (0.17 g) according to the
procedure outlined in Example 1, step iv). The residue was purified
by flash chromatography on silica gel, eluting with
EtOAc/iso-hexane (2:8) to give the subtitle compound as a
colourless oil. Yield: 0.11 g
[0341] MS: APCI (+ve) 567 [M+H]
EXAMPLE 20
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-1-piperazinesulfonamide
##STR00027##
[0343] To a solution of
4-[[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethox-
y]-4-pyrimidinyl]amino]sulfonyl], 1,1-dimethylethyl
ester1-piperazinecarboxylic acid (the product of step ii) (0.23 g)
in DCM (3 mL) was added trifluoroacetic acid (3 mL). The reaction
mixture was then stirred at room temperature for 1 h. The solvent
was removed and the residue purified by reverse phase HPLC using a
TFA (0.2%)/MeCN method to give the title compound as a white solid.
Yield: 77 mg
[0344] MS: APCI (+ve) 476 [M+H.sup.+]
[0345] .sup.1H NMR: .delta. (DMSO) 1.13 (d, 3H), 3.01-3.05 (m, 4H),
3.13-3.17 (m, 4H), 4.34-4.41 (m, 2H), 4.79 (s, 1H), 4.97-5.05 (m,
1H), 5.84 (s, 1H), 7.10-7.16 (m, 1H), 7.27-7.34 (m, 1H), 7.39-7.45
(m, 1H)
[0346] The intermediates for this compound were prepared as
follows:
(i)
4-[[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylet-
hoxy]-4-pyrimidinyl]amino]sulfonyl], 1,1-dimethylethyl
ester1-piperazinecarboxylic acid
[0347] A mixture of 4-(aminosulfonyl)-1,1-dimethylethyl
ester-1-piperazinecarboxylic acid (the product of example 15 step
i) (0.40 g), tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (1 g) and (2R)-propanoic
acid-2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-
-, ethyl ester (the product from example 11 step i) (0.40 g) in
dioxane (20 mL) was heated at reflux in a microwave at 100.degree.
C., 300 W, open vessel with cooling for 20 min. The reaction was
filtered through arbocel and then separated between EtOAc (200 mL)
and H.sub.2O (200 mL) and the aqueous was then further extracted
with EtOAc (2.times.200 mL). The combined organic layers were dried
(MgSO.sub.4), filtered and evaporated to give the subtitle compound
as a clear oil.
[0348] Yield: 0.93 g.
[0349] MS: APCI (+ve) 618 [M+H.sup.+]
(ii),
4-[[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methyl-
ethoxy]-4-pyrimidinyl]amino]sulfonyl]-, 1,1-dimethylethyl
ester1-piperazinecarboxylic acid
[0350] To a solution of
4-[[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethox-
y]-4-pyrimidinyl]amino]sulfonyl], 1,1-dimethylethyl
ester-1-piperazinecarboxylic acid (the product from step i) (0.93
g) in THF (20 mL) was added 2M LiBH.sub.4 in THF (3.0 mL). The
reaction mixture was then heated in a microwave at 50.degree. C.,
300 W, open vessel with cooling for 10 min. The reaction mixture
was then quenched with 2N HCl and the volatiles evaporated. The
residue was then separated between EtOAc (200 mL) and H.sub.2O (200
mL), the aqueous was then further extracted with EtOAc (2.times.200
mL). The combined organic layers were dried (MgSO.sub.4), filtered
and evaporated and the residue purified by reverse phase HPLC using
a TFA (0.2%)/MeCN method to give the title compound as a clear
oil.
[0351] Yield: 0.23 g.
[0352] MS: APCI (+ve) 576 [M+H.sup.+]
EXAMPLE 21
N-[6-(difluoromethoxy)-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]-
-1-methyl-1H-imidazole-4-sulfonamide
##STR00028##
[0354] The title compound was prepared according to the procedure
outlined in example 1 step (iv) using a mixture of
1-methyl-1H-imidazole-4-sulfonamide (0.25 g),
tris(dibenzylideneacetone)dipalladium (0) (0.10 g),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (60 mg), cesium carbonate (0.26 g),
4-chloro-6-(difluoromethoxy)-2-[[(2,3-difluorophenyl)methyl]thio]-pyrimid-
ine (product of example 12, step (0.18 g) and anhydrous dioxane (5
ml). Purification was by tituration with methanol/DCM. The
resulting white solid was diluted with H.sub.2O and extracted with
EtOAc. The organic layer was washed with H.sub.2O (.times.2) then
brine and dried (MgSO.sub.4), filtered and evaporated. The
resulting oil was triturated with methanol/DCM to give the title
compound as a white solid. Yield: 15 mg
[0355] MS: APCI (+ve) 464 [M+H.sup.+]
[0356] .sup.1H NMR: .delta. (DMSO) 3.67 (s, 3H), 4.45 (s, 2H), 6.38
(s, 1H), 7.10-7.18 (m, 1H), 7.30-7.40 (m, 2H), 7.70 (t, 1H), 7.82
(s, 1H), 8.08 (s, 1H)
EXAMPLE 22
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-1,6-dihydro-1-methyl-6-oxo-3-pyridinesulfonamide
##STR00029##
[0358] To a solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-methyl-2-(triphenylmeth-
oxy)ethoxy]-4-pyrimidinyl]-1,6-dihydro-1-methyl-6-oxo-3-pyridinesulfonamid-
e (the product from step ii) (0.16 g) in MeOH (10 mL) was added
p-toluenesulfonic acid (50 mg) and anisole (0.22 g). The reaction
was then stirred at room temperature for 18 h. The reaction was
partitioned between EtOAc (100 mL) and H.sub.2O (100 mL). The
aqueous layer was then further extracted with EtOAc (2.times.100
mL). Combined organic layers were dried (MgSO.sub.4), filtered and
evaporated. The residue was purified by reverse phase HPLC using
TFA (0.2%)/MeCN to give a white solid. Yield: 9 mg.
[0359] MS: APCI (+ve) 499 [M+H.sup.+]
[0360] .sup.1H NMR: .delta. (CD.sub.3OD) 1.12 (d, 3H), 3.47 (s,
3H), 3.50-3.53 (m, 2H), 4.30-4.33 (m, 2H), 5.08-5.19 (m, 1H), 5.95
(s, 1H), 6.45 (d, 1H), 6.93-7.11 (m, 2H), 7.14-7.21 (m, 1H),
7.69-7.74 (m, 1H), 8.39 (d, 1H)
[0361] The intermediates for this compound were prepared as
follows:
i) [(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)sulfonyl]-,
1,1-dimethylethyl ester carbamic acid
[0362] Chlorosulfbnyl isocyanate (6 mL) was added dropwise to a
solution of 2-methyl-2-propanol (6.5 mL) in DCM (75 mL) at
0.degree. C. After 5 min, 1-methyl-2(1H)-pyridinone (9 mL) was
added dropwise followed by N,N-diisopropylethylamine (14.5 mL) also
added dropwise. The reaction mixture was then allowed to warm to
room temperature over 18 h. H.sub.2O (100 mL) was added to the
reaction mixture and the organic layer was separated. The aqueous
was then further extracted with DCM (2.times.100 mL). The combined
organic layers were dried (MgSO.sub.4), filtered and evaporated to
give the subtitle compound as a pale yellow oil. Yield: 7 g
[0363] .sup.1H NMR: .delta. (CDCl.sub.3) 1.45 (s, 9H), 3.62 (s,
3H), 6.60-6.64 (m, 1H), 7.69-7.74 (m, 1H), 8.21-8.24 (m, 1H)
ii)
4-pyridinesulfonamide-N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)--
1-methyl-2-(triphenylmethoxy)ethoxy]-4-pyrimidinyl]
[0364] A mixture of
[(1,6-dihydro-1-methyl-6-oxo-3-pyridinyl)sulfonyl]-,
1,1-dimethylethyl ester carbamic acid (the product from step i)
(0.60 g), tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (1 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-methyl-2-(triphen-
ylmethoxy)ethoxy]-pyrimidine (the product of example 13 step iii),
0.40 g) in dioxane (20 mL) was heated at reflux in a microwave at
100.degree. C., 300 W, open vessel with cooling for 3 h. The
reaction mixture was diluted with DCM, filtered through arbocel and
the filtrate evaporated. The residue was purified by reverse phase
HPLC using a TFA (0.2%)/MeCN system to give the subtitle compound
as a yellow solid. Yield: 0.12 g.
[0365] MS: APCI (+ve) 741 [M+H.sup.+]
[0366] .sup.1H NMR: .delta. (DMSO) 1.16-1.23 (m, 3H), 3.06 (d, 2H),
3.35 (s, 3H), 4.33-4.41 (m, 2H), 5.39-5.47 (m, 1H), 6.06 (s, 1H),
6.47 (d, 1H), 7.04-7.11 (m, 2H), 7.17-7.34 (m, 17H), 7.67-7.71 (m,
1H), 8.54-8.56 (m, 1H)
EXAMPLE 23
2-[[6[(1-azetidinylsulfonyl)amino]-2-[[(2,3-difluorophenyl)methyl]thio]-4--
pyrimidinyl]oxy]-(2R)-propanoic acid ethyl ester
##STR00030##
[0368] The title compound was prepared according to the procedure
outlined in example 1 step (iv) using a mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.61 g), tris(dibenzylideneacetone)dipalladium (0)
(0.15 g),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (105 mg), cesium carbonate (0.77 g),
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (the product of example 11, step i)
(0.61 g) and dioxane (15 mL). Purification was by column
chromatography on silica gel using MeOH/DCM (5:95) as eluent,
followed by reverse phase HPLC (symmetry as the stationary phase
and TFA/acetonitrile as the mobile phase) to give the title
compound as a white solid. Yield: 46 mg
[0369] MS: APCI (+ve) 489 [M+H.sup.+]
[0370] .sup.1H NMR: .delta. (DMSO) 1.12 (t, 3H), 1.49 (d, 3H), 2.14
(quintet, 2H), 3.92 (t, 4H), 4.05-4.16 (m, 2H), 4.42 (dd, 2H), 5.26
(q, 1H), 6.21 (s, 1H), 7.12-7.21 (m, 1H), 7.31-7.41 (m, 2H), 11.24
(s, 1H)
EXAMPLE 24
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-1-azetidinesulfonamide
##STR00031##
[0372] To a suspension of
2-[[6-[(1-azetidinylsulfonyl)amino]-2-[[(2,3-difluorophenyl)methyl]thio]--
4-pyrimidinyl]oxy]-(2R)-propanoic acid ethyl ester, (the product of
example 23) (0.40 g) in TI-IF (10 mL) was added 2M lithium
borohydride in THF (0.82 mL) dropwise and the mixture was stirred
at ambient temperature for 20 h. The reaction mixture was cooled to
0.degree. C. and quenched with 1M aqueous hydrochloric acid. The
resulting mixture was extracted with EtOAc (.times.2). The combined
organic layers were washed with 1M aqueous hydrochloric acid then
brine and was dried (MgSO.sub.4), filtered and evaporated. The
residue was purified by column chromatography on silica gel using
EtOAc/isohexane (1:1) as eluent. The resulting oil was triturated
with DCM to give the title compound as a white solid. Yield: 0.25
g
[0373] MS: APCI (-ve) 445 [M-H.sup.-]
[0374] .sup.1H NMR 5 (CD.sub.3OD) 1.15 (d, 3H), 2.11 (quintet, 2H),
3.54 (d, 2H), 3.88 (t, 4H), 4.36 (dd, 2H), 5.16 (dt, 1H), 6.12 (s,
1H), 6.93-7.12 (m, 2H), 7.22-7.31 (m, 1H)
EXAMPLE 25
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1S)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-1-azetidinesulfonamide
##STR00032##
[0376] The title compound was prepared according to the procedure
outlined in example 24 using
2-[[6-[(1-azetidinylsulfonyl)amino]-2-[[(2,3-difluorophenyl)methyl]thio]--
4-pyrimidinyl]oxy]-(2S)-propanoic acid, ethyl ester, (the product
of step ii) (0.28 g), THF (8 mL) and 2M lithium borohydride in THF
(0.57 mL). Purification was by column chromatography on silica
using EtOAc/isohexane (2:3) as eluent to give the title compound as
a white solid. Yield: 0.15 g
[0377] MS: APCI (-ve) 445 [M-H.sup.-]
[0378] .sup.1H NMR: .delta. (CD.sub.3OD) 1.27 (d, 3H), 2.23
(quintet, 2H), 3.66 (d, 2H), 4.00 (t, 4H), 4.48 (dd, 2H), 5.28 (q,
1H), 6.24 (s, 1H), 7.05-7.23 (m, 2H), 7.33-7.43 (m, 1H)
[0379] The intermediates for this compound were prepared as
follows:
i)
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2-
S)-propanoic acid ethyl ester
[0380] The subtitle compound was prepared according to the
procedure outlined in example 1 step iii) using
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (product of
example 1 step ii) (0.77 g), THF (15 mL), 2-hydroxy-(2S)-propanoic
acid ethyl ester (0.40 mL) and 60% sodium hydride (0.14 g) to give
the subtitle compound as a clear, colourless oil. Yield: 1 g
[0381] MS: APCI (+ve) 389/391 [M+H.sup.+]
[0382] .sup.1H NMR: .delta. (DMSO) 1.13 (t, 3H), 1.51 (d, 3H),
3.99-4.17 (m, 2H), 4.37-4.50 (m, 2H), 5.28-5.38 (m, 1H), 7.02 (s,
1H), 7.13-7.23 (m, 1H), 7.28-7.42 (m, 2H)
ii)
2-[[6-[(1-azetidinylsulfonyl)amino]-2-[[(2,3-difluorophenyl)methyl]thi-
o]-4-pyrimidinyl]oxy]-(2S)-propanoic acid ethyl ester
[0383] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using a mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.13 g), tris(dibenzylideneacetone)dipalladium (0) (58
mg), 2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (42 mg), cesium carbonate (0.31 g),
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2S)-
-propanoic acid ethyl ester (product of step i) (0.25 g) and
dioxane (10 mL). Purification was by column chromatography on
silica gel using EtOAc/isohexane (3:7) as eluent to give the
subtitle compound as clear, colourless oil. Yield: 0.28 g
[0384] MS: APCI (+ve) 489 [M+H.sup.+]
EXAMPLE 26
2-[[6-[(1-azetidinylsulfonyl)amino]-2-[[(2,3-difluorophenyl)methyl]thio]-4-
-pyrimidinyl]oxy]-(2R)-propanamide
##STR00033##
[0386] To a solution of
2-[[6-chloro-2-[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)--
propanoic acid ethyl ester (the product of example 23) (103 mg) in
methanol (8 mL) ammonia gas was bubbled through at 0.degree. C. The
resulting mixture was stirred in a sealed tube at ambient
temperature for 48 h. The solvent was evapourated under reduced
pressure and the resulting solid was triturated with ether to give
the title compound was a white solid. Yield: 88 mg
[0387] MS: APCI (+ve) 460 [M+H.sup.+]
[0388] .sup.1H NMR: .delta. (DMSO) 1.43 (d, 3H), 2.13 (quintet,
2H), 3.91 (t, 4H), 4.45 (dd, 2H), 5.21 (q, 1H), 6.23 (s, 1H),
7.13-7.20 (m, 2H), 7.31-7.43 (m, 2H), 7.59 (s, 1H), 11.17 (s,
1H)
EXAMPLE 27
2-[[6-[(1-azetidinylsulfonyl)amino]-2-[[(2,3-difluorophenyl)methyl]thio]-4-
-pyrimidinyl]oxy]-N-methyl-(2R)-propanamide
##STR00034##
[0390] To a solution of
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (the product of example 23) (100 mg) in
ethanol (1.5 mL) was added 8M methylamine in ethanol. The resulting
mixture was stirred in a sealed tube at ambient temperature for 16
h. The solvent was evaporated under reduced pressure. Purification
was by reverse phase HPLC (symmetry as the stationary phase and
TFA/acetonitrile as the mobile phase) to give the title compound as
a white solid. Yield: 60 mg
[0391] MS: APCI (+ve) 474 [M+H.sup.+]
[0392] .sup.1H NMR: .delta. (DMSO) 1.41 (d, 3H), 2.14 (quintet,
2H), 2.57 (d, 3H), 3.92 (t, 4H), 4.43 (dd, 2H), 5.26 (q, 1H), 6.23
(s, 1H), 7.12-7.21 (m, 1H), 7.30-7.41 (m, 2H), 8.00-8.07 (m, 1H),
11.18 (s, 1H)
EXAMPLE 28
2-[[6-[(1-azetidinylsulfonyl)amino]-2-[[(2,3-difluorophenyl)methyl]thio]-4-
-pyrimidinyl]oxy]-(2R)-propanoic acid
##STR00035##
[0394] To a solution of
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (the product of example 23) (0.24 g) in
methanol (1 mL) was added 1M aqueous sodium hydroxide (1 mL). The
resulting mixture was stirred at ambient temperature for 16 h. The
reaction mixture was acidified using 2M aqueous HCl, then extracted
with EtOAc (.times.2). The combined organics were washed with brine
then dried (MgSO.sub.4), filtered and evaporated. The resulting oil
was triturated with DCM/iso-hexane to give the title compound was a
white solid. Yield: 0.20 g
[0395] MS: APCI (-ve) 459 [M-H.sup.-]
[0396] .sup.1H NMR: .delta. (DMSO) 1.49 (d, 3H), 2.13 (quintet,
2H), 3.91 (t, 4H), 4.43 (dd, 2H), 5.23 (q, 1H), 6.19 (s, 1H),
7.12-7.21 (m, 1H), 7.30-7.42 (m, 2H)
EXAMPLE 29
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-methanesulfonamide
##STR00036##
[0398] The title compound was prepared according to the procedure
outlined in example 24 using a mixture of
2-[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(methylsulfonyl)amino]-4-pyri-
midinyl]oxy]-(2R)-propanoic acid ethyl ester, (the product of step
i) (0.28 g), THF (8 mL) and 2M lithium borohydride in THF (1.3 mL).
Purification was by reverse phase HPLC (symmetry as the stationary
phase and TFA/acetonitrile as the mobile phase). The resulting oil
was triturated with toluene, DCM, then ether/iso-hexane to give the
title compound as a white solid. Yield: 0.18 g
[0399] MS: APCI (-ve) 440 [M-H.sup.-]
[0400] .sup.1H NMR: .delta. (DMSO) 1.17 (d, 3H), 3.29 (s, 3H),
3.47-3.50 (m, 3H), 4.47 (dd, 2H), 5.09-5.18 (m, 1H), 5.99 (s, 1H),
7.13-7.21 (m, 1H), 7.29-7.43 (m, 2H), 11.14 (s, 1H)
[0401] The intermediate for this compound was prepared as
follows:
i)
2-[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(methylsulfonyl)amino]-4-py-
rimidinyl]oxy]-(2R)-propanoic acid ethyl ester
[0402] The subtitle compound was prepared according to the
procedure outlined in example 1 step iv) using a mixture of
methanesulfonamide (93 mg), tris(dibenzylideneacetone)dipalladium
(0) (71 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (52 mg), cesium carbonate (0.38 g),
2-([6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (the product of Example 23 step i)
(0.30 g) and dioxane (10 mL). Purification was by column
chromatography on silica using EtOAc/isohexane (1:1) as eluent to
give the subtitle compound as an oil. Yield: 0.28 g
[0403] MS: APCI (+ve) 448 [M+H.sup.+]
EXAMPLE 30
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-4-morpholinesulfonamide
##STR00037##
[0405] The title compound was prepared according to the procedure
outlined in example 24 using a mixture of
2-[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(4-morpholinylsulfonyl)amino]-
-4-pyrimidinyl]oxy]-(2R)-propanoic acid ethyl ester, (the product
of step i) (0.34 g), THF (8 mL) and 2M lithium borohydride in THF
(1 mL). Purification was by reverse phase HPLC (symmetry as the
stationary phase and ammonium acetate/acetonitrile as the mobile
phase) to give the title compound as a white solid. Yield: 0.25
g
[0406] MS: APCI (-ve) 475 [M-H.sup.-]
[0407] .sup.1H NMR: .delta. (DMSO) 1.16 (d, 3H), 3.11 (s, 4H),
3.42-3.53 (m, 2H), 3.59 (t, 4H), 4.43 (dd, 2H), 4.84 (t, 1H), 5.10
(q, 1H), 5.98 (s, 1H), 7.12-7.19 (m, 1H), 7.29-7.37 (m, 1H),
7.39-7.45 (m, 1H)
[0408] The intermediate for this compound was prepared as
follows:
i)
2-[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(4-morpholinylsulfonyl)amin-
o]-4-pyrimidinyl]oxy]-(2R)-propanoic acid ethyl ester
[0409] The subtitle compound was prepared according to the
procedure outlined in example 1 step iv) using a mixture of
4-morpholinesulfonamide (prepared according to patent WO
2004/011443, 0.19 g), tris(dibenzylideneacetone)dipalladium (0) (71
mg), 2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (52 mg), cesium carbonate (0.38 g),
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (the product of Example 23 step i)
(0.30 g) and dioxane (10 mL). Purification was by column
chromatography on silica gel using EtOAc/isohexane (1:1) as eluent
to give the subtitle compound as an oil. Yield: 0.34 g
[0410] MS: APCI (+ve) 519 [M+H.sup.+]
EXAMPLE 31
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-1-pyrrolidinesulfonamide
##STR00038##
[0412] The title compound was prepared according to the procedure
outlined in example 24 using a mixture of
2-[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1-pyrrolidinylsulfonyl)amino-
]-4-pyrimidinyl]oxy]-(2R)-propanoic acid ethyl ester, (the product
of step i) (0.38 g), THF (8 mL) and 2M lithium borohydride in THF
(1.3 mL). Purification was by reverse phase HPLC (symmetry as the
stationary phase and TFA/acetonitrile as the mobile phase). The
resulting oil was titurated with methanol, toluene, DCM, then
ether/iso-hexane to give the title compound as a white solid.
Yield: 0.15 g
[0413] MS: APCI (-ve) 459 [M-H.sup.-]
[0414] .sup.1H NMR: .delta. (DMSO) 1.16 (d, 3H), 1.75-1.82 (m, 4H),
3.27-3.38 (m, 4H), 3.44-3.51 (m, 2H), 4.45 (dd, 2H), 5.10-5.18 (m,
1H), 5.97 (s, 1H), 7.13-7.20 (m, 1H), 7.29-7.42 (m, 2H), 10.91 (s,
1H)
[0415] The intermediate for this compound was prepared as
follows:
i)
2-[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1-pyrrolidinylsulfonyl)ami-
no]-4-pyrimidinyl]oxy]-(2R)-propanoic acid ethyl ester
[0416] The subtitle compound was prepared according to the
procedure outlined in example 1, step iv) using a mixture of
1-pyrrolidinesulfonamide (prepared according to patent WO
2004/011443, 0.19 g), tris(dibenzylideneacetone)dipalladium (0) (71
mg), 2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (52 mg), cesium carbonate (0.38 g),
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (the product of Example 23 step i)
(0.30 g) and dioxane (10 mL). Purification was by column
chromatography on silica gel using EtOAc/isohexane (1:1) as eluent
to give the subtitle compound as an oil. Yield: 0.38 g
[0417] MS: APCI (+ve) 475 [M+H.sup.+]
EXAMPLE 32
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-cyclopropanesulfonamide
##STR00039##
[0419] The title compound was prepared according to the procedure
outlined in example 24 using
2-[[6-[(cyclopropylsulfonyl)amino]-2-[[(2,3-difluorophenyl)methyl]thio]-4-
-pyrimidinyl]oxy]-(2R)-propanoic acid ethyl ester, (the product of
step i) (0.30 g), THF (8 mL) and 2M lithium borohydride in THF (2
mL). Purification was by reverse phase HPLC (symmetry as the
stationary phase and TFA/acetonitrile as the mobile phase). The
resulting oil was triturated with methanol, toluene, DCM, then
ether/iso-hexane to give the title compound as a white solid.
Yield: 0.20 g
[0420] MS: APCI (-ve) 430 [M-h.sup.-]
[0421] .sup.1H NMR: .delta. (DMSO) 1.00-1.10 (m, 4H), 1.17 (d, 3H),
2.93-3.04 (m, 1H), 3.47-3.50 (m, 2H), 4.47 (s, 2H), 5.08-5.20 (m,
1H), 6.06 (s, 1H), 7.11-7.21 (m, 1H), 7.28-7.45 (m, 2H), 11.10 (s,
1H)
[0422] The intermediate for this compound was prepared as
follows:
i)
2-[[6](cyclopropylsulfonyl)amino]-2-[[(2,3-difluorophenyl)methyl]thio]--
4-pyrimidinyl]oxy]-(2R)-propanoic acid ethyl ester
[0423] The subtitle compound was prepared according to the
procedure outlined in example 1, step iv) using a mixture of
cyclopropanesulfonamide (prepared according to patent WO
2003/099274, 0.14 g), tris(dibenzylideneacetone)dipalladium (0) (71
mg), 2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (52 mg), cesium carbonate (0.38 g),
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (the product of Example 23 step i)
(0.30 g) and dioxane (10 mL). Purification was by column
chromatography on silica gel using EtOAc/isohexane (1:1) as eluent
to give the subtitle compound as an oil. Yield: 0.30 g
[0424] MS: APCI (+ve) 503 [M+H.sup.+]
EXAMPLE 33
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-1-methyl-1H-imidazole-4-sulfonamide
##STR00040##
[0426] The title compound was prepared according to the procedure
outlined in example 24 using
2-[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1-methyl-1H-imidazol-4-yl)s-
ulfonyl]amino]-4-pyrimidinyl]oxy]-(2R)-propanoic acid ethyl ester
(the product of step i) (0.28 g), THF (8 mL) and 2M lithium
borohydride in THF (0.81 mL). Purification was by reverse phase
HPLC (symmetry as the stationary phase and TFA/acetonitrile as the
mobile phase). The resulting oil was triturated with toluene,
methanol, then ether/iso-hexane to give the title compound as a
white solid. Yield: 0.12 g
[0427] MS: APCI (-ve) 470 [M-H.sup.-]
[0428] .sup.1H NMR: .delta. (DMSO) 1.14 (d, 3H), 3.46 (m, 2H), 3.67
(s, 3H), 4.39 (t, 2H), 5.01-5.14 (m, 1H), 6.17 (s, 1H), 7.09-7.19
(m, 1H), 7.27-7.42 (m, 2H), 7.80 (s, 1H), 8.01 (s, 1H), 11.55 (s,
1H)
[0429] The intermediate for this compound was prepared as
follows:
i)
2-[[2-[[(2,3-difluorophenyl)methyl]thio]-6-[[(1-methyl-1H-imidazol-4-yl-
)sulfonyl]amino]-4-pyrimidinyl]oxy]-(2R)-propanoic acid ethyl
ester
[0430] The subtitle compound was prepared according to the
procedure outlined in example 1, step iv) using a mixture of
1-methyl-1H-imidazole-4-sulfonamide (0.19 g),
tris(dibenzylideneacetone)dipalladium (0) (71 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (52 mg), cesium carbonate (0.38 g),
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (the product of Example 23 step i)
(0.30 g) and dioxane (10 mL). Purification was by column
chromatography on silica gel using EtOAc/isohexane (1:1) as eluent
to give the subtitle compound as an oil. Yield: 0.28 g
[0431] MS: APCI (+ve) 514 [M+H.sup.+]
EXAMPLE 34
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1S)-2-ethoxy-1-(hydroxymethyl)-
ethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide
##STR00041##
[0433] To a solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-[[(1,1-dimethylethyl)di-
methylsilyl]oxy]-1-(ethoxymethyl)ethoxy]-4-pyrimidinyl]-1-azetidinesulfona-
mide, (product from step v) (0.79 g) in THF (10 mL) was added a 1M
solution of tetrabutylammoniumfluoride in THF (2.4 mL) with
stirring, at ambient temperature, for 72 h. The reaction mixture
was diluted with H.sub.2O and extracted with EtOAc (.times.2). The
organic layer was washed with H.sub.2O then brine and dried
(MgSO.sub.4), filtered and evaporated. The resulting oil was
purified by reverse phase HPLC (symmetry as the stationary phase
and TFA/acetonitrile as the mobile phase) then titurated with DCM
followed by ether/iso-hexane to give the title compound as a white
solid. Yield: 0.28 g
[0434] MS: APCI (-ve) 489 [M-H.sup.-]
[0435] .sup.1H NMR: .delta. (DMSO) 1.06 (t, 3H), 2.13 (quintet,
2H), 3.36-3.46 (m, 2H), 3.54-3.59 (m, 4H), 3.91 (t, 4H), 4.46 (dd,
2H), 4.88 (t, 1H), 5.25 (quintet, 1H), 6.12 (s, 1H), 7.12-7.19 (m,
1H), 7.30-7.38 (m, 1H), 7.40-7.45 (m, 1H), 11.14 (s, 1H)
[0436] The intermediates for this compound were prepared as
follows:
i) (4R)-4-(ethoxymethyl)-2,2-dimethyl-1,3-dioxolane
[0437] To a solution of 2,2-dimethyl-1,3-dioxolane-4-methanol (1.5
g), in dimethylfomylamide (30 mL), 60% sodium hydride (0.50 g) was
added portion-wise at 0.degree. C. then warmed to ambient
temperature. Iodoethane (3.5 mL) was added to the mixture at
0.degree. C. then stirred for 16 h at room temperature. The
reaction mixture was filtered then the filtrate was diluted with
H.sub.2O and extracted with EtOAc. The organic layer was washed
with H.sub.2O (.times.2) then brine and dried (MgSO.sub.4),
filtered and evaporated. Purification was by column chromatography
on silica gel using EtOAc/Et.sub.2O (1:1) as eluent to give the
subtitle compound as clear, colourless oil. Yield: 1 g
[0438] .sup.1H NMR: .delta. (DMSO) 1.10 (t, 3H), 1.27 (s, 3H), 1.32
(s, 3H), 3.32-3.50 (m, 4H), 3.54-3.62 (m, 1H), 3.93-4.01 (m, 1H),
4.11-4.20 (m, 1H)
ii) (2S)-3-ethoxy-1,2-propanediol
[0439] A solution of
(4R)-4-(ethoxymethyl)-2,2-dimethyl-1,3-dioxolane (product from step
i) (1 g) in 80% glacial acetic acid (30 mL) was stirred at ambient
temperature for 48 h. The solvent was evaporated, azeotroped with
methanol, ethanol and toluene then redissolved in DCM, dried
(MgSO.sub.4), filtered and evaporated to give the subtitle compound
as a yellow oil. Yield: 0.55 g.
[0440] .sup.1H NMR: .delta. (DMSO) 1.10 (t, 3H), 3.22-3.44 (m, 6H),
3.54 (quintet, 1H), 4.45 (t, 1H), 4.58 (d, 1H)
iii)
(2R)-1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-ethoxy-2-propanol
[0441] To a solution of (2S)-3-ethoxy-1,2-propanediol (product from
step (0.50 g) in DCM (30 mL) was added tert-butyldimethylsilyl
chloride (0.88 g), triethylamine (0.43 mL) and
4-(dimethylamino)pyridine (31 mg) at 0.degree. C. The solution was
then warmed to ambient temperature and stirred for 16 h. The
reaction mixture diluted with H.sub.2O and extracted with EtOAc.
The organic layer was washed with brine and evaporated.
Purification was by column chromatography on silica gel using
EtOAc/isohexane (2:8) as eluent to give the subtitle compound as an
oil. Yield: 0.69 g
[0442] .sup.1H NMR: .delta. (DMSO) 0.07 (s, 6H), 0.90 (s, 9H), 1.14
(t, 3H), 3.28-3.65 (m, 7H), 4.70 (d, 1H)
iv)
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-[[(1,1-dimethy-
lethyl)dimethylsilyl]oxy]-1-(ethoxymethyl)ethoxy]-pyrimidine
[0443] The subtitle compound was prepared according to the
procedure outlined in example 1 step iv) using
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (product of
example 1 step ii) (0.43 g),
(2R)-1-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-ethoxy-2-propanol
(product of step iii) (0.47 g), THF (20 mL) and 60% sodium hydride
(67 mg), to give the subtitle compound as a colourless oil. Yield:
0.7 g
[0444] MS: APCI (+ve) 505/507 [M+H.sup.+]
[0445] .sup.1H NMR: .delta. (DMSO) 0.03 (s, 6H), 0.80 (s, 9H), 1.09
(t, 3H), 3.39-3.50 (m, 2H), 3.60 (d, 2H), 3.75-3.81 (m, 2H), 4.49
(s, 2H), 5.35-5.44 (m, 1H), 6.90 (s, 1H), 7.14-7.23 (m, 1H),
7.32-7.43 (m, 2H)
v)
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-[[(1,1-dimethylethyl)-
dimethylsilyl]oxy]-1-(ethoxymethyl)ethoxy]-4-pyrimidinyl]-1-azetidinesulfo-
namide
[0446] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using a mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.29 g), tris(dibenzylideneacetone)dipalladium (0)
(0.13 g),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (93 mg), cesium carbonate (0.68 g),
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-2-[[(1,1-dimethylet-
hyl)dimethylsilyl]oxy]-1-(ethoxymethyl)ethoxy]-pyrimidine (the
product of step iv) (0.70 g) and dioxane (15 mL). Purification was
by column chromatography on silica gel using EtOAc/isohexane (3:7)
70:30 as eluent, to give the title compound as a white solid.
[0447] Yield: 0.22 g
[0448] MS: APCI (+ve) 605 [M+H.sup.+]
[0449] .sup.1H NMR: .delta. (DMSO) 0.02 (s, 6H), 0.84 (s, 9H),
1.04-1.11 (m, 3H), 2.08-2.18 (m, 2H), 3.53-3.59 (m, 2H), 3.72-3.77
(m, 2H), 3.86-3.94 (m, 4H), 3.99-4.07 (m, 2H), 4.49 (s, 2H), 5.34
(s, 1H), 6.14 (s, 1H), 7.10-7.20 (m, 1H), 7.29-7.45 (m, 2H), 11.17
(s, 1H)
EXAMPLE 35
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]azetidine--
1-sulfonamide
##STR00042##
[0451] The title compound was prepared according to the procedure
outlined in example 1, step iv). A mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.15 g), tris(dibenzylideneacetone)dipalladium (0) (44
mg), 2-dicyclohexylphosphino-2'4'6'-tri-iso-propyl-1,1'biphenyl (44
mg), cesium carbonate (0.36 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of step i) (0.23 g) in dioxane (7.2 mL). Acetic acid
(0.67 mL) was added and the reaction mixture was extracted with
EtOAc (.times.3). The combined organic layers were washed with
H.sub.2O, dried (MgSO.sub.4), filtered and the solvent evaporated
under reduced pressure. The residue was purified by flash column
chromatography on silica gel using EtOAc/isohexane (3:7) as eluent.
The resulting solid was further purified by trituration with
iso-hexane and dried under high vacuum at 40.degree. C. to give the
title compound as a pale yellow solid. Yield: 0.29 g.
[0452] MS: APCI (+ve) 403 [M+H]
[0453] .sup.1H NMR: .delta. (DMSO) 2.12 (m, 2H), 3.9 (m, 7H), 4.49
(s, 2H), 6.15 (s, 1H), 7.16 (m, 1H), 7.39 (m, 2H), 11.12 (s,
1H).
[0454] The intermediate for this compound was prepared as
follows:
i)
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
[0455] To a stirred solution of
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
Example 1, step (5 g) in dry methanol (40 mL) was added 60% sodium
hydride (0.68 g) batchwise over 5 min. The reaction mixture was
stirred for 5 h, H.sub.2O added and the solvents were partially
evaporated. The residue was extracted with EtOAc which was washed
with H.sub.2O, dried (MgSO.sub.4) and the solvent evaporated under
reduced pressure. The residue was purified by flash chromatography
on silica gel, eluting with Et.sub.2O/iso-hexane (5:95) to give the
subtitle compound as a white solid. Yield: 4.05 g.
[0456] MS: APCI (+ve) 303/305 [M+H]
EXAMPLE 36
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]piperazine-
-1-sulfonamide, trifluoroacetate salt
##STR00043##
[0458] 1,1-Dimethylethyl
4-[2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl
sulfamoyl]piperazine-1-carboxylate (the product of step i) (0.36 g)
and trifluoroacetic acid (1 mL) in dichloromethane (4 mL) were
stirred at room temperature for 30 min. The solvent was evaporated
under reduced pressure and the residue was azeotroped with toluene
(3.times.). The residual pale yellow solid was triturated with
EtOAc, filtered and dried at 40.degree. C. under high vacuum to
give the title compound as a cream solid. Yield: 0.24 g.
[0459] MS: APCI (+ve) 432 [M+H]
[0460] .sup.1H NMR: .delta. (DMSO) 3.17 (m, 4H), 3.40 (m, 4H), 3.90
(s, 3H), 4.49 (s, 2H), 6.08 (s, 1H), 7.18 (m, 1H), 7.38 (m,
2H).
[0461] The intermediates for this compound were prepared as
follows:
i) 1,1-Dimethylethyl
442-[[(2,3-difluorophenyl)methyl]thio]-6-methoxy pyrimidin-4-yl
sulfamoyl]piperazine-1-carboxylate
[0462] The subtitle compound was prepared from 1,1-dimethylethyl
4-sulfamoylpiperazine-1-carboxylate (the product of example 15,
step i), 0.22 g) and
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of Example 35, step i) (0.25 g) according to the
procedure outlined in Example 1, step iv). The crude material was
purified by column chromatography on silica gel using
EtOAc/isohexane (2:8) as eluent. Yield: 0.36 g
[0463] MS: APCI (-ve) 530 [M-H]
[0464] .sup.1H NMR: .delta. (CDCl.sub.3) 1.45 (s, 9H), 3.27 (t,
4H), 3.48 (t, 4H), 3.94 (s, 3H), 4.40 (s, 2H), 6.23 (s, 1H), 7.04
(m, 2H), 7.22 (m, 1H).
EXAMPLE 37
4-Acetyl-N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]p-
iperazine-1-sulfonamide
##STR00044##
[0466] Acetic anhydride (0.78 mL) was added to a mixture of
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]piperazin-
e-1-sulfonamide, trifluoroacetate salt (the title product of
Example 36, 0.84 g) and N,N-diisopropylethylamine (1 mL) in DCM (5
mL). The reaction mixture was stirred at room temperature for 30
min and the solvent evaporated under reduced pressure. The residue
was dissolved in EtOAc which was washed with aqueous citric acid,
H.sub.2O, dried (MgSO.sub.4) and the solvent evaporated under
reduced pressure. The residue was purified by flash chromatography
on silica gel, eluting with EtOAc to give the title compound as a
white solid. Yield: 78 mg.
[0467] MS: APCI (+ve) 474 [M+H]
[0468] .sup.1H NMR: .delta. (DMSO) 1.98 (s, 3H), 3.20 (m, 4H), 3.87
(s, 3H), 3.32 (br d, 4H), 4.48 (s, 2H), 6.07 (s, 1H), 7.17 (m, 1H),
7.33 (m, 1H), 7.42 (t, 1H), 11.18 (s, 1H).
EXAMPLE 38
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]morpholine-
-4-sulfonamide
##STR00045##
[0470] The title compound was prepared from
morpholine-4-sulfonamide (prepared according to patent WO
2004/011443, 0.20 g) and
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of Example 35, step i) (0.25 g) according to the
procedure outlined in Example 1, step iv). The crude material was
purified by column chromatography using EtOAc/isohexane (2:8) as
eluent. Yield: 0.26 g.
[0471] MS: APCI (+ve) 433 [M+H]
[0472] .sup.1H NMR: .delta. (DMSO) 3.17 (t, 4H), 3.59 (t, 4H), 3.88
(s, 3H), 4.48 (s, 2H), 6.09 (s, 1H), 7.17 (m, 1H), 7.34 (m, 1H),
7.43 (t, 1H), 11.17 (s, 1H).
EXAMPLE 39
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]methane-su-
lfonamide
##STR00046##
[0474] The title compound was prepared from methane sulfonamide
(0.11 g) and
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of Example 35, step i) (0.25 g) according to the
procedure outlined in Example 1, step iv). The crude material was
purified by column chromatography using EtOAc/isohexane (2:8) as
eluent. Yield: 0.12 g.
[0475] MS: APCI (+ve) 362 [M+H]
[0476] .sup.1H NMR: .delta. (DMSO) 3.28 (s, 3H), 3.87 (s, 3H), 4.49
(s, 2H), 6.03 (s, 1H), 7.17 (m, 1H), 7.37 (m, 2H), 11.14 (s,
1H).
EXAMPLE 40
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]-1-methyl--
1H-imidazole-4-sulfonamide
##STR00047##
[0478] The title compound was prepared from
1-methyl-1H-imidazole-4-sulfonamide (0.19 g) and
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of Example 35, step i) (0.25 g) according to the
procedure outlined in Example 1, step iv). The crude material was
purified by column chromatography using EtOAc/isohexane (2:8) as
eluent.
[0479] Yield: 0.11 g.
[0480] MS: APCI (+ve) 428 [M+H]
[0481] .sup.1H NMR: .delta. (DMSO) 3.67 (s, 3H), 3.83 (s, 3H), 4.41
(s, 2H), 6.20 (s, 1H), 7.15 (m, 1H), 7.36 (m, 2H), 7.78 (s, 1H),
8.00 (s, 1H), 11.55 (s, 1H)
EXAMPLE 41
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(S)-isoxazolidin-4-yl)oxy]pyrim-
idin-4-yl]azetidine-1-sulfonamide
##STR00048##
[0483] 1,1-Dimethylethyl
(S)-4-[6-(azetidine-1-sulfonylamino)-2-[[(2,3-difluorophenyl)methyl]thio]-
pyrimidin-4-yloxy]isoxazolidine-2-carboxylate (the product of step
(0.14 g) and trifluoroacetic acid (1 mL) in dichloromethane (2 mL)
were stirred at room temperature for 30 min. The solvent was
evaporated under reduced pressure and the residue was azeotroped
with toluene (3.times.). The residue was purified by reverse phase
HPLC eluting with acetonitrile/0.1% aqueous ammonium acetate
mixtures to give the title compound as a white solid. Yield: 80
mg.
[0484] MS: APCI (+ve) 458 [M+H]
[0485] .sup.1H NMR: .delta. (DMSO) 7.37 (m, 2H), 7.18 (m, 1H), 6.16
(s, 1H), 5.65 (bm, 1H), 4.49 (s, 2H), 3.91-3.81 (bs+t, 6H), 3.01
(bs, 1H), 2.13 (m, 2H).
[0486] The intermediates for this compound were prepared as
follows:
i) 1,1-Dimethylethyl
(S)-4-[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]pyrimidin-4-yloxy]-is-
oxazolidine-2-carboxylate
[0487] To a stirred solution of
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
Example 1, step ii) (0.25 g) and 1,1-dimethylethyl
(S)-4-hydroxyisoxazolidine-2-carboxylate (0.16 g) in dry THF (5 mL)
was added 60% Sodium hydride (0.034 g) over 5 min. The reaction
mixture was stirred and heated at 60.degree. C. for 7 days,
H.sub.2O was added and the solvents were partially evaporated. The
residue was extracted with EtOAc which was washed with H.sub.2O,
dried (MgSO.sub.4) and the solvent evaporated under reduced
pressure. The residue was purified by flash chromatography on
silica gel, eluting with Et.sub.2O/iso-hexane (1:9) to give the
subtitle compound as a gum. Yield: 0.15 g.
[0488] MS: APCI (+ve) 460/462 [M+H]
ii) 1,1-Dimethylethyl
(S)-4-[6-(azetidine-1-sulfonylamino)-2-[[(2,3-difluorophenyl)methyl]thio]-
pyrimidin-4-yloxy]isoxazolidine-2-carboxylate
[0489] The subtitle compound was prepared from
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.22 g) and 1,1-Dimethylethyl
(S)-4-[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]pyrimidin-4-yloxy]iso-
xazolidine-2-carboxylate (the product of step i) (0.13 g) according
to the procedure outlined in Example 1, step iv). The crude
material was purified by column chromatography using
EtOAc/isohexane (2:8) as eluent. Yield: 0.14 g
[0490] MS: APCI (-ve) 558 [M-H]
EXAMPLE 42
N-[6-((R)-2-amino-1-methylethoxy)-2-[[(2,3-Difluorophenyl)methyl]thio]pyri-
midin-4-yl]azetidine-1-sulfonamide
##STR00049##
[0492] The title compound was prepared from 1,1-dimethylethyl
[(R)-2-[6-azetidine-1-sulfonyl
amino)-2-[[(2,3-difluorophenyl)methyl]thio]pyrimidin-4-yloxy]propyl}carba-
mate (0.26 g) (the product of step ii) according to the procedure
outlined in Example 41. The crude material was purified by column
chromatography using EtOAc/isohexane (2:8) as eluent. Yield: 0.11
g
[0493] MS: APCI (+ve) 446 [M+H]
[0494] .sup.1H NMR: .delta. (DMSO) 1.19 (d, 3H), 1.97 (m, 2H), 2.99
(m, 2H), 3.58 (t, 4H), 4.38 (q, 2H), 5.15 (s, 1H), 5.97 (s, 1H),
7.12 (m, 1H), 7.30 (m, 1H), 7.43 (t, 1H), 7.49 (br s, 3H).
[0495] The intermediates for this compound were prepared as
follows:
i) 1,1-Dimethylethyl
[(R)-2-[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]pyrimidin-4-yloxy]pr-
opyl]carbamate
[0496] The subtitle compound was prepared from 1,1-dimethylethyl
((R)-2-hydroxypropyl) carbamate (0.15 g) and
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
Example 1, step (0.25 g) according to the procedure outlined in
Example 41, step i) with heating at 45.degree. C. for 18 h. The
crude material was purified by column chromatography using
EtOAc/isohexane (2:8) as eluent. Yield: 0.23 g.
[0497] MS: APCI (-ve) 444/446 [M-H]
ii) 1,1-Dimethylethyl
[(R)-2-[6-azetidine-1-sulfonylamino)-2-[[(2,3-difluorophenyl)methyl]thio]-
pyrimidin-4-yloxy]propy]carbamate
[0498] The subtitle compound was prepared from
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443, 0.11 g) and 1,1-Dimethylethyl
[(R)-2-[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]pyrimidin-4-yloxy]pr-
opyl]carbamate (the product of step i) (0.2 g) according to the
procedure outlined in Example 1, step iv). The crude material was
purified by column chromatography using EtOAc/isohexane (2:8) as
eluent. Yield: 0.14 g
[0499] MS: APCI (-ve) 544 [M-H]
EXAMPLE 43
N--[(R)-2-[6-[azetidine-1-sulfonylamino]-2-[[(2,3-difluorophenyl)methyl]th-
io]pyrimidin-4-yloxy]propyl]acetamide
##STR00050##
[0501] To a suspension of
N-[6-((R)-2-amino-1-methylethoxy)-2-[[(2,3-Difluorophenyl)methyl]thio]pyr-
imidin-4-yl]azetidine-1-sulfonamide (the title product of Example
42) (0.05 g) in dichloromethane (10 mL) was added pyridine (0.02
mL), followed by acetic anhydride (0.02 mL). The mixture was
stirred overnight at room temperature. Pyridine (0.02 mL) and
acetic anhydride (0.02 mL) were added and the reaction mixture was
stirred for a further 2 h Pyridine (1.0 mL) and acetic anhydride
(0.50 mL) were added and the reaction mixture was stirred for a
further 2 h. The reaction mixture was diluted with dichloromethane,
washed with aqueous citric acid, H.sub.2O, dried (MgSO.sub.4),
filtered and the solvent evaporated under reduced pressure. The
residue was purified by flash column chromatography on silica gel
using 40% EtOAc in isohexane as eluent. The isolated product was
further purified by reverse phase HPLC eluting with
acetonitrile/aq. 0.1% ammonium acetate mixtures to give the title
compound as a white solid. Yield: 55 mg.
[0502] MS: APCI (-ve) 486 [M-H]
[0503] .sup.1H NMR: 8 (DMSO) 1.11 (d, 3H), 1.80 (s, 3H), 1.96 (m,
2H), 3.20 (m, 2H), 3.55 (t, 4H), 4.34 (q, 2H), 5.02 (m, 1H), 5.88
(s, 1H), 7.12 (m, 1H), 7.29 (m, 1H), 7.41 (t, 1H), 7.99 (t,
1H).
EXAMPLE 44
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(R,S)-2-dimethylamino-1-methyle-
thoxy]pyrimidin-4-yl]azetidine-1-sulfonamide
##STR00051##
[0505] The title compound was prepared from azetidine-1-sulfonamide
(prepared according to patent WO 2004/011443, 0.15 g) and
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-N,N--
dimethyl-1-propanamine (the product of step i) (0.29 g) according
to the procedure outlined in Example 1, step iv). The reaction
product was purified by reverse phase HPLC eluting with
acetonitrile/aq. 0.1% ammonium acetate mixtures to give the title
compound as a pale yellow solid. Yield: 0.30 g
[0506] MS: APCI (+ve) 474 [M+H]
[0507] .sup.1H NMR: .delta. (DMSO) 1.17 (d, 3H), 2.07 (m, 2H), 2.24
(s, 6H), 2.44 (m, 1H), 2.64 (m, 1H), 3.79 (t, 4H), 4.24 (t, 2H),
5.27 (m, 1H), 6.00 (s, 1H), 7.15 (m, 1H), 7.33 (m, 1H), 7.42 (t,
1H).
[0508] The intermediate for this compound was prepared as
follows:
i)
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-N,-
N-dimethyl-1-propanamine
[0509] The subtitle compound was prepared according to the
procedure outlined in Example 41 step i) using
1-dimethylamino-2-propanol (80 mg),
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
Example 1 step (0.25 g) and 60% sodium hydride (30 mg) in THF (2
mL) at room temperature for 2 d to give the subtitle compound as a
pale yellow gum. Yield: 0.29 g.
[0510] MS: APCI (+ve) 374 [M+H]
EXAMPLE 45
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-{[(1R,2R)-2,3-dihydroxy-1-methyl-
propyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
##STR00052##
[0512] To a solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-[(4R)-2,2-dimethyl-1,3--
dioxolan-4-yl]ethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide (the
product of step vi) (0.13 g) in DCM (5 mL) was added iron (III)
chloride hexahydrate (0.26 g). The reaction mixture was stirred at
ambient temperature for 1.5 h, then saturated aqueous sodium
bicarbonate (1 mL) was added. The layers were separated and the
aqueous material extracted with DCM (.times.3) and ethyl acetate
(.times.3). The combined organic extracts were washed with
saturated aqueous sodium chloride, dried (MgSO.sub.4), filtered and
evaporated. The residual pale yellow solid was slowly precipitated
from DCM, filtered and the resulting material washed with minimal
cold DCM (2.times.1 mL) to afford the title compound as a white
powder. Yield: 64 mg.
[0513] MS: APCI (+ve) 477 [M+H.sup.+]
[0514] .sup.1H NMR: .delta. (CDCl.sub.3) 1.33 (d, 3H), 2.27
(quintet, 2H), 2.55 (d, 1H), 3.61-3.70 (m, 2H), 3.74-3.82 (m, 1H),
4.02 (t, 4H), 4.31-4.41 (m, 2H), 5.32 (quintet, 1H), 6.34 (s, 1H),
6.98-7.24 (m, 3H).
[0515] The intermediates for this compound were prepared as
follows:
i) (2S,3R)-3-(Benzyloxy)-2-hydroxybutanoic acid
[0516] To a solution of (2S,3R)-2-amino-3-benzyloxy-butyric acid
(1.1 g) in 2M sulfuric acid (6.31 mL) was added dropwise over 2 h a
solution of sodium nitrite (0.65 g) in water (6 mL), keeping the
internal temperature of the reaction below 0.degree. C. The
reaction mixture was stirred at -5.degree. C. for 6 h then allowed
to warm to room temperature overnight. The mixture was adjusted to
pH 4 with 50% aqueous sodium hydroxide then ethyl acetate was
added. The mixture was stirred vigorously and acidified to pH 2
with concentrated sulfuric acid. The layers were separated and the
aqueous layer extracted with further ethyl acetate (.times.2). The
combined organic extracts were washed with saturated aqueous sodium
chloride, dried (MgSO.sub.4), filtered and evaporated to give the
subtitle compound as a yellow crystalline solid which was used
without further purification. Yield: 0.84 g.
[0517] MS: APCI (+ve) 211, [M+H.sup.+]
[0518] .sup.1H NMR: .delta. (300 MHz, CDCl.sub.3) 1.31 (d, 3H),
3.99-4.05 (m, 1H), 4.16 (d, 1H), 4.51 (d, 1H), 4.69 (d, 1H),
7.22-7.38 (m, 5H).
ii) (2R,3R)-3-(Benzyloxy)butane-1,2-diol
[0519] To a solution of (2S,3R)-3-(benzyloxy)-2-hydroxybutanoic
acid (the product of step i) (0.79 g) and trimethyl borate (0.67
mL) in anhydrous tetrahydrofuran (4 mL) at 0.degree. C. was added
dropwise borane-dimethyl sulfide complex (3 mL, 2M in
tetrahydrofuran). The reaction mixture was stirred at room
temperature overnight, then further borane-dimethyl sulfide complex
(3 mL, 2M in tetrahydrofuran) was added at 0.degree. C. and the
reaction mixture stirred at room temperature for a further 2 d. The
mixture was cooled to 0.degree. C. and methanol (10 mL) slowly
added. When effervescence had ceased, the volatiles were
evaporated, further methanol added and the mixture concentrated
again to give the subtitle compound as a yellow oil which was used
without further purification. Yield: 0.68 g.
[0520] MS: APCI (+ve) 197, [M+H.sup.+]
[0521] .sup.1H NMR: .delta. (CDCl.sub.3) 1.25 (d, 3H), 2.17 (t,
1H), 2.77 (d, 1H), 3.52-3.77 (m, 4H), 4.43 (d, 1H), 4.69 (d, 1H),
7.27-7.39 (m, 5H).
iii)
(4R)-4-[(1R)-1-(Benzyloxy)ethyl]-2,2-dimethyl-1,3-dioxolane
[0522] A stirred solution of (2R,3R)-3-(benzyloxy)butane-1,2-diol
(the product of step ii) (0.68 g), p-toluene sulfonic acid
monohydrate (34 mg) and 2,2-dimethoxypropane (0.43 mL) in toluene
(10 mL) was heated to reflux for 30 min, then anhydrous sodium
sulfate was added and reflux continued for 2.5 h. The reaction
mixture was allowed to cool and diluted with EtOAc and saturated
aqueous sodium bicarbonate and the layers separated. The organic
extract was washed with brine, dried (MgSO.sub.4), filtered and
evaporated. The residue was purified by column chromatography on
silica gel using EtOAc/isohexane (1:9 to 1:1 gradient) as eluent to
give the subtitle compound as a colourless liquid. Yield: 0.46
g.
[0523] .sup.1H NMR: .delta. (CDCl.sub.3) 1.13 (d, 3H), 1.37 (s,
3H), 1.42 (s, 3H), 3.60 (quintet, 1H), 3.71 (dd, 1H), 3.99 (dd,
1H), 4.15 (quintet, 1H), 4.64 (d, 1H), 4.67 (d, 1H), 7.24-7.38 (m,
5H).
iv) (1R)-1-[(4R)-2,2-Dimethyl-1,3-dioxolan-4-yl]ethanol
[0524] Ammonia (c. 50 mL) was condensed at -78.degree. C. into a
three-necked flask which had been oven-dried overnight, and to it
was added a solution of
(4R)-4-[(1R)-1-(benzyloxy)ethyl]-2,2-dimethyl-1,3-dioxolane (the
product of step iii) (0.39 g) in tetrahydrofuran (7.5 mL). Sodium
was added in small pieces until the reaction mixture was dark blue,
then it was allowed to warm to -40.degree. C. and kept at this
temperature for 1.5 h, during which time further sodium was added
when the blue colour faded. The reaction mixture was quenched with
excess solid ammonium chloride and allowed to warm to room
temperature. Ether (20 mL) was added followed by water, cautiously
(10 mL). The layers were separated and the aqueous layer extracted
with further ether (.times.3). The combined organic extracts were
washed with saturated aqueous sodium chloride, dried (MgSO.sub.4),
filtered and evaporated to give the subtitle compound as a pale
yellow liquid which was used without further purification. Yield:
0.24 g.
[0525] .sup.1H NMR: .delta. (CDCl.sub.3) 1.16 (d, 3H), 1.37 (s,
3H), 1.44 (s, 3H), 3.67-3.77 (m, 2H), 3.93 (q, 1H), 4.00-4.05 (m,
1H).
v)
4-Chloro-2-[(2,3-difluorobenzyl)thio]-6-{(1R)-1-[(4R)-2,2-dimethyl-1,3--
dioxolan-4-yl]ethoxy}pyrimidine
[0526] To a solution of
(1R)-1-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]ethanol (the product of
step iv) (0.24 g) in dry THF (10 mL) at 0.degree. C. was added in
portions sodium hydride (91 mg as 60% dispersion in mineral oil)
followed in portions by
4,6-dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step ii) (0.50 g). The reaction mixture was stirred at
room temperature for 48 h then quenched with saturated aqueous
ammonium chloride (10 mL) and diluted with ethyl acetate. The
layers were separated and the aqueous layer extracted with further
ethyl acetate. The combined organic extracts were washed with
brine, dried (MgSO.sub.4), filtered and evaporated. The residue was
purified by column chromatography on silica gel using
EtOAc/isohexane (1:19 to 1:9 gradient) as eluent to give the
subtitle compound as a pale yellow solid. Yield: 0.42 g.
[0527] MS: APCI (+ve) 417/419 [M+H.sup.+]
[0528] .sup.1H NMR: .delta. (CDCl.sub.3) 1.24 (d, 3H), 1.36 (s,
3H), 1.40 (s, 3H), 3.74 (dd, 1H), 4.03 (dd, 1H), 4.21 (q, 1H), 4.40
(s, 2H), 5.28 (quintet, 1H), 6.44 (s, 1H), 6.98-7.11 (m, 2H),
7.26-7.31 (m, 1H).
vi)
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(1R)-1-[(4R)-2,2-dimethyl-1-
,3-dioxolan-4-yl]ethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide
[0529] A mixture of azetidine-1-sulphonamide (prepared according to
patent WO 2004/011443, 0.20 g),
tris(dibenzylideneacetone)-dipalladium (0) (33 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (17 mg), cesium carbonate (0.18 g) and
4-chloro-2-[[(2,3-difluorophenyl)-methyl]thio]-6-[(2-phenyl-1,3-dioxan-5--
yl)oxy]pyrimidine (the product of step v) (0.15 g) in dioxane (5
mL) was heated at reflux in a microwave at 100.degree. C., 300 W,
open vessel with cooling for 25 min. Saturated aqueous ammonium
chloride was added and the resulting mixture extracted with ethyl
acetate. The combined organic extracts were washed with brine,
dried (MgSO.sub.4), filtered and evaporated. The residue was
purified by column chromatography on silica gel using
EtOAc/isohexane (1:19 to 3:7 gradient) as eluent to give the
subtitle compound as a yellow oil. Yield: 0.14 g.
[0530] MS: APCI (+ve) 517 [M+H.sup.+]
[0531] .sup.1H NMR: .delta. (CDCl.sub.3) 1.23 (d, 3H), 1.38 (s,
3H), 1.43 (s, 3H), 2.25 (quintet, 2H), 3.77 (dd, 1H), 3.98-4.09 (m,
5H), 4.24 (q, 1H), 4.37 (s, 2H), 5.30 (quintet, 1H), 6.32 (s, 1H),
6.98-7.11 (m, 2H), 7.20-7.26 (m, 1H).
EXAMPLE 46
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[[(1R,2R)-2,3-dihydroxy-1-methyl-
propyl]oxy]-4-pyrimidinyl]-methanesulfonamide
##STR00053##
[0533] To a solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-[(4R)-2,2-dimethyl-1,3--
dioxolan-4-yl]ethoxy]-4-pyrimidinyl]-methanesulfonamide (the
product of step i) (0.23 g) in DCM (5 mL) was added iron (III)
chloride hexahydrate (0.25 g). The reaction mixture was stirred at
ambient temperature for 2 h then saturated aqueous sodium
bicarbonate (2 mL) was added. The layers were separated and the
aqueous material extracted with DCM (.times.3) and ethyl acetate
(.times.3). The combined organic extracts were washed with brine,
dried (MgSO.sub.4), filtered and evaporated. The residual yellow
solid was precipitated from 10% DCM in Et.sub.2O, filtered and the
resulting material washed with minimal Et.sub.2O (2.times.1 mL) to
afford the title compound as a white powder. Yield: 24 mg.
[0534] MS: APCI (+ve) 436, [M+H.sup.+]
[0535] .sup.1H NMR: .delta. (DMSO) 1.19 (d, 3H), 3.29 (s, 3H),
3.36-3.40 (m, 2H), 3.46-3.53 (m, 1H), 4.43 (d, 1H), 4.48 (d, 1H),
4.54-4.57 (m, 1H), 4.88 (d, 1H), 5.16-5.24 (m, 1H), 5.98 (s, 1H),
7.12-7.19 (m, 1H), 7.29-7.43 (m, 2H), 11.10 (s, 1H).
[0536] The intermediate for this compound was prepared as
follows:
i)
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-[(4R)-2,2-dimethyl-1,-
3-dioxolan-4-yl]ethoxy]-4-pyrimidinyl]-methanesulfonamide
[0537] A mixture of methanesulfonamide (0.11 g),
tris(dibenzylideneacetone)dipalladium (0) (26 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (14 mg), cesium carbonate (0.14 g) and
4-chloro-2-[[(2,3-difluorophenyl)-methyl]thio]-6-[(2-phenyl-1,3-dioxan-5--
yl)oxy]-pyrimidine (the subtitle product of example 46 step v)
(0.12 g) in dioxane (6 mL) was heated at reflux in a microwave at
100.degree. C., 300 W, open vessel with cooling for 15 min.
Saturated aqueous ammonium chloride was added and the resulting
mixture extracted with ethyl acetate. The combined organic extracts
were washed with brine, dried (MgSO.sub.4), filtered and
evaporated. The residue was purified by column chromatography on
silica gel using EtOAc/isohexane (1:19 to 3:7 gradient) as eluent
to give the subtitle compound as a yellow oil. Yield: 0.12 g.
[0538] MS: APCI (+ve) 476 [M+H.sup.+]
[0539] .sup.1H NMR (CDCl.sub.3) .delta. 1.23 (d, 3H), 1.37 (s, 3H),
1.42 (s, 3H), 3.22 (s, 3H), 3.76 (dd, 1H), 4.04 (dd, 1H), 4.23 (q,
1H), 4.38 (s, 2H), 5.30 (quintet, 1H), 6.23 (s, 1H), 6.97-7.11 (m,
2H), 7.22-7.28 (m, 1H).
EXAMPLE 47
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methyl-
propyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
##STR00054##
[0541] To a solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-[(4S)-2,2-dimethyl-1,3--
dioxolan-4-yl]ethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide (the
product of step (0.13 g) in DCM (5 mL) was added iron (III)
chloride hexahydrate (0.24 g). The reaction mixture was stirred at
ambient temperature for 1 h, then saturated aqueous sodium
bicarbonate (10 mL) was added. The layers were separated and the
aqueous material extracted with DCM (3.times.10 mL) and EtOAc
(3.times.10 mL). The combined organic extracts were washed with
saturated sodium chloride, dried (MgSO.sub.4), filtered and
evaporated. The residual pale yellow solid was slowly precipitated
from DCM, filtered and the resulting material washed with minimal
cold DCM (2.times.1 mL) to afford the title compound as a white
powder. Yield: 45 mg.
[0542] MS: APCI (/ve) 477 [M+H.sup.+]
[0543] .sup.1H NMR: .delta. (CDCl.sub.3) 1.36 (d, 3H), 2.27
(quintet, 2H), 2.34 (br s, 1H), 2.67 (d, 1H), 3.59-3.65 (m, 1H),
3.67-3.78 (m, 2H), 4.02 (t, 4H), 4.36 (s, 2H), 5.23 (quintet, 1H),
6.31 (s, 1H), 7.00-7.10 (m, 2H), 7.19-7.23 (m, 1H).
[0544] The intermediates for this compound were prepared as
follows:
i)
4-chloro-2-[(2,3-difluorobenzyl)thio]-6-{(1R)-1-[(4S)-2,2-dimethyl-1,3--
dioxolan-4-yl]ethoxy}pyrimidine
[0545] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iii) using
(1R)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]ethanol (prepared
according to Liebigs. Ann. Chem. 1987, 7-14) (0.25 g) and
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step ii) (0.53 g) in THF (20 mL) and 60% sodium hydride
(80 mg). Crude material was purified by column chromatography on
silica gel using EtOAc/isohexane (1:3) as eluent to give the
subtitle compound as a clear, colourless oil. Yield: 0.37 g.
[0546] MS: APCI (+ve) 417/419 [M+H.sup.+]
ii)
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(1R)-1-[(4S)-2,2-dimethyl-1-
,3-dioxolan-4-yl]ethoxy]-4-pyrimidinyl]-1-azetidinesulfonamide
[0547] A mixture of azetidine-1-sulphonamide (prepared according to
patent WO 2004/011443, 0.16 g),
tris(dibenzylideneacetone)-dipalladium (0) (33 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (17 mg), cesium carbonate (0.28 g) and
4-chloro-2-[[(2,3-difluorophenyl)-methyl]thio]-6-[(2-phenyl-1,3-dioxan-5--
yl)oxy]-pyrimidine (the product of step i) (0.25 g) in dioxane (10
mL) was heated at reflux in a microwave at 100.degree. C., 300 W,
open vessel with cooling for 20 min. Saturated ammonium chloride
was added and the resulting mixture extracted with EtOAc. The
combined organic extracts were washed with saturated aqueous sodium
chloride, dried (MgSO.sub.4), filtered and evaporated. The residue
was purified by column chromatography on silica gel using
EtOAc/isohexane (3:7) as eluent to give the subtitle compound as a
yellow oil. Yield: 0.13 g.
[0548] MS: APCI (+ve) 517 [M+H.sup.+]
EXAMPLE 48
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methyl-
propyl]oxy}-4-pyrimidinyl]-1-piperazinesulfonamide
##STR00055##
[0550] A solution of tert-butyl
4-{[(2-[(2,3-difluorobenzyl)thio]-6-{(1R)-1-[(4S)-2,2-dimethyl-1,3-dioxol-
an-4-yl]ethoxy}pyrimidin-4-yl)amino]sulfonyl}piperazine-1-carboxylate
(the product of step i) (0.23 g) in 10% trifluoroacetic acid/DCM (5
mL) was stirred at room temperature for 1 h. The mixture was
evaporated to dryness in vacuo. The resulting crude oil was
purified by reverse phase HPLC (75% to 5% gradient of 0.1% aqueous
ammonium acetate in acetonitrile as eluent) to give the title
compound as a white solid. Yield: 40 mg.
[0551] MS: APCI (+ve) 506 [M+H.sup.+]
[0552] .sup.1H NMR .delta. (DMSO) 1.14 (d, 3H), 2.99-3.05 (m, 4H),
3.11-3.17 (m, 4H), 3.25-3.40 (m, 2H), 3.54-3.61 (m, 1H), 4.34 (d,
1H), 4.41 (d, 1H), 4.54 (br s, 1H), 4.81 (d, 1H), 5.03 (dq, 1H),
5.82 (s, 1H), 7.09-7.16 (m, 1H), 7.26-7.35 (m, 1H), 7.43 (dd,
1H)
[0553] The intermediate for this compound was prepared as
follows:
i) tert-butyl
4-{[(2-[(2,3-difluorobenzyl)thio]-6-{(1R)-1-[(4S)-2,2-dimethyl-1,3-dioxol-
an-4-yl]ethoxy}pyrimidin-4-yl)amino]sulfonyl}piperazine-1-carboxylate
[0554] The subtitle compound was prepared from 1,1-dimethylethyl
4-sulfamoylpiperazine-1-carboxylate (the product of example 15,
step i), 0.26 g) and
4-chloro-2-[(2,3-difluorobenzyl)thio]-6-{(1R)-1-[(4S)-2,2-dimethyl-1,3-di-
oxolan-4-yl]ethoxy}pyrimidine (the product of Example 47, step i)
(0.21 g) according to the procedure outlined in Example 1, step
iv). Yield: 0.28 g
[0555] MS: APCI (-ve) 644 [M-H]
EXAMPLE 49
5-(azetidin-1-ylcarbonyl)-N-{2-[(2,3-difluorobenzyl)thio]-6-[(1R)-2-hydrox-
y-1-methylethoxy]pyrimidin-4-yl}furan-2-sulfonamide
##STR00056##
[0557] To a solution of
5-(azetidin-1-ylcarbonyl)-N-{2-[(2,3-difluorobenzyl)thio]-6-[(1R)-1-methy-
l-2-(triphenylmethyloxy)ethoxy]pyrimidin-4-yl}furan-2-sulfonamide
(the product of step iv) (0.24 g) in methanol (5 mL) was added
para-toluenesulfonic acid hydrate (58 mg) and anisole (0.34 mL).
After stirring at room temperature for 2 d, H.sub.2O (5 mL) was
added and the mixture extracted with EtOAc (3.times.10 mL). The
combined organic layers were washed with brine (10 mL), dried
(MgSO.sub.4), filtered and evaporated to dryness in vacuo. The
resulting crude solid was purified by reverse phase HPLC (50% to 5%
gradient of 0.1% aqueous ammonium acetate in acetonitrile as
eluent) to give the title compound as a white solid. Yield: 10
mg.
[0558] MS: APCI (+ve) 541 [M+H.sup.+]
[0559] .sup.1H NMR .delta. (CDCl.sub.3) 1.28 (d, 3H), 2.39
(quintet, 2H), 3.70 (dd, 1H), 3.76 (dd, 1H), 4.20 (t, 4H), 4.33 (d,
1H), 4.37 (d, 1H), 4.51 (t, 2H), 5.31 (dquintet, 1H), 6.41 (s, 1H),
6.99-7.08 (m, 2H), 7.11 (d, 1H), 7.17-7.22 (m, 1H), 7.21 (d,
1H)
[0560] The intermediates for this compound were prepared as
follows:
i) methyl 5-[(tert-butylamino)sulfonyl]-2-furoate
[0561] To a solution of methyl 5-(chlorosulfonyl)-2-furoate (3.0 g)
in DCM (100 mL) was added tert-butylamine (3.6 mL). After stirring
at room temperature for 2 days the mixture was filtered through a
pad of celite, washing with DCM (2.times.10 mL). The filtrate was
evaporated to dryness in vacuo. The resulting crude residue was
purified by column chromatography using EtOAc/isohexane (2:8) as
eluent to give the subtitle compound as a foam. Yield: 2.75 g.
[0562] MS: APCI (-ve) 260 [M-H]
ii) 5-(azetidin-1-ylcarbonyl)-N-(tert-butyl)furan-2-sulfonamide
[0563] To a solution of methyl
5-[(tert-butylamino)sulfonyl]-2-furoate (the product of step i)
(2.15 g) in methanol (80 mL) was added azetidine (1.15 mL). After
stirring at room temperature for 5 h the mixture was evaporated to
dryness in vacuo. The resulting residue was partitioned between
EtOAc (50 mL) and H.sub.2O (50 mL). The separated organic layer was
dried (MgSO.sub.4), filtered and evaporated to dryness in vacuo.
The resulting crude material was purified by column chromatography
(EtOAC as eluent) to give the subtitle compound as a pale yellow
oil. Yield: 3 g.
[0564] MS: APCI (+ve) 287 [M+H.sup.+]
iii) 5-(azetidin-1-ylcarbonyl)furan-2-sulfonamide
[0565] A solution of
5-(azetidin-1-ylcarbonyl)-N-(tert-butyl)furan-2-sulfonamide (the
product of step ii) (3 g) in trifluoroacetic acid (90 mL) was
stirred at room temperature. After 18 h the mixture was evaporated
to dryness in vacuo. The resulting oil was triturated with
Et.sub.2O and filtered to give the subtitle compound as a white
solid. Yield: 1.75 g.
[0566] MS: APCI (+ve) 231 [M+H.sup.+]
iv)
5-(azetidin-1-ylcarbonyl)-N-{2-[(2,3-difluorobenzyl)thio]-6-[(1R)-1-me-
thyl-2-(triphenylmethyloxy)ethoxy]pyrimidin-4-yl}furan-2-sulfonamide
[0567] The subtitle compound was prepared from
5-(azetidin-1-ylcarbonyl)furan-2-sulfonamide (the product of step
iii) (0.40 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-methyl-2-(triphen-
ylmethoxy)ethoxy]-pyrimidine (the product of Example 13, step iii)
(0.41 g) according to the procedure outlined in Example 1, step
iv). Yield: 0.25 g
[0568] MS: APCI (-ve) 781 [M-H]
EXAMPLE 50
N-(tert-butyl)-5-[({2-[(2,3-difluorobenzyl)thio]-6-[(1R)-2-hydroxy-1-methy-
lethoxy]pyrimidin-4-yl}amino)sulfonyl]-2-furamide
##STR00057##
[0570] To a solution of ethyl
(2R)-2-({6-[({5-[(tert-butylamino)carbonyl]-2-furyl}sulfonyl)amino]-2-[(2-
,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)propanoate (the product
of step iii) (0.25 g) in THF (10 mL) was added a solution of
lithium borohydride (0.6 mL, 2.0M in hexanes) dropwise at 0.degree.
C. The mixture was warmed to room temperature and stirred for 18 h.
After cooling to 0.degree. C., 1N HCl (20 mL) was added slowly, and
the mixture extracted with EtOAc (3.times.20 mL). The combined
organic layers were dried (MgSO.sub.4), filtered and evaporated to
dryness in vacuo. The resulting crude oil was purified by reverse
phase HPLC (75% to 5% gradient of 0.2% aqueous trifluoroacetic acid
in acetonitrile as eluent) to give the title compound as a white
solid. Yield: 90 mg.
[0571] MS: APCI (-ve) 555 [M-H]
[0572] .sup.1H NMR .delta. (CDCl.sub.3): 1.27 (d, 3H), 1.44 (s,
9H), 3.69 (dd, 1H), 3.75 (dd, 1H), 4.33 (d, 1H), 4.38 (d, 1H),
5.26-5.33 (m, 1H), 6.23 (br s, 1H), 6.32 (s, 1H), 6.98-7.08 (m,
2H), 7.09 (d, 1H), 7.17-7.21 (m, 1H), 7.23 (d, 1H)
[0573] The intermediates for this compound were prepared as
follows:
i) N-(tert-butyl)-5-cyanofuran-2-sulfonamide
[0574] A solution of 5-formylfuran-2-sulfonic acid sodium salt
(2.97 g), and hydroxylamine hydrochloride (1.05 g) in H.sub.2O
(1.35 mL) and acetic acid (21 mL) was heated at 60.degree. C. for 4
h. After cooling to room temperature the solvent was removed in
vacuo. The crude residue was triturated with Et.sub.2O (3.times.50
mL) and dried under high vacuum to give a crude pale brown solid. A
solution of this material (3.7 g) in phosphorusoxychloride (100 mL)
was heated at 60.degree. C. for 18 h. After cooling to room
temperature the mixture was partitioned between ice-water (100 mL)
and EtOAc (100 mL). The aqueous layer was separated and further
extracted with EtOAc (2.times.100 mL). The combined organic phases
were washed with brine (100 mL), dried (MgSO.sub.4), filtered and
evaporated to dryness in vacuo to give a crude brown oil. To a
solution of this crude oil (1.6 g) in DCM (85 mL) was added
tert-butylamine (1.8 mL). After stirring at room temperature for 2
days the mixture was filtered through celite, washing with DCM
(2.times.20 mL). The filtrate was evaporated to dryness in vacuo.
The resulting crude material was purified by column chromatography
using EtOAc/isohexane (2:8) as eluent to give the subtitle compound
as a pale yellow oil. Yield: 1.0 g.
[0575] MS: APCI (-ve) 227 [M-H]
ii) 5-(aminosulfonyl)-N-(tert-butyl)-2-furamide
[0576] A solution of N-(tert-butyl)-5-cyanofuran-2-sulfonamide (the
product of step i) (1.0 g) in trifluoroacetic acid (30 mL) was
stirred at room temperature for 24 h. The mixture was evaporated to
dryness in vacuo to leave a crude yellow oil that was triturated
with Et.sub.2O and filtered to give the subtitle compound as a
white solid. Yield: 0.25 g.
[0577] MS: APCI (-ve) 245 [M-H]
iii) ethyl
(2R)-2-({6-[({5-[(tert-butylamino)carbonyl]-2-furyl}sulfonyl)am-
ino]-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)propanoate
[0578] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using a mixture of
5-(aminosulfonyl)-N-(tert-butyl)-2-furamide (0.25 g),
tris(dibenzylideneacetone)dipalladium (0) (58 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (30 mg), cesium carbonate (0.65 g) and
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (product of Example 11 step i) (0.26 g)
in dioxane (1.0 mL). Purification was trituration with Et.sub.2O to
give the subtitle compound as a white solid. Yield: 0.25 g
[0579] MS: APCI (+ve) 599 [M+H.sup.+]
EXAMPLE 51
5-cyano-N-{2-[(2,3-difluorobenzyl)thio]-6-[(1R)-2-hydroxy-1-methylethoxy]p-
yrimidin-4-yl}furan-2-sulfonamide
##STR00058##
[0581] To a solution of
5-cyano-N-{2-[(2,3-difluorobenzyl)thio]-6-[(1R)-1-methyl-2-(triphenylmeth-
yloxy)ethoxy]pyrimidin-4-yl}furan-2-sulfonamide (the product of
step ii) (0.15 g) in methanol (5 mL) was added para-toluenesulfonic
acid hydrate (39 mg) and anisole (0.23 mL). After stirring at room
temperature for 5 h, H.sub.2O (5 mL) was added and the mixture
extracted with EtOAc (3.times.10 mL). The combined organic layers
were washed with brine (10 mL), dried (MgSO.sub.4), filtered and
evaporated to dryness in vacuo. The resulting crude solid was
purified by reverse phase HPLC (75% to 5% gradient of 0.1% aqueous
ammonium acetate in acetonitrile as eluent) to give the title
compound as a white solid. Yield: 20 mg.
[0582] MS: APCI (-ve) 481 [M+H.sup.-]
[0583] .sup.1H NMR .delta. (CDCl.sub.3): 1.28 (d, 3H), 3.71 (dd,
1H), 3.76 (dd, 1H), 4.34 (d, 1H), 4.38 (d, 1H), 5.29-5.33 (m, 1H),
6.31 (s, 1H), 7.00-7.11 (m, 2H), 7.15 (d, 1H), 7.18-7.21 (m, 1H),
7.24 (d, 1H)
[0584] The intermediates for this compound were prepared as
follows:
i) 5-cyanofuran-2-sulfonamide
[0585] A solution of N-(tert-butyl)-5-cyanofuran-2-sulfonamide (the
product of example 50, step i) (1.0 g) in trifluoroacetic acid (30
mL) was stirred at room temperature for 24 h. The mixture was
evaporated to dryness in vacuo to leave a crude yellow oil that was
triturated with Et.sub.2O and filtered. The filtrate was evaporated
to dryness in vacuo to give the subtitle compound as a pale yellow
oil. Yield: 0.29 g.
[0586] MS: APCI (-ve) 171 [M-H.sup.-]
ii)
5-cyano-N-{2-[(2,3-difluorobenzyl)thio]-6-[(1R)-1-methyl-2-(triphenylm-
ethyloxy)ethoxy]pyrimidin-4-yl}furan-2-sulfonamide
[0587] The subtitle compound was prepared from
5-cyanofuran-2-sulfonamide (the product of step i) (0.29 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-methyl-2-(triphen-
ylmethoxy)ethoxy]-pyrimidine (the product of Example 13, step (0.15
g) according to the procedure outlined in Example 1, step iv).
Purification was by column chromatography on silica gel using
EtOAc/isohexane (1:4 to 2:3 gradient) to give the subtitle compound
as a pale yellow solid. Yield: 0.25 g
[0588] MS: APCI (-ve) 723 [M-H]
EXAMPLE 52
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-pyrimidin-2-ylp-
iperazine-1-sulfonamide
##STR00059##
[0590] The title compound was prepared according to the procedure
outlined in example 1 step (iv) using a mixture of
4-pyrimidin-2-ylpiperazine-1-sulfonamide (0.24 g),
tris(dibenzylideneacetone)dipalladium (0) (60 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (31 mg), cesium carbonate (0.32 g) and
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of Example 35, step i) (0.20 g) in dioxane (6 ml). The
crude material was purified by column chromatography using
EtOAc/isohexane (2:8 to 1:1 gradient) as eluent to give the title
compound as a pale yellow foam. Yield: 0.19 g.
[0591] MS: APCI (+ve) 510 [M+H]
[0592] .sup.1H NMR: .delta. (DMSO) 3.26 (m, 4H), 3.77 (m, 4H), 3.86
(s, 3H), 4.47 (s, 2H), 6.08 (s, 1H), 6.67 (t, 1H), 7.13 (m, 1H),
7.33 (m, 1H), 7.40 (dt, 1H), 8.37 (d, 2H), 11.16 (bs, 1H)
[0593] The intermediate for this compound was prepared as
follows:
i) 4-Pyrimidin-2-ylpiperazine-1-sulfonamide
[0594] The subtitle compound was prepared according to the
procedure outlined in example 15 step i) using
2-piperazin-1-ylpyrimidine (3.0 g) and sulfamide (1.2 g) in dioxane
(30 mL) to give the subtitle compound as a white solid. Yield: 2.06
g.
[0595] .sup.1H NMR: .delta. (DMSO) 3.00 (t, 2H), 3.83 (t, 2H), 6.68
(t, 1H), 6.81 (bs, 1H), 8.39 (d, 2H)
EXAMPLE 53
N-{5-[({2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulfony-
l]-4-methyl-1,3-thiazol-2-yl}acetamide
##STR00060##
[0597] The title compound was prepared according to the procedure
outlined in example 1 step (iv) using a mixture of
N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]acetamide (0.25 g),
tris(dibenzylideneacetone)dipalladium (0) (64 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (33 mg), cesium carbonate (0.69 g) and
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of Example 35, step i) (0.21 g) in dioxane (6 ml). The
crude material was purified by column chromatography using
EtOAc/isohexane (2.5:7.5 to 4:6 gradient) as eluent to give the
title compound as a pale yellow solid. Yield: 85 mg.
[0598] MS: APCI (+ve) 502 [M+H]
[0599] .sup.1H NMR: .delta. (CDCl.sub.3) 2.26 (s, 3H), 2.57 (s,
3H), 3.90 (s, 3H), 4.38 (s, 2H), 6.32 (s, 1H), 7.03 (m, 2H), 7.19
(dt, 1H)
[0600] The intermediates for this compound were prepared as
follows:
i)
N-{5-[(tert-Butylamino)sulfonyl]-4-methyl-1,3-thiazol-2-yl}acetamide
[0601] To a suspension of
2-(acetylamino)-4-methyl-1,3-thiazole-5-sulfonyl chloride (1.0 g)
in DCM (10 ml) was added tert-butylamine (0.92 ml) and the mixture
was stirred at room temperature for 2 d. The mixture was diluted
with H.sub.2O and extracted with DCM (.times.3). The combined
organic extracts were dried (MgSO.sub.4), filtered and evaporated
to give the subtitle compound as a beige foam. Yield 1.1 g.
[0602] MS: APCI (+ve) 292 [M+H]
ii) N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]acetamide
[0603] A solution of
N-{5-[(tert-butylamino)sulfonyl]-4-methyl-1,3-thiazol-2-yl}acetamide
(1.1 g) in TFA (10 ml) was stirred at room temperature for 3 d. The
mixture was evaporated, redissolved in TFA (10 ml) and stirred for
a further ld. On evaporation the resulting oil was azeotroped with
DCM (.times.2) and triturated with Et.sub.2O to give the subtitle
compound as a beige solid. Yield 0.7 g.
[0604] MS: APCI (+ve) 236 [M+H]
EXAMPLE 54
2-Amino-N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-methyl--
1,3-thiazole-5-sulfonamide
##STR00061##
[0606] The title compound was prepared according to the procedure
outlined in example 1 step (iv) using a mixture of
2-amino-4-methyl-1,3-thiazole-5-sulfonamide (0.23 g),
tris(dibenzylideneacetone)dipalladium (0) (73 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (38 mg), cesium carbonate (0.39 g) and
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of Example 35, step i) (0.24 g) in dioxane (6 ml). The
crude material was purified by column chromatography using
EtOAc/isohexane (2:8 to 4.5:5.5 gradient) as eluent and trituration
with Et.sub.2O to give the title compound as a beige solid. Yield:
0.15 g.
[0607] MS: APCI (+ve) 460 [M+H]
[0608] .sup.1H NMR: .delta. (DMSO) 2.42 (s, 3H), 3.91 (s, 3H), 4.56
(s, 2H), 6.07 (s, 1H), 7.18 (dq, 1H), 7.35 (m, 2H), 7.55 (bs, 2H),
11.91 (bs, 1H)
[0609] The intermediate for this compound was prepared as
follows:
i) 2-Amino-4-methyl-1,3-thiazole-5-sulfonamide
[0610] A suspension of
N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]acetamide (the
product from Example 53, step (0.44 g) in hydrazine hydrate (1.5
ml) was stirred at room temperature for 4 h. The mixture was
diluted with H.sub.2O and extracted with EtOAc (.times.4). The
combined organic extracts were dried (MgSO.sub.4), filtered and
evaporated to give the subtitle compound as an off-white solid.
Yield 0.23 g.
[0611] MS: APCI (+ve) 194 [M+H]
EXAMPLE 55
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]o-
xy}pyrimidin-4-yl)methanesulfonamide
##STR00062##
[0613] To a solution of
N-(2-[(2,3-difluorobenzyl)thio]-6-{(1R)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-
-4-yl]ethoxy}pyrimidin-4-yl)methanesulfonamide (0.23 g) in MeOH (2
ml) was added TFA (0.4 ml) and the reaction was stirred at room
temperature for 20 h. The mixture was evaporated, suspended in
saturated sodium carbonate solution and then re-acidified to pH5
with glacial acetic acid with stirring. The resulting solid was
collected, washed with H.sub.2O and dried to give the title
compound as a cream solid. Yield 0.17 g.
[0614] MS: APCI (+ve) 436 [M+H]
[0615] .sup.1H NMR: .delta. (DMSO) 1.18 (d, 3H), 3.26 (s, 3H), 3.36
(t, 2H), 3.62 (quintet, 1H), 4.45 (quintet, 2H), 4.60 (t, 1H), 4.93
(d, 1H), 5.17 (quintet, 1H), 5.97 (s, 1H), 7.17 (m, 1H), 7.35 (m,
1H), 7.40 (m, 1H)
[0616] The intermediate for this compound was prepared as
follows:
i)
N-(2-[(2,3-Difluorobenzyl)thio]-6-{(1R)-1-[(4S)-2,2-dimethyl-1,3-dioxol-
an-4-yl]ethoxy}pyrimidin-4-yl)methanesulfonamide
[0617] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using a mixture of
methane sulfonamide (0.25 g), tris(dibenzylideneacetone)dipalladium
(0) (55 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (29 mg), cesium carbonate (0.30 g) and
4-chloro-2-[(2,3-difluorobenzyl)thio]-6-{(1R)-1-[(4S)-2,2-dimethyl-1,3-di-
oxolan-4-yl]ethoxy}pyrimidine (the product of Example 47, step i)
(0.25 g) in dioxane (5 ml). The crude material was purified by
column chromatography using EtOAc/isohexane (2:8) as eluent to give
the subtitle compound as a yellow oil. Yield: 0.25 g.
[0618] MS: APCI (+ve) 476 [M+H]
EXAMPLE 56
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]o-
xy}pyrimidin-4-yl)morpholine-4-sulfonamide
##STR00063##
[0620] To a solution of
N-(2-[(2,3-difluorobenzyl)thio]-6-{(1R)-1-[(4S)-2,2-dimethyl-1,3-dioxolan-
-4-yl]ethoxy}pyrimidin-4-yl)morpholine-4-sulfonamide (0.20 g) in
MeOH (2 ml) was added TFA (0.4 ml) and the reaction was stirred at
room temperature for 20 h. The mixture was evaporated, suspended in
saturated sodium carbonate solution and then re-acidified to pH5
with glacial acetic acid with stirring. The resulting solid was
collected, washed with H.sub.2O and dried to give the title
compound as a white solid. Yield 0.15 g.
[0621] MS: APCI (+ve) 507 [M+H]
[0622] .sup.1H NMR: .delta. (DMSO) 1.18 (d, 3H), 3.18 (m, 4H), 3.33
(m, 2H), 3.60 (m, 5H), 4.44 (q, 2H), 4.60 (t, 1H), 4.89 (d, 1H),
5.20 (quintet, 1H), 6.03 (s, 1H), 7.16 (m, 1H), 7.38 (m, 2H), 11.13
(bs, 1H)
[0623] The intermediate for this compound was prepared as
follows:
i)
N-(2-[(2,3-Difluorobenzyl)thio]-6-{(1R)-1-[(4S)-2,2-dimethyl-1,3-dioxol-
an-4-yl]ethoxy}pyrimidin-4-yl)morpholine-4-sulfonamide
[0624] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using a mixture of
4-morpholine sulfonamide (prepared according to patent WO
2004/011443) (0.15 g), tris(dibenzylideneacetone)dipalladium (0)
(55 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (29 mg), cesium carbonate (0.30 g) and
4-chloro-2-[(2,3-difluorobenzyl)thio]-6-{(1R)-1-[(4.5)-2,2-dimethyl-1,3-d-
ioxolan-4-yl]ethoxy}pyrimidine (the product of Example 47, step i)
(0.25 g) in dioxane (5 ml). The crude material was purified by
column chromatography using EtOAc/isohexane (1:9 to 2.5:7.5
gradient) as eluent to give the subtitle compound as an off-white
foam. Yield: 0.20 g.
[0625] MS: APCI (+ve) 547 [M+H]
EXAMPLE 57
N-[2-[(2,3-Difluorobenzyl)thio]-6-(methylthio)pyrimidin-4-yl]methanesulfon-
amide
##STR00064##
[0627] A mixture of methane sulfonamide (0.22 g),
tris(dibenzylideneacetone)-dipalladium (0) (33 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl(XPHOS)
(17 mg), cesium carbonate (0.58 g) and
4-chloro-2-[(2,3-difluorobenzyl)thio]-6-(methylthio)pyrimidine (the
product of step i) (0.38 g) in dioxane (10 mL) was heated at
100.degree. C. for 18 h. The mixture was cooled and saturated
ammonium chloride was added and the resulting mixture extracted
with EtOAc. The combined organic extracts were washed with
saturated aqueous sodium chloride, dried (MgSO.sub.4), filtered and
evaporated. The residue was purified by reverse phase HPLC eluting
with acetonitrile/aq. 0.1% TFA mixtures to give the title compound
as a white solid. Yield: 30 mg.
[0628] MS: APCI (+ve) 378 [M+H.sup.+]
[0629] .sup.1H NMR (CDCl.sub.3) .delta. 2.52 (3H, s), 3.21 (3H, s),
4.44 (2H, s), 6.73 (1H, s), 6.99-7.10 (2H, m), 7.21-7.24 (1H,
m)
[0630] The intermediate for this compound was prepared as
follows:
i)
4-chloro-2-[(2,3-difluorobenzyl)thio]-6-(methylthio)pyrimidine
[0631] To a solution of
4,6-dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step (1.54 g) in THF (50 mL) was added sodium
methanethiolate (0.39 g). The mixture was allowed to warm to room
temperature and stirring continued for 2 h. Saturated ammonium
chloride was added and the resulting mixture extracted with EtOAc.
The combined organic extracts were washed with saturated aqueous
sodium chloride, dried (MgSO.sub.4), filtered and evaporated to
give the subtitle compound as a pale yellow solid. Yield: 1.51
g.
[0632] MS: APCI (-ve) 317/319 [M-H.sup.-]
EXAMPLE 58
N-[2-[(2,3-Difluorobenzyl)thio]-6-(methylthio)pyrimidin-4-yl]azetidine-1-s-
ulfonamide
##STR00065##
[0634] A mixture of azetidine-1-sulfonamide (prepared according to
patent WO 2004/011443, 0.32 g),
tris(dibenzylideneacetone)-dipalladium (0) (33 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (17 mg), cesium carbonate (0.58 g) and
4-chloro-2-[(2,3-difluorobenzyl)thio]-6-(methylthio)pyrimidine (the
product of example 57, step i) (0.38 g) in dioxane (10 mL) was
heated at 100.degree. C. for 18 h. The mixture was cooled and
saturated ammonium chloride was added and the resulting mixture
extracted with EtOAc. The combined organic extracts were washed
with saturated aqueous sodium chloride, dried (MgSO.sub.4),
filtered and evaporated. The residue was purified by reverse phase
HPLC eluting with acetonitrile/aq. 0.1% ammonium acetate mixtures
to give the title compound as a white solid. Yield: 50 mg.
[0635] MS: APCI (+ve) 419 [M+H.sup.+]
[0636] .sup.1H NMR (CDCl.sub.3) .delta. 2.25 (2H, quintet), 2.51
(3H, s), 4.01 (4H, t), 4.43 (2H, s), 6.81 (1H, s), 6.98-7.10 (2H,
m), 7.21-7.24 (1H, m)
EXAMPLE 59
N-[2-[(2,3-Difluorobenzyl)thio]-6-(methylthio)pyrimidin-4-yl]morpholine-4--
sulfonamide
##STR00066##
[0638] A mixture of 4-morpholinesulfonamide (prepared according to
patent WO 2004/011443, 0.39 g),
tris(dibenzylideneacetone)-dipalladium (0) (33 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (17 mg), cesium carbonate (0.58 g) and
4-chloro-2-[(2,3-difluorobenzyl)thio]-6-(methylthio)pyrimidine (the
product of example 57, step i) (0.38 g) in dioxane (10 mL) was
heated at 100.degree. C. for 18 h. The mixture was cooled and
saturated ammonium chloride was added and the resulting mixture
extracted with EtOAc. The combined organic extracts were washed
with saturated aqueous sodium chloride, dried (MgSO.sub.4),
filtered and evaporated. The residue was purified by reverse phase
HPLC eluting with acetonitrile/aq. 0.1% ammonium acetate mixtures
to give the title compound as a white solid. Yield: 30 mg.
[0639] MS: APCI (+ve) 449 [M+H.sup.+]
[0640] .sup.1H NMR (CDCl.sub.3) .delta. 2.51 (3H, s), 3.30 (4H, t),
3.72 (4H, t), 4.43 (2H, s), 6.73 (1H, s), 7.00-7.10 (2H, m),
7.21-7.24 (1H, m)
EXAMPLE 60
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-{[(1R,2R)-2,3-dihydroxy-1-methyl-
propyl]oxy}-4-pyrimidinyl]-1-morpholinesulfonamide
##STR00067##
[0642] To a solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-[(4R)-2,2-dimethyl-1,3--
dioxolan-4-yl]ethoxy]-4-pyrimidinyl]-1-morpholinesulfonamide (the
product of step i) (0.17 g) in DCM (5 ml) was added iron (III)
chloride hexahydrate (0.25 g). The reaction mixture was stirred at
room temperature for 3 h after which time further iron (III)
chloride hexahydrate (0.25 g) was added. After a further 3 h
saturated aqueous sodium bicarbonate (1 ml) was added. The layers
were separated and the aqueous material extracted with DCM
(.times.3) and EtOAc (.times.3). The combined organic extracts were
washed with saturated aqueous sodium chloride, dried with sodium
sulfate, filtered and evaporated. The residual solid was purified
by reverse phase HPLC (gradient 25-95% acetonitrile in 0.2% aqueous
TFA) to afford the title compound as a white powder. Yield: 23
mg
[0643] MS: APCI (+ve) 507 [M+H.sup.+]
[0644] .sup.1H NMR: .delta. (400 MHz, CDCl.sub.3) 1.31 (d, 3H),
3.29-3.32 (m, 4H), 3.60-3.80 (m, 7H), 4.36 (1/2Abq, 1H), 4.36
(1/2Abq, 1H), 5.31 (quintet, 1H), 6.23 (s, 1H), 6.99-7.10 (m, 2H),
7.20-7.23 (m, 1H).
[0645] The intermediate for this compound was prepared as
follows:
i)
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(1R)-1-[(4R)-2,2-dimethyl-1,-
3-dioxolan-4-yl]ethoxy]-4-pyrimidinyl]-4-morpholinesulfonamide
[0646] A mixture of morpholine-4-sulfonamide (prepared according to
patent WO 2004/011443, 0.239 g),
tris(dibenzylideneacetone)-dipalladium (0) (33 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (17 mg), cesium carbonate (0.176 g) and
4-chloro-2-[(2,3-difluorobenzyl)thio]-6-{(1R)-1-[(4R)-2,2-dimethyl-1,3-di-
oxolan-4-yl]ethoxy}pyrimidine (the product of example 45 step vii)
(0.150 g) in anhydrous dioxane (6 ml) was heated at reflux in a
microwave at 100.degree. C., 300 W, open vessel with cooling for 20
min. Saturated aqueous ammonium chloride was added and the
resulting mixture extracted with EtOAc. The combined organic
extracts were washed with saturated aqueous sodium chloride, dried
with sodium sulfate, filtered and evaporated. The residue was
purified by column chromatography on silica using a 1:19 to 2:3
mixture of EtOAc and iso-hexane as eluent to give the subtitle
compound as a yellow gum. Yield: 0.165 g
[0647] MS: APCI (+ve) 547 [M+H.sup.+]
EXAMPLE 61
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-{[(1S,2R)-2,3-dihydroxy-1-methyl-
propyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
##STR00068##
[0649] To a solution of
N-(2-[(2,3-difluorobenzyl)thio]-6-{(1S)-1-[(2R)-1,4-dioxaspiro[4.5]dec-2--
yl]ethoxy}pyrimidin-4-yl)azetidine-1-sulfonamide (the product of
step (43 mg) in DCM (4 ml) was added iron (III) chloride
hexahydrate (73 mg). The reaction mixture was stirred at room
temperature for 2 h after which time further iron (III) chloride
hexahydrate (40 mg) was added. After 3 d at -18.degree. C.,
H.sub.2O and DCM were added. The layers were separated and the
aqueous material extracted with further DCM. The combined organic
extracts were washed with saturated aqueous sodium chloride, dried
with sodium sulfate, filtered and evaporated. TFA (1 ml) and DCM (4
ml) were added to the residue and the reaction mixture stirred at
room temperature for 2 d. The mixture was partitioned between
saturated aqueous sodium bicarbonate and DCM, then neutralised with
2M aqueous hydrochloric acid, the layers separated and the aqueous
material extracted with further DCM. The DCM extracts were allowed
to slowly evaporate and the resulting solid washed with minimal
cold DCM to afford the title compound as a white powder. Yield: 11
mg
[0650] MS: APCI (+ve) 477 [M+H.sup.+]
[0651] .sup.1H NMR: .delta. (300 MHz, CDCl.sub.3) 1.36 (d, 3H),
2.27 (quintet, 2H), 3.59-3.65 (m, 1H), 3.68-3.78 (m, 2H), 4.02 (t,
4H), 4.37 (s, 2H), 5.23 (quintet, 1H), 6.31 (s, 1H), 6.99-7.11 (m,
2H), 7.19-7.23 (m, 1H).
[0652] The intermediates for this compound were prepared as
follows:
i)
4-Chloro-2-[(2,3-difluorobenzyl)thio]-6-{(1S)-1-[(2R)-1,4-dioxaspiro[4.-
5]dec-2-yl]ethoxy}pyrimidine
[0653] A solution of
(1S)-1-[(2R)-1,4-dioxaspiro[4.5]dec-2-yl]ethanol (prepared
according to J. Org. Chem. 1995, 60, 585-587, 0.183 g of -2:1
mixture of diastereomers) in dry THF (5 ml) was cooled to 0.degree.
C. and to it was added (in portions) sodium hydride (46 mg as 60%
dispersion in mineral oil) followed in portions by
4,6-dichloro-2-(2,3-difluoro-benzylsulfanyl)-pyrimidine (product of
example 1 step ii, 0.252 g). The reaction mixture was stirred at
room temperature for 24 h then quenched with saturated aqueous
ammonium chloride (2 ml) and diluted with EtOAc. The layers were
separated and the aqueous layer extracted with further EtOAc. The
combined organic extracts were washed with saturated aqueous sodium
chloride, dried with sodium sulfate, filtered and evaporated to
leave a yellow oil which was purified by column chromatography on
silica using a 0.5 to 4% mixture of EtOAc in iso-hexane as eluent
to afford the subtitle compound as a white solid. Yield: 0.10 g
[0654] MS: APCI (+ve) 457/459 [M+H.sup.+]
ii)
N-(2-[(2,3-Difluorobenzyl)thio]-6-{(1S)-1-[(2R)-1,4-dioxaspiro[4.5]dec-
-2-yl]ethoxy}pyrimidin-4-yl)azetidine-1-sulfonamide
[0655] A mixture of azetidine-1-sulfonamide (prepared according to
patent WO 2004/011443, 0.131 g),
tris(dibenzylideneacetone)-dipalladium (0) (22 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (11 mg), cesium carbonate (0.117 g) and
4-chloro-2-[(2,3-difluorobenzyl)thio]-6-{(1S)-1-[(2R)-1,4-dioxaspiro[4.5]-
dec-2-yl]ethoxy}pyrimidine (the product of step i) (0.100 g) in
anhydrous dioxane (5 ml) was heated at reflux in a microwave at
100.degree. C., 300 W, open vessel with cooling for 15 min.
Saturated aqueous ammonium chloride was added and the resulting
mixture extracted with EtOAc. The combined organic extracts were
washed with saturated aqueous sodium chloride, dried with sodium
sulfate, filtered and evaporated. The residue was purified by
column chromatography on silica using a 1:19 to 3:7 mixture of
EtOAc and iso-hexane as eluent and then by reverse phase HPLC
(gradient 25-95% acetonitrile in 0.1% ammonium acetate) to give the
subtitle compound as a colourless gum. Yield: 43 mg
[0656] MS: APCI (+ve) 557 [M+H.sup.+]
EXAMPLE 62
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]-4-ethanes-
ulfonylpiperazine-1-sulfonamide
##STR00069##
[0658] The title compound was prepared from
4-ethanesulfonylpiperazine-1-sulfonamide (the product of step i)
(0.31 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of Example 35, step i) (0.25 g) according to the
procedure outlined in Example 1, step iv). The crude material was
purified by column chromatography using EtOAc/isohexane (1:1) as
eluent. Yield: 0.37 g
[0659] MS: APCI (+ve) 524 [M+H.sup.+]
[0660] .sup.1H NMR: .delta. (DMSO) 1.17 (t, 3H), 3.06 (q, 2H), 3.23
(d, 4H), 3.28 (d, 4H), 3.88 (s, 3H), 4.48 (s, 2H), 6.06 (s, 1H),
7.17 (m, 1H), 7.33 (m, 1H), 7.42 (t, 1H), 11.22 (bs, 1H).
[0661] The intermediate for this compound was prepared as
follows:
i) 4-Ethanesulfonylpiperazine-1-sulfonamide
[0662] To a solution of 1-ethanesulfonylpiperazine (1.0 g) in
dioxane (10 ml) was added sulfamide (0.51 g). The reaction was then
heated at 100.degree. C. for 24 h. The reaction was allowed to cool
before being concentrated in vacuo. The residue was stirred in
Et.sub.2O for 4 h and the mixture filtered to give the product as a
white solid. Yield: 1.3 g.
[0663] .sup.1H NMR: .delta. (DMSO) 1.21 (t, 3H), 3.02 (t, 4H), 3.09
(q, 2H), 3.28 (t, 4H), 6.89 (s, 2H).
EXAMPLE 63
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]-3-oxopipe-
razine-1-sulfonamide
##STR00070##
[0665] The title compound was prepared from
3-oxopiperazine-1-sulfonamide (the product of step i) (0.22 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of Example 35, step i) (0.25 g) according to the
procedure outlined in Example 1, step iv). The crude material was
purified by column chromatography using EtOAc/isohexane (1:1) as
eluent to give a white solid. This solid was dissolved in EtOAc and
Et.sub.2O and extracted with 1N sodium hydroxide. The basic
solution was washed with Et.sub.2O, acidified with dilute
hydrochloric acid and extracted with EtOAc. The organic solution
was washed with H.sub.2O, dried (MgSO.sub.4) and the solvent
evaporated in vacuo to give the product as a yellow foam.
[0666] Yield: 40 mg
[0667] MS: APCI (+ve) 446 [M+H.sup.+]
[0668] .sup.1H NMR: .delta. (DMSO) 3.19 (s, 2H), 3.43 (t, 2H), 3.80
(s, 2H), 3.88 (s, 3H), 4.48 (s, 2H), 6.03 (s, 1H), 7.17 (q, 1H),
7.34 (m, 1H), 7.41 (m, 1H), 8.07 (s, 1H), 11.29 (s, 1H).
[0669] The intermediate for this compound was prepared as
follows:
i) 3-Oxopiperazine-1-sulfonamide
[0670] The subtitle compound was prepared according to the
procedure outlined in Example 62 step i) using 2-oxopiperazine (0.5
g) and sulfamide (0.45 g) to give a beige solid. Yield: 0.83 g.
[0671] .sup.1H NMR: .delta. (DMSO) 3.14 (t, 2H), 3.25 (t, 2H), 3.50
(s, 2H), 7.02 (s, 2H), 8.04 (s, 1H).
EXAMPLE 64
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]-1,1-dioxo-
thiomorpholine-4-sulfonamide
##STR00071##
[0673] The title compound was prepared from
1,1-dioxothiomorpholine-4-sulfonamide (0.31 g, McManus, J. M. et
al, J. Med. Chem (1965) 8 766-776) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of Example 35, step i) (0.25 g) according to the
procedure outlined in Example 1, step iv). The crude material was
purified by column chromatography using EtOAc/isohexane (1:1) as
eluent. Yield: 0.48 g
[0674] MS: APCI (+ve) 481 [M+H.sup.+]
[0675] .sup.1H NMR: .delta. (DMSO) 3.24 (bt, 4H), 3.71 (bm, 4H),
3.89 (s, 3H), 4.49 (s, 2H), 6.01 (s, 1H), 7.17 (m, 1H), 7.34 (m,
1H), 7.40 (t, 1H).
EXAMPLE 65
4-O-{6-[(Azetidin-1-ylsulfonyl)amino]-2-[(2,3-difluorobenzyl)thio]pyrimidi-
n-4-yl}-2,5-dideoxy-D-threo-pentitol
##STR00072##
[0677] To a solution of
4-O-{6-[(azetidin-1-ylsulfonyl)amino]-2-[(2,3-difluorobenzyl)thio]pyrimid-
in-4-yl}-2,5-dideoxy-1,3-O-(4-methoxybenzylidene)-D-threo-pentitol
(the product from step vii) in MeOH (9 ml) was added TFA (1 ml)
dropwise. The reaction mixture was stirred at room temperature for
18 h. The reaction mixture was reduced in vacuo and the residue
redissolved in EtOAc (20 ml) before reducing in vacuo directly onto
silica and purifying by column chromatography on silica gel 50%
EtOAc/50% iso-hexane to give the title compound as a white solid.
Yield: 32 mg
[0678] MS: APCI (-ve) 489 [M+H.sup.-]
[0679] .sup.1H NMR: .delta. (DMSO) 1.25-1.29 (m, 3H), 1.73-1.80 (m,
2H), 2.25 (q, 2H), 3.88-3.96 (m, 3H), 4.02 (t, 4H), 4.32-4.40 (m,
2H), 5.12-5.20 (m, 1H), 6.32 (s, 1H), 6.99-7.10 (m, 2H), 7.21-7.25
(m, 1H)
[0680] The intermediates for this compound were prepared as
follows:
i) (2R)-2-{[tert-Butyl(diphenyl)silyl]oxy}propanoic acid
[0681] To a solution of (2R)-2-hydroxypropanoic acid (5 g) in DMF
(20 ml) was added TBDPSCl (33.0 g) and imidazole (16.4 g). The
reaction was then stirred overnight at RT. The reaction was
partitioned between EtOAc (200 ml) and H.sub.2O (200 ml). The
organics were recovered and washed with 10% citric acid (200 ml),
H.sub.2O (200 ml) and finally brine (200 ml). The organics were
then collected, dried (MgSO.sub.4) before being reduced in vacuo.
The residue was dissolved in MeOH (200 ml), cooled in an ice bath
and potassium carbonate (6.9 g) in H.sub.2O was added. After
stirring at room temperature for 6 h the solvent was removed in
vacuo and the residue diluted with H.sub.2O (100 ml). The pH was
then adjusted to pH 4 with 10% citric acid, and the aqueous
extracted three times with EtOAc (3.times.200 ml). The organics
were collected dried MgSO.sub.4 before reducing in vacuo to give
the subtitle compound as a colourless oil. Yield: 7.5 g
[0682] MS: APCI (-ve) 327, [M+H.sup.-]
ii) Ethyl
(4R)-4-{[tert-butyl(diphenyl)silyl]oxy}-3-oxopentanoate
[0683] To a solution of
(2R)-2-{[tert-Butyl(diphenyl)silyl]oxy}propanoic acid (the product
from step i, 7.85 g) in THF (300 ml) was added CDI (4.26 g) and the
reaction was stirred at room temperature for approximately 15 mins.
In a separate flask (71.7 ml) of a 1M heptane solution was added to
a solution of ethyl hydrogen malonate (9.47 g) in THF (300 ml) at
0.degree. C. This solution was then allowed to warm to RT. The acyl
imidazole solution was then transferred to the flask which
contained the magnesium salt and the reaction was monitored for the
next 2 d. When the reaction was complete it was quenched by the
addition of 250 ml of sat. aq NH.sub.4Cl solution. The reaction
mixture was then extracted with Et.sub.2O (3.times.200 ml). The
combined organics were dried (MgSO.sub.4), filtered and reduced to
yield a clear oil which was purified by column chromatography on
silica gel 4% EtOAc/96% iso-hexane. This gave the subtitle compound
as a colourless oil. Yield: 2.0 g
[0684] .sup.1H NMR: .delta. (DMSO) 1.03 (m, 9H), 1.11-1.19 (m, 6H),
3.31 (s, 2H), 4.07 (q, 2H), 4.23-4.31 (m, 1H), 7.37-7.52 (m, 6H),
7.57-7.66 (m, 4H)
iii)
4-O-[tert-Butyl(diphenyl)silyl]-2,5-dideoxy-D-glycero-pentitol
[0685] To a solution of Ethyl
(4R)-4-{([tert-butyl(diphenyl)silyl]oxy}-3-oxopentanoate (the
product from step ii) (2.0 g) in THF (100 ml) was added 2M
LiBH.sub.4 in THF (12 ml) The reaction was then stirred at room
temperature for 18 h. Saturated ammonium chloride (200 ml) was
added to the reaction mixture to quench any remaining LiBH.sub.4.
The reaction mixture was then extracted using EtOAc (3.times.200
ml). The organics were recovered and dried (MgSO.sub.4) before
reducing in vacuo. The residue was purified by column
chromatography on silica gel 30% EtOAc/70% iso-hexane to yield the
subtitle compound as a clear oil. Yield: 540 mg
[0686] .sup.1H NMR: .delta. (CDCl3) 1.00-1.03 (m, 3H), 1.07 (s,
9H), 1.61-1.68 (m, 2H), 3.63-3.84 (m, 4H), 7.36-7.47 (m, 6H),
7.65-7.70 (m, 4H)
iv)
4-O-[tert-Butyl(diphenyl)silyl]-2,5-dideoxy-1,3-O-(4-methoxybenzyliden-
e)-D-glycero-pentitol
[0687] To a solution of
4-O-[tert-butyl(diphenyl)silyl]-2,5-dideoxy-D-glycero-pentitol (the
product from step (0.60 g) and 1-(dimethoxymethyl)-4-methoxybenzene
(0.30 g) in DCM (60 ml) was added tosic acid (60 mg). The reaction
was the stirred at room temperature for 3 h before addition of more
1-(dimethoxymethyl)-4-methoxybenzene (0.61 g) and a further 2 h
stirring at RT. The reaction was worked up by reducing directly
onto silica and purifying by flash column chromatography on silica
gel 10% EtOAc/90% iso-hexane. This yielded the subtitle compound as
a clear colourless oil. Yield: 0.45 g
[0688] MS: APCI (+ve) 477, [M+H.sup.+]
v) (1R)-1-[2-(4-Methoxyphenyl)-1,3-dioxan-4-yl]ethanol
[0689] To a solution of
4-O-[tert-Butyl(diphenyl)silyl]-2,5-dideoxy-1,3-O-(4-methoxybenzylidene)--
D-glycero-pentitol (the product from step iv, 0.40 g) in THF was
added TBAF (2.76 ml). The reaction was then allowed to stir at room
temperature for 18 h. The reaction mixture was then reduced
directly onto silica and purified by column chromatography on
silica gel 25% EtOAc/75% iso-hexane. This gave the subtitle
compound as a clear colourless oil. Yield: 0.19 g
[0690] MS: APCI (+ve) 239 [M+H.sup.+]
vi)
2-O-{6-Chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}-1,4-dideoxy--
3,5-O-(4-methoxybenzylidene)-D-threo-pentitol
4-O-{6-Chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}-2,5-dideoxy-1,3--
O-(4-methoxybenzylidene)-D-erythro-pentitol
[0691] To a solution of (0.18 g)
(1R)-1-[2-(4-Methoxyphenyl)-1,3-dioxan-4-yl]ethanol and
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step (ii), 0.25 g) in anhydrous THF (10 ml) at room
temperature was added 60% sodium hydride (38 mg). After stirring
for 18 h the reaction mixture was partitioned between H.sub.2O (50
ml) solution and EtOAc (150 ml). The organics were separated and
the aqueous layer was re-extracted with EtOAc (2.times.150 ml) The
organics collected, dried (MgSO.sub.4) and solvents removed in
vacuo to give the subtitle compound as a colourless oil. The
residue was then purified by column chromatography on silica gel
10% EtOAc/90% iso-hex aneto separate the two diastereoisomers
2-O-{6-Chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}-1,4-dideoxy-3,5--
O-(4-methoxybenzylidene)-D-threo-pentitol
[0692] .sup.1H NMR: 8 (CDCl.sub.3) 1.36 (d, 3H), 1.52-1.59 (m, 1H),
1.83-1.96 (m, 1H), 3.80 (s, 3H), 3.90-3.98 (m, 1H), 4.26-4.30 (m,
1H), 4.40 (s, 2H), 5.28-5.33 (m, 1H), 5.47 (s, 1H), 6.43 (s, 1H),
6.88 (d, 2H), 6.96-7.10 (m, 2H), 7.24-7.29 (m, 1H), 7.37 (d, 2H).
Yield: 0.15 g.
4-O-{6-Chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}-2,5-dideoxy-1,3--
O-(4-methoxybenzylidene)-D-erythro-pentitol
[0693] .sup.1H NMR: .delta. (CDCl.sub.3) 1.32 (d, 3H), 1.52-1.59
(m, 1H), 1.86-1.98 (m, 1H), 3.79 (s, 3H), 3.91-4.01 (m, 1H),
4.26-4.31 (m, 1H), 4.40 (s, 2H), 5.35-5.41 (m, 1H), 5.46 (s, 1H),
6.43 (s, 1H), 6.86 (d, 2H), 6.96-7.09 (m, 2H), 7.25-7.30 (m, 1H),
7.34 (d, 2H). Yield: 0.20 g.
vii)
2-O-{6-[(Azetidin-1-ylsulfonyl)amino]-2-[(2,3-difluorobenzyl)thio]pyr-
imidin-4-yl}-1,4-dideoxy-3,5-O-(4-methoxybenzylidene)-D-threo-pentitol
[0694] A mixture of Azetidine-1-sulfonamide (73 mg),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.14 g) and 2-O--
(6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl)-1,4-dideoxy-3,5-O-(-
4-methoxybenzylidene)-D-threo-pentitol (the product of example 65
step vi the diastereoisomer which eluted first) (0.145 g) in
dioxane (10 mL) was heated at reflux in a microwave at 100.degree.
C., 300 W, open vessel with cooling for 30 min. The reaction
mixture was partitioned between aq. ammonium chloride solution (50
ml) and EtOAc (150 ml). The organics were separated and the aqueous
layer was re-extracted with EtOAc (2.times.150 ml). The organics
collected, dried (MgSO.sub.4) and solvents removed in vacuo to give
the subtitle compound as a yellow solid. Yield: 0.45 g.
[0695] MS: APCI (+ve) 609 [M+H.sup.+]
EXAMPLE 66
4-O-{6-[(Azetidin-1-ylsulfonyl)amino]-2-[(2,3-difluorobenzyl)thio]pyrimidi-
n-4-yl}-2,5-dideoxy-D-erythro-pentitol
##STR00073##
[0697] To a solution of
4-O-{6-[(azetidin-1-ylsulfonyl)amino]-2-[(2,3-difluorobenzyl)thio]pyrimid-
in-4-yl}-2,5-dideoxy-1,3-O-(4-methoxybenzylidene)-D-erythro-pentitol
(the product from step i) in MeOH (9 ml) was added TFA (1 ml)
dropwise. The reaction mixture was stirred at room temperature for
18 h. The reaction mixture was reduced in vacuo and the residue
redissolved in EtOAc (20 ml) before reducing in vacuo directly onto
silica and purifying by column chromatography on silica 50%
EtOAc/50% iso-hexane to give the title compound as a white solid.
Yield: 12 mg
[0698] MS: APCI (+ve) 489 [M+H.sup.+]
[0699] .sup.1H NMR: .delta. (DMSO) 1.29 (d, 3H), 1.72-1.77 (m, 2H),
2.26 (q, 2H), 3.83-3.94 (m, 2H), 3.99-4.07 (m, 5H), 4.37 (s, 2H),
5.18-5.24 (m, 1H), 6.32 (s, 1H), 6.99-7.10 (m, 2H), 7.20-7.24 (m,
1H)
[0700] The intermediate for this compound was prepared as
follows:
i)
4-O-{6-[(Azetidin-1-ylsulfonyl)amino]-2-[(2,3-difluorobenzyl)thio]pyrim-
idin-4-yl}-2,5-dideoxy-1,3-O-(4-methoxybenzylidene)-D-erythro-pentitol
[0701] A mixture of azetidine-1-sulfonamide (0.13 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.23 g) and
4-O-{(6-Chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}-2,5-dideoxy-1,-
3-O-(4-methoxybenzylidene)-D-erythro-pentitol (the product of
example 65 step vi the diastereoisomer which eluted second) (0.20
g) in dioxane (10 mL) was heated at reflux in a microwave at
100.degree. C., 300 W, open vessel with cooling for 30 mins. The
reaction mixture was partitioned between aq. ammonium chloride
solution (50 ml) and EtOAc (150 ml). The organics were separated
and the aqueous layer was re-extracted with EtOAc (2.times.150 ml).
The organics collected, dried (MgSO.sub.4) and solvents removed in
vacuo to give the subtitle compound as a yellow solid. Yield: 0.50
g.
[0702] MS: APCI (+ve) 609.9 [M+H.sup.+]
EXAMPLE 67
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]4-methyl-piperazine-1-sulfonamide
##STR00074##
[0704] To a solution of
N-{2-[(2,3-difluorobenzyl)thio]-6-[(1R)-1-methyl-2-(trityloxy)ethoxy]pyri-
midin-4-yl}-4-methylpiperazine-1-sulfonamide (the product from step
(100 mg) in DCM (3 ml) was added TFA (3 ml) dropwise. The reaction
was then allowed to stir at room temperature for the following 3 h
until complete. The reaction was then reduced in vacuo and the
resulting residue was purified by preparative HPLC to yield the
title compound as a white solid. Yield: 45 mg
[0705] MS: APCI (+ve) 490 [M+H.sup.+]
[0706] .sup.1H NMR: .delta. (DMSO) 1.27 (d, 3H), 2.31 (s, 3H), 2.50
(t, 4H), 3.36 (t, 4H), 3.67-3.77 (m, 2H), 4.31-4.41 (m, 2H),
5.26-5.32 (m, 1H), 6.24 (s, 1H), 7.00-7.10 (m, 2H), 7.19-7.24 (m,
1H)
[0707] The intermediates for this compound were prepared as
follows:
i) 4-Methylpiperazine-1-sulfonamide
[0708] To a solution of 1-Methylpiperazine (1.58 g) in dioxane was
added sulfamide (4.0 g) and the reaction mixture was then heated at
reflux in dioxane for 18 h. The reaction mixture was then reduced
in vacuo and the residue partitioned between EtOAc (100 ml) and
H.sub.2O (100 ml). The organics were separated and the aqueous
layer was re-extracted with EtOAc (2.times.100 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo to give the
subtitle compound as a white solid. Yield: 640 mg
[0709] .sup.1H NMR: .delta. (DMSO) 2.18 (s, 3H), 2.37 (t, 4H), 2.94
(t, 4H), 6.74 (s, 2H)
ii)
N-{2-[(2,3-Difluorobenzyl)thio]-6-[(1R)-1-methyl-2-(trityloxy)ethoxy]p-
yrimidin-4-yl}-4-methylpiperazine-1-sulfonamide
[0710] A mixture of 4-Methylpiperazine-1-sulfonamide (the product
from step i) (0.64 g), tris(dibenzylideneacetone)dipalladium (0)
(50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.55 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-methyl-2-(triphen-
ylmethoxy)ethoxy]-pyrimidine ((the product of example 13 step 0.50
g) in dioxane (40 mL) was heated at reflux in a microwave at
100.degree. C., 300 W, open vessel with cooling for 1 h. The
reaction mixture was diluted with DCM, filtered through arbocel and
the filtrate evaporated. The residue was purified by reverse phase
HPLC using a TFA (0.2%)/MeCN system to give the subtitle compound
as a yellow solid. Yield: 0.22 g.
[0711] .sup.1H NMR: .delta. (CDCl.sub.3) 1.27 (d, 3H), 2.21 (s,
3H), 2.33-2.47 (m, 4H), 3.24-3.35 (m, 4H), 4.29-4.42 (m, 2H),
5.42-5.54 (m, 1H), 6.26 (s, 1H), 6.93-7.08 (m, 2H), 7.18-7.31 (m,
10H), 7.37-7.41 (m, 6H)
EXAMPLE 68
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-1,4-diazepane-1-sulfonamide
##STR00075##
[0713] To a solution of
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(1R)-1-methyl-2-(trityloxy)eth-
oxy]-4-pyrimidinyl]-sulfamoyl-1,4-diazepane-1-carboxylic acid
tert-butyl ester (the product of step ii, 100 mg) in DCM (3 ml) was
added TFA (3 ml) dropwise. The reaction was then allowed to stir at
room temperature for the following 3 h until complete. The reaction
was then reduced in vacuo and the resulting residue was purified by
preparative HPLC to yield the title compound as a white solid.
Yield: 62 mg
[0714] MS: APCI (+ve) 490 [M+H.sup.+]
[0715] .sup.1H NMR: .delta. (DMSO) 1.13 (d, 3H), 1.90-1.97 (m, 2H),
3.34-3.55 (m, 10H), 4.36-4.42 (m, 2H), 5.02-5.08 (m, 1H), 5.77 (s,
1H)), 7.11-7.18 (m, 1H), 7.29-7.36 (m, 1H), 7.37-7.44 (m, 1H)
[0716] The intermediates for this compound were prepared as
follows:
i) 4-Sulfamoyl-1,4-diazepane-1-carboxylic acid tert-butyl ester
[0717] To a solution of 1,4-Diazepane-1-carboxylic acid tert-butyl
ester (3.16 g) in dioxane (40 ml) was added sulfamide (4.0 g) and
the reaction mixture was then heated at reflux for 18 h. The
reaction mixture was then reduced in vacuo and the residue
partitioned between EtOAc (100 ml) and H.sub.2O (100 ml). The
organics were separated and the aqueous layer was re-extracted with
EtOAc (2.times.100 ml). Organics were combined, dried (MgSO.sub.4)
and reduced in vacuo to give the subtitle compound as a white
solid. Yield: 4.27 g
[0718] .sup.1H NMR: (DMSO) .delta. 1.40 (s, 9H), 1.70-1.77 (m, 2H),
3.12-3.23 (m, 4H), 3.32-3.44 (m, 2H), 6.72 (s, 2H)
ii)
N-{2-[(2,3-Difluorobenzyl)thio]-6-[(1R)-1-methyl-2-(trityloxy)ethoxy]p-
yrimidin-4-yl}-4-pyrimidinyl]sulfamoyl-1,4-diazepane-1-carboxylic
acid tert-butyl ester
[0719] A mixture of 4-Sulfamoyl-1,4-diazepane-1-carboxylic acid
tert-butyl ester (the product from step i) (0.84 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.55 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-[(1R)-1-methyl-2-(triphen-
ylmethoxy)ethoxy]-pyrimidine (the product of example 13 step iii),
0.50 g) in dioxane (20 mL) was heated at reflux in a microwave at
100.degree. C., 300 W, open vessel with cooling for 3 h. The
reaction mixture was then reduced in vacuo and the residue
partitioned between EtOAc (100 ml) and H.sub.2O (100 ml). The
organics were separated and the aqueous layer was re-extracted with
EtOAc (2.times.100 ml). Organics were combined, dried (MgSO.sub.4)
and reduced in vacuo and the resulting residue was purified by prep
HPLC to give the subtitle compound as a clear colourless oil.
Yield: 0.11 g
[0720] .sup.1H NMR: (CDCl.sub.3) .delta. 1.27 (d, 3H), 1.43 (s,
9H), 1.88 (quintet, 2H), 3.09-3.16 (m, 1H), 3.24-3.30 (m, 1H),
3.34-3.53 (m, 8H), 4.28-4.44 (m, 2H), 5.47-5.54 (m, 1H), 6.03-6.11
(m, 2H), 6.93-7.08 (m, 2H), 7.18-7.30 (m, 10H), 7.35-7.41 (m,
6H)
EXAMPLE 69
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-4-ethyl-piperazine-1-sulfonamide
##STR00076##
[0722] To a solution of
ethyl(2R)-2-[(2-[(2,3-Difluorobenzyl)thio]-6-{[(4-ethylpiperazin-1-yl)sul-
fonyl]amino}pyrimidin-4-yl)oxy]propanoate (the product from step i)
(0.72 g) in THF (10 ml) was added 2M LiBH.sub.4 in TI-IF (1.3 ml).
The reaction was then stirred for 18 h at RT. Saturated NH.sub.4Cl
(150 ml) was then added to the reaction mixture which was extracted
with DCM (3.times.150 ml). Organics were combined, dried
(MgSO.sub.4) and reduced in vacuo and the resulting residue was
purified by prep HPLC to give the title compound as a white
solid.
[0723] Yield: 45 mg
[0724] MS: APCI (+ve) 504 [M+H.sup.+]
[0725] .sup.1H NMR: (CDCl.sub.3) .delta. 1.15 (d, 3H), 1.24 (t,
3H), 3.13 (q, 2H), 2.50 (t, 4H), 3.36 (t, 4H), 3.67-3.77 (m, 2H),
4.31-4.41 (m, 2H), 5.32-5.26 (m, 1H), 6.24 (s, 1H), 7.00-7.10 (m,
2H), 7.19-7.24 (m, 1H)
[0726] The intermediate for this compound was prepared as
follows:
i) Ethyl
(2R)-2-[(2-[(2,3-difluorobenzyl)thio]-6-{[(4-ethylpiperazin-1-yl)-
sulfonyl]amino}pyrimidin-4-yl)oxy]propanoate
[0727] To a solution of 1-Ethylpiperazine (1 g) in dioxane (10 ml)
was added sulfamide (0.746 g) and the reaction mixture was then
heated at reflux in dioxane for 72 h. The reaction mixture was
purified by loading onto SCX and eluting with (200 ml)
MeOH/NH.sub.3. The eluent was then reduced in vacuo to yield
4-Ethylpiperazine-1-sulfonamide as a white solid. A mixture of
4-ethylpiperazine-1-sulfonamide (0.289 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.628 g) and
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester ((the product of example 5 step i),
0.50 g) in dioxane (10 mL) was heated at reflux in a microwave at
100 C, 300 W, open vessel with cooling for 30 min. The reaction
mixture was then reduced in vacuo and the residue was partitioned
between EtOAc (150 ml) and H.sub.2O (100 ml). The organics were
separated and the aqueous layer was re-extracted with EtOAc
(2.times.150 ml). Organics were combined, dried (MgSO.sub.4) and
reduced in vacuo to give the subtitle compound as a yellow solid.
Yield: 0.720 g
[0728] MS: APCI (+ve) 546 [M+H.sup.+]
EXAMPLE 70
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-4-(4-pyridyl)piperazine-1-sulfonamide
##STR00077##
[0730] To a solution of
ethyl(2R)-2-[(2-[(2,3-Difluorobenzyl)thio]-6-{[(4-pyridin-4-ylpiperazine)-
sulfonyl]amino}pyrimidin-4-yl)oxy]propanoate (the product from step
i) (0.72 g) in THF (10 ml) was added 2M LiBH.sub.4 in THF (1.3 ml).
The reaction was then stirred for 18 h at RT. Saturated NH.sub.4Cl
(150 ml) was then added to the reaction mixture which was extracted
with DCM (3.times.150 ml). Organics were combined, dried
(MgSO.sub.4) and reduced in vacuo and the resulting residue was
purified by prep HPLC to give the title compound as a white solid.
Yield: 10 mg
[0731] MS: APCI (+ve) 553 [M+H.sup.+]
[0732] .sup.1H NMR: (DMSO) .delta. 1.16 (d, 3H), 3.37-3.41 (m, 4H),
3.46-3.51 (m, 2H), 3.75-3.79 (m, 4H), 4.40-4.48 (m, 2H), 5.11-5.17
(m, 1H), 6.01 (s, 1H), 7.13-7.21 (m, 3H), 7.31-7.39 (m, 2H), 8.28
(d, 2H)
[0733] The intermediate for this compound was prepared as
follows:
i) Ethyl
(2R)-2-[(2-[(2,3-difluorobenzyl)thio]-6-{[(4-pyridin-4-ylpiperazi-
n-1-yl)sulfonyl]amino}pyrimidin-4-yl)oxy]propanoate
[0734] To a solution of 1-pyridin-4-ylpiperazine (1.23 g) in
dioxane (10 ml) was added sulfamide (0.746 g) and the reaction
mixture was then heated at reflux in dioxane for 72 h. The reaction
mixture was purified by loading onto SCX and eluting with (200 ml)
MeOH/NH.sub.3. The eluent was then reduced in vacuo to yield
4-pyridin-4-ylpiperazine-1-sulfonamide as a white solid. A mixture
of 4-pyridin-4-ylpiperazine-1-sulfonamide (0.260 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.438 g) and
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester ((the product of example 5 step i),
0.350 g) in dioxane (10 ml) was heated at reflux in a microwave at
100 C, 300 W, open vessel with cooling for 30 mins. The reaction
mixture was then reduced in vacuo and the residue was partitioned
between EtOAc (150 ml) and H.sub.2O (100 ml). The organics were
separated and the aqueous layer was re-extracted with EtOAc
(2.times.150 ml). Organics were combined, dried (MgSO.sub.4) and
reduced in vacuo to give the subtitle compound as a yellow solid.
Yield: 0.720 g
[0735] MS: APCI (+ve) 595 [M+H.sup.+]
EXAMPLE 71
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-(3R)-3-ethylpiperazine-1-sulfonamide
##STR00078##
[0737] To a solution of
ethyl(2R)-2-[(2-[(2,3-difluorobenzyl)thio]-6-([((3R)-3-ethylpiperazine)su-
lfonyl]amino)pyrimidin-4-yl)oxy]propanoate (the product from step
i) (0.71 g) in THF (10 ml) was added 2M LiBH.sub.4 in THF (1.3 ml).
The reaction was then stirred for 18 h at RT. Saturated NH.sub.4Cl
(150 ml) was then added to the reaction mixture which was extracted
with DCM (3.times.150 ml). Organics were combined, dried
(MgSO.sub.4) and reduced in vacuo and the resulting residue was
purified by prep HPLC to give the title compound as a white solid.
Yield: 70 mg
[0738] MS: APCI (+ve) 504 [M+H.sup.+]
[0739] .sup.1H NMR: (CDCl.sub.3) .delta. 0.87 (t, 3H), 1.28 (d,
3H), 1.53-1.63 (m, 1H), 1.63-1.73 (m, 1H), 2.79-2.88 (m, 1H),
2.95-3.08 (m, 2H), 3.61-3.80 (m, 4H), 3.97-4.05 (m, 1H), 4.08-4.16
(m, 1H), 4.33-4.44 (m, 2H), 5.28-5.36 (m, 1H), 6.28 (m, 1H),
6.99-7.12 (m, 2H), 7.19-7.24 (m, 1H)
[0740] The intermediate for this compound was prepared as
follows:
i) Ethyl
(2R)-2-[(2-[(2,3-difluorobenzyl)thio]-6-{[((3R)-3-ethylpiperazine-
-1-sulfonamide)sulfonyl]amino}pyrimidin-4-yl)oxy]propanoate
[0741] To a solution of (3R)-3-ethylpiperazine (0.5 g) in dioxane
(10 ml) was added sulfamide (0.373 g) and the reaction mixture was
then heated at reflux in dioxane for 3 d. The reaction mixture was
purified by loading onto SCX and eluting with (200 ml)
MeOH/NH.sub.3. The eluent was then reduced in vacuo to yield
(3R)-3-ethylpiperazine-1-sulfonamide as a white solid. A mixture of
(3R)-3-ethylpiperazine-1-sulfonamide (0.260 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.438 g) and
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester ((the product of example 5 step i),
0.350 g) in dioxane (10 ml) was heated at reflux in a microwave at
100 C, 300 W, open vessel with cooling for 30 min. The reaction
mixture was then reduced in vacuo and the residue was partitioned
between EtOAc (150 ml) and H.sub.2O (100 ml). The organics were
separated and the aqueous layer was re-extracted with EtOAc
(2.times.150 ml). Organics were combined, dried (MgSO.sub.4) and
reduced in vacuo to give the subtitle compound as a yellow solid.
Yield: 0.705 g
[0742] MS: APCI (+ve) 546 [M+H.sup.+]
EXAMPLE 72
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-(3R,5S)-3,5-dimethylpiperazine-1-sulfonamide
##STR00079##
[0744] To a solution of
Ethyl(2R)-2-[(2-[(2,3-difluorobenzyl)thio]-6-{[((3R,5S)-3,5-dimethylpiper-
azine)sulfonyl]amino}pyrimidin-4-yl)oxy]propanoate (the product
from step i), 0.50 g) in THF (10 ml) was added 2M LiBH.sub.4 in THF
(0.9 ml). The reaction was then stirred for 18 h at RT. Saturated
NH.sub.4Cl (150 ml) was then added to the reaction mixture which
was extracted with DCM (3.times.150 ml). Organics were combined,
dried (MgSO.sub.4) and reduced in vacuo and the resulting residue
was purified by prep HPLC to give the title compound as a white
solid. Yield: 80 mg
[0745] MS: APCI (+ve) 504 [M+H.sup.+]
[0746] .sup.1H NMR: (DMSO) .delta. 1.13 (d, 6H), 3.01-3.21 (m, 2H),
3.37-3.57 (m, 4H), 4.33-4.43 (m, 2H), 4.76-4.81 (m, 2H), 4.97-5.05
(m, 1H), 5.81 (s, 1H), 7.09-7.17 (m, 1H), 7.26-7.35 (m, 1H),
7.39-7.45 (m, 1H)
[0747] The intermediate for this compound was prepared as
follows:
i) Ethyl
(2R)-2-[(2-[(2,3-difluorobenzyl)thio]-6-{[((3R,5S)-3,5-dimethylpi-
perazine)sulfonyl]amino}pyrimidin-4-yl)oxy]propanoate
[0748] To a solution of (2R,6S)-2,6-dimethylpiperazine (1 g) in
dioxane (10 ml) was added sulfamide (0.746 g) and the reaction
mixture was then heated at reflux in dioxane for 72 h. The reaction
mixture was partitioned between EtOAc (150 ml) and H.sub.2O (150
ml) and the aqueous re-extracted with EtOAc (2.times.150 ml).
Organics were collected dried and reduced in vacuo to yield
(3R,5S)-3,5-dimethylpiperazine-1-sulfonamide as a white solid (0.29
g). A mixture of (3R,5S)-3,5-dimethylpiperazine-1-sulfonamide (0.29
g), tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.628 g) and
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (the product of example 5 step i), 0.5
g) in dioxane (10 mL) was heated at reflux in a microwave at
100.degree. C., 300 W, open vessel with cooling for 30 min. The
reaction mixture was then reduced in vacuo and the residue was
partitioned between EtOAc (150 ml) and H.sub.2O (100 ml). The
organics were separated and the aqueous layer was re-extracted with
EtOAc (2.times.150 ml). Organics were combined, dried (MgSO.sub.4)
and reduced in vacuo to give the subtitle compound as a yellow
solid. Yield: 0.940 g
[0749] MS: APCI (+ve) 546 [M+H.sup.+]
EXAMPLE 73
N-{2-[(2,3-Difluorobenzyl)thio]-6-[(1R)-2-hydroxy-1-methylethoxy]pyrimidin-
-4-yl}-9-methyl-3,9-diazabicyclo[4.2.1]nonane-3-sulfonamide
##STR00080##
[0751] To a solution of ethyl
(2R)-2-[(2-[(2,3-difluorobenzyl)thio]-6-{[(9-methyl-3,9-diazabicyclo[4.2.-
1]non-3-yl)sulfonyl]amino}pyrimidin-4-yl)oxy]propanoate (the
product from step i), 0.35 g) in THF (10 ml) was added 2M
LiBH.sub.4 in THF (0.6 ml). The reaction was then stirred for 18 h
at room temperature. Saturated NH.sub.4Cl (150 ml) was then added
to the reaction mixture which was extracted with DCM (3.times.150
ml). Organics were combined, dried (MgSO.sub.4) and reduced in
vacuo and the resulting residue was purified by prep HPLC to give
the title compound as a white solid. Yield 20 mg
[0752] MS: APCI (+ve) 530 [M+H.sup.+]
[0753] .sup.1H NMR: (CDCL.sub.3) .delta. 1.27 (d, 3H), 1.32-1.40
(m, 2H), 1.65-1.80 (m, 4H), 2.54 (s, 3H), 2.91-3.05 (m, 2H),
3.39-3.48 (m, 2H), 3.65-3.75 (m, 2H), 4.03-4.11 (m, 1H), 4.16-4.24
(m, 1H), 4.32-4.46 (m, 2H), 5.22-5.28 (m, 1H), 6.19 (s, 1H),
6.98-7.08 (m, 2H), 7.20-7.32 (m, 1H)
[0754] The intermediate for this compound was prepared as
follows:
i) Ethyl
(2R)-2-[(2-[(2,3-difluorobenzyl)thio]-6-{[(9-methyl-3,9-diazabicy-
clo[4.2.1]non-3-yl)sulfonyl]amino}pyrimidin-4-yl)oxy]propanoate
[0755] To a solution of 9-methyl-3,9-diazabicyclo[4.2.1]nonane
(0.56 g) in 1,4-dioxane (10 ml) was added sulfamide (0.37 g) and
the reaction mixture was then heated at reflux in 1,4-dioxane for
72 h. The reaction mixture was purified by loading onto SCX and
eluting with 7N NH.sub.3/MeOH (200 ml). The eluent was then reduced
in vacuo to yield
9-methyl-3,9-diazabicyclo[4.2.1]nonane-3-sulfonamide (0.13 g) as a
yellow solid. A mixture of
9-methyl-3,9-diazabicyclo[4.2.1]nonane-3-sulfonamide (0.13 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.31 g) and
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (the product of example 5 step i), 0.25
g) in 1,4-dioxane (10 mL) was heated at reflux in a microwave at
100.degree. C., 300 W, open vessel with cooling for 30 min. The
reaction mixture was then reduced in vacuo and the residue was
partitioned between EtOAc (150 ml) and H.sub.2O (100 ml). The
organics were separated and the aqueous layer was re-extracted with
EtOAc (2.times.150 ml). Organics were combined, dried (MgSO.sub.4)
and reduced in vacuo to give the subtitle compound as a yellow
solid. Yield 0.35 g
[0756] MS: APCI (+ve) 572 [M+H.sup.+]
EXAMPLE 74
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-[(1R)-2-hydroxy-1-methylethoxy]--
4-pyrimidinyl]-(3S)-3-methylpiperazine-1-sulfonamide
##STR00081##
[0758] To a solution of Ethyl
(2R)-2-[(2-[(2,3-difluorobenzyl)thio]-6-{[((3S)-3-methylpiperazine-1-sulf-
onamide)sulfonyl]amino}pyrimidin-4-yl)oxy]propanoate (the product
from step i) (0.94 g) in THF (10 ml) was added 2M LiBH.sub.4 in THF
(1.8 ml). The reaction was then stirred for 18 h at RT. Saturated
NH.sub.4Cl (150 ml) was then added to the reaction mixture which
was extracted with DCM (3.times.150 ml). Organics were combined,
dried (MgSO.sub.4) and reduced in vacuo and the resulting residue
was purified by prep HPLC to give the title compound as a white
solid. Yield: 35 mg
[0759] MS: APCI (+ve) 490 [M+H.sup.+]
[0760] .sup.1H NMR: (CDCl.sub.3) .delta. 1.36 (d, 3H), 1.61 (d,
3H), 2.81-3.03 (m, 3H), 3.20-3.39 (m, 4H), 3.67-3.84 (m, 2H),
4.22-4.44 (m, 2H), 5.29-5.37 (m, 1H), 6.18 (s, 1H), 7.02-7.11 (m,
2H), 7.13-7.19 (m, 1H)
[0761] The intermediate for this compound was prepared as
follows:
i) Ethyl
(2R)-2-[(2-[(2,3-difluorobenzyl)thio]-6-{[(3S)-3-methylpiperazine-
)sulfonyl]amino}pyrimidin-4-yl)oxy]propanoate
[0762] To a solution of (2S)-2-methylpiperazine (0.914 g) in
dioxane (10 ml) was added sulfamide (0.746 g) and the reaction
mixture was then heated at reflux in dioxane for 3 d. The reaction
mixture was partitioned between EtOAc (150 ml) and H.sub.2O (150
ml) and the aqueous re-extracted with EtOAc (2.times.150 ml).
Organics were collected dried and reduced in vacuo to yield
(3S)-3-methylpiperazine-1-sulfonamide as a white solid (0.27 g). A
mixture of (3S)-3-methylpiperazine-1-sulfonamide (0.27 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.628 g) and
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester ((the product of example 5 step i),
0.50 g) in dioxane (20 mL) was heated at reflux in a microwave at
100.degree. C., 300 W, open vessel with cooling for 30 mins. The
reaction mixture was then reduced in vacuo and the residue was
partitioned between EtOAc (150 ml) and H.sub.2O (100 ml). The
organics were separated and the aqueous layer was re-extracted with
EtOAc (2.times.150 ml). Organics were combined, dried (MgSO.sub.4)
and reduced in vacuo to give the subtitle compound as a yellow
solid. Yield: 0.940 g
[0763] MS: APCI (+ve) 532 [M+H.sup.+]
EXAMPLE 75
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxy-methylpropyl]oxy}pyr-
imidin-4-yl)-1,4-diazepane-1-sulfonamide
##STR00082##
[0765]
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxy-methylpropyl]-
oxy}pyrimidin-4-yl)-tert-butyl
4-(aminosulfonyl)-1,4-diazepane-1-carboxylate (1.6 g) was dissolved
in DCM (30 ml) and stirred until in solution. To this solution was
added TFA (30 ml). The reaction was then allowed to stir at room
temperature overnight. The reaction was then reduced in vacuo and
the resulting yellow residue purified by HPLC to give the title
compound as a white solid.
[0766] Yield: 76 mg
[0767] MS: APCI (+ve) 504 [M+H.sup.+]
[0768] .sup.1H NMR: (DMSO) .delta. 1.04 (d, 3H), 1.14 (d, 3H),
1.96-2.02 (m, 2H), 3.16-3.24 (m, 2H), 3.41-3.45 (m, 4H), 3.66-3.74
(m, 2H), 4.41-4.49 (m, 2H), 4.99-5.05 (m, 1H), 5.09 (s, 1H),
7.14-7.23 (m, 1H), 7.31-7.40 (m, 2H), 8.65-8.72 (m, 2H)
[0769] The intermediate for this compound was prepared as
follows:
i)
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxy-methylpropyl]oxy}-
pyrimidin-4-yl)-tert-butyl
4-(aminosulfonyl)-1,4-diazepane-1-carboxylate
[0770] A mixture of 4-sulfamoyl-1,4-diazepane-1-carboxylic acid
tert-butyl ester (the product from example 68 step i) (0.541 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.55 g) and
(2R,3R)-3-({6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)butan-
-2-ol (the product of example 4 step i), 0.541 g) in dioxane (40
mL) was heated at reflux in a microwave at 100.degree. C., 300 W,
open vessel with cooling for 15 mins. The reaction mixture was then
reduced in vacuo and the residue separated between DCM (200 ml) and
H.sub.2O (150 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.200 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo and the resulting
residue was purified by prep HPLC to give the subtitle compound as
a yellow oil. Yield: 1.6 g
[0771] MS: APCI (+ve) 604 [M+H.sup.+]
EXAMPLE 76
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxy-methylpropyl]oxy}pyr-
imidin-4-yl)-(3R,5S)-3,5-dimethylpiperazine-1-sulfonamide
##STR00083##
[0773] To a solution of (2R,6S)-2,6-Dimethylpiperazine (1 g) in
dioxane (10 ml) was added sulfamide (0.746 g) and the reaction
mixture was then heated at reflux in dioxane for 3 d. The reaction
mixture was partitioned between EtOAc (150 ml) and H.sub.2O (150
ml) and the aqueous re-extracted with EtOAc (2.times.150 ml).
Organics were collected dried and reduced in vacuo to yield
(3R,5S)-3,5-dimethylpiperazine-1-sulfonamide as a white solid (1.05
g). A mixture of (3R,5S)-3,5-dimethylpiperazine-1-sulfonamide
(0.541 g), tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.731 g) and
(2R,3R)-3-({6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)butan-
-2-ol ((the product of example 4 step i), 0.541 g) in dioxane (40
mL) was heated at reflux in a microwave at 100.degree. C., 300 W,
open vessel with cooling for 20 min. The reaction mixture was then
reduced in vacuo and the residue separated between DCM (200 ml) and
H.sub.2O (200 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.200 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo and the resulting
residue was purified by prep HPLC to give the title compound as a
white solid. Yield: 80 mg
[0774] MS: APCI (+ve) 518 [M+H.sup.+]
[0775] .sup.1H NMR: (CD.sub.3OD) .delta. 1.16 (d, 3H), 1.22 (d,
3H), 1.33 (d, 6H), 2.89-2.96 (m, 2H), 3.37-3.48 (m, 2H), 3.78-3.85
(m, 1H), 3.99-4.04 (m, 2H), 4.40-4.50 (m, 2H), 5.09-5.16 (m, 1H),
5.99 (s, 1H), 7.07-7.21 (m, 2H), 7.30-7.36 (m, 2H)
EXAMPLE 77
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxymethylpropyl]oxy}pyri-
midin-4-yl)-piperazine-1-sulfonamide
##STR00084##
[0777]
N-(2-[(2,3-difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxymethylpropyl]o-
xy}pyrimidin-4-yl) tert-butyl
4-(aminosulfonyl)piperazine-1-carboxylate (1.45 g) was dissolved in
DCM (10 ml) and allowed to stir at room temperature until
homogeneous. TFA (10 ml) was then slowly added and the reaction
mixture stirred overnight. The reaction mixture was reduced in
vacuo, dissolved in MeOH and purified by prep HPLC to give the
title compound as a white solid
[0778] Yield: 25 mg
[0779] MS: APCI (+ve) 490 [M+H.sup.+]
[0780] .sup.1H NMR: (DMSO) .delta. 1.02 (d, 3H), 1.09 (d, 3H),
3.01-3.05 (m, 4H), 3.14-3.18 (m, 4H), 3.64-3.71 (m, 2H), 4.32-4.42
(m, 2H), 4.69-4.73 (m, 1H), 4.87-4.94 (m, 1H), 5.84 (s, 1H),
7.10-7.17 (m, 1H), 7.27-7.34 (m, 1H), 7.40-7.46 (m, 1H)
[0781] The intermediate for this compound was prepared as
follows:
i)
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxymethylpropyl]oxy}p-
yrimidin-4-yl)tert-butyl
4-(aminosulfonyl)piperazine-1-carboxylate
[0782] A mixture of 4-(Aminosulfonyl)-1,1-dimethylethyl
ester-1-piperazinecarboxylic acid (0.663 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.731 g) and
(2R,3R)-3-{[6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)butan-
-2-ol ((the product of example 4 step i), 0.541 g) in dioxane (40
mL) was heated at reflux in a microwave at 100.degree. C., 300 W,
open vessel with cooling for 1.5 h. The reaction mixture was then
reduced in vacuo and the residue partitioned between EtOAc (200 ml)
and H.sub.2O (200 ml). The organics were separated and the aqueous
layer was re-extracted with EtOAc (2.times.200 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo to give the
subtitle compound as a yellow solid. Yield: 1.45 g
[0783] MS: APCI (+ve) 590 [M+H.sup.+]
EXAMPLE 78
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxymethylpropyl]oxy}pyri-
midin-4-yl)-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
##STR00085##
[0785]
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxymethylpropyl]o-
xy}pyrimidin-4-yl)
2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
(the product from step 0.54 g) was added to a solution of 7N
NH.sub.3 in MeOH (20 ml), sealed and stirred at room temperature
for 1 h. The reaction was reduced in vacuo and the resulting
residue purified by prep HPLC to give the title compound as a white
solid. Yield: 180 mg
[0786] MS: APCI (+ve) 537 [M+H.sup.+]
[0787] .sup.1H NMR: (DMSO) .delta. 0.98 (d, 3H), 1.04 (d, 3H), 2.95
(t, 2H), 3.30 (t, 2H), 3.60-3.67 (m, 1H), 4.22 (s, 2H), 4.25-4.27
(m, 2H), 4.78-4.85 (m, 1H), 5.63 (s, 1H), 7.09-7.15 (m, 1H),
7.21-7.23 (m, 1H), 7.26-7.39 (m, 2H), 7.56-7.61 (m, 2H)
[0788] The intermediates for this compound were prepared as
follows:
i)
N-(tert-Butyl)-2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-sul-
fonamide
[0789] To a solution of
2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-sulfonyl
chloride (3 g) in DCM (50 ml) was added 2-methylpropan-2-amine
(1.73 g). The reaction was then allowed to stir at room temperature
18 h. The reaction was partitioned between H.sub.2O (100 ml) and
DCM (100 ml). The organics were separated and the aqueous layer was
re-extracted with DCM (2.times.200 ml). Organics were combined,
dried (MgSO.sub.4) and reduced in vacuo to give the subtitle
compound as colourless oil. Yield: 3.56 g
[0790] .sup.1H NMR: (DMSO) .delta. 1.10 (s, 9H), 2.95-3.02 (m, 2H),
3.80-3.86 (m, 2H), 4.79-4.86 (m, 2H), 7.37-7.49 (m, 2H), 7.63-7.72
(m, 1H)
ii) 1,2,3,4-Tetrahydroisoquinoline-7-sulfonamide
[0791]
N-(tert-Butyl)-2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-
-sulfonamide (the product from step i), 1.78 g) was dissolved in
TFA and stirred at room temperature for 96 h. The reaction was
reduced in vacuo and the residue purified by column chromatography
on silica gel 50% EtOAc/50% iso-hexane to give the subtitle
compound as a white solid. Yield: 0.65 g
[0792] .sup.1H NMR: (DMSO) .delta. 2.95-3.02 (m, 2H), 3.80-3.86 (m,
2H), 4.80-4.85 (m, 2H), 7.38-7.43 (m, 1H), 7.64-7.77 (m, 2H)
iii)
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxymethylpropyl]oxy-
}pyrimidin-4-yl)2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-sulfo-
namide
[0793] A mixture of 1,2,3,4-Tetrahydroisoquinoline-7-sulfonamide
(the product from step 0.65 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.731 g) and
(2R,3R)-3-({6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)butan-
-2-ol (the product of example 4 step i), 0.432 g) in dioxane (40
mL) was heated at reflux in a microwave at 100.degree. C., 300 W,
open vessel with cooling for 20 min. The reaction mixture was then
reduced in vacuo and the residue separated between DCM (100 ml) and
H.sub.2O (100 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.100 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo and the resulting
residue was purified by column chromatography on silica 50%
EtOAc/50% iso-hexane to give the subtitle compound as a clear oil.
Yield: 0.54 g
[0794] MS: APCI (+ve) 633 [M+H.sup.+]
EXAMPLE 79
N-{2-[(2,3-Difluorobenzyl)thio]-6-[(1S)-2-hydroxy-1-(isopropoxymethyl)etho-
xy]pyrimidin-4-yl}-1-methyl-1H-imidazole-4-sulfonamide
##STR00086##
[0796] The title compound was prepared according to the procedure
outlined in example 34 using
N-{6-[(1R)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-(isopropoxymethyl)ethoxy]-
-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}-1-methyl-1H-imidazole-4-sulfo-
namide (the product from step (v) (90 mg) in THF (5 mL) and 1M
solution of tetrabutylammoniumfluoride in THF (0.28 mL) to give the
title compound as a white solid. Yield: 30 mg.
[0797] MS: APCI (+ve) 530 [M+H.sup.+]
[0798] .sup.1H NMR: (DMSO) .delta. 0.98-1.04 (m, 6H), 3.47-3.56 (m,
4H), 3.67 (s, 3H), 4.40 (s, 2H), 5.14 (q, 1H), 6.17 (s, 1H),
7.07-7.18 (m, 1H), 7.28-7.41 (m, 2H), 7.79 (d, 1H), 8.00 (d, 1H),
11.57 (s, 1H)
[0799] The intermediates for this compound were prepared as
follows:
i) (4R)-4-(isoPropoxymethyl)-2,2-dimethyl-1,3-dioxolane
[0800] To a solution of 2,2-dimethyl-1,3-dioxolane-4-methanol (2
g), in DMSO (50 mL), powdered potassium hydroxide was added
portionwise at 0.degree. C. then warmed to room temperature.
2-Iodo-propane (43 mL) was added to the mixture at 0.degree. C.
then stirred for 72 h at room temperature. The reaction mixture was
diluted with H.sub.2O and extracted with EtOAc. The organic layer
was washed with H.sub.2O then brine (.times.2) and dried
(MgSO.sub.4), filtered and evaporated to give the subtitle compound
as clear, colourless oil. Yield: 2 g
[0801] .sup.1H NMR: (DMSO) .delta. 1.08 (d, 6H), 1.26 (d, 3H), 1.31
(s, 3H), 3.30-3.43 (m, 2H), 3.51-3.61 (m, 2H), 3.94-4.00 (m, 1H),
4.08-4.15 (m, 1H)
ii) (2S)-3-isoPropoxypropane-1,2-diol
[0802] Acetyl chloride was added dropwise into a solution of MeOH
(30 mL) at 0.degree. C. with stirring for min. A solution of
(4R)-4-(isopropoxymethyl)-2,2-dimethyl-1,3-dioxolane (1.7 g) (the
product from step (i), in MeOH (30 mL), was added dropwise to the
reaction mixture. The solution was then warmed to room temperature
and stirred for 2 h. The reaction mixture was evaporated to give
the subtitle compound as clear oil. Yield: 0.8 g
[0803] .sup.1H NMR: (DMSO) .delta. 1.07 (dd, 6H), 3.21-3.37 (m,
4H), 3.47-3.55 (m, 2H)
iii)
(2R)-1-{[tert-Butyl(dimethyl)silyl]oxy}-3-isopropoxypropan-2-ol
[0804] The subtitle compound was prepared according to the
procedure outlined in example 34 step iii) using
(2S)-3-isopropoxypropane-1,2-diol (0.80 g) (the product from step
(ii) in DCM (10 mL), tert-butyldimethylsilyl chloride (1.59 g),
triethylamine (1.43 mL) and 4-(dimethylamino)pyridine (50 mg) at
0.degree. C. to give the subtitle compound as a clear, colourless
oil. Yield: 1.86 g
[0805] .sup.1H NMR: (DMSO) .delta. 0.07 (s, 6H), 0.91 (s, 9H), 1.11
(d, 6H), 3.26-3.35 (m, 2H), 3.37-3.45 (m, 2H), 3.49-3.61 (m, 2H),
4.63 (d, 1H)
iv)
4-[(1R)-2-{[tert-Butyl(dimethyl)silyl]oxy}-1-(isopropoxymethyl)ethoxy]-
-6-chloro-2[(2,3-difluorobenzyl)thio]pyrimidine
[0806] The subtitle compound was prepared according to the
procedure outlined in example 1 step iii) using
4,6-Dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (product of
example 1 step ii) (0.46 g),
(2R)-1-{[tert-butyl(dimethyl)silyl]oxy}-3-isopropoxypropan-2-ol
(product of step (0.66 g), THF (5 mL) and 60% sodium hydride (80
mg), to give the subtitle compound as a colourless oil. Yield: 0.56
g
[0807] MS: APCI (+ve) 519/521 [M+H.sup.+]
v)
N-{6-[(1R)-2-{[tert-Butyl(dimethyl)silyl]oxy}-1-(isopropoxymethyl)ethox-
y]-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}-1-methyl-1H-imidazole-4-sul-
fonamide
[0808] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using a mixture of
azetidine-1-sulfonamide (prepared according to patent WO
2004/011443) (0.19 g), tris(dibenzylideneacetone)dipalladium (0)
(0.53 g),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (39 mg), cesium carbonate (0.28 g),
4-[(1R)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-(isopropoxymethyl)ethoxy]-6--
chloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of step
iv) (0.3 g) and dioxane (15 mL). Purification was by column
chromatography on silica gel using EtOAc/iso-hexane (2:8) 50:70 as
eluent, to give the title compound as a white solid. Yield: 90
mg
[0809] MS: APCI (+ve) 645 [M+H.sup.+]
EXAMPLE 80
N-{2-[(2,3-Difluorobenzyl)thio]-6-[(1R)-2-hydroxy-1-methylethoxy]pyrimidin-
-4-yl}-1,2-dimethyl-1H-imidazole-4-sulfonamide
##STR00087##
[0811] The title compound was prepared according to the procedure
outlined in example 11 using a mixture of ethyl
(2R)-2-[(2-[(2,3-difluorobenzyl)thio]-6-{[(1,2-dimethyl-1H-imidazol-4-yl)-
sulfonyl]amino}pyrimidin-4-yl)oxy]propanoate (the product from step
(i) (0.25 g), lithium borohydride (2M solution in THF, 0.48 mL) and
THF (6 mL). Purification was by reverse phase HPLC (symmetry as the
stationary phase and TFA/acetonitrile as the mobile phase) then
titurated with Toluene, DCM and then Et.sub.2O/iso-hexane to give
the title compound as a white solid. Yield: 44 mg
[0812] MS: APCI (+ve) 486 [M+H.sup.+]
[0813] .sup.1H NMR: (DMSO) .delta. 1.14 (d, 3H), 2.27 (s, 3H),
3.44-3.49 (m, 2H), 3.56 (s, 3H), 4.41 (s, 2H), 5.02-5.14 (m, 1H),
6.11 (s, 1H), 7.08-7.20 (m, 1H), 7.25-7.43 (m, 2H), 7.92 (s, 1H),
11.44 (s, 1H)
[0814] The intermediate for this compound was prepared as
follows:
i) Ethyl
(2R)-2-[(2-[(2,3-difluorobenzyl)thio]-6-{[(1,2-dimethyl-1H-imidaz-
ol-4-yl)sulfonyl]amino}pyrimidin-4-yl)oxy]propanoate
[0815] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using a mixture of
1,2-Dimethyl-1H-imidazole-4-sulfonic acid amide (0.19 g),
tris(dibenzylideneacetone)dipalladium (0) (56 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (41 mg), cesium carbonate (0.32 g),
2-[[6-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-4-pyrimidinyl]oxy]-(2R)-
-propanoic acid ethyl ester (the product of example 11 step i)
(0.24 g) and dioxane (20 mL). Purification was by column
chromatography on silica gel using DCM/MeOH (100:1 to 90:10
gradient) as eluent, to give the title compound as a pale yellow
solid. Yield: 0.25 g
[0816] MS: APCI (+ve) 528 [M+H.sup.+]
EXAMPLE 81
2-{4-[2-(2,3-Difluoro-benzylsulfanyl)-6-methoxy-pyrimidin-4-ylsulfamoyl]-p-
iperazin-1-yl}-N,N-dimethyl-acetamide
##STR00088##
[0818] To a solution of N,N-Dimethyl-2-piperazin-1-yl-acetamide
(0.51 g), in dioxane (20 mL) was added sulfamide (0.29 g). The
reaction mixture was then heated at reflux for 24 h. The reaction
mixture was allowed to cool before being reduced in vacuo to give
the intermediate compound as an off white solid. Yield: 0.65 g
[0819] The title compound was prepared according to the procedure
outlined in example 1 step (iv) using a mixture of the above
intermediate compound (0.38 g),
tris(dibenzylideneacetone)dipalladium (0) (92 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (67 mg), cesium carbonate (0.49 g),
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of example 35 step i) (0.30 g) and dioxane (10 mL).
Purification was by reverse phase HPLC (symmetry as the stationary
phase and TFA/acetonitrile as the mobile phase) then titurated with
MeOH followed by DCM to give the title compound as a white solid.
Yield: 0.24 g
[0820] MS: APCI (+ve) 517 [M+H.sup.+]
[0821] .sup.1H NMR: (CD.sub.3OD) .delta. 3.00 (s, 3H), 3.02 (s,
3H), 3.41-3.53 (m, 4H), 3.64-3.80 (m, 4H), 3.97 (s, 3H), 4.29 (s,
2H), 4.54 (s, 2H), 6.09 (s, 1H), 7.08-7.25 (m, 2H), 7.33-7.41 (m,
1H)
EXAMPLE 82
4-Pyridin-4-ylmethyl-piperazine-1-sulfonic acid
[2-(2,3-difluoro-benzylsulfanyl)-6-methoxy-pyrimidin-4-yl]-amide
##STR00089##
[0823] The title compound was prepared according to the procedure
outlined in example 81 using a mixture of
1-Pyridin-4-ylmethyl-piperazine (0.53 g), sulfamide (0.29 g) and
dioxane (20 mL). Followed by tris(dibenzylideneacetone)dipalladium
(0) (92 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (67 mg), cesium carbonate (0.49 g),
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of example 35 step i) (0.30 g) and dioxane (10 mL).
Purification was by reverse phase HPLC (symmetry as the stationary
phase and TFA/acetonitrile as the mobile phase) then titurated with
MeOH followed by DCM to give the title compound as a white solid.
Yield: 0.23 g
[0824] MS: APCI (+ve) 523 [M+H.sup.+]
[0825] .sup.1H NMR: (CD.sub.3OD) .delta. 2.77 (t, 4H), 3.47 (t,
4H), 3.96 (s, 3H), 4.01 (s, 2H), 4.51 (s, 2H), 6.13 (s, 1H),
7.07-7.24 (m, 2H), 7.34-7.42 (m, 1H), 7.99 (d, 2H), 8.76 (d,
2H)
EXAMPLE 83
4-(Tetrahydro-furan-2-ylmethyl)-piperazine-1-sulfonic acid
[2-(2,3-difluoro-benzylsulfanyl)-6-methoxy-pyrimidin-4-yl]-amide
##STR00090##
[0827] The title compound was prepared according to the procedure
outlined in example 81 using a mixture of
1-(tetrahydrofuran-2-yl)-1-piperazine (0.51 g), sulfamide (0.29 g)
and dioxane (20 mL). Followed by
tris(dibenzylideneacetone)dipalladium (0) (92 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (67 mg), cesium carbonate (0.49 g),
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of example 35 step i) (0.30 g) and dioxane (10 mL).
Purification was by reverse phase HPLC (symmetry as the stationary
phase and TFA/acetonitrile as the mobile phase) then titurated with
Toluene, MeOH followed by DCM to give the title compound as a white
solid.
[0828] Yield: 0.15 g
[0829] MS: APCI (+ve) 516 [M+H.sup.+]
[0830] .sup.1H NMR: (CD3OD) .delta. 1.53-1.67 (m, 2H), 1.92-2.03
(m, 2H), 2.10-2.22 (m, 1H), 3.13-3.96 (m, 11H), 3.99 (s, 3H),
4.21-4.34 (m, 1H), 4.55 (s, 2H), 6.08 (s, 1H), 7.08-7.25 (m, 2H),
7.32-7.40 (m, 1H)
EXAMPLE 84
4-(3-Dimethylamino-propyl)-piperazine-1-sulfonic acid
[2-(2,3-difluoro-benzylsulfanyl)-6-methoxy-pyrimidin-4-yl]-amide
##STR00091##
[0832] The title compound was prepared according to the procedure
outlined in example 81 using a mixture of
N,N-dimethyl-3-piperazi-1-ylpropan-1-amine (0.51 g), sulfamide
(0.29 g) and dioxane (20 mL). Followed by
tris(dibenzylideneacetone)dipalladium (0) (92 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (67 mg), cesium carbonate (0.49 g),
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of example 35 step i) (0.30 g) and dioxane (10 mL).
Purification was by reverse phase HPLC (symmetry as the stationary
phase and TFA/acetonitrile as the mobile phase) then titurated with
Toluene, MeOH followed by DCM to give the title compound as a white
solid.
[0833] Yield: 0.14 g
[0834] MS: APCI (+ve) 517 [M+H.sup.+]
[0835] .sup.1H NMR: (DMSO) .delta. 1.85-2.00 (m, 2H), 2.48-2.53 (m,
10H), 2.78 (s, 6H), 3.02-3.11 (m, 2H), 3.90 (s, 3H), 4.49 (s, 2H),
6.12 (s, 1H), 7.13-7.22 (m, 1H), 7.30-7.44 (m, 2H)
EXAMPLE 85
Piperazine-1,4-disulfonic acid
[2-(2,3-difluoro-benzylsulfanyl)-6-methoxy-pyrimidin-4-yl]-amide
dimethylamide
##STR00092##
[0837] The title compound was prepared by adding dimethyl sulfamoyl
chloride to a solution of
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]piperazin-
e-1-sulfonamide, trifluoroacetate salt (the product from example
36) (0.25 g) in DCM (5 mL). Purification was by reverse phase HPLC
(symmetry as the stationary phase and TFA/acetonitrile as the
mobile phase) then titurated with Toluene, DCM followed by
Et.sub.2O to give the title compound as a white solid. Yield: 0.11
g
[0838] MS: APCI (+ve) 539 [M+H.sup.+]
[0839] .sup.1H NMR: (DMSO) .delta.2.73 (s, 6H), 3.16-3.30 (m, 8H),
3.88 (s, 3H), 4.48 (s, 2H), 6.07 (s, 1H), 7.11-7.20 (m, 1H),
7.29-7.45 (m, 2H), 11.28 (s, 1H)
EXAMPLE 86
{4-[2-(2,3-Difluoro-benzylsulfanyl)-6-methoxy-pyrimidin-4-ylsulfamoyl]-pip-
erazin-1-yl}-acetic acid
##STR00093##
[0841] The title compound was prepared by adding 1M NaOH (1 mL) to
a solution of
{4-[2-(2,3-Difluoro-benzylsulfanyl)-6-methoxy-pyrimidin-4-ylsulfamoyl]-pi-
perazin-1-yl}-acetic acid ethyl ester (the product from step i)
(0.31 g) in MeOH (1 mL). Purification was by reverse phase HPLC
(symmetry as the stationary phase and TFA/acetonitrile as the
mobile phase) then titurated with Toluene, DCM followed by
Et.sub.2O to give the title compound as a white solid. Yield: 85
mg
[0842] MS: APCI (+ve) 490 [M+H.sup.+]
[0843] .sup.1H NMR: (CD3OD) .delta. 2.99-3.05 (m, 4H), 3.39 (s,
2H), 3.46-3.53 (m, 4H), 3.92 (s, 3H), 4.47 (s, 2H), 6.10 (s, 1H),
7.05-7.24 (m, 3H), 7.35 (t, 1H)
[0844] The intermediate for this compound was prepared as
follows:
i)
{4-[2-(2,3-Difluoro-benzylsulfanyl)-6-methoxy-pyrimidin-4-ylsulfamoyl]--
piperazin-1-yl}-acetic acid ethyl ester
[0845] The subtitle compound was prepared by adding 60% sodium
hydride (0.18 g) portionwise to a solution of
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]piperazin-
e-1-sulfonamide, trifluoroacetate salt (the product from example
36) (0.53 g) and ethyl 2-bromoacetate (0.36 mL) in THF (10 mL). The
reaction mixture was diluted with H.sub.2O and extracted with
EtOAc. The organic layer was washed with brine and evaporated to
give the subtitle compound as an oil.
[0846] MS: APCI (+ve) 518 [M+H.sup.+]
EXAMPLE 87
4-(2-Hydroxy-ethyl)-piperazine-1-sulfonic acid
[2-(2,3-difluoro-benzylsulfanyl)-6-methoxy-pyrimidin-4-yl]-amide
##STR00094##
[0848] The title compound was prepared according to the procedure
outlined in example 24 using a mixture of
{4-[2-(2,3-Difluoro-benzylsulfanyl)-6-methoxy-pyrimidin-4-ylsulfamoyl]-pi-
perazin-1-yl}-acetic acid ethyl ester (the product from example 86
step i) (0.31 g) lithium borohydride (1M solution in THF (1.2 mL)
in THF (5 mL). Purification was by reverse phase HPLC (symmetry as
the stationary phase and NH.sub.4OAc/acetonitrile as the mobile
phase) then titurated with Toluene, MeOH followed by DCM to give
the title compound as a white solid.
[0849] Yield: 13 mg
[0850] MS: APCI (+ve) 476 [M+H.sup.+]
[0851] .sup.1H NMR: (CD3OD) .delta. 2.52-2.61 (m, 6H), 3.34 (t,
4H), 3.65 (t, 2H), 3.91 (s, 3H), 4.47 (s, 2H), 6.14 (s, 1H),
7.04-7.19 (m, 2H), 7.35 (t, 1H)
Synthesis of Examples 88-107
[0852] Examples 88-107 were synthesised using the following
procedure:--
[0853] To a solution of the aldehyde (0.2 mmol) in NMP (0.8 mL),
N-[2-([(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]piperazin-
e-1-sulfonamide trifluoroacetate salt (the product from example 36)
(65 mg) was added as an NMP solution (0.4 ml) followed by resin
bound cyanoborohydride (88 mg) and acetic acid (1.8 .mu.L). The
reaction mixture was agitated for 48 h, then filtered to remove the
resin followed by centrifugal evaporation to dryness. The product
was purified by LCMS directed purification (XTerra as the
stationary phase and ammonia/acetonitrile as the mobile phase) to
give the title compound.
TABLE-US-00001 ##STR00095## Example M/Z number Example R [M + H] 88
N-{2-[(2,3-Difluorobenzyl)thio]-6- methoxypyrimidin-4-yl}-4-(1H-
imidazol-2-ylmethyl)piperazine-1- sulfonamide ##STR00096## 512 89
N-[4-({4-[({2-[(2,3- Difluorobenzyl)thio]-6- methoxypyrimidin-4-
yl}amino)sulfonyl]piperazin-1- yl}methyl)phenyl]acetamide
##STR00097## 578 90 N-{2-[(2,3-Difluorobenzyl)thio]-6-
methoxypyrimidin-4-yl}-4-(2,3- dihydroxypropyl)piperazine-1-
sulfonamide ##STR00098## 505 91 N-{2-[(2,3-Difluorobenzyl)thio]-6-
methoxypyrimidin-4-yl}-4-(3- furylmethyl)piperazine-1-sulfonamide
##STR00099## 511 92 N-{2-[(2,3-Difluorobenzyl)thio]-6-
methoxypyrimidin-4-yl}-4-(1,3-thiazol-
2-ylmethyl)piperazine-1-sulfonamide ##STR00100## 528 93
N-{2-[(2,3-Difluorobenzyl)thio]-6-
methoxypyrimidin-4-yl}-4-[(4-oxo-4H-
chromen-3-yl)methyl]piperazine-1- sulfonamide ##STR00101## 589 94
N-{2-[(2,3-Difluorobenzyl)thio]-6-
methoxypyrimidin-4-yl}-4-(1H-pyrazol-
3-ylmethyl)piperazine-1-sulfonamide ##STR00102## 511 95
N-{2-[(2,3-Difluorobenzyl)thio]-6- methoxypyrimidin-4-yl}-4-[3-
(dimethylamino)-2,2- dimethylpropyl]piperazine-1- sulfonamide
##STR00103## 544 96 N-{2-[(2,3-Difluorobenzyl)thio]-6-
methoxypyrimidin-4-yl}-4-(1,2,3-
thiadiazol-4-ylmethyl)piperazine-1- sulfonamide ##STR00104## 529 97
4-{[1-(2-Cyanoethyl)-1H-pyrrol-2- yl]methyl}-N-{2-[(2,3-
difluorobenzyl)thio]-6- methoxypyrimidin-4-yl}piperazine-1-
sulfonamide ##STR00105## 563 98 N-{2-[(2,3-Difluorobenzyl)thio]-6-
methoxypyrimidin-4-yl}-4-[4-hydroxy-
3-(hydroxymethyl)benzyl]piperazine-1- sulfonamide ##STR00106## 567
99 N-{2-[(2,3-Difluorobenzyl)thio]-6-
methoxypyrimidin-4-yl}-4-[(1,3,6- trimethyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5- yl)methyl]piperazine-1-sulfonamide
##STR00107## 597 100 N-{2-[(2,3-Difluorobenzyl)thio]-6-
methoxypyrimidin-4-yl}-4-{[2- (dimethylamino)pyrimidin-5-
yl]methyl}piperazine-1-sulfonamide ##STR00108## 566 101
N-{2-[(2,3-Difluorobenzyl)thio]-6- methoxypyrimidin-4-yl}-4-[(3-
morpholin-4-yl-1H-pyrazol-5- yl)methyl]piperazine-1-sulfonamide
##STR00109## 596 102 N-{2-[(2,3-Difluorobenzyl)thio]-6-
methoxypyrimidin-4-yl}-4-[(1-methyl-
1H-1,2,4-triazol-5-yl)methyl]piperazine- 1-sulfonamide ##STR00110##
526 103 N-{2-[(2,3-Difluorobenzyl)thio]-6-
methoxypyrimidin-4-yl}-4-(5-hydroxy-
2-nitrobenzyl)piperazine-1-sulfonamide ##STR00111## 582 104
N-{2-[(2,3-Difluorobenzyl)thio]-6- methoxypyrimidin-4-yl}-4-(1H-
imidazol-4-ylmethyl)piperazine-1- sulfonamide ##STR00112## 511 105
N-{2-[(2,3-Difluorobenzyl)thio]-6- methoxypyrimidin-4-yl}-4-[4-(1H-
1,2,4-triazol-1-yl)benzyl]piperazine-1- sulfonamide ##STR00113##
588 106 2-[4-({4-[({2-[(2,3- Difluorobenzyl)thio]-6-
methoxypyrimidin-4- yl}amino)sulfonyl]piperazin-1-
yl}methyl)phenoxy]acetamide ##STR00114## 594 107
N-{2-[(2,3-Difluorobenzyl)thio]-6- methoxypyrimidin-4-yl}-4-[(3,5-
dimethylisoxazol-4- yl)methyl]piperazine-1-sulfonamide ##STR00115##
540
EXAMPLE 108
N-{2-[(3-Chloro-2-fluorobenzyl)thio]-6-methoxypyrimidin-4-yl}piperazine-1--
sulfonamide
##STR00116##
[0855] The title compound was prepared according to the procedure
outlined in example 15 using tert-butyl
4-[({2-[(3-chloro-2-fluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulf-
onyl]piperazine-1-carboxylate (the product from step ii) (0.26 g),
trifluoroacetic acid (0.5 mL) and DCM (10 mL). Purification was by
reverse phase HPLC (Symmetry as the stationary phase and
TFA/acetonitrile as the mobile phase) then triturated with MeOH
followed by Et.sub.2O to give the title compound as a white solid.
Yield: 40 mg
[0856] MS: APCI (+ve) 448 [M+H.sup.+]
[0857] .sup.1H NMR: (DMSO) .delta. 3.15-3.24 (m, 4H), 3.36-3.48 (m,
4H), 3.92 (s, 3H), 4.50 (s, 2H), 6.10 (s, 1H), 7.22 (t, 1H),
7.49-7.63 (m, 2H), 8.74 (s, 1H)
[0858] The intermediates for this compound were prepared as
follows:
i)
4-Chloro-2-[(3-chloro-2-fluorobenzyl)thio]-6-methoxypyrimidine
[0859] The subtitle compound was prepared according to the
procedure outlined in example 35 Step (i) using
4,6-dichloro-2-[(3-chloro-2-fluorobenzyl)thio]pyrimidine
(prepared according to patent WO 2004/011443) (0.65 g), methanol (8
mL) and 60% sodium hydride (88 mg). Yield: 0.57 g.
[0860] .sup.1H NMR: (CDCl.sub.3) .delta. 3.93 (s, 3H), 4.41-4.43
(m, 2H), 6.43 (s, 1H), 6.99-7.05 (m, 1H), 7.25-7.32 (m, 1H),
7.40-7.46 (m, 1H)
ii) tert-Butyl
4-[({2-[(3-chloro-2-fluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulf-
onyl]piperazine-1-carboxylate
[0861] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using
4-chloro-2-[(3-chloro-2-fluorobenzyl)thio]-6-methoxypyrimidine (the
product from step i) (0.26 g), 4-(aminosulfonyl)-1,1-dimethylethyl
ester-1-piperazinecarboxylic acid (the product of example 15 step
i) (0.23 g), tris(dibenzylideneacetone)dipalladium (0) (73 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (53 mg), cesium carbonate (0.33 g), and dioxane (8 mL).
Purification was by column chromatography on silica gel using
EtOAc/isohexane (2:8 to 3:7 gradient) as eluent to give the
subtitle compound as a white solid. Yield: 0.26 g
[0862] MS: APCI (-ve) 546 [M-H.sup.-]
EXAMPLE 109
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-3-hydroxyazetidin-
e-1-sulfonamide
##STR00117##
[0864] The title compound was prepared according to the procedure
outlined in example 34 using
3-{[tert-butyl(diphenyl)silyl]oxy}-N-{2-[(2,3-difluorobenzyl)thio]-6-meth-
oxypyrimidin-4-yl}azetidine-1-sulfonamide (the product from step
ii) (0.29 g) and 1M solution of tetrabutylammoniumfluoride in THF
(5 mL). Purification was by reverse phase HPLC (symmetry as the
stationary phase and TFA/acetonitrile as the mobile phase) then
triturated with MeOH, Et.sub.2O followed by iso-hexane to give the
title compound as a white solid. Yield: 40 mg
[0865] MS: APCI (+ve) 419 [M+H.sup.+]
[0866] .sup.1H NMR: (DMSO) .delta. 3.70 (t, 2H), 3.86 (s, 3H), 3.97
(t, 2H), 4.29-4.39 (m, 1H), 4.46 (s, 2H), 5.79 (d, 1H), 6.16 (s,
1H), 7.10-7.18 (m, 1H), 7.32 (q, 1H), 7.41 (t, 1H), 11.23 (s,
1H)
[0867] The intermediates for this compound were prepared as
follows:
i) 3-(tert-Butyl-diphenyl-silanyloxy)-azetidine-1-sulfonamide
[0868] The subtitle compound was prepared according to the
procedure outlined in example 15 step (i) using
3-(tert-butyl-diphenyl-silanyloxy)-azetidine (prepared according to
patent WO 2003/072557) (0.93 g), dioxane (20 mL) and sulfamide
(0.34 g). Isolation was by filtration to remove excess sulfamide,
the filtrate was then reduced in vacuo to give the subtitle
compound as a brown oil. Yield: 1.2 g
[0869] MS: APCI (-ve) 389 [M-H.sup.-]
ii)
3-{[tert-Butyl(diphenyl)silyl]oxy}-N-{2-[(2,3-difluorobenzyl)thio]-6-m-
ethoxypyrimidin-4-yl}azetidine-1-sulfonamide
[0870] The subtitle compound was prepared according to the
procedure outlined in example 1 step (iv) using a mixture of
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of example 35 step i) (0.16 g),
3-(tert-butyl-diphenyl-silanyloxy)-azetidine-1-sulfonamide (the
product from step i) (0.17 g),
tris(dibenzylideneacetone)dipalladium (0) (33 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (24 mg), cesium carbonate (0.16 g) and dioxane (8 mL).
Purification was by column chromatography on silica gel using
EtOAc/isohexane (1:9 to 2:8 gradient) as eluent to give the
subtitle compound as a yellow oil. Yield: 0.12 g
[0871] MS: APCI (+ve) 657 [M+H.sup.+]
EXAMPLE 110
N'-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-N-[2-(dimethylam-
ino)ethyl]-N-methylsulfamide
##STR00118##
[0873] The title compound was prepared according to the procedure
outlined in example 1 step (iv) using a mixture of
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of example 35 step i) (0.35 g),
N-[2-(dimethylamino)ethyl]-N-methylsulfamide (prepared according to
procedure outlined in Org. Letts 2004, 6 (16), 2705-2708) (0.18 g),
tris(dibenzylideneacetone)dipalladium (0) (73 mg),
2-dicyclohexylphosphino-2,4',6'-tri-isopropyl-1,1'-biphenyl (XPHOS)
(53 mg), cesium carbonate (0.39 g) and dioxane (20 mL).
Purification was by reverse phase HPLC (symmetry as the stationary
phase and TFA/acetonitrile as the mobile phase) then titurated with
MeOH followed by Et.sub.2O to give the title compound as a white
solid. Yield: 0.12 g
[0874] MS: APCI (+ve) 448 [M+H.sup.+]
[0875] .sup.1H NMR (DMSO) .delta. 2.84 (6H, s), 2.86 (3H, s), 3.33
(2H, t), 3.57 (2H, t), 3.93 (3H, s), 4.53 (2H, s), 6.05 (1H, s),
7.16-7.24 (1H, m), 7.32-7.45 (2H, m)
EXAMPLE 111
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxymethylpropyl]oxy}pyri-
midin-4-yl)-(2S)-2-methylpiperazine-1-sulfonamide
##STR00119##
[0877]
N-(2-[(2,3-difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxymethylpropyl]o-
xy}pyrimidin-4-yl) tert-butyl
4-(aminosulfonyl)piperazine-1-carboxylate (the product from step
ii), 0.65 g) was dissolved in DCM (15 ml) and allowed to stir at
room temperature until homogeneous. TFA (15 ml) was then slowly
added and the reaction mixture stirred overnight. The reaction
mixture was reduced in vacuo, dissolved in MeOH and purified by
prep HPLC to give the title compound as a white solid
[0878] Yield 105 mg
[0879] .sup.1H NMR: (DMSO) .delta. 1.04 (d, 3H), 1.14 (d, 3H), 1.27
(d, 3H), 2.82-2.91 (m, 1H), 2.97-3.06 (m, 1H), 3.19-3.27 (m, 2H),
3.36-3.44 (m, 1H), 3.67-3.77 (m, 2H), 4.14-4.21 (m, 1H), 4.41-4.50
(m, 2H), 4.98-5.05 (m, 1H), 5.91 (s, 1H), 7.14-7.21 (m, 1H),
7.31-7.41 (m, 2H), 11.28 (s, 1H)
[0880] MS: APCI (+ve) 504.1 [M+H.sup.+]
[0881] The intermediates for this compound were prepared as
follows:
i) tert-Butyl
(3S)-4-(aminosulfonyl)-3-methylpiperazine-1-carboxylate
[0882] To a solution of (2S)-2-methylpiperazine-1-sulfonamide (0.5
g) in dioxane (40 ml) was added sulfamide (0.288 g) and the
reaction mixture was then heated at reflux in the microwave at
100.degree. C., 300 W, open vessel with cooling for 4 h in dioxane.
The reaction mixture was partitioned between DCM (100 ml) and
H.sub.2O (100 ml) and the aqueous re-extracted with DCM
(2.times.100 ml). Organics were collected dried and reduced in
vacuo to give the subtitle compound as a clear colourless oil (745
mg)
[0883] .sup.1H NMR: (DMSO) .delta. 1.11 (d, 3H), 1.40 (s, 9H),
2.84-3.13 (m, 3H), 3.32 (s, 2H), 3.64-3.72 (m, 1H), 3.78-3.93 (m,
1H), 6.80 (s, 2H)
ii)
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(1R,2R)-2-hydroxymethylpropyl]oxy}-
pyrimidin-4-yl)-tert-butyl
(3S)-4-(aminosulfonyl)-3-methylpiperazine-1-carboxylate
[0884] A mixture of tert-butyl
(3S)-4-(aminosulfonyl)-3-methylpiperazine-1-carboxylate ((the
product from step i), 0.373 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.488 g) and
(2R,3R)-3-((6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl)oxy)butan-
-2-ol ((the product of example 4 step i), 0.361 g) in dioxane (20
ml) was heated at reflux in a microwave at 100.degree. C., 300 W,
open vessel with cooling for 1.5 h. The reaction mixture was then
reduced in vacuo and the residue separated between EtOAc (200 ml)
and H.sub.2O (200 ml). The organics were separated and the aqueous
layer was re-extracted with EtOAc (2.times.200 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo to give the
subtitle compound as a yellow solid
[0885] Yield 0.65 g
[0886] MS: APCI (+ve) 604.5 [M+H.sup.+]
EXAMPLE 112
N-[2-[(2,3-Difluorobenzyl)thio]-6-(2-hydroxyethoxy)pyrimidin-4-yl]methanes-
ulfonamide
##STR00120##
[0888] A mixture of methanesulfonamide (0.228 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.585 g) and
2-({6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)ethanol
((the product step i), 0.400 g) in dioxane (20 ml) was heated at
reflux in a microwave at 100.degree. C., 300 W, open vessel with
cooling for 30 mins. The reaction mixture was then reduced in vacuo
and the residue separated between DCM (150 ml) and H.sub.2O (100
ml). The organics were separated and the aqueous layer was
re-extracted with DCM (2.times.150 ml). Organics were combined,
dried (MgSO.sub.4) and reduced in vacuo and the resulting residue
was purified by prep HPLC to give the title compound as a white
solid. Yield: 102 mg
[0889] .sup.1H NMR: (DMSO) .delta. 3.28 (s, 3H), 3.63-3.68 (m, 2H),
4.29 (t, 2H), 4.47 (s, 2H), 4.87 (t, 1H), 6.03 (s, 1H), 7.13-7.19
(m, 1H), 7.31-7.43 (m, 2H), 11.12 (s, 1H)
[0890] MS: APCI (+ve) 391.9 [M+H.sup.+]
[0891] The intermediate for this compound was prepared as
follows:
i)
2-({6-Chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)ethanol
[0892] To a solution of
4,6-dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine ((the product
of example 1 step ii) 5 g) and ethylene glycol (1.517 g) in THF
(100 ml) was added NaH (1.3 g) slowly and the reaction was then
allowed to stir overnight at RT. The reaction mixture was then
partitioned between EtOAc (200 ml) and H.sub.2O (200 ml). The
organics were separated and the aqueous layer was re-extracted with
EtOAc (2.times.200 ml). Organics were combined, dried (MgSO.sub.4)
and reduced in vacuo and the resulting residue was purified by
column chromatography on silica gel 10% EtOAc/90% iso-Hex to give
the subtitle compound as a clear oil. Yield: 2.4 g
[0893] MS: APCI (+ve) 332/334 [M+H.sup.+]
[0894] .sup.1H NMR: (DMSO) .delta. 3.90-3.95 (m, 2H), 4.42 (s, 2H),
4.45-4.48 (m, 2H), 6.48 (s, 1H), 6.98-7.10 (m, 2H), 7.24-7.30 (m,
1H)
EXAMPLE 113
N-[2-[(2,3-Difluorobenzyl)thio]-6-(2-hydroxyethoxy)pyrimidin-4-yl]piperazi-
ne-1-sulfonamide
##STR00121##
[0896] To a solution of
N-[2-[(2,3-difluorobenzyl)thio]-6-(2-hydroxyethoxy)pyrimidin-4-yl]tert-bu-
tyl 4-(aminosulfonyl)piperazine-1-carboxylate ((the product from
step i), 0.70 g) in DCM (20 ml) was added TFA (20 ml). The reaction
was then stirred at room temperature for 18 h. The reaction was
then reduced in vacuo and the residue dissolved in 7N NH.sub.3/MeOH
(20 ml) and stirred at room temperature for 1 h. The reaction was
then reduced in vacuo and the residue purified by prep HPLC to give
the title compound as a white solid. Yield: 33 mg
[0897] MS: APCI (+ve) 462 [M+H.sup.+]
[0898] .sup.1H NMR: (DMSO) .delta. 3.01-3.05 (m, 4H), 3.13-3.17 (m,
4H), 3.60-3.64 (m, 2H), 4.16 (t, 2H), 4.38 (m, 2H), 4.79 (s, 1H),
5.87 (s, 1H), 7.09-7.17 (m, 1H), 7.26-7.35 (m, 1H), 7.41-7.46 (m,
1H)
[0899] The intermediate for this compound was prepared as
follows:
i)
N-[2-[(2,3-Difluorobenzyl)thio]-6-(2-hydroxyethoxy)pyrimidin-4-yl]tert--
butyl 4-(aminosulfonyl)piperazine-1-carboxylate
[0900] A mixture of 4-(aminosulfonyl)-1,1-dimethylethyl
ester-1-piperazinecarboxylic acid (the product from example 15 step
i) (0.637 g), tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.385 g) and
2-({6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)ethanol
(the product from example 112 step 0.400 g) in dioxane (20 ml) was
heated at reflux in a microwave at 100.degree. C., 300 W, open
vessel with cooling for 30 mins. The reaction mixture was then
reduced in vacuo and the residue separated between DCM (150 ml) and
H.sub.2O (100 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.150 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo to give the
subtitle compound as a yellow solid. Yield: 0.70 g
[0901] MS: APCI (-ve) 560 [M-H.sup.-]
[0902] .sup.1H NMR: (DMSO) .delta. 3.28 (s, 3H), 3.63-3.68 (m, 2H),
4.29 (t, 2H), 4.47 (s, 2H), 4.87 (t, 1H), 6.03 (s, 1H), 7.13-7.19
(m, 1H), 7.31-7.43 (m, 2H), 11.12 (s, 1H)
EXAMPLE 114
N-[2-[(2,3-Difluorobenzyl)thio]-6-(2-hydroxyethoxy)pyrimidin-4-yl]morpholi-
ne-4-sulfonamide
##STR00122##
[0904] A mixture of morpholine-4-sulfonamide (prepared according to
patent WO 2004/011443, 0.399 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.585 g) and
2-({6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)ethanol
(the product from example 112 step 0.400 g) in dioxane (20 ml) was
heated at reflux in a microwave at 100.degree. C., 300 W, open
vessel with cooling for 30 mins. The reaction mixture was then
reduced in vacuo and the residue separated between DCM (150 ml) and
H.sub.2O (100 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.150 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo and the resulting
residue purified by prep HPLC to give the title compound as a white
solid. Yield: 0.15 g
[0905] MS: APCI (+ve) 463 [M+H.sup.+]
[0906] .sup.1H NMR: (DMSO) .delta. 3.18 (t, 4H), 3.60 (t, 4H), 3.66
(t, 2H), 4.30 (t, 2H), 4.47 (s, 2H), 4.88 (s, 1H), 6.10 (s, 1H),
7.13-7.20 (m, 1H), 7.31-7.38 (m, 1H), 7.39-7.44 (m, 1H)
EXAMPLE 115
N-[(2,3-Difluorobenzyl)thio]-6-(2-hydroxyethoxy)pyrimidin-4-yl]-azetidine--
1-sulfonamide
##STR00123##
[0908] A mixture of azetidine-1-sulfonamide (0.33 g, prepared
according to patent WO2004/011443),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.585 g) and
2-({6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)ethanol
((the product from example 112 step ii), 0.400 g) in dioxane (20
ml) was heated at reflux in a microwave at 100.degree. C., 300 W,
open vessel with cooling for 30 mins. The reaction mixture was then
reduced in vacuo and the residue separated between DCM (150 ml) and
H.sub.2O (150 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.150 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo and the resulting
residue purified by prep HPLC to give the title compound as a white
solid. Yield: 0.13 g
[0909] MS: APCI (+ve) 433 [M+H.sup.+]
[0910] .sup.1H NMR: (DMSO) .delta.2.13 (quintet, 2H), 3.65-3.68 (m,
2H), 3.91 (t, 4H), 4.30 (t, 2H), 4.47 (s, 2H), 4.91 (s, 1H), 6.16
(s, 1H), 7.13-7.19 (m, 1H), 7.30-7.38 (m, 1H), 7.40-7.45 (m, 1H),
11.13 (s, 1H)
EXAMPLE 116
N-{2-[(2,3-Difluorobenzyl)thio]-6-isopropoxypyrimidin-4-yl}azetidine-1-sul-
fonamide
##STR00124##
[0912] A mixture of azetidine-1-sulfonamide (0.327 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.585 g) and
4-chloro-2-[(2,3-difluorobenzyl)thio]-6-isopropoxypyrimidine (the
product from step i), 0.400 g) in dioxane (20 ml) was heated at
reflux in a microwave at 100.degree. C., 300 W, open vessel with
cooling for 30 mins. The reaction mixture was then reduced in vacuo
and the residue separated between DCM (150 ml) and H.sub.2O (150
ml). The organics were separated and the aqueous layer was
re-extracted with DCM (2.times.150 ml). Organics were combined,
dried (MgSO.sub.4) and reduced in vacuo and the resulting residue
purified by prep HPLC to give the title compound as a white solid.
Yield: 0.18 g
[0913] MS: APCI (+ve) 432 [M+H.sup.+]
[0914] .sup.1H NMR: (DMSO) .delta.1.31 (d, 6H), 2.26 (quintet, 2H),
4.02 (t, 4H), 4.41 (s, 2H), 5.33 (septet, 1H), 6.32 (s, 1H),
6.98-7.10 (m, 2H), 7.18-7.28 (m, 1H)
[0915] The intermediate for this compound was prepared as
follows:
i) 4-Chloro-2-[(2,3-difluorobenzyl)thio]-6-isopropoxypyrimidine
[0916] To a solution of
4,6-dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine ((the product
of example 1 step ii), 3 g) in propan-2-ol (20 ml) was added NaH
(0.43 g) slowly and the reaction was then allowed to stir overnight
at RT. The reaction mixture was then partitioned between DCM (100
ml) and H.sub.2O (100 ml). The organics were separated and the
aqueous layer was re-extracted with DCM (2.times.100 ml). Organics
were combined, dried (MgSO.sub.4) and reduced in vacuo to give the
subtitle compound as a pale yellow solid. Yield: 1.8 g
[0917] .sup.1H NMR: (DMSO) .delta. 1.26 (d, 6H), 4.45 (s, 2H),
5.23-5.32 (m, 1H), 6.77 (s, 1H), 7.14-7.22 (m, 1H), 7.31-7.39 (m,
2H)
EXAMPLE 117
(3S)-3-Amino-N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}pyrro-
lidine-1-sulfonamide
##STR00125##
[0919] To a solution of tert-butyl
{(3S)-1-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sul-
fonyl]pyrrolidin-3-yl}carbamate (the product from step ii), 0.75 g)
in DCM (10 ml) was added TFA slowly. The reaction then stirred at
room temperature for 18 h. The reaction was reduced in vacuo and
the residue purified by prep HPLC to give the title compound as a
white solid. Yield: 70 mg
[0920] MS: APCI (+ve) 432 [M+H.sup.+]
[0921] .sup.1H NMR: (DMSO) .delta.1.89-2.02 (m, 1H), 2.07-2.20 (m,
1H), 3.30-3.56 (m, 4H), 3.74-3.81 (m, 1H), 3.82 (s, 3H), 4.43 (s,
2H), 5.89 (s, 1H), 7.12-7.20 (m, 1H), 7.28-7.43 (m, 2H)
[0922] The intermediates for this compound were prepared as
follows:
i) tert-Butyl [(3S)-1-(aminosulfonyl)pyrrolidin-3-yl]carbamate
[0923] To a solution of tert-butyl (3S)-pyrrolidin-3-ylcarbamate
(1.3 g) in dioxane (50 ml) was added sulfamide (1.55 g) and the
reaction was heated at 110.degree. C. for 18 h. The reaction
mixture was then partitioned between DCM (150 ml) and H.sub.2O (100
ml). The organics were separated and the aqueous layer was
re-extracted with DCM (2.times.150 ml). Organics were combined,
dried (MgSO.sub.4) and reduced in vacuo to give the subtitle
compound as a pale yellow solid. Yield: 1.44 g
[0924] .sup.1H NMR: (DMSO) .delta. 1.39 (s, 9H), 1.67-1.77 (m, 1H),
1.98-2.07 (m, 1H), 2.82-2.87 (m, 1H), 3.06-3.13 (m, 1H), 3.15-3.22
(m, 1H), 3.30-3.35 (m, 1H), 3.93-4.00 (m, 1H), 6.72 (s, 2H)
ii) tert-Butyl
{(3S)-1-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sul-
fonyl]pyrrolidin-3-yl}carbamate
[0925] A mixture of tert-butyl
[(3S)-1-(aminosulfonyl)pyrrolidin-3-yl]carbamate (the product from
step i), 0.525 g), tris(dibenzylideneacetone)dipalladium (0) (50
mg), 2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.429 g) and
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
((the product from example 35 step i), 0.400 g) in dioxane (20 ml)
was heated at reflux in a microwave at 100.degree. C., 300 W, open
vessel with cooling for 40 mins. The reaction mixture was then
reduced in vacuo and the residue separated between DCM (150 ml) and
H.sub.2O (150 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.150 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo to give the
subtitle compound as a yellow solid. Yield: 0.75 g
[0926] MS: APCI (-ve) 530 [M-H.sup.-]
EXAMPLE 118
(3R)-3-Amino-N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}pyrro-
lidine-1-sulfonamide
##STR00126##
[0928] To a solution of tert-butyl
{(3R)-1-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sul-
fonyl]pyrrolidin-3-yl}carbamate (0.75 g) in DCM (10 ml) was added
TFA (10 ml) slowly. The reaction then stirred at room temperature
for 18 h. The reaction was reduced in vacuo and the residue
purified by prep HPLC to give the subtitle compound as a white
solid.
[0929] Yield: 0.17 g
[0930] .sup.1H NMR: (DMSO) .delta.1.89-2.02 (m, 1H), 2.07-2.20 (m,
1H), 3.30-3.56 (m, 4H), 3.74-3.81 (m, 1H), 3.82 (s, 3H), 4.43 (s,
2H), 5.89 (s, 1H), 7.12-7.20 (m, 1H), 7.28-7.43 (m, 2H)
[0931] MS: APCI (+ve) 431.9 [M+H.sup.+]
[0932] The intermediates for this compound were prepared as
follows:
i) tert-Butyl [(3R)-1-(aminosulfonyl)pyrrolidin-3-yl]carbamate
[0933] To a solution of tert-butyl (3R)-pyrrolidin-3-ylcarbamate
(1.3 g) in dioxane (50 ml) was added sulfamide (1.55 g) and the
reaction was heated at 110.degree. C. for 18 h. The reaction
mixture was then partitioned between DCM (100 ml) and H.sub.2O (100
ml). The organics were separated and the aqueous layer was
re-extracted with DCM (2.times.100 ml). Organics were combined,
dried (MgSO.sub.4) and reduced in vacuo to give the subtitle
compound as a pale yellow solid. Yield: 1.69 g
[0934] .sup.1H NMR: (DMSO) .delta. 1.39 (s, 9H), 1.68-1.76 (m, 1H),
1.98-2.07 (m, 1H), 2.82-2.87 (m, 1H), 3.06-3.13 (m, 1H), 3.15-3.22
(m, 1H), 3.29-3.35 (m, 1H), 3.92-4.00 (m, 1H), 6.72 (s, 2H)
ii)
(3S)-3-Amino-N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}t-
ert-butyl[(3S)-1-(aminosulfonyl)pyrrolidin-3-yl]carbamate
[0935] A mixture of tert-butyl
[(3S)-1-(aminosulfonyl)pyrrolidin-3-yl]carbamate (0.525 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.429 g) and
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product from example 35 step i), 0.400 g) in dioxane (20 ml)
was heated at reflux in a microwave at 100.degree. C., 300 W, open
vessel with cooling for 40 mins. The reaction mixture was then
reduced in vacuo and the residue separated between DCM (150 ml) and
H.sub.2O (150 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.150 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo to give the title
compound as a yellow solid. Yield: 0.77 g
[0936] MS: APCI (-ve) 539 [M-H.sup.-]
EXAMPLE 119
(3R)-3-Amino-N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}pyrro-
lidine-1-sulfonamide
##STR00127##
[0938] To a solution of tert-butyl
(3R)-4-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulf-
onyl]-3-methylpiperazine-1-carboxylate (0.75 g) in DCM (10 ml) was
added TFA (10 ml) slowly. The reaction then stirred at room
temperature for 18 h. The reaction was reduced in vacuo and the
residue purified by prep HPLC to give the title compound as a white
solid. Yield: 0.27 g
[0939] MS: APCI (+ve) 446 [M+H.sup.+]
[0940] .sup.1H NMR: (CDCl.sub.3) .delta. 1.43 (d, 3H), 3.07 (t,
1H), 3.15 (d, 1H), 3.26 (d, 1H), 3.33 (d, 1H), 3.60 (t, 1H), 3.86
(d, 1H), 3.95 (s, 3H), 4.30-4.37 (m, 1H), 4.42 (s, 2H), 6.01 (s,
1H), 6.99-7.10 (m, 2H), 7.19-7.22 (m, 1H)
[0941] The intermediates for this compound were prepared as
follows:
i) tert-Butyl (3R)-3-methylpiperazine-1-carboxylate
[0942] To a solution of (2R)-2-methylpiperazine (1 g) in THF (10
ml) was added di-tert-butyl dicarbonate (1.45 g). The reaction
mixture was allowed to stir at room temperature for 18 h. The
reaction mixture was then partitioned between DCM (100 ml) and
H.sub.2O (100 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.150 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo to give the
subtitle compound as a clear oil. Yield: 1.1 g
[0943] .sup.1H NMR: (DMSO) .delta. 0.92 (d, 3H), 1.38 (s, 9H),
2.57-2.70 (m, 1H), 2.76-2.81 (m, 1H), 2.87-2.99 (m, 1H), 3.66-3.74
(m, 4H)
ii) tert-Butyl
(3R)-4-(aminosulfonyl)-3-methylpiperazine-1-carboxylate
[0944] To a solution of tert-butyl
(3R)-3-methylpiperazine-1-carboxylate ((the product from step i),
1.1 g) in dioxane (60 ml) was added sulfamide (1.06 g) and the
reaction was heated at 110.degree. C. for 18 h. The reaction
mixture was then partitioned between DCM (150 ml) and H.sub.2O (150
ml). The organics were separated and the aqueous layer was
re-extracted with DCM (2.times.150 ml). Organics were combined,
dried (MgSO.sub.4) and reduced in vacuo to give the subtitle
compound as a pale yellow oil. Yield: 1.44 g
[0945] .sup.1H NMR: (DMSO) .delta. 1.10 (d, 3H), 1.39 (s, 9H),
3.00-3.11 (m, 3H), 3.27-3.31 (m, 2H), 3.63-3.71 (m, 1H), 3.79-3.87
(m, 1H), 6.79 (s, 2H)
iii) tert-Butyl
(3R)-4-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulf-
onyl]-3-methylpiperazine-1-carboxylate
[0946] A mixture of tert-butyl
(3R)-4-(aminosulfonyl)-3-methylpiperazine-1-carboxylate ((the
product from step 0.554 g), tris(dibenzylideneacetone)dipalladium
(0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.429 g) and
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product from example 35 step i), 0.400 g) in dioxane (20 ml)
was heated at reflux in a microwave at 100.degree. C., 300 W, open
vessel with cooling for 60 mins. The reaction mixture was then
reduced in vacuo and the residue separated between DCM (150 ml) and
H.sub.2O (100 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (3.times.150 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo to give the
subtitle compound as a yellow oil. Yield: 0.75 g
[0947] MS: APCI (-ve) 543 [M-H.sup.-]
EXAMPLE 120
(3S)-3-Amino-N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-(2S)-
-2-methylpiperizine-1-sulfonamide
##STR00128##
[0949] To a solution of tert-butyl
(3S)-4-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulf-
onyl]-3-methylpiperazine-1-carboxylate (0.75 g) in DCM (10 ml) was
added TFA (10 ml) slowly. The reaction was then stirred at room
temperature for 18 h. The reaction was reduced in vacuo and the
residue purified by prep HPLC to give the title compound as a white
solid. Yield: 0.18 g
[0950] MS: APCI (+ve) 446 [M+H.sup.+]
[0951] .sup.1H NMR: (CDCl.sub.3) .delta. 1.43 (d, 3H), 3.07 (t,
1H), 3.15 (d, 1H), 3.26 (d, 1H), 3.33 (d, 1H), 3.60 (t, 1H), 3.86
(d, 1H), 3.95 (s, 3H), 4.30-4.37 (m, 1H), 4.42 (s, 2H), 6.01 (s,
1H), 6.99-7.10 (m, 2H), 7.19-7.22 (m, 1H)
[0952] The intermediates for this compound were prepared as
follows:
i) tert-Butyl
(3S)-4-(aminosulfonyl)-3-methylpiperazine-1-carboxylate
[0953] To a solution of tert-butyl
(3S)-3-methylpiperazine-1-carboxylate (0.5 g) in dioxane (40 ml)
was added sulfamide (0.29 g) and the reaction was heated at
110.degree. C. for 18 h. The reaction mixture was then partitioned
between DCM (150 ml) and H.sub.2O (150 ml). The organics were
separated and the aqueous layer was re-extracted with DCM
(2.times.150 ml). Organics were combined, dried (MgSO.sub.4) and
reduced in vacuo to give the subtitle compound as a pale yellow
oil. Yield: 0.66 g
[0954] .sup.1H NMR: (DMSO) .delta. 1.10 (d, 3H), 1.40 (s, 9H),
3.00-3.11 (m, 3H), 3.26-3.34 (m, 2H), 3.63-3.71 (m, 1H), 3.79-3.87
(m, 1H), 6.79 (s, 2H)
ii) tert-Butyl
(3S)-4-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulf-
onyl]-3-methylpiperazine-1-carboxylate
[0955] A mixture of tert-butyl
(3S)-4-(aminosulfonyl)-3-methylpiperazine-1-carboxylate (0.372 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.286 g) and
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
((the product from example 35 step i), 0.373 g) in dioxane (20 ml)
was heated at reflux in a microwave at 100.degree. C., 300 W, open
vessel with cooling for 60 min. The reaction mixture was then
reduced in vacuo and the residue separated between DCM (150 ml) and
H.sub.2O (100 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (3.times.150 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo to give the
subtitle compound as a yellow solid. Yield: 0.65 g
[0956] MS: APCI (-ve) 544 [M-H.sup.-]
EXAMPLE 121
N-[6-Methoxy-2-[(2-phenylethyl)thio]pyrimidin-4-yl]azetidine-1-sulfonamide
##STR00129##
[0958] A solution of
N-[(4-methoxyphenyl)methyl]-N-[6-methoxy-2-[(2-phenylethyl)thio]pyrimidin-
-4-yl]azetidine-1-sulfonamide (the product of step iii, 0.17 g) in
DCM (1 ml) and TFA (2 ml) was stirred at room temperature for 18 h.
The solvent was evaporated under reduced pressure. The residue was
recrystallised from EtOAc and iso-hexane to give the title product
as a white solid. Yield: 50 mg.
[0959] MS: APCI (+ve) 381 [M+H]
[0960] .sup.1H NMR: .delta. (DMSO) 2.12 (quintet, 2H), 3.00 (m,
2H), 3.35 (m, 2H), 3.91 (t, 7H), 6.13 (s, 1H), 7.23 (m, 1H), 7.29
(m, 4H), 11.04 (bs, 1H).
[0961] The intermediates for this compound were prepared as
follows:
i)
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]-N-[(4--
methoxyphenyl)methyl]azetidine-1-sulfonamide
[0962] 60% Sodium hydride (0.42 g) was added to a solution of
N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]azetidine-
-1-sulfonamide (the product of Example 35) (3.82 g) in anhydrous
DMF (38 ml) stirred at 0.degree. C. under nitrogen. The reaction
mixture was stirred for a further 15 min when
4-methoxybenzylchloride (2.98 g) was added dropwise over one min
followed by potassium iodide (1.66 g). After stirring at room
temperature for 18 h. the reaction mixture was partitioned between
EtOAc and H.sub.2O. The aqueous layer was separated and further
extracted with EtOAc (2.times.). The combined organic extracts were
washed with H.sub.2O, dried (MgSO.sub.4), filtered and the solvent
evaporated under reduced pressure. The residue was purified by
flash column chromatography on silica gel using EtOAc/iso-hexane
(2:8) as eluent. The product was further purified by flash column
chromatography on silica gel using DCM/isohexane (6:4) as eluent to
give the subtitle product as a white solid. Yield: 2.4 g.
[0963] MS: APCI (+ve) 523 [M+H]
ii)
N-[2-[[(2,3-Difluorophenyl)methyl]sulfonyl)-6-methoxypyrimidin-4-yl]-N-
4(4-methoxyphenyl)methyl]azetidine-1-sulfonamide
[0964] A mixture of the product of step i) (3.3 g) and mCPBA (1.1
g) in DCM was stirred at room temperature for 5 h. The reaction
mixture was washed with aqueous sodium thiosulfate solution
(3.times.100 ml; 15 g/100 ml), aqueous NaHCO.sub.3, H.sub.2O, dried
(MgSO.sub.4) and filtered. The solvent was evaporated under reduced
pressure to give the subtitle product as a yellow foam.
[0965] Yield: 3.18 g.
[0966] MS: APCI (+ve) 555 [M+H]
iii)
N-[(4-Methoxyphenyl)methyl]-N-[6-methoxy-2-[(2-phenylethyl)thio]pyrim-
idin-4-yl]azetidine-1-sulfonamide
[0967] 60% Sodium hydride (29 mg) was added to a solution of the
product of step (0.36 g) and 2-phenylethylthiol (0.1 g) in
anhydrous DMF (4 ml) stirred under nitrogen. The reaction mixture
was stirred for 18 h., diluted with EtOAc and washed with H.sub.2O.
The separated organic solution was dried (MgSO.sub.4), filtered and
the solvent evaporated under reduced pressure. The residue was
purified by flash column chromatography on silica gel using
Et.sub.2O/isohexane (3:7) as eluent to give the product as a white
solid. Yield: 0.17 g.
[0968] MS: APCI (+ve) 501 [M+H]
EXAMPLE 122
N-{6-Methoxy-2-[[(pyridin-4-yl)methyl]thio]pyrimidin-4-yl}azetidine-1-sulf-
onamide
##STR00130##
[0970] The title compound was prepared from
N-[(4-methoxyphenyl)methyl]-N-[6-methoxy-2-[[(pyridin-4-yl)methyl]thio]py-
rimidin-4-yl]azetidine-1-sulfonamide (the product of step i) (46
mg) by the procedure outlined in Example 121. The crude material
was purified by preparative plate chromatography using EtOAc with
0.5% of 7N NH.sub.3/MeOH as eluent to give the title product as a
white solid. Yield: 31 mg.
[0971] MS: APCI (+ve) 368 [M+H]
[0972] .sup.1H NMR: .delta. (DMSO) 2.09 (bt, 2H), 3.84 (bm, 7H),
4.39 (bs, 2H), 6.11 (bs, 1H), 7.47 (bs, 2H), 8.48 (bs, 2H).
[0973] The intermediate for this compound was prepared as
follows:
i)
N-[(4-Methoxyphenyl)methyl]-N-[6-methoxy-2-[[(pyridin-4-yl)methyl]thio]-
pyrimidin-4-yl]azetidine-1-sulfonamide
[0974] 60% NaH (27 mg) was added batchwise to a solution of
4-pyridylethanethiol hydrochloride (60 mg) in anhydrous DMF (2 ml)
stirred under nitrogen. After 30 min. the subtitle product of
Example 121 step ii) (0.2 g) was added. The reaction mixture was
stirred for a further 18 h. KOtBu (40 mg) was added and after 30
min. a further quantity of KOtBu (40 mg) was added. After 10 min,
KOtBu (40 mg) followed by 4-pyridylmethyl bromide hydrobromide (96
mg) were added. The reaction mixture was stirred for 5 min.,
diluted with EtOAc and washed with H.sub.2O and aqueous
Na.sub.2CO.sub.3. The separated organic solution was dried
(MgSO.sub.4), filtered and the solvent evaporated under reduced
pressure. The residue was purified by flash column chromatography
on silica gel using EtOAc/iso-hexane (7:3) as eluent to give the
product as a yellow gum. Yield: 46 mg.
[0975] MS: APCI (+ve) 488 [M+H]
EXAMPLE 123
N-{2-[[(2-Cyanophenyl)methyl]thio]-6-methoxypyrimidin-4-yl}azetidine-1-sul-
fonamide
##STR00131##
[0977] The title compound was prepared from
N-[2-[[(2-cyanophenyl)methyl]thio]-6-methoxy
pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-azetidine-1-sulfonamide
(60 mg) (the product of step i) by the procedure outlined in
Example 121. The crude material was purified by preparative plate
chromatography using EtOAc/isohexane (3:7) as eluent to give the
title product as a yellow gum. Yield: 31 mg.
[0978] MS: APCI (+ve) 392 [M+H]
[0979] .sup.1H NMR: .delta. (DMSO) 2.12 (quintet, 2H), 3.90 (m,
7H), 4.59 (s, 2H), 6.15 (s, 1H), 7.47 (t, 1H), 7.66 (t, 1H), 7.84
(m, 2H), 11.13 (bs, 1H).
[0980] The intermediate for this compound was prepared as
follows:
i)
N-{2-[[(2-Cyanophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]-N-[(4-metho-
xy-phenyl)methyl}azetidine-1-sulfonamide
[0981] The subtitle compound was prepared from the product of
Example 121 step (0.20 g) and (2-cyanophenyl)methyl bromide (78 mg)
by the procedure outlined in Example 122 step i). The crude
material was purified by flash column chromatography on silica gel
using EtOAc/isohexane (3.5:6.5) as eluent to give the product as a
gum. Yield: 60 mg
[0982] MS: APCI (+ve) 512 [M+H]
EXAMPLE 124
N-{6-Methoxy-2-[(phenylmethyl)thio]pyrimidin-4-yl}azetidine-1-sulfonamide
##STR00132##
[0984] The title compound was prepared from
N-[(4-methoxyphenyl)methyl]-N-[2-[(phenylmethyl)
thio]-6-methoxypyrimidin-4-yl]azetidine-1-sulfonamide (the product
of step i) (46 mg) by the procedure outlined in Example 121. The
crude material was purified by preparative plate chromatography
using EtOAc/isohexane (3:7) as eluent to give the title product as
a gum.
[0985] Yield: 18 mg.
[0986] MS: APCI (+ve) 367 [M+H]
[0987] .sup.1H NMR: .delta. (DMSO) 2.04 (quintet, 2H), 3.74 (t,
4H), 3.81 (s, 3H), 4.36 (s, 2H), 6.02 (s, 1H), 7.23 (m, 1H), 7.30
(m, 2H), 7.48 (d, 2H).
[0988] The intermediate for this compound was prepared as
follows:
i)
N-[(4-Methoxyphenyl)methyl]-N-[6-methoxy-2-[(phenylmethyl)thio]pyrimidi-
n-4-yl]azetidine-1-sulfonamide
[0989] KOtBu (46 mg) was added to a mixture of the product of
Example 121 step ii) (0.20 g) and phenylmethylthiol (50 mg) in DMF
(3 ml) stirred under nitrogen. After 2.5 h, 60% NaH (12 mg) was
added. The reaction mixture was stirred for a further 18 h.,
diluted with EtOAc and washed with H.sub.2O. The separated organic
solution was dried (MgSO.sub.4), filtered and the solvent
evaporated under reduced pressure. The residue was purified by
flash column chromatography on silica gel using EtOAc/isohexane
(2:8) as eluent to give the product as a gum. Yield: 45 mg.
[0990] MS: APCI (+ve) 487 [M+H]
EXAMPLE 125
N-{6-Methoxy-2-([2(-pyrazin-2-yl)ethyl]thio]pyrimidin-4-yl}azetidine-1-sul-
fonamide
##STR00133##
[0992] The title compound was prepared from
N-[(4-methoxyphenyl)methyl]-N-[6-methoxy-2-[2-[(pyrazin-2-yl)ethyl]thio]p-
yrimidin-4-yl]azetidine-1-sulfonamide (the product of step i) (44
mg) by the procedure outlined in Example 121. The crude material
was purified by flash column chromatography on silica gel using
EtOAc/isohexane (7:3) as eluent to give the product as a white
solid. Yield: 15 mg.
[0993] MS: APCI (+ve) 383 [M+H]
[0994] .sup.1H NMR: .delta. (DMSO) 2.12 (quintet, 2H), 3.22 (t,
2H), 3.43 (t, 2H), 3.72 (t, 4H), 3.80 (s, 3H), 5.98 (s, 1H), 8.49
(s, 1H), 8.58 (s, 1H), 8.63 (s, 1H).
[0995] The intermediate for this compound was prepared as
follows:
i)
N-[(4-Methoxyphenyl)methyl]-N-[6-methoxy-2-[(pyrazin-2-ylethyl)thio]pyr-
imidin-4-yl]azetidine-1-sulfonamide
[0996] The subtitle compound was prepared from the product of
Example 121 step ii) (0.20 g) and 2-(pyrazin-2-yl)ethanethiol (57
mg) by the procedure outlined in Example 124 step i). The crude
material was purified by flash column chromatography on silica gel
using EtOAc/isohexane (1:1) as eluent to give the product as a gum.
Yield: 44 mg.
[0997] MS: APCI (+ve) 503 [M+H]
EXAMPLE 126
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-1,4-diazepane-1-s-
ulfonamide
##STR00134##
[0999] A solution of tert-Butyl
4-[({2-((2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulfonyl]-
-1,4-diazepane-1-carboxylate (the product of step i, 0.22 g) in 1:1
TFA:methanol (6 ml) was stirred at room temperature for 3 h then
the volatiles evaporated and 7M ammonia in methanol (5 ml) added to
the residue. The solution was stirred for 30 min then the volatiles
evaporated and the resulting solid washed with methanol, DCM,
dimethyl sulfoxide and H.sub.2O to afford the title compound as a
white powder. Yield: 51 mg
[1000] MS: APCI (+ve) 446 [M+H.sup.+]
[1001] .sup.1H NMR: .delta. 4DMSO) 1.90-1.98 (2H, m), 3.17 (4H, t,
J=6.0 Hz), 3.36 (2H, t, J=5.9 Hz), 3.49 (2H, t, J=5.8 Hz), 3.77
(3H, s), 4.41 (2H, s), 5.78 (1H, s), 7.11-7.19 (1H, m), 7.28-7.37
(1H, m), 7.42-7.46 (1H, m).
[1002] The intermediate for this compound was prepared as
follows:
i) tert-Butyl
4-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulfonyl]-
-1,4-diazepane-1-carboxylate
[1003] A mixture of tert-Butyl
4-(aminosulfonyl)-1,4-diazepane-1-carboxylate (the product of
example 75, 0.277 g), tris(dibenzylideneacetone)-dipalladium (0)
(45 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (24 mg), cesium carbonate (0.242 g) and
4-chloro-2-([(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of example 35 step i, 0.15 g) in anhydrous dioxane (6
ml) was heated at reflux in a microwave at 100.degree. C., 300 W,
open vessel with cooling for 15 min. Saturated aqueous ammonium
chloride was added and the resulting mixture extracted with EtOAc.
The combined organic extracts were washed with saturated aqueous
sodium chloride, dried with sodium sulfate, filtered and
evaporated. The residue was purified by column chromatography on
silica using a 1:19 to 3:7 mixture of EtOAc and iso-hexane as
eluent to give the subtitle compound as a yellow oil. Yield: 0.223
g
[1004] MS: APCI (+ve) 546 [M+H.sup.+]
EXAMPLE 127
(3R,5S)--N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-3,5-dime-
thylpiperazine-1-sulfonamide
##STR00135##
[1006] A mixture of (3R,5S)-3,5-dimethylpiperazine-1-sulfonamide
(the product of example 72, 0.26 g),
tris(dibenzylideneacetone)-dipalladium (0) (61 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (32 mg), cesium carbonate (0.32 g) and
4-chloro-2[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of example 35 step i, 0.20 g) in anhydrous dioxane (8
ml) was heated at reflux in a microwave at 100.degree. C., 300 W,
open vessel with cooling for 15 min. Saturated aqueous ammonium
chloride (5 ml) and EtOAc (5 ml) were added, followed by H.sub.2O.
The layers were separated and the organic layer extracted with
H.sub.2O (.times.3). The organic layer was discarded and the
combined aqueous extracts exhaustively extracted with further
EtOAc. These extracts were combined, washed with saturated aqueous
sodium chloride, dried with sodium sulfate, filtered and
evaporated. The resulting solid was washed with H.sub.2O to afford
the title compound as a white solid. Yield: 0.111 g
[1007] MS: APCI (+ve) 460 [M+H.sup.+]
[1008] .sup.1H NMR: .delta. (300 MHz, DMSO) 1.15 (d, 6H), 2.44-2.51
(m, 2H), 3.08-3.23 (m, 2H), 3.57 (dd, 2H), 3.78 (s, 3H), 4.43 (s,
2H), 5.84 (s, 1H), 7.12-7.19 (m, 1H), 7.29-7.38 (m, 1H), 7.45-7.50
(m, 1H).
EXAMPLE 128
3-Amino-N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}azetidine--
1-sulfonamide
##STR00136##
[1010] A solution of tert-butyl
{1-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulfonyl-
]azetidin-3-yl}carbamate (the product of step ii, 0.48 g) and TFA
(2 ml) in methanol (6 ml) was stirred at room temperature for 1.5 h
then the volatiles evaporated and 7M ammonia in methanol (6 ml)
added to the residue. The solution was stirred for 2 h then the
volatiles evaporated and the residue purified by column
chromatography on silica using a 2-8% mixture of methanol in DCM
and then further purified by reverse phase HPLC (gradient 5-95%
acetonitrile in 0.1% aqueous ammonium acetate) to afford the title
compound as a white solid. Yield: 73 mg
[1011] MS: APCI (+ve) 418 [M+H.sup.+]
[1012] .sup.1H NMR: .delta. (300 MHz, DMSO) 3.64 (dd, 2H),
3.75-3.83 (m, 1H), 3.79 (s, 3H), 3.90 (t, 2H), 4.43 (s, 2H), 5.93
(s, 1H), 7.12-7.19 (m, 1H), 7.28-7.38 (m, 1H), 7.43-7.48 (m,
1H).
[1013] The intermediates for this compound were prepared as
follows:
i) tert-Butyl [1-(aminosulfonyl)azetidin-3-yl]carbamate
[1014] A solution of tert-butyl azetidin-3-ylcarbamate
hydrochloride (prepared according to J. Antibiot. 1986, 39,
1243-1256, 0.755 g), Proton-Sponge.RTM. (0.85 g) and sulfamide
(0.42 g) in dioxane (23 ml) was heated at reflux for 48 h. The
residue was partitioned between H.sub.2O and EtOAc, and the aqueous
layer then extracted with further EtOAc (.times.4). The combined
organic extracts were washed quickly with 2M aqueous hydrochloric
acid (.times.3) then with saturated aqueous sodium bicarbonate,
H.sub.2O and saturated aqueous sodium chloride, dried with sodium
sulfate, filtered and evaporated to afford the subtitle compound as
a pale brown powder.
[1015] Yield: 0.44 g
[1016] .sup.1H NMR: .delta. (300 MHz, DMSO) 1.38 (s, 9H), 3.55 (t,
2H), 3.82 (t, 2H), 4.09-4.18 (m, 1H), 6.87 (s, 2H), 7.53 (d,
1H).
ii) tert-Butyl
{1-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulfonyl-
]azetidin-3-yl}carbamate
[1017] A mixture of tert-butyl
[1-(aminosulfonyl)azetidin-3-yl]carbamate (0.50 g),
tris(dibenzylideneacetone)-dipalladium (0) (0.12 g),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (63 mg), cesium carbonate (0.65 g) and
4-chloro-2[-(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of example 35 step i, 0.400 g) in anhydrous dioxane
(17 ml) was heated to reflux in a microwave at 100.degree. C., 300
W, open vessel with cooling for 15 min. Saturated aqueous ammonium
chloride was added and the resulting mixture extracted with EtOAc.
The combined organic extracts were washed with saturated aqueous
sodium chloride, dried with sodium sulfate, filtered and
evaporated. The residue was purified by column chromatography on
silica using a 1:19 to 3:7 mixture of EtOAc and iso-hexane as
eluent to give the subtitle compound as a yellow oil. Yield: 0.48
g
[1018] MS: APCI (+ve) 518 [M+H.sup.+]
EXAMPLE 129
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-3-hydroxy-3-methy-
lazetidine-1-sulfonamide
##STR00137##
[1020] A mixture of 3-hydroxy-3-methylazetidine-1-sulfonamide (0.25
g) (prepared according to patent WO 2004/011443),
tris(dibenzylideneacetone)-dipalladium (0) (13 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (10 mg), cesium carbonate (0.68 g) was treated with a
solution of
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of example 35 step i) (0.4 g) in dioxane (10 ml) and
the whole then heated at reflux for 30 min. H.sub.2O (10 ml) was
added followed by 1N hydrochloric acid solution (5 ml) and the
resulting mixture extracted with EtOAc. The combined organic
extracts were washed with saturated aqueous sodium chloride, dried
(MgSO.sub.4), filtered and evaporated. The residue was purified by
column chromatography on silica gel using EtOAc/DCM (1:4) as eluent
to give the subtitle compound as a white solid.
[1021] Yield: 0.5 g.
[1022] MS: APCI (+ve) 433 [M+H.sup.+], APCI (-ve) 431
[M-H.sup.-]
[1023] .sup.1H NMR .delta. (DMSO): 1.28 (s, 3H), 3.70 (d, 1H), 3.80
(d, 1H), 3.85 (s, 3H), 4.30 (s, 2H), 5.70 (s, 1H), 6.10 (s, 1H),
7.18 (m, 1H), 7.35 (dd, 1H), 7.43 (t, 1H), 11.20 (bs, 1H)
EXAMPLE 130
3-Amino-N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-3-methyla-
zetidine-1-sulfonamide
##STR00138##
[1025] A solution of
N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-3-hydroxy-3-meth-
ylazetidine-1-sulfonamide (the product from example 129, 0.2 g) in
THF (5 ml) was treated with diisopropylethylamine (0.45 ml) and
methanesulfonylchloride (0.11 ml) under nitrogen.
[1026] The whole was stirred at room temperature for 4 h. The
solvents were then evaporated in vacuo to dryness and the residue
treated with 7N ammonia in methanol (9 ml) and then heated in a
sealed vessel at 75.degree. C. for 48 h. The volatiles were then
evaporated in vacuo and the residue purified by silica gel
chromatography eluting with 10% methanol in DCM to give the
subtitle product as a colourless gum. This was triturated with
Et.sub.2O and iso-hexane mixtures and filtered to give the title
product as a white solid. Yield: 50 mg.
[1027] MS: APCI (+ve) 432 [M+H.sup.+], APCI (-ve) 430
[M-H.sup.-]
[1028] .sup.1H NMR .delta. (CDCl.sub.3): 1.45 (s, 3H), 2.90 (bs,
2H), 3.80 (q, 4H), 3.94 (s, 3H), 4.40 (s, 2H), 6.30 (s, 1H), 7.10
(m, 1H), 7.20 (m, 2H)
EXAMPLE 131
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-3-methyl-3-(methy-
lamino)azetidine-1-sulfonamide
##STR00139##
[1030] A solution of
N-(2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl)-3-hydroxy-3-meth-
ylazetidine-1-sulfonamide (the product from example 129, 0.16 g) in
THF (8 ml) was treated with diisopropylethylamine (0.5 ml) and
methanesulfonylchloride (0.113 ml) under nitrogen.
[1031] The whole was stirred at room temperature for 16 h. The
mixture was then treated with 33% methylamine in ethanol (10 ml)
and then heated in a sealed vessel at 70.degree. C. for 24 h. The
volatiles were then evaporated in vacuo and the residue purified by
silica gel chromatography eluting with 10% methanol in DCM to give
the subtitle product as a colourless gum. This was triturated with
ethanol and filtered to give the title product as a white solid.
Yield: 57 mg.
[1032] MS: APCI (+ve) 446 [M+H.sup.+], APCI (-ve) 444
[M-H.sup.-]
[1033] .sup.1H NMR. (DMSO): 1.33 (s, 3H), 2.35 (s, 3H), 3.60 (d,
2H), 3.80 (s, 3H), 3.85 (d, 2H), 4.40 (s, 2H), 5.92 (s, 1H), 7.10
(m, 1H), 7.30 (m, 1H), 7.40 (m, 1H)
EXAMPLE 132
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-glycylpiperazin-
e-1-sulfonamide, hydrochloride salt
##STR00140##
[1035] A solution of tert-butyl
(2-{4-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulfo-
nyl]piperazin-1-yl}-2-oxoethyl)carbamate (the product of step ii,
0.19 g) in 10% TFA/DCM (5 mL) was stirred at room temperature for 3
h. The solution was evaporated, and then redissolved in 4N HCl in
dioxane (2 mL) and MeOH (8 mL). Evaporation gave a crude residue
that was triturated in Et.sub.2O, filtered and dried in a vacuum
oven at 40.degree. C. overnight to give the title compound as a
white solid. Yield: 140 mg.
[1036] MS: APCI (-ve) 487 [M-H.sup.-]
[1037] .sup.1H NMR (DMSO) .delta. 3.20-3.27 (4H, m), 3.41-3.46 (2H,
m), 3.53-3.58 (2H, m), 3.86 (2H, s), 3.88 (3H, s), 4.48 (2H, s),
6.09 (1H, s), 7.13-7.21 (1H, m), 7.37-7.44 (2H, m), 8.06 (2H, br
s), 11.26 (1H, br s)
the intermediates for this compound were prepared as follows
i)
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]piperaz-
ine-1-sulfonamide, hydrochloride salt
[1038] A solution of
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]piperazin-
e-1-sulfonamide, trifluoroacetate salt (the product of example 36,
0.6 g) in 4N HCl/dioxane (2 mL) and Et.sub.2O (20 mL) was stirred
at room temperature for 20 min. The resulting suspension was
filtered and the residue dried in a vacuum oven at 40.degree. C.
for 2 h to give the subtitle compound as a white solid. Yield: 0.55
g.
[1039] MS: APCI (+ve) 432 [M+H.sup.+]
tert-Butyl
(2-{4-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}a-
mino)sulfonyl]piperazin-1-yl}-2-oxoethyl)carbamate
[1040] To a solution of N-(tert-butoxycarbonyl)glycine (0.11 g) in
DMF (10 mL) was added 1,3-Dicyclohexycarbodiimide (0.14 g) and
1-hydroxybenzotriazole hydrate (94 mg). After stirring at room
temperature for 1 h, a solution of
N-[2-[[(2,3-Difluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl]piperazin-
e-1-sulfonamide, hydrochloride salt (the product of step i, 0.27 g)
and N-methylmorpholine (78 .mu.L) in DMF (5 mL) was added dropwise
and stirring continued at room temperature for 24 h. The mixture
was filtered, rinsed with DCM and the filtrate evaporated. The
crude material was purified by column chromatography on silica gel
using EtOAc/isohexane (3:2) as eluent to give the subtitle compound
as a foam. Yield: 0.24 g
[1041] MS: APCI (-ve) 587 [M-H]
EXAMPLE 114
4-.beta.-Alanyl-N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}pi-
perazine-1-sulfonamide, hydrochloride salt
##STR00141##
[1043] The title compound was prepared from tert-butyl
(3-{4-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulfo-
nyl]piperazin-1-yl}-3-oxopropyl)carbamate (the product of step i,
0.22 g) according to the procedure outlined in example 132 to give
a white solid.
[1044] Yield: 0.15 g.
[1045] MS: APCI (+ve) 503 [M+H.sup.+]
[1046] .sup.1H NMR (DMSO) .delta. 2.66 (2H, t), 2.98 (2H, q),
3.19-3.26 (4H, m), 3.45-3.49 (2H, m), 3.51-3.54 (2H, m), 3.88 (3H,
s), 4.48 (2H, s), 6.08 (1H, s), 7.14-7.20 (1H, m), 7.31-7.39 (1H,
m), 7.40-7.44 (1H, m), 7.72 (2H, br s), 11.24 (1H, br s)
[1047] The intermediate for this compound was prepared as
follows:
[1048] i) tert-Butyl
(3-{4-[({2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}amino)sulfo-
nyl]piperazin-1-yl}-3-oxopropyl)carbamate
[1049] The subtitle compound was prepared from
N-(tert-butoxycarbonyl).beta.-alanine (0.12 g) according to the
procedure outline in example 132, step ii). The crude material was
purified by column chromatography on silica gel using
EtOAc/isohexane (3:2) as eluent to give the subtitle compound as a
foam. Yield: 0.22 g
[1050] MS: APCI (-ve) 601 [M-H]
EXAMPLE 134
N-(2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl)-1,2,3,4-tetrahydr-
oisoquinoline-7-sulfonamide
##STR00142##
[1052] N-(2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl)
2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
(0.805 g) was added to a solution of 7N NH.sub.3 in MeOH (20 ml),
sealed and stirred at room temperature for 2 h. The reaction was
reduced in vacuo and the resulting residue purified by prep HPLC to
give the title compound as a white solid. Yield: 70 mg
[1053] MS: APCI (+ve) 479 [M+H.sup.+]
[1054] .sup.1H NMR: (DMSO) .delta. 3.01-3.08 (m, 2H), 3.35-3.42 (m,
2H), 3.83 (s, 3H), 4.33-4.40 (m, 2H), 4.38 (s, 2H), 6.06 (s, 1H),
7.09-7.20 (m, 1H), 7.31-7.40 (m, 2H), 7.44-7.50 (m, 1H), 7.78-7.87
(m, 2H), 9.00-9.09 (m, 2H)
[1055] The intermediate for this compound was prepared as
follows:
i)
N-(2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl)2-(trifluoroace-
tyl)-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
[1056] A mixture of 1,2,3,4-tetrahydroisoquinoline-7-sulfonamide
(the product from example 78 step ii, 0.61 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.43 g) and,
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product from example step i, 0.4 g) in dioxane (20 ml) was
heated at reflux in a microwave at 100.degree. C., 300 W, open
vessel with cooling for 3 h. The reaction mixture was then reduced
in vacuo and the residue partitioned between DCM (150 ml) and
H.sub.2O (150 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.150 ml). Organics were
combined, dried (MgSO.sub.4) and reduced under to give the subtitle
compound as a yellow solid. Yield: 0.81 g
[1057] MS; APCI (+ve) 575 [M+H.sup.+]
EXAMPLE 135
N-(2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl)-(2S,5R)-2,5-dimet-
hylpiperazine-1-sulfonamide
##STR00143##
[1059] To a solution of (2R,5S)-2,5-dimethylpiperazine (2 g) in
dioxane (100 ml) was added sulfamide (2.5 g) and the reaction
mixture was then heated at reflux in dioxane (100 ml) for 72 h. The
reaction mixture was partitioned between EtOAc (150 ml) and
H.sub.2O (150 ml) and the aqueous re-extracted with EtOAc
(2.times.150 ml). Organics were collected, dried and reduced in
vacuo to give (2S,5R)-2,5-dimethylpiperazine-1-sulfonamide as a
white solid (1.2 g). A mixture of
(2S,5R)-2,5-dimethylpiperazine-1-sulfonamide (0.38 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.43 g) and,
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product from example 35 step i), 0.4 g) in dioxane (20 mL) was
heated at reflux in a microwave at 100.degree. C., 300 W, open
vessel with cooling for 4 h. The reaction mixture was then reduced
in vacuo and the residue partitioned between DCM (150 ml) and
H.sub.2O (150 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.150 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo to give a yellow
solid. This residue was then purified by prep HPLC to give the
title compound as a white solid. Yield: 9 mg
[1060] MS: APCI (+ve) 460 [M+H.sup.+]
[1061] .sup.1H NMR: (DMSO) .delta. 1.05 (d, 3H), 1.23 (d, 3H),
2.58-2.67 (m, 1H), 2.72-2.80 (m, 1H), 3.01-3.54 (m, 4H), 3.77 (s,
3H), 4.40 (s, 2H), 5.83 (s, 1H), 7.07-7.21 (m, 1H), 7.24-7.47 (m,
2H)
EXAMPLE 136
N-(2-(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl)-4-(aminomethyl)ben-
zenesulfonamide
##STR00144##
[1063] A mixture of 4-(aminomethyl)benzenesulfonamide (0.37 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (1.0 g) and,
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product from example 35 step i), (0.25 g) in dioxane (20 ml)
was heated at reflux in a microwave at 100.degree. C., 300 W, open
vessel with cooling for 3 h. The reaction mixture was then reduced
in vacuo and the residue partitioned between DCM (150 ml) and
H.sub.2O (150 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.150 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo to give a yellow
solid. This solid was then purified by prep HPLC to give the title
compound as a white solid. Yield: 19 mg
[1064] MS: APCI (+ve) 453 [M+H.sup.+]
[1065] .sup.1H NMR: (DMSO) .delta. 3.83 (s, 3H), 4.09-4.14 (m, 2H),
4.37 (s, 2H), 6.08 (s, 1H), 7.09-7.22 (m, 1H), 7.31-7.38 (m, 2H),
7.66 (d, 2H), 7.98 (d, 2H), 8.16-8.24 (m, 2H)
EXAMPLE 137
N-{2-[[(3-Fluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl}azetidine-1-su-
lfonamide
##STR00145##
[1067] The title compound was prepared from
N-{2-[[(3-fluorophenyl)methyl]thio]-6-methoxypyrimidin-4-yl}-N-[(4-methox-
yphenyl)methyl]azetidine-1-sulfonamide (the product of step iv) (42
mg) by the procedure outlined in Example 121. The crude material
was purified by preparative plate chromatography using
EtOAc/isohexane (4:6) as eluent to give the title product as a gum.
Yield: 22 mg.
[1068] MS: APCI (+ve) 385 [M+H]
[1069] .sup.1H NMR: .delta. (DMSO) 2.10 (quintet, 2H), 3.87 (m,
7H), 4.41 (s, 2H), 6.12 (s, 1H), 7.07 (m, 1H), 7.33 (m, 3H), 11.11
(bs, 1H).
[1070] The intermediates for this compound were prepared as
follows:
i)
N-[(4-Methoxyphenyl)methyl]-N-[6-methoxy-2-[[(2,3,4-trifluorophenyl)met-
hyl]thio]pyrimidin-4-yl]azetidine-1-sulfonamide
[1071] The subtitle compound was prepared from
N-[6-Methoxy-2-[[(2,3,4-trifluorophenyl)methyl]thio]pyrimidin-4-yl]azetid-
ine-1-sulfonamide (the product of Example 146, (5.1 g) by the
procedure outlined in Example 121 step i). The crude product was
purified by flash column chromatography on silica gel using
EtOAc/isohexane (2:8) as eluent to give the product as an oil.
Yield: 4.2 g.
[1072] MS: APCI (+ve) 541 [M+H]
ii)
N-[(4-Methoxyphenyl)methyl]-N-[6-methoxy-2-[[(2,3,4-trifluorophenyl)me-
thyl]sulfonyl]pyrimidin-4-yl]azetidine-1-sulfonamide
[1073] The subtitle compound was prepared from
N-[(4-Methoxyphenyl)methyl]-N-[6-methoxy-2-[[(2,3,4-trifluorophenyl)methy-
l]thio]pyrimidin-4-yl]azetidine-1-sulfonamide (the subtitle product
of step i), (4.2 g) by the procedure outlined in Example 121 step
ii). The crude product was purified by flash column chromatography
on silica gel using EtOAc/isohexane (1:1) as eluent to give the
product as a white foam. Yield: 3.3 g.
[1074] MS: APCI (+ve) 573 [M+H]
iii)
N-[6-Methoxy-2-thiopyrimdin-4-yl]-N-[(4-methoxyphenyl)methyl]azetidin-
e-1-sulfonamide
[1075] NaSH (40 mg) was added to a solution of
N-[(4-Methoxyphenyl)methyl]-N-[6-methoxy-2-[[(2,3,4-trifluorophenyl)methy-
l]sulfonyl]pyrimidin-4-yl]azetidine-1-sulfonamide (the subtitle
product of step (0.10 g) and stirred in water (1 ml) under nitrogen
at 95.degree. C. for 45 min NaSH (40 mg) followed by DMF (1 ml)
were added. The reaction mixture was stirred for a further 1.5 h at
95.degree. C., cooled, acidified with dilute HCl and extracted with
EtOAc. The separated organic solution was washed with water, dried
(MgSO.sub.4), filtered and the solvent evaporated under reduced
pressure to give the subtitle product as a clear oil.
[1076] Yield: 90 mg
[1077] MS: APCI (4-ve) 397 [M+H]
iv) N-[2-[[(3-Fluorophenyl)methyl]thio]-6-methoxy
pyrimidin-4-yl]-N-[(4-methoxy-phenyl)methyl]-azetidine-1-sulfonamide
[1078] 60% NaH (8 mg) was added to a solution of
N-[6-Methoxy-2-thiopyrimdin-4-yl]-N4(4-methoxyphenyl)methyl]azetidine-1-s-
ulfonamide (the subtitle product of step iii), (90 mg) in anhydrous
DMF (1 ml). After stirring under nitrogen for 5 min
(3-fluorophenyl)methyl bromide (42 mg) was added. The reaction
mixture was stirred at room temperature for a further 18 h and then
diluted with EtOAc. The separated organic solution was washed with
water, dried (MgSO.sub.4), filtered and the solvent evaporated
under reduced pressure. The crude material was purified by flash
column chromatography on silica gel using EtOAc/isohexane (3:7) as
eluent to give the product as a gum. Yield: 47 mg
[1079] MS: APCI (+ve) 505 [M+H]
EXAMPLE 138
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-pyrrolidin-1-yl-
piperidine-1-sulfonamide
##STR00146##
[1081] The title compound was prepared according to the procedure
outlined in example 129 using
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of example 35 step i) (0.3 g),
tris(dibenzylideneacetone)-dipalladium (0) (20 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (15 mg), cesium carbonate (0.70 g) and
4-pyrrolidin-1-ylpiperidine-1-sulfonamide (the product from step
i), (0.4 g). The resulting crude material was purified using silica
gel chromatography eluting with 5% methanol in DCM and trituration
with Et.sub.2O to give the title compound as a white solid.
[1082] Yield: 0.27 g
[1083] MS: APCI (+ve) 500 [M+H.sup.+], APCI (-ve) 498
[M-H.sup.-]
[1084] .sup.1H NMR .delta. (DMSO) .delta. 1.60 (m, 2H), 1.90 (bs,
4H), 2.10 (d, 2H), 3.10 (m, 5H), 3.70 (d, 4H), 3.90 (3, 3H), 4.50
(s, 2H), 6.05 (s, 1H), 7.20 (m, 1H), 7.40 (m, 2H)
[1085] The intermediates for this compound were prepared as
follows:
i) 4-pyrrolidin-1-ylpiperidine-1-sulfonamide
[1086] A mixture of 4-pyrrolidin-1-ylpiperidine (0.67 g) and
sulfamide (0.46 g) were heated at 115.degree. C. in dry 1,4-dioxane
(30 ml) for 16 h. The solvents were evaporated in vacuo and the
residue partitioned between EtOAc (containing a little methanol)
and H.sub.2O. The organic phase was collected and the aqueous layer
further extracted with EtOAc (.times.2). The combined organic
phases collected, dried (MgSO.sub.4) and the solvent evaporated.
The residue was triturated with Et.sub.2O and filtered to give the
subtitle product as a beige solid. Yield: 0.43 g
[1087] .sup.1H NMR .delta. (DMSO) .delta. 1.50 (m, 2H), 1.70 (m,
4H), 1.90 (m, 2H), 2.05 (m, 1H), 2.50 (m, 2H), 2.60 (m, 2H), 3.40
(m, 4H), 6.70 (s, 2H)
EXAMPLE 139
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-3-morpholin-4-yla-
zetidine-1-sulfonamide
##STR00147##
[1089] A solution of
N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-3-hydroxyazetidi-
ne-1-sulfonamide (the product from example 109) (0.28 g) in DCM (10
ml) was treated with triethylamine (0.8 ml) and
methanesulfonykhloride (0.9 ml) under nitrogen. After heating the
mixture at 50.degree. C. for 16 h the reaction mixture was
partitioned between DCM and aqueous NaHCO.sub.3. The organic
extracts were dried (MgSO.sub.4), filtered and the solvent
evaporated under reduced pressure. To a solution of the resulting
residue in MeOH (10 mL) and morpholine (8 ml) K.sub.2CO.sub.3 (0.19
g) was added and heated at 80.degree. C. for 16 h. The reaction
mixture was then partitioned between EtOAc and H.sub.2O The organic
extracts were washed with brine, dried (MgSO.sub.4), filtered and
the solvent evaporated under reduced pressure. The residue was
purified by reverse phase HPLC (symmetry as the stationary phase
and NH.sub.4OAc/acetonitrile as the mobile phase) then titurated
with Et.sub.2O to give the title compound as a white solid.
[1090] Yield: 15 mg
[1091] MS: APCI (+ve) 488 [M+H.sup.+]
[1092] .sup.1H NMR .delta. (DMSO) 2.23 (s, 4H), 3.00-3.08 (m, 1H),
3.51 (t, 4H), 3.76-3.81 (m, 4H), 3.87 (s, 3H), 4.49 (s, 2H), 6.10
(s, 1H), 7.12-7.19 (m, 1H), 7.29-7.38 (m, 1H), 7.44 (t, 1H)
EXAMPLES 140-145
[1093] Examples 140-145 were synthesised using the following
procedure:--
[1094] The title compounds, tabulated below, were prepared from the
appropriate 2-thio substituted
N-[(4-methoxyphenyl)methyl]-N-[6-methoxy-2-thio]pyrimidin-4-yl]azetidine--
1-sulfonamides (the products of step i) by the procedure outlined
in Example 121. The crude materials were purified by mass directed
purification.
TABLE-US-00002 ##STR00148## Example M/Z Number Example R' [M - H]
140 N-[2-[[(2-Fluorophenyl)methyl]thio]-6-methoxy
pyrimidin-4-yl]azetidine-1-sulfonamide ##STR00149## 383 141
N-[6-Methoxy-2-[[(pyridin-3-yl)methyl]thio]
pyrimidin-4-yl]azetidine-1-sulfonamide ##STR00150## 366 142
N-[6-Methoxy-2-[[(pyridin-2-yl)methyl]thio]
pyrimidin-4-yl]azetidine-1-sulfonamide ##STR00151## 366 143
N-[6-Methoxy-2-[[(thiazol-4-yl)methyl]thio]
pyrimidin-4-yl]azetidine-1-sulfonamide ##STR00152## 372 144
N-[2-[[(4-Cyanophenyl)methyl]thio]-6-methoxy
pyrimidin-4-yl]azetidine-1-sulfonamide ##STR00153## 390 145
N-[2-[[(4-Methanesulfonylphenyl)methyl]-
thio]-6-methoxypyrimidin-4-yl]azetidine-1- sulfonamide ##STR00154##
443
[1095] The intermediates for compounds 140-145 were prepared as
follows:
i) Thio-substituted
N-[(4-Methoxyphenyl)methyl]-N-[6-methoxy-2-thio]pyrimidin-4-yl]azetidine--
1-sulfonamides
[1096] Sodium thiolate (30 mg) was added to a solution of
N-[(4-Methoxyphenyl)methyl]-N-[6-methoxy-2-[[(2,3,4-trifluorophenyl)methy-
l]sulfonyl]pyrimidin-4-yl]azetidine-1-sulfonamide (the product of
Example 137 step (0.15 g) stirred in anhydrous DMSO under nitrogen.
After 30 min, the appropriate bromide or chloride (see R' in the
table below) (0.81 mM) was added. The reaction mixture was stirred
for a further 30 min, diluted with water and the product extracted
with EtOAc. The separated organic solution was washed with water,
dried (MgSO.sub.4), filtered and the solvent evaporated under
reduced pressure. The crude products were purified by flash column
chromatography on silica gel using mixtures of EtOAc/isohexane as
eluent to give the products, Examples 140 i)-145 i), tabulated
below.
TABLE-US-00003 ##STR00155## Example M/Z Number Example R' [M + H]
140(i) N-[2-[[(2-Fluorophenyl)methyl]thio]-6-methoxy
pyrimidin-4-yl]-N-[(4-methoxyphenyl)methyl]-
azetidine-1-sulfonamide ##STR00156## 505 141(i)
N-[(4-Methoxyphenyl)methyl]-N-[6-methoxy-2-
[[(pyridin-3-yl)methyl]thio]pyrimidin-4-yl]-
azetidine-1-sulfonamide ##STR00157## 488 142(i)
N-[(4-Methoxyphenyl)methyl]-N-[6-methoxy-2-
[[(pyridin-2-yl)methyl]thio]pyrimidin-4-yl]-
azetidine-1-sulfonamide ##STR00158## 488 143(i)
N-[(4-Methoxyphenyl)methyl]-N-[6-ethoxy-2-
[[(thiazol-4-yl)methyl]thio]pyrimidin-4-yl]-
azetidine-1-sulfonamide ##STR00159## 494 144(i)
N-[2-[[(4-Cyanophenyl)methyl]thio]-6-methoxy
pyrimidin-4-yl]-N-[(4-methoxy-
phenyl)methyl]-azetidine-1-sulfonamide ##STR00160## 512 145(i)
N-[2-[[(4-Methanesulfonylphenyl)methyl]-
thio]-6-methoxypyrimidin-4-yl]N-[(4-methoxy
phenyl)methyl]-azetidine-1-sulfonamide ##STR00161## 565
EXAMPLE 146
N-[6-Methoxy-2-[[(2,3,4-trifluorophenyl)methyl]thio]pyrimidin-4-yl]azetidi-
ne-1-sulfonamide
##STR00162##
[1098] The title compound was prepared from
4-Chloro-6-methoxy-2-[[(2,3,4-trifluorophenyl)methyl]thio]pyrimidine
(the subtitle product of step iii) (7.2 g) by the procedure
outlined in Example 1 step iv). The crude material was purified by
recrystallisation from isohexane/EtOAc to give the product as a
yellow solid. Yield: 5.1 g.
[1099] MS: APCI (+ve) 421 [M+H]
[1100] .sup.1H NMR: .delta. (DMSO) .delta. 2.13 (quintet, 2H), 3.88
(s, 3H), 3.90 (t, 4H), 4.46 (s, 2H), 6.15 (s, 1H), 7.32-7.24 (m,
1H), 7.53-7.46 (m, 1H), 11.13 (s, 1H)
[1101] The intermediates for this compound were prepared as
follows:
i) 2-[[(2,3,4-Trifluorophenyl)methyl]thio]pyrimidine-4,6-diol
[1102] The subtitle compound was prepared from
2-thiopyrimidine-4,6-diol (80.0 g) and
(2,3,4-trifluorophenyl)methyl bromide (125 g) by the procedure
outlined in Example 1 step i).
[1103] Yield: 150 g.
[1104] .sup.1H NMR: .delta. (DMSO) 4.41 (s, 2H), 5.22 (bs, 1H),
7.30 (m, 1H), 7.49 (m, 1H).
ii)
4,6-Dichloro-2-[[(2,3,4-trifluorophenyl)methyl]thio]pyrimidine
[1105] The subtitle compound was prepared from the subtitle product
of step i) (150 g) by the procedure outlined in Example 1 step ii).
The crude material was purified by flash column chromatography on
silica gel using EtOAc/isohexane (3:7) as eluent to give the
product as a white solid. Yield: 70 g.
[1106] .sup.1H NMR: .delta. (CDCl.sub.3) 4.37 (s, 2H), 6.91 (m,
1H), 7.06 (s, 1H), 7.26 (m, 1H).
iii)
4-Chloro-6-methoxy-2-[[(2,3,4-trifluorophenyl)methyl]thio]pyrimidine
[1107] The subtitle compound was prepared from the subtitle product
of step (25.0 g) by the procedure outlined in Example 35 step i).
The crude material was purified by recrystallisation from isohexane
to give the product as white crystals. Yield: 16.4 g.
[1108] MS: APCI (+ve) 321/323 [M+H]
EXAMPLE 147
N'-2{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-N-methyl-N-(1-m-
ethylpiperidin-4-yl)sulfamide
##STR00163##
[1110] The title compound was prepared from
N-methyl-N-(1-methylpiperidin-4-yl)sulfamide (the product of step
i) (0.26 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of Example 35, step i) (0.25 g) according to the
procedure outlined in Example 1, step iv). The crude material was
purified by column chromatography using EtOAc/MeOH (9:1 to 8.5:1.5)
as eluent. Yield: 0.17 g
[1111] MS: APCI (+ve) 474 [M+H]
[1112] .sup.1H NMR: .delta. (DMSO) 1.50 (bd, 2H), 1.66 (m, 2H),
2.02 (t, 2H), 2.20 (s, 3H), 2.67 (s, 3H), 2.84 (bd, 2H), 3.63 (m,
1H), 3.82 (s, 3H), 4.44 (s, 2H), 5.90 (s, 1H), 7.14 (q, 1H), 7.33
(q, 1H), 7.41 (t, 1H).
[1113] The intermediate for this compound was prepared as
follows:
i) N-Methyl-N-(1-methylpiperidin-4-yl)sulfamide
[1114] A solution of 1-methyl-4-(methylamino)piperidine (2.6 g) and
sulfamide (4.0 g) in 1,4-dioxane (30 ml) was heated at 110.degree.
C. for 18 h. The reaction mixture was cooled, the solvent
evaporated under reduced pressure and the residue dissolved in
water. The aqueous solution was extracted with EtOAc which was
washed with a small volume of saturated aqueous brine, dried
(MgSO.sub.4) and the solvent evaporated under reduced pressure to
give the subtitle product as a pale yellow solid. Yield: 1.5 g
[1115] .sup.1H NMR: .delta. (CDCl.sub.3) 1.80 (m, 4H), 2.04 (dt,
2H), 2.27 (s, 3H), 2.79 (s, 3H), 2.91 (bd, 2H), 3.74 (quintet, 1H),
4.44 (bs, 2H).
EXAMPLE 148
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-morpholin-4-ylp-
iperidine-1-sulfonamide
##STR00164##
[1117] Sodium triacetoxyborohydride (0.48 g) was added to a
solution of
N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-oxopiperidine--
1-sulfonamide (the product of step iii) (0.249 g), morpholine (0.2
mL) and 2M aqueous acetic acid (0.5 mL) in DCM (12 mL). The mixture
was stirred at room temperature for 18 h then 2M aqueous sodium
hydroxide (10 mL) added to the residue. The mixture was shaken
vigorously then acidified to pH 8 with 2M aqueous hydrochloric acid
and extracted with ethyl acetate. The combined organic extracts
were washed with saturated aqueous sodium chloride, dried with
sodium sulfate, filtered and evaporated. The residue was purified
by column chromatography on silica using a 3:7 to 1:0 mixture of
ethyl acetate and iso-hexane as eluent then precipitated slowly
from methanol, filtered and washed with further methanol to afford
the title compound as a pale yellow solid. Yield: 53 mg
[1118] MS: APCI (+ve) 516 [M+H.sup.+]
[1119] .sup.1H NMR: .delta. (300 MHz, DMSO) 1.26-1.41 (m, 2H),
1.76-1.83 (m, 2H), 2.28 (t, 1H), 2.41-2.44 (m, 4H), 2.83 (t, 2H),
3.52-3.58 (m, 4H), 3.68 (d, 2H), 3.88 (s, 3H), 4.49 (s, 2H), 6.07
(s, 1H), 7.14-7.21 (m, 1H), 7.31-7.47 (m, 2H).
[1120] The intermediates for this compound were prepared as
follows:
i) 1,4-Dioxa-8-azaspiro[4.5]decane-8-sulfonamide
[1121] A solution of 1,4-dioxa-8-aza-spiro[4.5]decane (2 mL) and
sulfamide (1.65 g) in 1,4-dioxane (28 mL) was heated at reflux for
48 h, then the volatiles were evaporated to afford the title
compound as a pale yellow solid. Yield: 3.4 g
[1122] .sup.1H NMR: .delta. (300 MHz, DMSO) 1.71 (dd, 4H), 3.08
(dd, 4H), 3.91 (s, 4H), 6.77 (s, 2H).
ii)
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-1,4-dioxa-8-a-
zaspiro[4.5]decane-8-sulfonamide
[1123] A mixture of 1,4-dioxa-8-azaspiro[4.5]decane-8-sulfonamide
(the product of step i), (0.29 g),
tris(dibenzylideneacetone)-dipalladium (0) (61 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (32 mg), cesium carbonate (0.32 g) and
4-chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product of example 35 step i, 0.20 g) in anhydrous dioxane (8
mL) was heated at reflux in a microwave at 100.degree. C., 300 W,
open vessel with cooling for 15 min. Saturated aqueous ammonium
chloride was added and the resulting mixture extracted with ethyl
acetate. The combined organic extracts were washed with saturated
aqueous sodium chloride, dried with sodium sulfate, filtered and
evaporated. The residue was purified by column chromatography on
silica using a 1:19 to 2:3 mixture of ethyl acetate and iso-hexane
as eluent to give the subtitle compound as a yellow foam. Yield:
0.27 g
[1124] MS: APCI (+ve) 489 [M+H.sup.+]
iii)
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-oxopiperid-
ine-1-sulfonamide
[1125]
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-1,4-dioxa--
8-azaspiro[4.5]decane-8-sulfonamide (the product of step ii) (0.85
g) was heated to 50.degree. C. in a mixture of 2M aqueous
hydrochloric acid (17 mL) and THF (17 mL). After 24 h, the reaction
was allowed to cool to room temperature then diluted with ethyl
acetate, the layers separated and the organic material washed with
saturated aqueous sodium bicarbonate, water, saturated aqueous
sodium chloride, dried with sodium sulfate, filtered and evaporated
to afford the subtitle compound as a yellow oil. Yield: 0.83 g
[1126] MS: APCI (+ve) 445 [M+H.sup.+]
EXAMPLE 149
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-(4-methylpipera-
zin-1-yl)piperidine-1-sulfonamide
##STR00165##
[1128] A solution of 1-methyl-piperazine (0.13 mL) in DCM (2 mL)
was added to a solution of acetic acid (0.03 mL) and
N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-oxopiperidine--
1-sulfonamide (the product of example 148, step iii) (0.10 g) in
DCM (2 mL). The solution was stirred at room temperature for 1 h
then sodium triacetoxyborohydride (0.24 g) was added in portions.
The mixture was stirred at room temperature overnight then the DCM
was evaporated and 3M aqueous sodium hydroxide (6 mL) added to the
residue. The mixture was shaken vigorously then acidified to pH 8
with 2M aqueous hydrochloric acid and extracted with ethyl acetate.
The combined organic extracts were washed with water, saturated
aqueous sodium chloride, dried with sodium sulfate, filtered and
evaporated. The residue was purified by reverse phase HPLC
(gradient 25-95% acetonitrile in 0.1% aqueous ammonium acetate) to
afford the title compound as a white powder. Yield: 22 mg
[1129] MS: APCI (+ve) 529 [M+H.sup.+]
[1130] .sup.1H NMR: .delta. (300 MHz, DMSO) 1.26-1.42 (m, 2H),
1.75-1.78 (m, 2H), 2.25-2.77 (m, 11H), 2.27 (s, 3H), 3.63 (d, 2H),
3.84 (s, 3H), 4.46 (s, 2H), 6.01 (s, 1H), 7.13-7.20 (m, 1H),
7.31-7.40 (m, 1H), 7.43-7.48 (m, 1H).
EXAMPLE 150
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-hydroxypiperidi-
ne-1-sulfonamide
##STR00166##
[1132] From the crude material obtained after work up to prepare
N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-morpholin-4-yl-
piperidine-1-sulfonamide (Example 148), a second product was also
isolated. This was further purified by reverse phase HPLC (gradient
25-95% acetonitrile in 0.1% aqueous ammonium acetate) to afford the
title compound as a white powder. Yield: 33 mg
[1133] MS: APCI (+ve) 447 [M+H.sup.+]
[1134] .sup.1H NMR: .delta. (300 MHz, DMSO) 1.33-1.44 (m, 2H),
1.70-1.76 (m, 2H), 3.00-3.08 (m, 2H), 3.41-3.49 (m, 2H), 3.57-3.64
(m, 1H), 3.89 (s, 3H), 4.49 (s, 2H), 4.75 (d, 1H), 6.08 (s, 1H),
7.14-7.21 (m, 1H), 7.32-7.47 (m, 2H), 11.07 (s, 1H).
EXAMPLE 151
4-Azetidin-1-yl-N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}pi-
peridine-1
##STR00167##
[1136] Azetidine hydrochloride (0.11 g) was added to a solution of
acetic acid (0.025 mL) and
N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-oxopiperidine--
1-sulfonamide (the product of example 148, step iii) (0.10 g) in
DCM (4 mL). The solution was stirred at room temperature for 1 h
then sodium triacetoxyborohydride (0.24 g) was added in portions.
The mixture was stirred at room temperature overnight then 3M
aqueous sodium hydroxide (6 mL) added to the residue. The mixture
was shaken vigorously then acidified to pH 8 with 2M aqueous
hydrochloric acid and extracted with ethyl acetate. The combined
organic extracts were concentrated then methanol (1 mL) was added
and the resulting suspension filtered. The solid was washed with
water, methanol and ethyl acetate to afford the title compound as a
white powder. Yield: 47 mg
[1137] MS: APCI (+ve) 486 [M+H.sup.+]
[1138] .sup.1H NMR: .delta. (300 MHz, DMSO) 1.15-1.26 (m, 2H),
1.69-1.78 (m, 2H), 2.01-2.09 (m, 2H), 2.47-3.51 (m, 9H), 3.83 (s,
3H), 4.45 (s, 2H), 5.96 (s, 1H), 7.13-7.20 (m, 1H), 7.30-7.39 (m,
1H), 7.43-7.48 (m, 1H).
EXAMPLE 152
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-(ethylamino)pip-
eridine-1-sulfonamide
##STR00168##
[1140] Ethylamine (0.56 mL of 2M solution in methanol) was added to
a solution of acetic acid (0.025 mL) and
N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-oxopiperidine--
1-sulfonamide (the product of example 148, step iii) (0.10 g) in
DCM (4 mL). The solution was stirred at room temperature for 1 h
then sodium triacetoxyborohydride (0.24 g) was added in portions.
The mixture was stirred at room temperature overnight then 3M
aqueous sodium hydroxide (6 mL) added to the residue. The mixture
was shaken vigorously then acidified to pH 8 with 2M aqueous
hydrochloric acid and extracted with ethyl acetate. The combined
organic extracts were concentrated then methanol (1 mL) was added
and the resulting suspension filtered. The solid was washed with
water, methanol and ethyl acetate to afford the title compound as a
very pale yellow powder. Yield: 52 mg
[1141] MS: APCI (+ve) 474 [M+H.sup.+]
[1142] .sup.1H NMR: .delta. (300 MHz, DMSO) 1.17 (t, 3H), 1.41-1.52
(m, 2H), 1.96-2.01 (m, 2H), 2.57-2.61 (m, 2H), 2.94 (q, 2H),
3.00-3.08 (m, 1H), 3.55 (d, 2H), 3.74 (s, 3H), 4.40 (s, 2H), 5.84
(s, 1H), 7.11-7.18 (m, 1H), 7.28-7.36 (m, 1H), 7.44-7.49 (m,
1H).
EXAMPLE 153
4-(Cyclopropylamino)-N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4--
yl}piperidine-1-sulfonamide
##STR00169##
[1144] A solution of cyclopropylamine (0.08 mL) in DCM (2 mL) was
added to a solution of acetic acid (0.025 mL) and
N-{2-[(2,3-difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}-4-oxopiperidine--
1-sulfonamide (the product of example 148, step iii) (0.10 g) in
DCM (2 mL). The solution was stirred at room temperature for 1 h
then sodium triacetoxyborohydride (0.24 g) was added in portions.
The mixture was stirred at room temperature overnight then 3M
aqueous sodium hydroxide (6 mL) added to the residue. The mixture
was shaken vigorously then acidified to pH 8 with 2M aqueous
hydrochloric acid and extracted with ethyl acetate. The combined
organic extracts were washed with water, saturated aqueous sodium
chloride, dried with sodium sulfate, filtered and evaporated. The
crude material was purified by reverse phase HPLC (gradient 25-95%
acetonitrile in 0.1% aqueous ammonium acetate) to afford the title
compound as a white powder. Yield: 21 mg
[1145] MS: APCI (+ve) 486 [M+H.sup.+]
[1146] .sup.1H NMR: .delta. (300 MHz, DMSO)-0.02-0.17 (m, 4H),
0.90-1.04 (m, 2H), 1.53-1.58 (m, 2H), 1.85-1.92 (m, 1H), 2.40-2.48
(m, 3H), 3.21 (d, 2H), 3.48 (s, 3H), 4.10 (s, 2H), 5.63 (s, 1H),
6.77-6.84 (m, 1H), 6.95-7.03 (m, 1H), 7.07-7.12 (m, 1H).
EXAMPLE 154
N-[2-[(2,3-Difluorobenzyl)thio]-6-(3-hydroxypropoxy)pyrimidin-4-yl]piperaz-
ine-1-sulfonamide
##STR00170##
[1148] To a solution of tert-butyl
4-({[2-[(2,3-difluorobenzyl)thio]-6-(3-hydroxypropoxy)pyrimidin-4-yl]amin-
o}sulfonyl)piperazine-1-carboxylate (the product from step ii),
0.83 g) in DCM (5 ml) was added TFA (5 ml) slowly. The reaction was
then stirred at room temperature for 18 h. The reaction was reduced
in vacuo and the residue purified by prep HPLC to give the title
compound as a white solid. Yield 160 mg
[1149] MS: APCI (+ve) 476 [M+H.sup.+]
[1150] .sup.1H NMR: (DMSO) .delta. 2.52 (q, 2H), 3.19 (t, 4H), 3.44
(t, 4H), 3.52 (t, 2H), 4.38 (t, 2H), 4.49 (s, 2H), 4.59 (s, 1H),
6.07 (s, 1H), 6.99 (s, 1H), 7.14-7.24 (m, 1H), 7.31-7.45 (m,
2H)
[1151] The intermediates for this compound was prepared as
follows:
(i)
3-({6-Chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)propan-1-o-
l
[1152] To a solution of
4,6-dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step ii), 3 g) and propane-1,3-diol (1.1 g) in THF (50
ml) was added NaH (390 mg) slowly and the reaction was then allowed
to stir at room temperature for 18 h. The reaction mixture was then
partitioned between DCM (150 ml) and H.sub.2O (100 ml). The
organics were separated and the aqueous layer was re-extracted with
DCM (2.times.150 ml). Organics were combined, dried (MgSO.sub.4)
and reduced in vacuo to give the subtitle compound as a yellow oil.
Yield 2.9 g
[1153] MS: APCI (+ve) 347/349 [M+H.sup.+]
ii) tert-Butyl
4-({[2-[(2,3-difluorobenzyl)thio]-6-(3-hydroxypropoxy)pyrimidin-4-yl]amin-
o}sulfonyl)piperazine-1-carboxylate
[1154] A mixture of 4-(aminosulfonyl)-1-piperazinecarboxylic
acid-1,1-dimethylethyl ester (the product from example 15, step i),
0.4 g), tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.43 g) and
3-({6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}oxy)propan-1-ol
(the product from step i), 0.4 g) in 1,4-dioxane (40 ml) was heated
at reflux in a microwave at 100.degree. C., 300 W, open vessel with
cooling for 3 h. The reaction mixture was then reduced in vacuo and
the residue separated between DCM (150 ml) and H.sub.2O (150 ml).
The organics were separated and the aqueous layer was re-extracted
with DCM (2.times.150 ml). Organics were combined, dried
(MgSO.sub.4) and reduced in vacuo to give the subtitle compound as
a yellow solid. Yield 0.83 g
[1155] MS: APCI (+ve) 576 [M+H.sup.+]
EXAMPLE 155
N-{2-[(2,3-Difluorobenzyl)thio]-6-methoxypyrimidin-4-yl}piperidine-4-sulfo-
namide
##STR00171##
[1157] A mixture of piperidine-4-sulfonamide (0.33 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.43 g) and,
4-Chloro-2-[[(2,3-difluorophenyl)methyl]thio]-6-methoxypyrimidine
(the product from example 35 step i), 0.4 g) in dioxane (20 ml) was
heated at reflux in a microwave at 100.degree. C., 300 W, open
vessel with cooling for 2 h. The reaction mixture was then reduced
in vacuo and the residue partitioned between DCM (100 ml) and
H.sub.2O (100 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.100 ml). Organics were
combined, dried (MgSO.sub.4) and reduced in vacuo and the resulting
yellow residue was purified prep HPLC to give the title compound as
a white solid. Yield 13 mg
[1158] MS: APCI (+ve) 431 [M+H.sup.+]
[1159] .sup.1H NMR: (DMSO) .delta. 1.74-1.86 (m, 2H), 2.00-2.10 (m,
2H), 2.73-2.85 (m, 2H), 3.24-3.60 (m, 3H), 3.73 (s, 3H), 4.40 (s,
2H), 5.71 (s, 1H), 7.09-7.18 (m, 1H), 7.25-7.36 (m, 1H), 7.42-7.50
(m, 1H)
[1160] The intermediates for this compound was prepared as
follows:
i) Benzyl 4-(aminosulfonyl)piperidine-1-carboxylate
[1161] To a solution of 0.88 NH.sub.3 (50 ml) was added benzyl
4-(chlorosulfonyl)piperidine-1-carboxylate (4 g) and the reaction
stirred for 72 h at RT. The reaction was then extracted with DCM
(3.times.150 ml). Organics were recovered, dried (MgSO.sub.4) and
reduced in vacuo to give the subtitle compound as a clear oil.
Yield 3.3 g
[1162] .sup.1H NMR: (DMSO) .delta.1.40-1.52 (m, 2H), 1.97-2.03 (m,
2H), 2.81-2.92 (m, 2H), 3.01-3.09 (m, 1H), 4.07-4.12 (m, 2H), 5.07
(s, 2H), 6.77 (s, 2H), 7.28-7.40 (m, 5H)
ii) Piperidine-4-sulfonamide
[1163] Benzyl 4-(aminosulfonyl)piperidine-1-carboxylate (the
product from step i), 3.3 g) was dissolved in MeOH (20 ml). To this
solution was added acetic acid (0.5 ml) and a catalytic amount of
Pd/C. The reaction mixture was subjected to a pressure of 5 bar
under an atmosphere of hydrogen gas for 18 h at RT. The reaction
was filtered through celite and the filtrate was reduced in vacuo
to give the subtitle compound as a white solid. Yield 1.7 g
[1164] .sup.1H NMR: (DMSO) .delta.1.46-1.57 (m, 21-1''), 1.91-1.98
(m, 2H), 2.48-2.57 (m, 2H), 2.85-2.93 (m, 1H), 3.05-3.10 (m, 2H),
5.38 (s, 2H), 6.71 (s, 1H)
EXAMPLE 156
N-(2-[(2,3-Difluorobenzyl)thio]-6-{[(trans)-2-hydroxycyclopentyl]oxy}pyrim-
idin-4-yl)azetidine-1-sulfonamide
##STR00172##
[1166] A mixture of azetidine-1-sulfonamide (0.27 g),
tris(dibenzylideneacetone)dipalladium (0) (50 mg),
2-dicyclohexylphosphino-2',4',6'-tri-isopropyl-1,1'-biphenyl
(XPHOS) (50 mg), cesium carbonate (0.43 g) and
(trans)-2-(6-chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl)cyclopenta-
nol (the product from step i), 0.50 g) in dioxane (20 ml) was
heated at reflux in a microwave at 100.degree. C., 300 W, open
vessel with cooling for 1 h. The reaction mixture was then reduced
in vacuo and the residue partitioned between DCM (150 ml) and
H.sub.2O (150 ml). The organics were separated and the aqueous
layer was re-extracted with DCM (2.times.150 ml). Organics were
combined, dried (MgSO.sub.4) and reduced under vacuo and the
resulting residue purified by prep HPLC to give the title compound
as a white solid. Yield 74 mg
[1167] MS: APCI (+ve) 473 [M+H.sup.+]
[1168] .sup.1H NMR: (DMSO) .delta. 1.61-1.84 (m, 4H), 2.02-2.18 (m,
2H), 2.26 (q, 2H), 4.01 (t, 4H), 4.11-4.18 (m, 1H), 4.38 (s, 2H),
4.98-5.03 (m, 1H), 6.34 (s, 1H), 6.98-7.11 (m, 2H), 7.17-7.24 (m,
1H)
[1169] The intermediate for this compound was prepared as
follows:
(i)
(trans)-2-{6-Chloro-2-[(2,3-difluorobenzyl)thio]pyrimidin-4-yl}cyclope-
ntanol
[1170] To a solution of
4,6-dichloro-2-[(2,3-difluorobenzyl)thio]pyrimidine (the product of
example 1 step ii), 2.3 g) and (trans)-cyclopentane-1,2-diol (1 g)
in THF (50 ml) was added NaH (0.30 g) slowly and the reaction was
then allowed to stir for 18 h at RT. The reaction mixture was then
partitioned between DCM (150 ml) and H.sub.2O (100 ml). The
organics were separated and the aqueous layer was re-extracted with
DCM (2.times.150 ml). Organics were combined, dried (MgSO.sub.4)
and reduced in vacuo and the resulting clear oil was purified by
column chromatography on silica gel EtOAc/iso-Hexane (2:8) to give
the subtitle compound as a clear colourless oil. Yield 0.94 g
[1171] MS: APCI (+ve) 373/375 [M+H.sup.+]
* * * * *